text,chunk_id,title,publication_date,authors,disease
"Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome Diffuse oesophageal leiomyomatosis is a rare benign disease in the paediatric population. This report highlights a recent clinical case, together with a narrative review of current world literature. An early middle childhood girl with recurrent lower respiratory tract infections for 2 years was noted to have a retrocardiac lesion on chest X-ray, later confirmed to be an oesophageal mass on CT imaging. She underwent an Ivor-Lewis",0_0,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"mass on CT imaging. She underwent an Ivor-Lewis oesophagogastrectomy and a Heineke-Mikulicz pyloroplasty. Pathology examination revealed type I diffuse oesophageal leiomyomatosis. Alport syndrome was later confirmed following an episode of postoperative haematuria, which was corroborated by electron microscopy examination following renal biopsy. With an oesophageal mass lesion and Alport syndrome, oesophageal leiomyomatosis should be suspected in any patient with a clinical history of dysphagia and/or",0_1,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"with a clinical history of dysphagia and/or respiratory symptoms. Endoscopic ultrasound-guided tissue biopsy is valuable for diagnosis of all suspected lesions. Surgical resection is mandatory to effect cure.  Diffuse oesophageal leiomyomatosis (DEL) is an extremely rare disease in the paediatric age group, with a scarcity of consensus or best practice guidelines. In 1975, Fernandes classified DEL into two distinct types<xref rid=""R1"" ref-type=""bibr""><sup>1</sup></xref>—(1) a diffuse thickening of the",0_2,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"a diffuse thickening of the oesophageal musculature and (2) confluent myomatous nodules involving the muscles of the oesophagus.<xref rid=""R2"" ref-type=""bibr""><sup>2 3</sup></xref> Several early reports also refer to diffuse fibromyoma,<xref rid=""R4"" ref-type=""bibr""><sup>4 5</sup></xref> oesophageal hypertrophic stenosis<xref rid=""R6"" ref-type=""bibr""><sup>6</sup></xref> and/or oesophageal leiomyoma with pathological descriptions akin to Fernandes type 2 lesion(s).<xref rid=""R1"" ref-type=""bibr""><sup>1 7",0_3,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"lesion(s).<xref rid=""R1"" ref-type=""bibr""><sup>1 7 8</sup></xref> Autopsy diagnosis is also prevalent.<xref rid=""R3"" ref-type=""bibr""><sup>3 5 6 9</sup></xref> In 1983, Torres and Guarner suggested an association with Alport syndrome (DEL-AS), while other authors reported that leiomyomatosis could involve other organ systems, notably the tracheobronchial tree, genitourinary/gastrointestinal tract and anorectal musculature.<xref rid=""R1"" ref-type=""bibr"">15 9</xref><xref rid=""R13"" ref-type=""bibr"">13</xref>",0_4,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"9</xref><xref rid=""R13"" ref-type=""bibr"">13</xref> Findings from imaging studies often reveal prominent oesophageal thickening in the distal oesophagus, extending for some distance to also involve the oesophagogastric junction creating a longer stenosis than that typically seen with achalasia.<xref rid=""R5"" ref-type=""bibr""><sup>5 14 15</sup></xref> Endoscopic ultrasound (EUS)-guided biopsy can greatly aid diagnosis by accessing pathological muscular lesions.<xref rid=""R15"" ref-type=""bibr"">15</xref><xref",0_5,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"rid=""R15"" ref-type=""bibr"">15</xref><xref rid=""R17"" ref-type=""bibr"">17</xref> Anecdotal therapies have included periodic oesophageal dilatation(s)<xref rid=""R6"" ref-type=""bibr""><sup>6</sup></xref> and oesophageal myotomy/myectomy.<xref rid=""R2"" ref-type=""bibr""><sup>2 5</sup></xref> Current interventions include both oesophageal resection and oesophageal substitution or replacement surgery. An early middle childhood girl with four previous episodes of bronchitis and pneumonia in the last 2 years presented to",0_6,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"and pneumonia in the last 2 years presented to hospital with a fifth attack of bronchitis. A chest X-ray (CXR) film showed an incidental finding of a retrocardiac mass (<xref rid=""F1"" ref-type=""fig"">figure 1A</xref>). CT coronal imaging later revealed long-segment oesophageal thickening (<xref rid=""F1"" ref-type=""fig"">figure 1B</xref>). Patient history showed progressively poor feeding and earlier hospital admissions included haematuria—first experienced in her early childhood without further detailed",0_7,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"in her early childhood without further detailed investigations. Her body weight was 15.35 kg (body mass index 12.77). Serum blood nitrogen urea and creatinine were 15 and 0.38 mg/dL, respectively. Oesophagography (<xref rid=""F1"" ref-type=""fig"">figure 1C</xref>), oesophagogastroscopy with a submucosal single-incision knife biopsy and EUS-guided biopsy (<xref rid=""F1"" ref-type=""fig"">figure 1D–F</xref>) were performed, respectively. The biopsy specimens failed to yield an adequate full pathological diagnosis",0_8,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"to yield an adequate full pathological diagnosis between normal and hypertrophic smooth muscle(s). Ivor-Lewis oesophagogastrectomy (with gastric pull-up) (<xref rid=""F2"" ref-type=""fig"">figure 2A</xref>) and a Heineke-Mikulicz pyloroplasty were thereafter performed with a routine follow-up postoperative contrast study (<xref rid=""F2"" ref-type=""fig"">figure 2B</xref>). The surgical resected specimen confirmed Fernandes type 1 leiomyomatosis (<xref rid=""F2"" ref-type=""fig"">figure 2C,D</xref>). On the third",0_9,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"ref-type=""fig"">figure 2C,D</xref>). On the third postoperative day, the patient developed haematuria, raising the clinical suspicion of Alport syndrome. Normal orbital and auditory examinations were confirmed but the child’s parents refused full medical genetics testing. Subsequent renal biopsy with histopathology and electron microscopy studies showed the hallmark features, notably thin focal thickness membranes with areas of duplication and diffuse foot process effacement of podocytes—characteristics of",0_10,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"effacement of podocytes—characteristics of Alport syndrome. Screening the first-degree relatives and a number of second-degree relatives revealed that they had normal CXR films and urinalyses. Family pedigree revealed that no other family member was affected in three generations with the typical features of Alport syndrome. At 2 months postoperatively, the patient experienced some eating and swallowing difficulty. An oesophagogram study showed a narrowed anastomosis and gastro-oesophageal reflux. A mild",0_11,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"anastomosis and gastro-oesophageal reflux. A mild stricture was easily dilated with balloon dilatation. A CT scan at 1-year follow-up showed non-progressive thickening of residual oesophagus. At a follow-up period of 2 years with 2 kg body weight gain, the patient experienced a recurrent stricture due to reflux inflammation of the substitution graft anastomosis even under full doses of proton-pump inhibitors. Four oesophageal balloon dilations with ongoing periodic dysphagia later led to undertaking",0_12,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"periodic dysphagia later led to undertaking endoscopic stricturotomy, with normal eating restored now for over 1 year. From our narrative review of the available literature, notably including abstracts or full articles published from 1916 to December 2022 under the search terms “esophag*, leiomyomatosis, muscular hypertrophy, human” on PubMed and Google search engines, we sought to study all paediatric patients who had symptoms before 18 years of age. This amounted to some 67 index cases with our case",0_13,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"amounted to some 67 index cases with our case being the 68th. For statistical analysis, we used Stata 14.1 software: (1) categorical data using Fisher’s exact test and χ<sup>2</sup> test, (2) continuous data using Wilcoxon Mann–Whitney test and Student’s t-test and (3) nominal variables comparison using Cramér’s V correlation. The first firm diagnosis of oesophageal leiomyomatosis was established in 1975. Putative links with Alport syndrome (DEL-AS) were later reported in 1983 (<xref rid=""F3""",0_14,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"were later reported in 1983 (<xref rid=""F3"" ref-type=""fig"">figure 3</xref>). Before these reports, patients were often wrongly misdiagnosed as having oesophageal achalasia. Index diagnoses of oesophageal leiomyomatosis were also later revealed in detailed postmortem examination(s) (<xref rid=""T1"" ref-type=""table"">table 1</xref>). Incidentally detected oesophageal mass lesions are frequently recorded. Symptoms are mainly related to dysphagia or gastro-oesophageal reflux disease. The data after 1975, mean",0_15,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"reflux disease. The data after 1975, mean age at onset of dysphagia is typically recorded as 7.4±3.9 years. Although not previously reported in a systematic review study, a higher incidence of DEL is seemingly apparent in females (2:1) and DEL-AS in males.<xref rid=""R18"" ref-type=""bibr""><sup>18</sup></xref> Leiomyoma(s) in other organs may include the anorectal region, genital tract, urogenital system, tracheobronchial tree and other parts of the intestinal tract; they mostly discovered at or sometimes",0_16,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"tract; they mostly discovered at or sometimes after the primary diagnosis of DEL and were usually recorded as presenting later in adulthood years.<xref rid=""R11"" ref-type=""bibr""><sup>11 12</sup></xref> (<xref rid=""T2"" ref-type=""table"">table 2</xref>). The familial history of esophageal leiomyomatosis or Alport, patient’s Alport, and occurences of other organs leiomyoma(s) correlate not all significant; genetic related studies elicited familial DEL and Alport (<xref rid=""T3"" ref-type=""table"">table",0_17,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"and Alport (<xref rid=""T3"" ref-type=""table"">table 3</xref>). <xref rid=""T4"" ref-type=""table"">Table 4</xref> lists pathological sites typically involved in patients. These are predominantly in the oesophagus (93%), that is, isolated distal oesophagus (41%), mid-to-distal oesophagus (13%), whole oesophagus (32 %) and the oesophagogastric junction (56%). Surgical management options include oesophageal resection or a total oesophagectomy. Conservative management has been considered in a minority of cases",0_18,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"has been considered in a minority of cases including oesophageal myotomy/myectomy, which has had limited success. After-care patient follow-up has shown variable practice management (<xref rid=""T1"" ref-type=""table"">table 1</xref>). Median follow-up (range) in published studies has been defined as 2.4 years (0.3–21 years). No reports of carcinomatous change have been documented in the residual native oesophagus at the time of writing this report. EUS is a valuable investigative diagnostic tool for defining",0_19,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"investigative diagnostic tool for defining the primary site of origin of an oesophageal mass lesion and may permit targeted guided biopsy. Oesophageal lesions usually involve the middle oesophagus to the oesophagogastric junction,<xref rid=""R5"" ref-type=""bibr""><sup>5</sup></xref> whereas a proximal oesophageal location may be revealed on manometry study and contrast swallow imaging may reveal disorders of peristalsis with a notably thickened proximal oesophagus.<xref rid=""R15"" ref-type=""bibr""><sup>15 19",0_20,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"rid=""R15"" ref-type=""bibr""><sup>15 19 20</sup></xref> It is strongly advised that all paediatric patients with a new diagnosis of an oesophageal mass lesion should be screened for Alport syndrome with or without a family history. EUS-guided tissue biopsy is valuable for diagnosis of all suspected lesions. Surgical resection is mandatory for cure. Finally, a surveillance after-care program is advisable to effectively monitor and detect new leiomyoma(s) in other organ systems in index patients, especially in",0_21,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"organ systems in index patients, especially in those with familial history of Alport syndrome.",0_22,Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome,2024,,Alport_Syndrome
"A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome Alport syndrome (AS) is the most common inherited glomerular disease caused by <italic toggle=""yes"">COL4A3/4/5</italic> variants, which is a leading cause of kidney failure worldwide, yet the only standard care available is renin-angiotensin-aldosterone system inhibition.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> An unmet need exists for AS treatment. In disease models of AS and other glomerular",1_0,A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome,30 7 2024,,Alport_Syndrome
"In disease models of AS and other glomerular diseases, the involvement of angiotensin II and endothelin-1, either individually or in concert, in mediating glomerular injury has been well documented, leading to the development of proteinuria and kidney damage.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> Previous studies revealed that treatment of Alport mice with sitaxentan, an endothelin A receptor antagonist, resulted in delayed onset",1_1,A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome,30 7 2024,,Alport_Syndrome
"A receptor antagonist, resulted in delayed onset of proteinuria, prevention of fibrosis and glomerulosclerosis, and prolonged life span in treated animals compared with controls.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref> More recent DUPLEX trial in focal segmental glomerulosclerosis (Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis) and PROTECT trial in IgA nephropathy (Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy)",1_2,A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome,30 7 2024,,Alport_Syndrome
"the Treatment of Patients With IgA Nephropathy) showed promising results in significant reductions in proteinuria and preservation of kidney function by sparsentan, a dual endothelin angiotensin receptor antagonist.<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><sup>,</sup><xref rid=""bib6"" ref-type=""bibr""><sup>6</sup></xref> This raises the question of whether the therapeutic in AS is the same as in these forms of glomerular diseases, and whether other endothelin receptor antagonists available on the",1_3,A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome,30 7 2024,,Alport_Syndrome
"endothelin receptor antagonists available on the market are effective as well, such as ambrisentan, a selective endothelin receptor antagonist, which has been approved at a dose of 5 to 10 mg, once daily for patients with pulmonary arterial hypertension.<xref rid=""bib7"" ref-type=""bibr""><sup>7</sup></xref> Thus, this pilot study explores the efficacy and safety of ambrisentan on lowering proteinuria in patients with AS.  This pilot study suggests that introducing a highly selective antagonist for",1_4,A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome,30 7 2024,,Alport_Syndrome
"introducing a highly selective antagonist for ET<sub>A</sub> on top of renin-angiotensin-aldosterone system inhibition, with or without sodium-glucose cotransporter-2 inhibitors/mineralocorticoid receptor antagonists, provides an additional antiproteinuric effect. A relatively high percentage of patients discontinued the drug in this pilot (4/12) because of adverse reactions, suggesting that clinicians should pay attention to these adverse reactions during the initial period of use. Few effects on renal",1_5,A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome,30 7 2024,,Alport_Syndrome
"the initial period of use. Few effects on renal function were observed. Future prospective large-scale randomized studies are highly warranted to demonstrate the effect and safety of ambrisentan or other endothelin receptor antagonists in AS. The manuscript has received approval from all authors, who declare no potential conflict of interest. The patients have given consent for their clinical information to be published in the journal.",1_6,A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome,30 7 2024,,Alport_Syndrome
"Finerenone and other future therapeutic options for Alport syndrome Alport syndrome is a rare genetic disease that results in disordered basement membrane type IV collagen resulting in haematuria, proteinuria and often development of renal fibrosis leading to progressive kidney disease. The therapeutic blockage of the renin-angiotensin-aldosterone system, which slows the progression to kidney failure, is supported by strong evidence. Recent clinical trials using sodium-glucose co-transporter-2 (SGLT2)",2_0,Finerenone and other future therapeutic options for Alport syndrome,8 11 2023,,Alport_Syndrome
"using sodium-glucose co-transporter-2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRA) in patients with chronic kidney disease have changed the therapeutic landscape. Patients with Alport syndrome and progressive kidney disease may benefit from treatment with MRAs because research has shown that these drugs are nephroprotective through a variety of mechanisms, including by preventing fibrosis. Ongoing clinical trials show great promise in order to help establish the long-term safety and",2_1,Finerenone and other future therapeutic options for Alport syndrome,8 11 2023,,Alport_Syndrome
"order to help establish the long-term safety and efficacy of Finerenone, a MRA. This review discusses the evidence for the use of MRAs as a potential treatment in Alport syndrome that may slow the progression of chronic kidney disease and prevent patients reaching kidney failure. In the last few years, the pharmacological management of patients with chronic kidney disease (CKD), including Alport syndrome (AS) has changed significantly [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Clinical trials have",2_2,Finerenone and other future therapeutic options for Alport syndrome,8 11 2023,,Alport_Syndrome
"rid=""CR1"">1</xref>]. Clinical trials have highlighted the beneficial effects of the use of renin–angiotensin system (RAAS) blockers on renal outcomes (angiotensin-converting–enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARB]) and, more recently, sodium–glucose co-transporter 2 (SGLT2) inhibitors [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR3"">3</xref>]. However, despite the use of these, the need for new therapies remains. Finerenone is a selective, nonsteroidal",2_3,Finerenone and other future therapeutic options for Alport syndrome,8 11 2023,,Alport_Syndrome
"remains. Finerenone is a selective, nonsteroidal mineralocorticoid receptor antagonist (MRA). It differs to steroidal mineralocorticoid receptor antagonists due to increased potency and selectivity for mineralocorticoid receptors, shorter half-life and lack of active metabolites [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. In brief, its nephroprotective effects revolve around preservation of kidney structures due to its combined anti-fibrotic, anti-inflammatory and anti-oxidative effects [<xref",2_4,Finerenone and other future therapeutic options for Alport syndrome,8 11 2023,,Alport_Syndrome
"and anti-oxidative effects [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. A clinical trial demonstrated that in patients with CKD and type 2 diabetes (T2DM), treatment with Finerenone resulted in lower risks of CKD progression and cardiovascular events when compared to a placebo [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. This poses the question whether the use of MRAs such as Finerenone may be beneficial in the management of patients at risk of renal fibrosis leading to a progressive loss of kidney function,",2_5,Finerenone and other future therapeutic options for Alport syndrome,8 11 2023,,Alport_Syndrome
"leading to a progressive loss of kidney function, for example those with AS, which commonly leads to kidney failure at a relatively young age. Looking ahead, the combination of ongoing clinical trials, new pharmaceutical advancements and further research to help gain a greater understanding of disease mechanisms, the future of how we manage AS looks promising. The role of Finerenone in the management of AS needs to be explored further, alongside several additional drugs, such as SGLT2 inhibitors and gene",2_6,Finerenone and other future therapeutic options for Alport syndrome,8 11 2023,,Alport_Syndrome
"drugs, such as SGLT2 inhibitors and gene editing therapeutics. There is extreme optimism for improved and better treatments for CKD associated with AS in the near future.",2_7,Finerenone and other future therapeutic options for Alport syndrome,8 11 2023,,Alport_Syndrome
"Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report Alport syndrome (AS) is a rare, progressive hereditary kidney disease characterized by sensorineural hearing loss and visual abnormalities. It is caused by a mutation in the collagen type IV alpha-4 (COL4A4) gene, which produces type IV collagen, and often manifests in individuals with hematuria, proteinuria, edema, and hypertension. Here, we present a case of AS in a 15-year-old boy with a COL4A4 gene mutation, with",3_0,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"15-year-old boy with a COL4A4 gene mutation, with renal and extrarenal findings. The patient presented with subnephrotic proteinuria and microscopic hematuria, autoimmune hypothyroidism, and keratoconus. Light microscopy examination of renal biopsy revealed three globally sclerosed renal cortical parenchyma areas with periglomerular fibrosis, and electron microscopy showed variable thickness of glomerular basement membrane with festooned appearance, as well as splitting of lamina densa giving basket weave",3_1,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"as splitting of lamina densa giving basket weave and criss-cross pattern. According to certain theories, the modern era of Alport syndrome (AS) began in the 1970s with observations of distinctive ultrastructural anomalies in the glomerular basement membranes (GBMs) of affected individuals [<xref rid=""REF1"" ref-type=""bibr"">1</xref>-<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. These ground-breaking findings sparked a series of inquiries that resulted in the discovery of collagen IV (COL4) as the protein",3_2,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"discovery of collagen IV (COL4) as the protein responsible for AS. Collagen type IV alpha 3 (COL4A3), collagen type IV alpha 4 (COL4A4), and collagen type IV alpha 5 (COL4A5) genes cloning and sequencing, and the identification of variations in these genes in AS families [<xref rid=""REF4"" ref-type=""bibr"">4</xref>-<xref rid=""REF8"" ref-type=""bibr"">8</xref>]. The alpha 3, alpha 4, and alpha 5 chains of COL4 are encoded by the genes COL4A3, COL4A4, and COL4A5, respectively. The main element of the kidney's",3_3,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"respectively. The main element of the kidney's GBM is COL4. COL4 alpha chains are mainly found in the kidneys, eyes, and cochlea. The splitting of the GBM or more serious pathological lesions affecting the kidney is caused by pathogenic mutations involving this gene [<xref rid=""REF9"" ref-type=""bibr"">9</xref>]. These genes have three different inheritance patterns and more than 1,700 mutations. Three inheritance types are X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS), and",3_4,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"autosomal recessive Alport syndrome (ARAS), and autosomal dominant Alport syndrome (ADAS). This condition is characterized by progressive nephritis with GBM ultrastructural alterations, hematuria, and proteinuria, ultimately leading to kidney failure. Usually, extra-renal manifestations such as sensorineural hearing loss and ophthalmologic illnesses like lenticonus or retinal flecks are present [<xref rid=""REF10"" ref-type=""bibr"">10</xref>]. It is crucial to diagnose AS as soon as possible, as its",3_5,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"to diagnose AS as soon as possible, as its consequences typically appear in childhood or early adulthood, and renal disease can lead to death in early adulthood if treatment is not started on time [<xref rid=""REF11"" ref-type=""bibr"">11</xref>]. Technology has progressed to the point where a variety of different research methods, in addition to electron microscopy, have increased the number of clinical and research applications to identify changes in AS [<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. These",3_6,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"rid=""REF12"" ref-type=""bibr"">12</xref>]. These methods include genetic testing and immunohistochemistry (IHC) investigation of the expression of the basement membrane COL4 by skin or renal biopsy [<xref rid=""REF13"" ref-type=""bibr"">13</xref>]. The first and most important factor in treating AS is managing and delaying the progression of renal damage. The doctor will prescribe appropriate treatment like angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, calcium channel blockers, and a low-sodium",3_7,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"calcium channel blockers, and a low-sodium and low-protein diet. When kidney disease reaches end-stage renal disease, dialysis or kidney transplantation are the only treatment options available. The patient is a 15-year-old boy who was found to have subnephrotic proteinuria with microscopic hematuria, autoimmune thyroiditis, and keratoconus at the age of 11 years. He had a history of sickle cell trait, AS pattern, and he was operated on for phimosis when he was seven years old. At the age of eight years,",3_8,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"was seven years old. At the age of eight years, he was diagnosed with bilateral hydrocele and was referred to a pediatric surgeon. When he was 12 years old, he developed an acute kidney injury due to an acute viral infection, which was cured. At 14 years, on clinical examination, it was found that the patient had micropenis (length = 44 mm) and cushingoid facies and skin lesions over his face; he was moderately anemic (9 gm/dL). The patient had 24 hours of urine protein was 567 mg/24 hrs, which increased",3_9,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"urine protein was 567 mg/24 hrs, which increased gradually over a few months to 879 mg/24 hrs; creatinine levels were 1.83 mg/dL. His urinalysis demonstrated reddish urine with hazy transparency, with pus cells 50-100/hpf (high power field), 3+ proteinuria, protein/creatinine ratio 6.25, and 3+ urobilinogen. Ocular examination revealed corneal ectasia and keratoconus in both eyes. Based on the subnephrotic range of proteinuria and subsequent discussion with the patient's mother, it was discovered that the",3_10,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"the patient's mother, it was discovered that the patient's maternal second uncle and aunt had passed away due to kidney disease (Figure <xref rid=""FIG1"" ref-type=""fig"">1</xref>). In March 2019, ultrasonography, renal biopsy, and genetic testing were done (Figure <xref rid=""FIG2"" ref-type=""fig"">2</xref>). On ultrasonography, bilateral small kidneys (7.1 x 3.4 cm right; 7.2 x 3.3 cm left) with raised cortical echotexture, loss of corticomedullary differentiation, and grade 3 renal parenchymal disease with",3_11,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"and grade 3 renal parenchymal disease with splenomegaly were noted. Renal biopsy showed prominent alterations in the arrangement of collagen in GBMs, including the splitting of GBM, ""basket weave""-like appearance, and ""criss-cross"" patterns, and widespread significant effacement of foot processes of visceral epithelial cells (about 60-70%). Variability of GBM thickness with thin and thick areas (maximum and minimum GBM thickness being 121.1 and 918.3 nm, respectively) confirmed the diagnosis of AS (Figure",3_12,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"confirmed the diagnosis of AS (Figure <xref rid=""FIG2"" ref-type=""fig"">2</xref>). According to genetic testing, the patient had a heterozygous intronic mutation in the COL4A4 gene, where thiamine was substituted for guanine at nucleotide 871 (c871-72G > T and c871-64A > T). This mutation is expected to modify the splicing sites and final protein product. In October 2022, the patient presented to the hospital complaining of generalized weakness, gastritis, and edema around the eyes. His clinical examination",3_13,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"edema around the eyes. His clinical examination revealed blood pressure 130/80 mmHg, blood urea 156 mg/dL, creatinine 9.6 mg/dL, potassium 5.2 meq/L, and urinalysis showed 2+ proteinuria, pus cells 1-2/hpf. The treatment was started when the patient was nine years old, and rabeprazole and telmisartan were given initially. The patient's condition deteriorated over the years, for which the patient is currently on dialysis and given supportive care treatment such as Thyrox 50 mcg once daily (thyroxine),",3_14,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"such as Thyrox 50 mcg once daily (thyroxine), Amlokind 5 mg once daily (antihypertensive), Dilzem 30 mg twice daily (calcium channel blocker), C2D3 (calcium and vitamin supplement), Sobisis 500 mg (antacid). AS is an uncommon condition that leads to progressive nephritis. In 85% of instances, an X chromosomal aberration linked to the COL4A5 gene has been found. The youngster in this case was diagnosed with AS based on the findings of a kidney biopsy and genetic testing, due to recurrent observations of",3_15,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"genetic testing, due to recurrent observations of severe hematuria and proteinuria. Improvements in renal biopsy and genetic testing have made kidney disease diagnosis and treatment more accessible [<xref rid=""REF14"" ref-type=""bibr"">14</xref>,<xref rid=""REF15"" ref-type=""bibr"">15</xref>]. In 15% of cases of AS, ARAS is caused by mutations in the COL4A3 and COL4A4 genes [<xref rid=""REF16"" ref-type=""bibr"">16</xref>,<xref rid=""REF17"" ref-type=""bibr"">17</xref>]. COL4A3 and COL4A4 gene mutations are present in",3_16,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"COL4A3 and COL4A4 gene mutations are present in 5% of people with ADAS. AS affects the integrity of the basement membrane of the eye, cochlea, and glomerulus due to a disruption in the COL4A5 gene. In the AS kidney, longitudinal GBM splitting develops later, and the basement membrane weakens earlier under electron microscopy. Recurrent bouts of gross hematuria are one of the clinical symptoms, especially in young children. Typically, asymptomatic microhematuria occurs before other symptoms. In the early",3_17,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"occurs before other symptoms. In the early stages of the condition, plasma creatinine levels and blood pressure remain normal; however, later on, hypertension, azotemia, and proteinuria may develop. In the later stages, patients may present with end-stage renal disease. Eye and ear involvement are the most common extrarenal features. Hearing conversational speech becomes increasingly difficult over time due to sensorineural hearing loss, which initially affects high-frequency sounds. Eye changes include",3_18,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"high-frequency sounds. Eye changes include anterior lenticonus, white or yellow flecking of the perimacular portion of the retina, and corneal lesions such as recurrent corneal erosions, posterior polymorphous dystrophy, and, very rarely, keratoconus [<xref rid=""REF9"" ref-type=""bibr"">9</xref>]. Diagnosis of AS is typically supported by a thorough family history of renal illness, as done in this case. However, in 15% of cases, there is no family history, and a kidney biopsy is used for diagnosis. A renal",3_19,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"a kidney biopsy is used for diagnosis. A renal biopsy examining COL4 expression in the kidney can confirm or rule out AS. Supportive care includes medications such as ACE inhibitors and calcium channel blockers to reduce proteinuria and control hypertension. Patients with end-stage renal disease also receive dialysis. Research into AS gene therapy is ongoing, with current studies involving the administration of the human alpha-5 (IV) chain of GBM in a canine model of XLAS [<xref rid=""REF18""",3_20,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"GBM in a canine model of XLAS [<xref rid=""REF18"" ref-type=""bibr"">18</xref>]. In this case, the boy also presented with autoimmune thyroiditis. To date, there is no evidence or research linking autoimmune thyroiditis with AS. AS is a rare disorder, which makes it a compelling case to investigate different approaches to therapy. It presents with distinct clinical symptoms, including renal failure, visual involvement, and hearing loss. Here, we report a rare case of XLAS in a 15-year-old adolescent boy with",3_21,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"case of XLAS in a 15-year-old adolescent boy with an unusual extrarenal clinical manifestation of keratoconus, along with autoimmune hypothyroidism and sickle cell trait. Symptomatic relief can be achieved with a multidisciplinary approach and supportive therapy, as there is no cure for this illness. The patient received maintenance dialysis and supportive care and treatment. Early diagnosis of the disease allows for appropriate genetic counseling for both the patient and other family members.",3_22,Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report,11 9 2024,,Alport_Syndrome
"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report Alport syndrome (AS) is a hereditary kidney disorder of type IV collagen caused by pathogenic variants in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> genes. Previously several cases of digenic AS, caused by two pathogenic variants in two of the three <italic",4_0,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"pathogenic variants in two of the three <italic toggle=""yes"">COL4A</italic> genes, have been reported. Patients with digenic AS may present with a more severe phenotype compared to patients with single variants, depending on the percentage affected type IV trimeric collagen chain. We report a newly discovered case of trigenic AS. A 52-year-old female presented with hematuria at the age of 24 years and developed hypertension by the age of 30. Over the years, she developed chronic kidney disease; the most",4_1,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"she developed chronic kidney disease; the most recent eGFR was 44 mL/min/1.73 m<sup>2</sup>. She has symmetric high-tone sensorineural hearing loss. Full genetic analysis revealed a heterozygous pathogenic variant c.2691del in <italic toggle=""yes"">COL4A3,</italic> a heterozygous pathogenic variant c.1663dup in <italic toggle=""yes"">COL4A4,</italic> and a complete heterozygous deletion of <italic toggle=""yes"">COL4A5</italic>. We describe the first patient with AS caused by pathogenic variants in all three",4_2,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"AS caused by pathogenic variants in all three <italic toggle=""yes"">COL4A</italic> genes, designated trigenic AS. This case report emphasizes the importance of examining all three <italic toggle=""yes"">COL4A</italic> genes, even in patients with a mild Alport phenotype, for optimal follow-up of the patient and adequate genetic counseling of family members. Alport syndrome (AS) is an inherited disorder of type IV collagen expressed in the basement membranes of kidney glomeruli, eyes and cochleae. AS is caused",4_3,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"kidney glomeruli, eyes and cochleae. AS is caused by (likely) pathogenic variants in the <italic toggle=""yes"">COL4A</italic> genes: <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic>. Variants in the <italic toggle=""yes"">COL4A5</italic> gene, located on the X-chromosome, cause X-linked AS (XLAS). Variants in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic>, located head-to-head on chromosome 2, cause autosomal",4_4,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"head-to-head on chromosome 2, cause autosomal recessive or dominant AS [<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>]. Conventionally, genetic analysis in patients with AS was performed using Sanger sequencing, which was time-consuming given the extensive size of the genes (<italic toggle=""yes"">COL4A3</italic> 52 exons, <italic toggle=""yes"">COL4A4</italic> 48 exons, and <italic toggle=""yes"">COL4A5</italic> 53 exons, respectively). Furthermore, a sequential gene analysis",4_5,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"Furthermore, a sequential gene analysis was terminated when a pathogenic variant was detected. Nowadays, next-generation sequencing (NGS) is the most efficient method for analyzing the <italic toggle=""yes"">COL4A</italic> genes collectively, detecting all variants present. Since NGS may fail to detect exon deletions and duplications, additional multiplex ligation-dependent probe amplification is performed [<xref rid=""B3"" ref-type=""bibr"">3</xref>]. Implementation of NGS resulted in the discovery of digenic",4_6,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"of NGS resulted in the discovery of digenic AS: pathogenic variants in two of the <italic toggle=""yes"">COL4A</italic> genes. In digenic AS, all possible combinations have been described and the phenotype is more severe compared to patients with one heterozygous variant in <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> [<xref rid=""B4"" ref-type=""bibr"">4</xref>–<xref rid=""B6"" ref-type=""bibr"">6</xref>]. When variants are configured in cis (i.e., located on the same allele), this",4_7,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"in cis (i.e., located on the same allele), this mimics autosomal dominant inheritance, however, with a more severe phenotype. Two variants in trans (i.e., located on different alleles) mimic autosomal recessive inheritance, though with a less severe phenotype for the offspring [<xref rid=""B4"" ref-type=""bibr"">4</xref>–<xref rid=""B7"" ref-type=""bibr"">7</xref>]. Based on the population frequency of <italic toggle=""yes"">COL4A</italic> pathogenic variants, we expect more patients to be identified with digenic AS",4_8,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"more patients to be identified with digenic AS in the future using the current genetic analyses [<xref rid=""B8"" ref-type=""bibr"">8</xref>]. We present a case in which genetic analyses revealed pathogenic variants in all three <italic toggle=""yes"">COL4A</italic> genes. This case emphasizes the current guideline advice to analyze all three <italic toggle=""yes"">COL4A</italic> genes in patients suspected with AS [<xref rid=""B7"" ref-type=""bibr"">7</xref>]. A 52-year-old female (shown in <xref rid=""F1""",4_9,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"A 52-year-old female (shown in <xref rid=""F1"" ref-type=""fig"">Fig. 1</xref>; III:2 and referred to as index case) was referred for evaluation of her kidney disease. She was diagnosed with hematuria at age 24 and developed hypertension by the age of 30. During pregnancy (at 35 years of age) she was diagnosed with preeclampsia and nephrotic syndrome with severe proteinuria (up to 17 grams/day) for over 6 weeks. Post pregnancy the proteinuria decreased to levels between 0.5 and 1.5 g/day with ACE inhibitor",4_10,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"between 0.5 and 1.5 g/day with ACE inhibitor treatment. The index case developed postpartum cardiomyopathy (with left ventricle dilatation), which recovered over the years. She underwent a gastric bypass at the age of 43 to treat obesity. She suffers from high-tone sensorineural hearing loss and has been wearing hearing aids since the age of 36. She experienced rapid loss of kidney function in the period between 2006 and 2013 as shown in online supplementary File 1 (for all online suppl. material, see",4_11,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"File 1 (for all online suppl. material, see <ext-link http://www.w3.org/1999/xlink href=""10.1159/000538587"" ext-link-type=""doi"">https://doi.org/10.1159/000538587</ext-link>). However, the rate of kidney function decline improved after recovery from other medical conditions (obesity, preeclampsia, and cardiomyopathy). Currently, chronic kidney disease (CKD) is classified as stage G3bA2 with an eGFR of 44 mL/min/1.73 m<sup>2</sup> and an albumin/creatinine ratio of 46 mg/g with ACE inhibitor therapy.",4_12,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"ratio of 46 mg/g with ACE inhibitor therapy. X-linked AS was suspected based on the disease symptoms (<xref rid=""T1"" ref-type=""table"">Table 1</xref>), and genetic analysis was performed. We describe a female patient with AS and pathogenic variants in all three <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> genes. We designated this to be trigenic AS. Based on the population frequency of a digenic predicted pathogenic <italic",4_13,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"of a digenic predicted pathogenic <italic toggle=""yes"">COL4A3</italic> plus a <italic toggle=""yes"">COL4A4</italic> variant of 1:44,793 and 1:245,920 for combinations of <italic toggle=""yes"">COL4A5</italic> plus <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic>, trigenic AS must be extremely rare [<xref rid=""B8"" ref-type=""bibr"">8</xref>]. We were unable to investigate the inheritance of the three respective variants in the index case (III:2) in full detail. Because we only",4_14,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"case (III:2) in full detail. Because we only detected the <italic toggle=""yes"">COL4A3</italic> variant in the son (IV:1), the <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> variants are inherited in <italic toggle=""yes"">trans</italic>. The <italic toggle=""yes"">COL4A4</italic> variant is maternal (II:2); the <italic toggle=""yes"">COL4A3</italic> variant is likely paternal (II:1). However, since the father passed away at an early age this could not be genetically confirmed. He",4_15,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"age this could not be genetically confirmed. He was not reported as hypertensive or having hematuria, proteinuria or kidney failure, or deafness at the time of death, suggesting the <italic toggle=""yes"">COL4A5</italic> deletion in the index patient is likely de novo. Yet, there is also a slight possibility of paternal (or maternal) postzygotic gonadal mosaicism of the <italic toggle=""yes"">COL4A5</italic> deletion. Deletions of <italic toggle=""yes"">COL4A5</italic> extending to <italic",4_16,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"toggle=""yes"">COL4A5</italic> extending to <italic toggle=""yes"">COL4A6</italic> are associated with diffuse leiomyomatosis-AS (DL-AS). The deletion detected in the index case extends beyond exon 4 of <italic toggle=""yes"">COL4A6</italic> and she does not have symptoms of DL-AS. This is in line with previously reported cases showing deletions of exon 1 and 2 of the <italic toggle=""yes"">COL4A6</italic> gene cause DL-AS, while further expanding deletions do not lead to DL-AS. The exact pathogenesis of this",4_17,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"not lead to DL-AS. The exact pathogenesis of this phenomenon is unclear [<xref rid=""B11"" ref-type=""bibr"">11</xref>, <xref rid=""B12"" ref-type=""bibr"">12</xref>]. In our index patient, the kidney function and proteinuria recovered over time and the decline in kidney function has slowed down ever since (now CKD stage G3bA2 at 52 years of age). In our view, this illustrates the contribution of lifestyle factors to CKD. The renal phenotype of AS appears relatively mild. Longer follow-up of this index case is",4_18,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"mild. Longer follow-up of this index case is needed to determine if kidney function will deteriorate to end-stage kidney disease in the future. We can speculate on the possible genotype-phenotype correlation for all three pathogenic variants. Heterogenous phenotype has been described in females with heterozygous <italic toggle=""yes"">COL4A5</italic> variants, heterozygous <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> variants, and in digenic AS. Disease severity spans the",4_19,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"and in digenic AS. Disease severity spans the entire spectrum between normal phenotype and progression to end-stage kidney disease [<xref rid=""B13"" ref-type=""bibr"">13</xref>, <xref rid=""B14"" ref-type=""bibr"">14</xref>]. Asymptomatic cases are reported in 2.5% of females with XLAS [<xref rid=""B13"" ref-type=""bibr"">13</xref>] and 5.2% of individuals with heterozygous <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> variants [<xref rid=""B14"" ref-type=""bibr"">14</xref>]. In the",4_20,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"rid=""B14"" ref-type=""bibr"">14</xref>]. In the population-based Geisinger MyCode/DiscovEHR study the percentage of asymptomatic individuals was even higher; 36% for pathogenic variants in <italic toggle=""yes"">COL4A3</italic> [<xref rid=""B15"" ref-type=""bibr"">15</xref>]. In digenic AS including a <italic toggle=""yes"">COL4A5</italic> variant, although all women had hematuria, proteinuria was absent in 38% of them. Similarly, proteinuria was absent in 34% of cases of digenic AS with <italic",4_21,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"absent in 34% of cases of digenic AS with <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> variants [<xref rid=""B6"" ref-type=""bibr"">6</xref>]. The reported cases of digenic AS indicate that the phenotype is, in general, more severe compared to individuals with a single variant [<xref rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B14"" ref-type=""bibr"">14</xref>]. Thus, we would expect the phenotype in trigenic AS to be even more severe than in digenic AS. However, the phenotype",4_22,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"severe than in digenic AS. However, the phenotype of our case matches the spectrum of phenotypes described for digenic AS (due to variants in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic>), except our case presented with proteinuria at an earlier age than described in the literature for digenic AS due to variants in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> and later than the median age described for digenic AS including a variant in",4_23,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"described for digenic AS including a variant in <italic toggle=""yes"">COL4A5</italic> [<xref rid=""B6"" ref-type=""bibr"">6</xref>]. We suggest several explanations for this mild phenotype. First, we hypothesize that heterozygosity of respective <italic toggle=""yes"">COL4A3, COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> variants explains the relatively mild phenotype [<xref rid=""B6"" ref-type=""bibr"">6</xref>]. Based on the calculated prediction and considering a 50:50 X-inactivation, we would expect",4_24,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"a 50:50 X-inactivation, we would expect 87.5% of triple helix collagen molecules to be defective. However, the contribution of the deletion of <italic toggle=""yes"">COL4A5</italic> may be limited due to possible skewing of X-inactivation [<xref rid=""B16"" ref-type=""bibr"">16</xref>]. The percentage of residual functional triple helix collagen may therefore be >12.5%. The contribution of the <italic toggle=""yes"">COL4A5</italic> variant is also potentially weak for the extrarenal phenotype: hearing loss is also",4_25,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"the extrarenal phenotype: hearing loss is also described in patients with digenic AS (due to variants in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic>) and also, but less frequent, in patients with heterozygous <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> variants [<xref rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B14"" ref-type=""bibr"">14</xref>]. Also, the type of mutations could contribute to a more favorable phenotype. The heterozygous",4_26,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"to a more favorable phenotype. The heterozygous complete deletion of the <italic toggle=""yes"">COL4A5</italic> gene results either in normal expression of the α5(IV) chain or in absent expression in cells. Jais et al. [<xref rid=""B13"" ref-type=""bibr"">13</xref>] described a large group of women with XLAS, including 12 families with large deletions of <italic toggle=""yes"">COL4A5</italic> involving the <italic toggle=""yes"">COL4A6</italic> gene, and 10 patients exhibiting DL-AS. Three of these individuals had",4_27,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"exhibiting DL-AS. Three of these individuals had normal urinalysis. The <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> pathogenic variants in our index patient were both probable protein-truncating variants. In the Geisinger MyCode/DiscovEHR study, only 52% of the patients with a protein-truncating variant in <italic toggle=""yes"">COL4A3</italic> had any phenotypic feature, showing that protein-truncating variants are associated with a milder phenotype compared to glycine",4_28,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"with a milder phenotype compared to glycine substitutions. The absence of disease symptoms in patients with protein-truncating mutations may be explained by production of functional collagen heteromers by the non-truncated allele [<xref rid=""B15"" ref-type=""bibr"">15</xref>]. In the literature, genetic modifiers in AS have been described [<xref rid=""B7"" ref-type=""bibr"">7</xref>]. Our patient also illustrates the role of lifestyle factors since proteinuria was reduced with treatment of blood pressure using",4_29,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"reduced with treatment of blood pressure using ACE inhibitors, and weight reduction after bariatric surgery for obesity. The history of the son illustrates that hypertension and infections could have a modifying effect. This suggests that patients with collagenopathies could have a mild phenotype but show increased vulnerability of the glomerular basement membrane to intercurrent events, dependent on the percentage of residual functional triple helix collagen. Although trigenic pathogenic variants have",4_30,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"Although trigenic pathogenic variants have been described before in a family with hypertrophic cardiomyopathy, we describe the first case of AS in the literature with trigenic pathogenic variants [<xref rid=""B17"" ref-type=""bibr"">17</xref>]. There is an earlier report by Zhang et al. [<xref rid=""B18"" ref-type=""bibr"">18</xref>] describing an individual with three variants. However, the described variant in <italic toggle=""yes"">COL4A3</italic> should be interpreted as a variant of unknown significance based",4_31,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"as a variant of unknown significance based on amino acid conservation between species and paralogous type IV collagen NC1 domains [<xref rid=""B19"" ref-type=""bibr"">19</xref>], allele frequency in the population (dbSNP, gnomAD) and the LOVD, so this case does not meet the criteria for trigenic AS. Our findings are relevant for nephrologists, clinical geneticists, and patients with AS to be aware of the possibility of trigenic variants. It emphasizes the importance of examining all three <italic",4_32,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"the importance of examining all three <italic toggle=""yes"">COL4A</italic> genes in patients with suspected AS, even when a familial pathogenic variant is identified before. It is also important to identify the nature of the variants, e.g., inheritance in <italic toggle=""yes"">cis</italic> or <italic toggle=""yes"">trans</italic>, as this helps determine the risk of inheritance and prognosis for family members [<xref rid=""B5"" ref-type=""bibr"">5</xref>, <xref rid=""B6"" ref-type=""bibr"">6</xref>]. In conclusion,",4_33,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"ref-type=""bibr"">6</xref>]. In conclusion, this case report expands knowledge of the genetic diagnosis of AS, revealing the possibility of trigenic pathogenic variants. It is crucial to examine all three <italic toggle=""yes"">COL4A</italic> genes, even in patients with a relatively mild Alport phenotype, for optimal follow-up of the patient and counseling of family members. In accordance with Dutch law, this Case Report did not require formal approval by the Medical Ethics Committee. This was confirmed by",4_34,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
Medical Ethics Committee. This was confirmed by our hospital’s human research committee. The authors declare that they have obtained written consent from the patients reported in this Case Report. Consent was obtained from the participants for publication of the details of their medical case that appears within this Case Report and associated supplementary material. The authors have no conflicts of interest to declare. This work was supported by the Dutch Kidney Foundation (PhD student Grant 19OP020). Data,4_35,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"Foundation (PhD student Grant 19OP020). Data collection: Dipti Rao, Marlies Cornelissen, and Michel van Geel. Genetic analysis and interpretation: Michel van Geel. Clinical data interpretation: Dipti Rao, Rutger Maas, Marlies Cornelissen, and Jack Wetzels. Drafting the article: Dipti Rao. Review and revisions: Dipti Rao, Rutger Maas, Marlies Cornelissen, Jack Wetzels, and Michel van Geel. Reading and approving the final manuscript: Dipti Rao, Rutger Maas, Marlies Cornelissen, Jack Wetzels, and Michel van",4_36,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"Marlies Cornelissen, Jack Wetzels, and Michel van Geel.",4_37,"Trigenic <italic toggle=""yes"">COL4A3</italic>/<italic toggle=""yes"">COL4A4</italic>/<italic toggle=""yes"">COL4A5</italic> Pathogenic Variants in Alport Syndrome: A Case Report",28 3 2024,,Alport_Syndrome
"Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome Alport syndrome (AS) is a prevalent genetic kidney disease known as hereditary nephritis and oculo-auriculo-renal syndrome. It is caused by mutations in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> genes, which encode the α3, α4, and α5 chains of type IV collagen. X-linked dominant, autosomal recessive, or autosomal dominant inheritance",5_0,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"recessive, or autosomal dominant inheritance are the modes of inheritance of AS, which causes hematuria, proteinuria, sensorineural deafness, ocular abnormalities, and kidney damage that leads to end-stage renal disease (ESRD) (<xref rid=""B3"" ref-type=""bibr"">Daga et al., 2022</xref>). X-linked Alport syndrome (XLAS, OMIM: 301050) is caused by a pathogenic variant in the <italic toggle=""yes"">COL4A5</italic> gene and is the most common mode of inheritance. Men have up to a 100% risk of progression to ESRD,",5_1,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"have up to a 100% risk of progression to ESRD, and the age of progression and extrarenal manifestations correlate with the genotype; women have a 25% risk and an increased risk with age (<xref rid=""B1"" ref-type=""bibr"">Alport Syndrome Collaborative, National Clinical Research Center of Kidney, & Rare Diseases Branch of Beijing Medical, 2023</xref>). A history of childhood hematuria, steadily deteriorating proteinuria, and sensorineural deafness are risk factors for the advancement of this illness (<xref",5_2,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"for the advancement of this illness (<xref rid=""B6"" ref-type=""bibr"">Jais et al., 2003</xref>). Patients with AS can exhibit various clinical symptoms, which may not include the typical signs during the initial stages. Consequently, when AS occurs alongside other kidney diseases, patients may be mistakenly diagnosed with IgA nephropathy, nephrotic syndrome (NS), purpura nephritis, or thin basement membrane nephropathy (<xref rid=""B4"" ref-type=""bibr"">Deng, Zhou and Zhou, 2023</xref>). Cases of AS with NS as",5_3,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"and Zhou, 2023</xref>). Cases of AS with NS as its primary symptom are infrequently documented, leading to the potential oversight of AS and subsequent delays in diagnosis, ultimately culminating in the progression to ESRD. This article presents three pedigrees of XLAS resulting from variations in the <italic toggle=""yes"">COL4A5</italic> gene, with the identification of two novel mutation sites. Unexpectedly, all three probands presented with NS as their primary clinical symptom, with two of them",5_4,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"their primary clinical symptom, with two of them experiencing NS as their initial symptom. We conducted genetic and phenotypic analyses of the three pedigrees, highlighting the crucial nature of renal pathological examination and genetic testing in diagnosing atypical kidney diseases.   As estimated, 1/10,000–1/5,000 people have AS, which accounts for 0.5% of newly diagnosed adult cases of ESRD (<xref rid=""B10"" ref-type=""bibr"">Mallett et al., 2014</xref>). Nonetheless, it was shown that COL4A5 variants",5_5,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"Nonetheless, it was shown that COL4A5 variants with potential for disease were often found in renal failure queues and normal reference data, suggesting that the occurrence rate of XLAS was around 1/5,000 (<xref rid=""B5"" ref-type=""bibr"">Groopman et al., 2019</xref>; <xref rid=""B2"" ref-type=""bibr"">Connaughton and Hildebrandt, 2020</xref>). This supports AS being the second leading cause of hereditary renal failure after autosomal dominant polycystic kidney disease (<xref rid=""B15"" ref-type=""bibr"">Savige et",5_6,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"(<xref rid=""B15"" ref-type=""bibr"">Savige et al., 2021</xref>). Nephrotic syndrome is a rare but dangerous kidney illness that affects people worldwide, including adults and children. Edema, proteinuria, hypoalbuminemia, and hyperlipidemia are common symptoms (C. S. <xref rid=""B17"" ref-type=""bibr"">Wang and Greenbaum, 2019</xref>). Incidence rates are 3 per 100,000 adults and 2–7 per 100,000 children annually. Although it occurs rarely, it is responsible for 20% of pediatric ESRD cases and roughly 12% of all",5_7,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"of pediatric ESRD cases and roughly 12% of all ESRD cases (<xref rid=""B16"" ref-type=""bibr"">Verma and Patil, 2024</xref>). Numerous conditions can lead to NS, including primary glomerulonephritis, infections, tumors, and drug-induced illnesses. In our pedigree study, all three probands met the diagnostic criteria for the nephrotic syndrome: albumin levels less than 30 g/L, 24-h urine protein levels more than 3.5 g/L, edema, and/or high lipid levels (<xref rid=""B9"" ref-type=""bibr"">Kodner, 2016</xref>). We",5_8,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"rid=""B9"" ref-type=""bibr"">Kodner, 2016</xref>). We did not delay performing renal puncture for the two patients with AS whose first manifestation was nephrotic syndrome; however, proband C was not diagnosed with AS in a timely manner, probably because of limited medical technology or a lack of awareness of AS at that time. He was also not found to carry the <italic toggle=""yes"">COL4A5</italic> mutant until he progressed to ESRD by genetic testing. Nephrotic syndrome primarily arises from the impairment or",5_9,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"syndrome primarily arises from the impairment or malfunction of glomerular components, such as the glomerular basement membrane, endothelial surface, or epithelial cells (podocytes) (<xref rid=""B12"" ref-type=""bibr"">Politano, Colbert, and Hamiduzzaman, 2020</xref>). This results in the excretion of protein in the urine and encompasses three primary types of pathology: microscopic lesion disease, FSGS, and idiopathic membranous nephropathy. Among these, FSGS is the primary cause of ESRD in nephrotic syndrome",5_10,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"the primary cause of ESRD in nephrotic syndrome (<xref rid=""B11"" ref-type=""bibr"">Ozeki et al., 2021</xref>). Furthermore, AS leads to the development of either segmental or widespread mesangial cell hyperplasia, accompanied by an increase in mesangial stroma as the disease advances, and some cases may present glomerulopathy with FSGS (<xref rid=""B1"" ref-type=""bibr"">Alport Syndrome Collaborative et al., 2023</xref>). Proband C’s second renal pathology was diagnosed as mesangial proliferative",5_11,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"was diagnosed as mesangial proliferative glomerulonephritis with FSGS, which aligns with AS-related renal pathology. The patient experienced prolonged hematuria starting at the age of 3, which is more likely to be attributed to an inherited nephrotic disease-related nephrotic syndrome in a pediatric patient with a family history of the disease. In the remaining two probands, electron microscopy revealed tearing and layering alterations in the basement membrane of the kidneys. Additionally,",5_12,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"basement membrane of the kidneys. Additionally, immunofluorescence analysis showed a lack of α3 and α5 collagen staining, which aligns with the characteristic renal damage observed in individuals with AS. Therefore, both patients can be classified as having AS-related nephrotic syndrome. What sets these previous patients apart is that they not only exhibit the classic symptoms of nephrotic syndrome, but they also have hematuria. Hematuria can be a significant clinical sign of nephrotic syndrome when",5_13,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"clinical sign of nephrotic syndrome when combined with AS. A case report from China details the presentation of an 11-month-old infant with AS who primarily exhibited nephrotic syndrome (D. <xref rid=""B18"" ref-type=""bibr"">Wang et al., 2021</xref>). Additionally, the child experienced extensive hematuria, but her renal function remained unaffected. Another Chinese child diagnosed with AS exhibited nephrotic syndrome as the major symptom, along with the presence of microscopic hematuria (<xref rid=""B4""",5_14,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"presence of microscopic hematuria (<xref rid=""B4"" ref-type=""bibr"">Deng et al., 2023</xref>). Therefore, we should not assume that hematuria is solely caused by nephrotic syndrome since it may serve as a crucial indicator in our investigation of the underlying cause of nephrotic syndrome. Undoubtedly, type IV collagen α-chain component anomalies in probands A and B necessitate genetic testing. Furthermore, patients should have undergone <italic toggle=""yes"">COL4A5</italic> genetic testing if they have",5_15,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"genetic testing if they have persistently abnormal hematuria for more than 6 months or persistent proteinuria greater than 0.5 g per day in addition to renal biopsy confirmation of FSGS (<xref rid=""B14"" ref-type=""bibr"">Savige et al., 2022</xref>), so proband C should have undergone genetic testing much earlier. Through genetic testing, it was determined that all three probands were XLAS patients. Among male XLAS patients, there was a significant correlation between their genetic makeup and the severity of",5_16,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"between their genetic makeup and the severity of their kidney symptoms. Patients with truncating variants, such as nonsense variants or small insertions/deletions that cause premature termination of codons, exhibited more severe symptoms compared to patients with missense variants or small in-frame variants (<xref rid=""B19"" ref-type=""bibr"">Yamamura et al., 2020</xref>). As of the current date (2024-03-14), the ClinVar (<ext-link http://www.w3.org/1999/xlink href=""https://www.ncbi.nlm.nih.gov/clinvar""",5_17,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"href=""https://www.ncbi.nlm.nih.gov/clinvar"" ext-link-type=""uri"">https://www.ncbi.nlm.nih.gov/clinvar</ext-link>) database includes 192 frameshift mutations and 113 nonsense mutations, all of which are classified as pathogenic or likely pathogenic. Out of the three mutations we found, mutation c.5020C>T is harmful and associated with bilateral symmetrical sensorineural deafness (<xref rid=""B20"" ref-type=""bibr"">Zhang et al., 2018</xref>). Coincidentally, both proband A and his mother, who also has the",5_18,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"both proband A and his mother, who also has the mutation c.5020C>T, have a simultaneous combination of hearing impairment. Patients with missense mutations have a 60% risk of hearing loss by the age of 30, while patients with other types of mutations have a 90% risk (<xref rid=""B7"" ref-type=""bibr"">Jais et al., 2000</xref>). Most patients with hearing loss experience mild to moderate hearing loss, which worsens over time. The other two families, although currently unaffected, will need ongoing hearing",5_19,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"currently unaffected, will need ongoing hearing tests. The mutation sites c.4435_4445del and c.1584_1587+6del have not been previously documented. The ACMG recommendations classify c.4435_4445del as pathogenic and c.1584_1587+6del as probabilistically pathogenic. We conducted a three-dimensional protein structure analysis and discovered that both mutations result in the production of shortened proteins. The region that is absent encompasses not just the specific mutation site c.5020C>T but also extends",5_20,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"specific mutation site c.5020C>T but also extends beyond it. Therefore, we hypothesize that both mutations may have an impact on the protein’s function and are likely to be pathogenic. Currently, there is no definitive remedy for AS. The treatment primarily aims to decrease proteinuria and slow down the advancement of kidney disease. Although treatment can postpone the start of renal impairment, most AS patients will eventually require dialysis or renal transplantation. For men diagnosed with XLAS, it is",5_21,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"For men diagnosed with XLAS, it is advisable to start renin–angiotensin–aldosterone system (RAAS) blocker medication (<xref rid=""B8"" ref-type=""bibr"">Kashtan and Gross, 2021</xref>). Probands A and B were instructed to take oral valsartan and dapagliflozin to decrease the excretion of protein in the kidneys. Furthermore, both patients had the additional condition of nephrotic syndrome. After taking glucocorticoids, there was a considerable improvement in edema for both patients, and adjuvant medications",5_22,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"edema for both patients, and adjuvant medications such as compound α-ketoacid, calcium, gastric preservation medication, and atorvastatin were utilized. Moreover, the two probands’ continued to experience hematuria while showing improvement in proteinuria during the follow-up. The fact that glucocorticoid therapy usually has no effect on nephrotic syndrome associated with Alport syndrome (D. <xref rid=""B18"" ref-type=""bibr"">Wang et al., 2021</xref>) leads us to consider that the two patients may have",5_23,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"us to consider that the two patients may have combined minimal change nephrotic syndrome. Proband C and the mother of both probands had reached ESRD and needed renal replacement treatment. New mutations c.4435_4445del and c.1584_1587+6del enriched the <italic toggle=""yes"">COL4A5</italic> gene mutation spectrum, and carriers of these two mutation sites and c.5020C>T may present nephrotic syndrome as the predominant clinical symptom. Renal pathological examination and genetic testing are crucial to",5_24,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"examination and genetic testing are crucial to diagnosing AS when NS is the major indication. This is because the standard renal signs are lost, making it easy to detect or misdiagnose.",5_25,Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome,09 8 2024,,Alport_Syndrome
"Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children Alport syndrome (AS) is a hereditary glomerulopathy due to pathogenic variants in <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5.</italic> Treatment with Renin–Angiotensin–Aldosterone System (RAAS) inhibitors can delay progression to end stage renal disease (ESRD). From 2018 until today, we performed Whole Exome Sequencing (WES) in 19 patients with AS phenotype with or",6_0,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"(WES) in 19 patients with AS phenotype with or without positive family history. Fourteen of these patients were children. Genetic testing was extended to family members at risk. All patients received a genetic diagnosis of AS: five X-linked AS (XLAS) males, five X-linked AS (XLAS) females, six autosomal dominant AS (ADAS), and one autosomal recessive AS (ARAS). After cascade screening four XLAS males and eight XLAS females, six ADAS and three ARAS heterozygotes were added to our initial results. Fifteen",6_1,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"were added to our initial results. Fifteen patients were eligible to start treatment with RAAS inhibitors after their diagnosis. All XLAS female patients, ARAS heterozygotes, and ADAS have been advised to be followed up, so that therapeutic intervention can begin in the presence of microalbuminuria. Genetic diagnosis of AS ensures early therapeutic intervention and appropriate follow up to delay progression to chronic kidney disease, especially in thet pediatric population. Alport syndrome (AS) is a",6_2,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"pediatric population. Alport syndrome (AS) is a hereditary progressive glomerulopathy that often results in end-stage renal disease (ESRD) [<xref rid=""B1-genes-15-01016"" ref-type=""bibr"">1</xref>]. Apart from the renal manifestations, the patient might suffer from sensorineural hearing loss and ocular abnormalities (i.e., anterior lenticonus, posterior subcapsular cataract, posterior polymorphous dystrophy, and retinal flecks) [<xref rid=""B2-genes-15-01016"" ref-type=""bibr"">2</xref>]. The incidence varies",6_3,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"ref-type=""bibr"">2</xref>]. The incidence varies from 1 in 5000 to 53,000 and is mainly due to differences in the populations studied [<xref rid=""B3-genes-15-01016"" ref-type=""bibr"">3</xref>]. AS occurs in 0.5% of newly developed ESRD in adults and 12.9% in children [<xref rid=""B4-genes-15-01016"" ref-type=""bibr"">4</xref>]. There are three types of Alport syndrome according to the mode of inheritance [<xref rid=""B4-genes-15-01016"" ref-type=""bibr"">4</xref>] (<xref rid=""genes-15-01016-t001""",6_4,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"(<xref rid=""genes-15-01016-t001"" ref-type=""table"">Table 1</xref>):<list list-type=""simple""><list-item><label>-</label><p>Alport Syndrome 1: X-linked AS (XLAS), with pathogenic genetic variants in <italic toggle=""yes"">COL4A5.</italic></p></list-item><list-item><label>-</label><p>Alport Syndrome 2: Autosomal recessive AS (ARAS), with pathogenic variants in <italic toggle=""yes"">COL4A4.</italic></p></list-item><list-item><label>-</label><p>Alport Syndrome 3a: Autosomal dominant AS (ADAS), with pathogenic",6_5,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"3a: Autosomal dominant AS (ADAS), with pathogenic variants in <italic toggle=""yes"">COL4A3.</italic></p></list-item><list-item><label>-</label><p>Alport Syndrome 3b: Autosomal recessive AS (previously known as Thin Basement Membrane disease), with pathogenic variants in <italic toggle=""yes"">COL4A3.</italic></p></list-item></list> Alport 1 occurs in 80% of all cases while Alport 2 and 3 share the remaining 20% [<xref rid=""B4-genes-15-01016"" ref-type=""bibr"">4</xref>]. Pathogenic genetic variants in genes",6_6,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"Pathogenic genetic variants in genes <italic toggle=""yes"">COL4A3–5</italic> cause a defective synthesis of the a3, a4, and a5 chains of collagen type IV. These three a- chains are found in the Glomerular Basement Membrane (GBM), in the Cochlear Basement Membrane, and the base of the ocular lens [<xref rid=""B5-genes-15-01016"" ref-type=""bibr"">5</xref>]. This results in the heterogenicity of renal and extrarenal manifestations. In terms of renal disease, these pathogenic genetic variants produce a number of",6_7,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"pathogenic genetic variants produce a number of phenotypes varying from microscopic hematuria, proteinuria, to chronic kidney disease (CKD) [<xref rid=""B6-genes-15-01016"" ref-type=""bibr"">6</xref>]. Children often present as asymptomatic with the phenotype of early-stage AS, therefore the initiation of diagnostic investigation is triggered after an abnormal urine analysis during a routine check- up. The most common findings are isolated persistent microscopic hematuria and/or proteinuria with a mean age of",6_8,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"hematuria and/or proteinuria with a mean age of presentation of 5 years. In retrospect, a positive family history (FH) will arouse suspicion of AS [<xref rid=""B7-genes-15-01016"" ref-type=""bibr"">7</xref>]. Clinical presentation may vary according to the type of AS (<xref rid=""genes-15-01016-t001"" ref-type=""table"">Table 1</xref>) [<xref rid=""B4-genes-15-01016"" ref-type=""bibr"">4</xref>,<xref rid=""B8-genes-15-01016"" ref-type=""bibr"">8</xref>,<xref rid=""B9-genes-15-01016"" ref-type=""bibr"">9</xref>,<xref",6_9,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"ref-type=""bibr"">9</xref>,<xref rid=""B10-genes-15-01016"" ref-type=""bibr"">10</xref>]. Before the establishment of genetic testing, pathology findings on renal biopsy samples were essential for the diagnosis. However, this method has serious limitations, especially in children. Such limitations include the non-typical findings in GBM in the early stages of AS, the need for electron microscopy (which is not always available), and the risks that accompany the performance of an invasive procedure in children.",6_10,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"performance of an invasive procedure in children. Essentially, the non-specific findings of Light Microscopy, such as mesangial proliferation, Focal Segmental Glomerulosclerosis (FSGS), renal tubular atrophy foam cell formation, and interstitial fibrosis, are not definitely diagnostic for AS at an early stage. Electron microscopy (EM) that can reveal abnormalities of the GBM and lamination and splitting in lamina densa defines the diagnosis of AS. However, in the early stages of the disease, the only",6_11,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"in the early stages of the disease, the only apparent finding might be the thinning of the GBM, especially in female XLAS and ADAS. Thus, it is becoming more imperative to consider genetic testing as a first-line diagnosis for AS [<xref rid=""B11-genes-15-01016"" ref-type=""bibr"">11</xref>]. Although there is no radical treatment for AS in children, (RAAS) inhibitors have been used efficiently for significantly delaying the progression to ESRD. The mechanism of how these medications act has been described as",6_12,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"how these medications act has been described as reducing proteinuria by decreasing filtration pressure [<xref rid=""B12-genes-15-01016"" ref-type=""bibr"">12</xref>]. This treatment has been proven to alter the natural course of the disease [<xref rid=""B13-genes-15-01016"" ref-type=""bibr"">13</xref>]. The “Updated Clinical practice recommendations for the diagnosis and management of Alport Syndrome in children and young adults 2020” established the onset of treatment at the time of diagnosis for male XLAS and",6_13,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"at the time of diagnosis for male XLAS and ARAS patients and when microalbuminuria is present for female XLAS and ADAS patients with microalbuminuria [<xref rid=""B14-genes-15-01016"" ref-type=""bibr"">14</xref>]. This has contributed to highlighting the significance of early genetic diagnosis. From 2018 until today, we have clinically and genetically diagnosed 52 cases for AS at the Laboratory of Medical Genetics, National and Kapodistrian University of Athens, Greece. The children with clinical findings",6_14,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"Greece. The children with clinical findings suggestive of AS were referred mainly by the Pediatric Nephrology Unit of the First Department of Pediatrics, “Agia Sofia” Children’s Hospital, Athens, Greece. Three cases were referred by the Pediatric Nephrology Department of “P. and A. Kyriakou” Children’s Hospital. The main reasons for referral were macroscopic hematuria, isolated microscopic hematuria or proteinuria, and a combination of microscopic hematuria and proteinuria. Some patients exhibited a",6_15,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"and proteinuria. Some patients exhibited a combination of the above and/or extrarenal manifestations. In most cases (11/19), there was a positive family history (FH) of similar findings in urine analysis, extrarenal manifestations, end-stage renal disease, and a combination of the above. We have also included one case in which a pathogenic genetic variant in <italic toggle=""yes"">COL4A3</italic> was detected as an incidental finding. It is noted that none of our patients had received a definite diagnosis",6_16,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"of our patients had received a definite diagnosis for their condition and many of them were not under any treatment. Medical and family histories were taken, followed by clinical examination and a review of medical notes and laboratory investigations. Inclusion criteria were renal and extrarenal manifestations of AS combined with positive FH. When strong clinical suspicion was present, patients were included in the study regardless of their FH. The method used was Whole Exome Sequencing (WES) because this",6_17,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"was Whole Exome Sequencing (WES) because this secured a possible diagnosis even in cases where the clinical findings would resemble AS but the genetic variant could include pathogenic variants in genes other than <italic toggle=""yes"">COL4A3–5</italic>, such as <italic toggle=""yes"">MYH9</italic>, <italic toggle=""yes"">LMX1B</italic>, <italic toggle=""yes"">LAMB2</italic>, and <italic toggle=""yes"">PAX2</italic> [<xref rid=""B15-genes-15-01016"" ref-type=""bibr"">15</xref>]. Patients and families were investigated",6_18,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
Patients and families were investigated with WES after obtaining informed written consent and a blood sample. WES was performed using genomic DNA extracted from whole blood. Library preparation was implemented using the Human Core Exome kit by Twist Bioscience or the Exome Solution kit by Sophia Genetics SA or IDT xGen Exome Research v2 by Integrated DNA Technologies following the manufacturer’s recommendations. The resulting libraries were subjected to paired-end sequencing on an Illumina NextSeq 500,6_19,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"paired-end sequencing on an Illumina NextSeq 500 platform. Variant annotation, filtration, and interpretation processes were performed using VarAFT v2.17 (<uri http://www.w3.org/1999/xlink href=""http://varaft.eu"">http://varaft.eu</uri>, accessed on 2 July 2018) [<xref rid=""B16-genes-15-01016"" ref-type=""bibr"">16</xref>], Franklin (<uri http://www.w3.org/1999/xlink href=""https://franklin.genoox.com/clinical-db/home"">https://franklin.genoox.com/clinical-db/home</uri>, accessed on 1 June 2019), and Varsome",6_20,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"accessed on 1 June 2019), and Varsome Clinical platforms (<uri http://www.w3.org/1999/xlink href=""https://varsome.com/"">https://varsome.com/</uri>, accessed on 1 June 2019) [<xref rid=""B17-genes-15-01016"" ref-type=""bibr"">17</xref>]. Variant filtration and classification were based on the phenotype-driven strategy [<xref rid=""B15-genes-15-01016"" ref-type=""bibr"">15</xref>] and according to the American College of Medical Genetics and Genomics (ACMG) guidelines [<xref rid=""B18-genes-15-01016""",6_21,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"(ACMG) guidelines [<xref rid=""B18-genes-15-01016"" ref-type=""bibr"">18</xref>]. A genetic WES report was communicated to the referring physician. Three possible outcomes emerged following data analysis of the results: (a) A pathogenic variant was detected in <italic toggle=""yes"">COL4A3–5</italic>, that could fully explain the clinical phenotype. In such cases, the families were advised to receive appropriate follow up and treatment in accordance with clinical guidelines by the nephrology department. Cascade",6_22,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"guidelines by the nephrology department. Cascade screening was offered and performed in other family members especially where renal and extrarenal manifestations of AS were present. (b) Variants of unknown significance (VUSs) were detected in <italic toggle=""yes"">COL4A3–5.</italic> In these cases, parents were tested by Sanger Sequencing and the results were interpreted according to the presence and severity of their symptoms. (c) No pathogenic variant was detected. These cases are not included in the",6_23,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"was detected. These cases are not included in the study. The patients that did not receive a conclusive diagnosis are being followed up by the Laboratory of Medical Genetics on a yearly basis and re-analysis of their WES genetic data is performed where and when appropriate. From 2018, we have collected 52 patients (n = 52), 32 adults and 20 children, most of which had a clinical phenotype of AS and were found to carry a genetic variant in one of the genes <italic toggle=""yes"">COL4A3</italic>, <italic",6_24,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"<italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5.</italic> These patients were members of 19 families (<xref rid=""genes-15-01016-t002"" ref-type=""table"">Table 2</xref>). The patients were referred from their treating physicians for genetic testing mainly because of AS renal manifestations (hematuria, proteinuria, and chronic renal disease) with or without positive family history. In cases where no other family members seemed to have symptoms of",6_25,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"other family members seemed to have symptoms of renal disease, we still chose to proceed with genetic testing. More specifically, eight cases had strong clinical suspicion for AS and WES was performed, although family history was negative. Amongst these were five cases of persistent hematuria over many years, one case where a genetic variant in <italic toggle=""yes"">COL4A3</italic> was an incidental finding, and two cases with significant proteinuria and a renal biopsy was performed indicating Thin Basement",6_26,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"biopsy was performed indicating Thin Basement Membrane disease and Focal Segmental Glomerulosclerosis, respectively. The same was applied for the extrarenal manifestations of AS, such as neurosensory hearing loss and refractory anomalies of the eye. <xref rid=""genes-15-01016-t003"" ref-type=""table"">Table 3</xref> includes the results of positive genetic variants in <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4,</italic> and <italic toggle=""yes"">COL4A5</italic> in our probands. Out of 19",6_27,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"in our probands. Out of 19 patients (11 females and 8 males) that were investigated, 14 were children (probands 1, 3, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 19) aged 0.5–16 years (mean age 7 years). In two cases, although the proband was a child, we initially performed WES in the affected parental sample with a definite clinical phenotype (probands 11 and 17). The main reason for referral was microscopic hematuria (6/19 patients), followed by hematuria and proteinuria combined (10/19 patients).",6_28,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"and proteinuria combined (10/19 patients). Isolated proteinuria was seen in only 2/19 patients (probands 18 and 19)—one of those was of nephrotic range. All patients had hematuria and/or proteinuria with the exception of only one case (proband 13) that was investigated for dysplastic kidneys and chronic kidney disease, where a variant in <italic toggle=""yes"">COL4A3</italic> was an incidental finding. In the majority of patients where hematuria was present, urinalysis was positive for Red Blood Cells (RBCs)",6_29,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"was positive for Red Blood Cells (RBCs) from a very young age (mean age of 5 years), with the younger patient testing positive for RBCs at the age of 5 months who shortly after developed microalbuminuria (proband 1). Positive FH was present in 11/19 cases, chronic kidney disease in 4/19 cases, and extrarenal manifestations in 5/19 cases. More specifically, the extrarenal manifestations were retinal dystrophy (proband 12), significant myopia (−8.5) (proband 17), moderate myopia (−3.5/−3.25) and astigmatism",6_30,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"17), moderate myopia (−3.5/−3.25) and astigmatism (proband 10), difficulty in swallowing (proband 16), and neurosensory hearing loss (proband 11) (<xref rid=""genes-15-01016-t002"" ref-type=""table"">Table 2</xref>). Genetic variants in the three genes that are closely related to Alport were found in all 19 patients. Eleven patients carried a pathogenic variant in <italic toggle=""yes"">COL4A5</italic>, three in <italic toggle=""yes"">COL4A4,</italic> and five in <italic toggle=""yes"">COL4A3</italic> (<xref",6_31,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"in <italic toggle=""yes"">COL4A3</italic> (<xref rid=""genes-15-01016-t003"" ref-type=""table"">Table 3</xref>). After the initial genetic testing, there were five new diagnoses of XLAS males (probands 1, 2, 5, 15, and 16), six XLAS females (probands 4, 6, 8, 12, 17, and 18), seven ADAS (probands 3, 9, 10, 11, 13, 14, and 19), and one ARAS (proband 7). Following parental cascade testing, probands 18 and 19 proved to carry likely pathogenic (LP) variants, probably with reduced penetrance (or hypomorphic allele)",6_32,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"with reduced penetrance (or hypomorphic allele) as their parent carriers of the same variants were completely asymptomatic [<xref rid=""B19-genes-15-01016"" ref-type=""bibr"">19</xref>]. Cascade screening was conducted in nine families, and 28 individuals at risk were tested (<xref rid=""genes-15-01016-t004"" ref-type=""table"">Table 4</xref>). The outcome was positive for 19 of them. The remaining nine did not carry a pathogenic genetic variant of <italic toggle=""yes"">COL4A3–5</italic>, although among these there",6_33,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"although among these there was one case with intermittent microscopic hematuria. With cascade screening, we were able to identify an additional eight XLAS females, four XLAS males, three ARAS heterozygotes, and four ADAS (<xref rid=""genes-15-01016-t004"" ref-type=""table"">Table 4</xref>). Genetic testing is beneficial for providing definitive diagnosis, while contributing to proper usage of useful health resources [<xref rid=""B20-genes-15-01016"" ref-type=""bibr"">20</xref>]. In the case of AS, prompt diagnosis",6_34,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"In the case of AS, prompt diagnosis offers an additional benefit because of available treatment that is not curative but can alter prognosis as it dramatically delays the progression to ESRD, especially if initiated at an early stage, before there is any reduction in the Glomerular Filtration Rate (GFR) [<xref rid=""B11-genes-15-01016"" ref-type=""bibr"">11</xref>,<xref rid=""B21-genes-15-01016"" ref-type=""bibr"">21</xref>]. Children are an ideal target group for early diagnosis of AS with genetic testing, as",6_35,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"early diagnosis of AS with genetic testing, as they often are asymptomatic and the decline in GFR has not yet occurred in most cases. Thus, they benefit the most from prompt initiation of medication. This study had dual goals, firstly in identifying new patients with AS with WES, as well as applying cascade screening to members of their family. WES can help identify possible genetic variants in <italic toggle=""yes"">MYH9</italic>, <italic toggle=""yes"">LMX1B</italic>, <italic toggle=""yes"">LAMB2</italic>, and",6_36,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"<italic toggle=""yes"">LAMB2</italic>, and <italic toggle=""yes"">PAX2</italic> where there is a similar clinical phenotype (proteinuria is the most profound clinical finding) and pathological findings (lamellation of the GBM) [<xref rid=""B4-genes-15-01016"" ref-type=""bibr"">4</xref>]. In all cases, with the exception of three (probands 7, 13, and 19), the phenotype was clearly indicative of AS. Before the establishment of genetic testing, it was thought that screening relatives at risk with urine analysis, when",6_37,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"relatives at risk with urine analysis, when AS was suspected in the family, would be sufficient for early detection of the disease [<xref rid=""B11-genes-15-01016"" ref-type=""bibr"">11</xref>]. However, in XLAS female patients, hematuria might be intermittent [<xref rid=""B11-genes-15-01016"" ref-type=""bibr"">11</xref>,<xref rid=""B22-genes-15-01016"" ref-type=""bibr"">22</xref>]. The same applies for patients with heterozygous variants in <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic>",6_38,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"or <italic toggle=""yes"">COL4A4</italic> [<xref rid=""B11-genes-15-01016"" ref-type=""bibr"">11</xref>,<xref rid=""B23-genes-15-01016"" ref-type=""bibr"">23</xref>,<xref rid=""B24-genes-15-01016"" ref-type=""bibr"">24</xref>]. Family member cascade screening is essential because it can reveal family members at risk. In terms of therapeutic intervention, we managed to identify several cases, amongst which were a few children that were eligible to instantly start treatment or be closely monitored for the presence of",6_39,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"or be closely monitored for the presence of microalbuminuria [<xref rid=""B14-genes-15-01016"" ref-type=""bibr"">14</xref>]. Amongst our cohort, we identified an additional six patients that were eligible to immediately start treatment with RAAS inhibitors. From this group of 10 patients (9 XLAS males and 1 ARAS), only half were already on this treatment. Three female XLAS and two ADAS with microalbuminuria were also strongly advised to receive treatment. So far, all our pediatric patients have normal renal",6_40,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"far, all our pediatric patients have normal renal function with serum creatinine and eGFR within a normal range. Those that already had microalbuminuria have responded well to RAAS inhibitors with the exception of proband 7 that receives both an ACE inhibitor and Angiotensin II AT 1 receptor antagonist and still has proteinuria of 1 gr/24 h. Studies from previous years show that XLAS female patients [<xref rid=""B25-genes-15-01016"" ref-type=""bibr"">25</xref>] and ARAS heterozygotes [<xref",6_41,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"and ARAS heterozygotes [<xref rid=""B26-genes-15-01016"" ref-type=""bibr"">26</xref>] were thought to be only carriers of the disease and quite often were discharged from follow up. What we now know is that they can also advance to ESRD [<xref rid=""B19-genes-15-01016"" ref-type=""bibr"">19</xref>,<xref rid=""B27-genes-15-01016"" ref-type=""bibr"">27</xref>]. Proband 17 is such an example and was diagnosed with AS after WES testing. We note that she presented to our clinic with her 13-year-old son that was monitored",6_42,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"with her 13-year-old son that was monitored for intermittent microscopic hematuria. When taking FH, proband 17 proved to have hematuria, proteinuria, chronic renal disease, and high myopia. Genetic testing was performed on her, because of AS phenotype suspicion, and the genetic variant c.1871G>A, p.(Gly624Asp) in <italic toggle=""yes"">COL4A5</italic> was identified. Up to that point, she was treated as a chronic kidney disease patient of unidentified cause, and she had also undergone a renal biopsy with",6_43,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"and she had also undergone a renal biopsy with pathological findings of interstitial nephritis and Thin Basal Membrane disease. Her son carried the same variant and was advised to begin treatment with RAAS inhibitors at the time of genetic diagnosis. This example illustrates the significance of cascade screening and how inheritance pattern (in this case XLAS) can guide follow up and management when appropriate. In our cohort, we identified 14 XLAS female patients that now receive proper treatment and",6_44,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"patients that now receive proper treatment and follow up. This indicates that the most significant achievement of this study was the identification of the cases that would not have received treatment promptly had it not been for genetic diagnosis. Moreover, some of the XLAS male patients presented only with microscopic hematuria and had no clinical indication for treatment. This was only started after AS diagnosis and is bound to alter the natural course of the disease and offer them better prognosis,",6_45,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"of the disease and offer them better prognosis, which is even more important in the cases of probands diagnosed at a younger age and having normal GFR. Another example is proband 3 (ADAS) who presented with microscopic hematuria. This patient’s mother was found to have the same genetic variant, suffer from ESRD, and is on dialysis. The maternal grandmother who also has raised creatinine, hematuria, and proteinuria was also tested and has the same variant. After these results, our patient (proband 3) was",6_46,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"After these results, our patient (proband 3) was advised to be monitored very closely and start treatment as soon as she develops microalbuminuria. Also, ARAS heterozygotes that would until recently not have a diagnosis of renal disease are currently under follow up and will be given RAAS inhibitors in the event of microalbuminuria. An ARAS carrier of c.1598G>A, p.(Gly533Asp) in <italic toggle=""yes"">COL4A4</italic>, had been initially diagnosed with IgA nephropathy due to non-specific pathological findings",6_47,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"due to non-specific pathological findings in a renal biopsy performed due to hematuria and proteinuria [<xref rid=""B28-genes-15-01016"" ref-type=""bibr"">28</xref>]. Cascade screening was not difficult to implement because in most cases, relatives were willing to be tested, especially when they experienced symptoms themselves and were hoping for a diagnosis/treatment, or when they were at reproductive age and planning to start or expand their family. We did, however, encounter logistical difficulties such as",6_48,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"encounter logistical difficulties such as the cost of the test since it is not covered by state insurance and family relations. Ten patients with positive genetic testing had undergone renal biopsy a few years earlier. Six of these consisted in our main probands that were initially tested with WES (probands 2, 11, 16, 17, 18, and 19) and the remaining four were part of cascade screening. Renal biopsy results in the first group were as follows: Secondary Focal Segmental Glomerulosclerosis (FSGS), and Thin",6_49,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"Segmental Glomerulosclerosis (FSGS), and Thin Basal Membrane disease (six cases). In the second group, pathological reports were as follows: AS, Thin Basal Membrane disease, and non-specific findings of Mesangial Proliferative Glomerulonephritis (four cases). However, in most cases, the renal tissue had not been examined by electron microscopy (EM), mainly because this was not available at the time. Renal biopsy is a highly invasive procedure that is often followed by complications and requires a hospital",6_50,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"followed by complications and requires a hospital stay. We therefore remain reluctant in applying it as a diagnostic tool especially in children. Adding the non- specific diagnosis that we often obtain in AS, it is becoming increasingly clear that genetic testing is the method of choice for AS [<xref rid=""B28-genes-15-01016"" ref-type=""bibr"">28</xref>]. Our patients received the genetic diagnosis of AS that hopefully will lead to more targeted treatment avoiding unnecessary immunosuppressant medications",6_51,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"unnecessary immunosuppressant medications that are often given in this group of patients. Cyclosporin has proven to be non-beneficial in AS with the phenotype of FSGS [<xref rid=""B29-genes-15-01016"" ref-type=""bibr"">29</xref>]. In the case of proband 12 with c.1871G>A, p. (Gly624Asp), there was the extrarenal manifestation of retinal dystrophy which, interestingly enough, was due to an additional genetic variant in <italic toggle=""yes"">TGFBI</italic> (c. 370C>T, p.(Arg124Cys)). This case underlines that WES",6_52,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"p.(Arg124Cys)). This case underlines that WES is the method of choice to diagnose AS, as GenePanel testing has the risk of missing additional variants responsible for complex phenotypes, as was the case for the specific proband whose retinal dystrophy might have been attributed to AS and therefore would receive the wrong follow up, treatment, prognosis, and genetic counseling. Even though we only had 19 probands, we nonetheless found some common genetic variants: c.1871G>A, p.(Gly624Asp) in four cases;",6_53,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"variants: c.1871G>A, p.(Gly624Asp) in four cases; c.1006G>T, p. (Gly336Cys) in two cases; and c.1321_1369+3del in another two cases. Last, in the individuals with no genetic findings, it was felt that there was a clinical benefit as the result altered their follow up by reducing unnecessary laboratory testing (i.e., urinalysis) and, in the case of one individual with persistent microscopic hematuria, to guide follow-up and investigation towards non-genetic diagnoses [<xref rid=""B27-genes-15-01016""",6_54,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"diagnoses [<xref rid=""B27-genes-15-01016"" ref-type=""bibr"">27</xref>]. Moreover, promising new therapeutic agents that have evolved from current clinical trials include Endothelin Type A Receptor (ETAR) and Angiotensin II Type 1 Receptor (AT1R) inhibitors, lipid-modifying drugs, Discoidin Domain Receptor 1 (DRR1) inhibitors, Osteopontin Blocking Agents, and genome editing therapies, and they remain to be assessed further for their safety and efficacy in the child population [<xref rid=""B30-genes-15-01016""",6_55,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"child population [<xref rid=""B30-genes-15-01016"" ref-type=""bibr"">30</xref>]. Thus, genetic testing in children will eventually, if it has not already, become the gold standard for the diagnostic approach of AS. This study underlines the importance of using WES as a first line of genetic testing in patients with the spectrum of phenotypes compatible with Alport syndrome because an accurate diagnosis is very important for the appropriate follow up, treatment, and genetic counseling, especially in children.",6_56,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"and genetic counseling, especially in children. Moreover, early genetic diagnosis improves quality of life for the patients and their families, mainly by removing uncertainty. As there are limited data from long-term treatment with RAAS inhibitors for AS in children, more multicenter perspective studies should be performed. We aim to continue the follow-up of our patient cohort, anticipating more positive outcomes, by identifying new cases and by expanding cascade screening to all family members at risk.",6_57,Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children,02 8 2024,,Alport_Syndrome
"Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome Alport syndrome (AS) is an inherited disease characterized by progressive renal failure, hearing loss, and ocular abnormalities. This disease is caused by mutations in the collagen IV genes COL4A3, COL4A4, and COL4A5, which lead to deficiency of the type IV α3α4α5 collagen network in the basement membrane.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref><sup>–</sup><xref rid=""bib3""",7_0,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> The common ocular features of AS include corneal clouding, anterior lenticonus, fleck retinopathy, and temporal retinal thinning.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref><sup>,</sup><xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> In recent years, ocular manifestations of AS have been increasingly reported.<xref rid=""bib6"" ref-type=""bibr""><sup>6</sup></xref><sup>–</sup><xref",7_1,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref> However, it is difficult to obtain ocular tissue from patients, especially retina and cornea samples; thus, associated research on AS tissue is limited. Studies on ocular changes in patients with AS have focused mainly on clinical manifestations, and few of them have used histologic or molecular research. An animal model with phenotypic recapitulation of AS-associated ocular features is useful to study pathogenesis of this disease. Col4a3<sup>−/−</sup> mice is",7_2,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"of this disease. Col4a3<sup>−/−</sup> mice is widely used as a murine model for autosomal AS. The Col4a3<sup>−/−</sup> mouse model develops progressive glomerulonephritis with microhematuria and proteinuria, recapitulating the main features of human AS.<xref rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref><sup>,</sup><xref rid=""bib10"" ref-type=""bibr""><sup>10</sup></xref> No previous reports have described the ocular characteristics of Col4a3<sup>−/−</sup> mice, and the effects of Col4a3 gene knockout on the",7_3,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
and the effects of Col4a3 gene knockout on the eyes have not been characterized. Whether this model is suitable for investigating ocular abnormalities in patients with AS is unknown. We performed this study to characterize the effects of the Col4a3 knockout mutation on the visual system. The goal of the analyses was to determine whether Col4a3<sup>−/−</sup> mice are a suitable model for assessing ocular abnormalities in patients with AS and to explore the potential pathogenesis of these changes.  In this,7_4,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"potential pathogenesis of these changes.  In this study, we examined the Col4a3 mRNA expression and confirmed the Col4a3 was knocked out in corneas, lenses, and retinas of Col4a3<sup>−/−</sup> mice (<xref rid=""tvst-13-7-16_s001"" ref-type=""supplementary-material"">Supplementary Fig. S1</xref>). We examined abnormal corneal, lens and retinal structures in Col4a3<sup>−/−</sup> mice by hematoxylin and eosin (H&E) staining, thickness measurements, immunohistochemistry, and TEM to explore the mechanisms involved",7_5,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"and TEM to explore the mechanisms involved in AS ocular manifestations. Alport syndrome (AS) is characterized by basement membrane abnormalities, and ocular lesions are important changes in AS. Approximately 20% to 90% of patients with AS have ocular abnormalities.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> Some characteristic ocular manifestations, such as anterior lenticonus<xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref> and temporal retinal thinning,<xref rid=""bib18""",7_6,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"and temporal retinal thinning,<xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref> have great value for assisting in the diagnosis of AS. Nevertheless, studies on AS-related ocular diseases are still insufficient. Research on the mechanism of AS ocular disease has been impeded by the lack of an animal model. Although Col4a3<sup>−/−</sup> mice are widely used to study renal dysfunction induced by AS,<xref rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref><sup>,</sup><xref rid=""bib10""",7_7,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"rid=""bib10"" ref-type=""bibr""><sup>10</sup></xref> whether this knockout mouse can serve as a model for AS-associated ocular diseases remains to be explored. With the goal of identifying an animal model to study ocular changes in AS, we characterized the ocular features of Col4a3<sup>−/−</sup> mice. Corneal pathological changes in AS, including recurrent corneal epithelial erosion (RCE)<xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref><sup>,</sup><xref rid=""bib20"" ref-type=""bibr""><sup>20</sup></xref> and",7_8,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"ref-type=""bibr""><sup>20</sup></xref> and posterior corneal pleomorphic atrophy,<xref rid=""bib21"" ref-type=""bibr""><sup>21</sup></xref><sup>,</sup><xref rid=""bib22"" ref-type=""bibr""><sup>22</sup></xref> result from abnormalities in the structure of the corneal epithelial basement membrane and Descemet's membrane in the sub-endothelium.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> A lack of the collagen IV a3a4a5 network in the corneal epithelial basement membrane was found in patients with recurrent",7_9,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"membrane was found in patients with recurrent corneal epithelial erosion.<xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref> The research of Hsu et al.<xref rid=""bib23"" ref-type=""bibr""><sup>23</sup></xref> showed that abnormalities in collagen IV in the corneal epithelial basement membrane leading to poor adhesion and erosion. Abnormal structure and distribution of the hemidesmosomes of the corneal epithelium are related to reduced epithelial adhesion<xref rid=""bib12""",7_10,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"to reduced epithelial adhesion<xref rid=""bib12"" ref-type=""bibr""><sup>12</sup></xref><sup>,</sup><xref rid=""bib13"" ref-type=""bibr""><sup>13</sup></xref> and delayed corneal epithelial wound closure.<xref rid=""bib24"" ref-type=""bibr""><sup>24</sup></xref> We found that the expression of collagen IV in the corneal epithelial basement membrane was reduced in Col4a3<sup>−/−</sup> mice. The ultrastructure of the corneal epithelial basement membrane revealed that the hemidesmosome structure was abnormal in the",7_11,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"the hemidesmosome structure was abnormal in the Col4a3<sup>−/−</sup> mice. Therefore, we hypothesized that recurrent corneal epithelial erosion in some patients with AS may be due to abnormal hemidesmosomes. A few reports mentioned posterior corneal pleomorphic atrophy in patients with AS, found vesicular lesions<xref rid=""bib21"" ref-type=""bibr""><sup>21</sup></xref> and a network of irregularly arranged hyper-reflective fibrillar structures<xref rid=""bib22"" ref-type=""bibr""><sup>22</sup></xref> at the level",7_12,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"ref-type=""bibr""><sup>22</sup></xref> at the level of Descemet's membrane, but no information was provided on collagen IV changes in Descemet's membrane in patients with AS. In our study, we did not observe differences in collagen IV expression between WT and knockout mice. This indicates that posterior corneal pleomorphic atrophy in patients with AS may not directly result from collagen IV abnormalities. Lenticonus is a common ocular anomaly of AS that clinically manifests as progressive and aggravated",7_13,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"manifests as progressive and aggravated myopia and astigmatism due to abnormal lens shape, mostly involving both eyes. The incidence of lenticonus in patients with AS was reported to be approximately 24% to 37%.<xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref> Type IV collagen is the most important component of the normal anterior lens capsule,<xref rid=""bib26"" ref-type=""bibr""><sup>26</sup></xref> and other components of the lens capsule include type I collagen, type Ⅲ collagen, laminin, and",7_14,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"type I collagen, type Ⅲ collagen, laminin, and fibronectin.<xref rid=""bib27"" ref-type=""bibr""><sup>27</sup></xref> By electron microscopy, several researchers have found that the anterior lens capsule of patients with AS was thinner than that of healthy people and that there were dehiscences perpendicular to the surface of the capsule located in the inner two-thirds of the anterior lens capsule.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref><sup>,</sup><xref rid=""bib17""",7_15,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref><sup>,</sup><xref rid=""bib28"" ref-type=""bibr""><sup>28</sup></xref> We observed that the anterior lens capsule in Col4a3<sup>−/−</sup> mice was thinner than that in WT mice in age of the 12-week and the 21-week groups, which was in accordance with previous reports.<xref rid=""bib28"" ref-type=""bibr""><sup>28</sup></xref> We noticed abnormally shaped lenses in two 21-week-old Col4a3<sup>−/−</sup> mice, which resembled the lenticonus observed in patients with AS.",7_16,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"the lenticonus observed in patients with AS. Although the shape of the lenticonus in mice is different from that in humans,<xref rid=""bib29"" ref-type=""bibr""><sup>29</sup></xref> we presumed that the central protrusion of the lens in Col4a3<sup>−/−</sup> mice was a result of lens capsule thinning. However, we did not observe splits in the anterior lens capsule of Col4a3<sup>−/−</sup> mice through TEM analysis, and further investigation is needed to confirm this speculation. The expression of collagen IV in",7_17,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"speculation. The expression of collagen IV in anterior lens capsule did not differ between WT and Col4a3<sup>−/−</sup> mice because the lens capsule is mainly composed of type IV collagen α1 and α2 chains.<xref rid=""bib14"" ref-type=""bibr""><sup>14</sup></xref> Although there was some incongruity in the lens features between knockout mice and patients with AS, which may be due to differences in the composition and structure of collagen IV in the lens capsule between mice and humans, the thinner capsule and",7_18,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"between mice and humans, the thinner capsule and abnormal lens shape still make Col4a3<sup>−/−</sup> mice a potential model for studying the lens abnormities in AS. Retinopathy in patients with AS mainly manifests as parafoveal fleck retinopathy and temporal retinal thinning. The incidence of fleck retinopathy in patients with AS is about 50% to 70%,<xref rid=""bib30"" ref-type=""bibr""><sup>30</sup></xref> whereas the incidence of temporal retinal thinning may be as high as 90% in patients with AS.<xref",7_19,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"may be as high as 90% in patients with AS.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref> Because mice lack a retinal macular area, we did not study fleck retinopathy in Col4a3<sup>−/−</sup> mice. Cho et al.<xref rid=""bib31"" ref-type=""bibr""><sup>31</sup></xref> examined the retina of patients with AS by stratified Enface optical coherence tomography (OCT) scanning and found retinal flecks in the ILM and RPE basement membrane by",7_20,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"flecks in the ILM and RPE basement membrane by horizontal scanning. Savige et al.<xref rid=""bib32"" ref-type=""bibr""><sup>32</sup></xref> found that the α3, α4, and α5 chains of type IV collagen were the main components of the ILM and RPE basement membrane. In our study, the expression of collagen IV in the ILM was reduced in Col4a3<sup>−/−</sup> mice, and the ultrastructure of the ILM was incomplete in Col4a3<sup>−/−</sup> mice. The ultrastructural changes in the RPE of Col4a3<sup>−/−</sup> mice revealed",7_21,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"in the RPE of Col4a3<sup>−/−</sup> mice revealed that the basal folds of the RPE basement membrane were thicker, shorter, and even absent in certain regions. These findings suggested abnormalities in the ILM and RPE in knockout mice, which could be helpful for elucidating the pathogenesis of retinal flecks. Temporal retinal thinning is a prominent sign associated with AS. Ahmed et al.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref> reported that in patients with X-linked Alport syndrome (XLAS), 70% had",7_22,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"with X-linked Alport syndrome (XLAS), 70% had severe thinning and 11% had moderate thinning. Our previous study revealed that 76.74% of patients with XLAS exhibited temporal retinal thinning.<xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref> Chen et al.<xref rid=""bib33"" ref-type=""bibr""><sup>33</sup></xref> reported that 89% of male patients with XLAS, 75% of female patients with XLAS, and 100% of patients with autosomal recessive AS experienced temporal retinal thinning. Researchers have noted that the",7_23,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"retinal thinning. Researchers have noted that the temporal thinning index (TTI) calculated with retinal thickness is of great value in the diagnosis of AS.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib33"" ref-type=""bibr""><sup>33</sup></xref> The pathological basis for temporal retinal thinning has not been elucidated in previous reports. Therefore, an animal model for studying retinal changes will be helpful for exploring the underlying mechanisms involved. We measured the",7_24,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"underlying mechanisms involved. We measured the retinal thickness of Col4a3<sup>−/−</sup> mice, and our results confirmed retinal thinning in knockout mice in all age groups. We previously found that the retinal inner layers were thinning in patients with XLAS, including GCL, IPL, and INL.<xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref> Furthermore, Savige et al.<xref rid=""bib32"" ref-type=""bibr""><sup>32</sup></xref> compared retinal thickness in each quadrant of the macular area in patients with AS",7_25,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"quadrant of the macular area in patients with AS and found that the decrease in retinal thickness was due to thinning of the inner layers, including ILM/nerve fiber layer (NFL) and INL. In this study, we found that retinal thinning in Col4a3<sup>−/−</sup> mice due to the thinning of the IPL, which is in accordance with the results reported in patients. There was no significant difference of ONL thickness between the two groups. ONL is composed of the nuclei of photoreceptors, and it may undergo thinning in",7_26,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"of photoreceptors, and it may undergo thinning in cases of vision impairment.<xref rid=""bib11"" ref-type=""bibr""><sup>11</sup></xref><sup>,</sup><xref rid=""bib34"" ref-type=""bibr""><sup>34</sup></xref><sup>,</sup><xref rid=""bib35"" ref-type=""bibr""><sup>35</sup></xref> The stable thickness of the ONL may provide an explanation for the preservation of normal vision in the majority of individuals with AS retinal abnormalities.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> Savige et al.<xref rid=""bib32""",7_27,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"Savige et al.<xref rid=""bib32"" ref-type=""bibr""><sup>32</sup></xref> reported that retinopathy of AS may originate in Müller cells. Ahmed et al.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref> speculated that temporal thinning may be related to aberrant Müller cell adhesion. We found that glial cells in knockout mouse retinas were markedly activated, thus further suggesting that Müller cells are involved in retinopathy of AS. The ILM is thinner and more susceptible to tractional forces from the",7_28,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"more susceptible to tractional forces from the vitreous, which can interfere with nutrient transport and waste clearance in Col4a3<sup>−/−</sup> mice.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib32"" ref-type=""bibr""><sup>32</sup></xref> We also observed an abnormal ILM structure in Col4a3<sup>−/−</sup> mice. Therefore, we speculate that damage to the ILM caused by abnormal collagen chains leads to an aberrant retinal microenvironment and triggers Müller cell activation. In",7_29,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"and triggers Müller cell activation. In addition, damaged RPE<xref rid=""bib31"" ref-type=""bibr""><sup>31</sup></xref><sup>,</sup><xref rid=""bib32"" ref-type=""bibr""><sup>32</sup></xref><sup>,</sup><xref rid=""bib36"" ref-type=""bibr""><sup>36</sup></xref> and drusen<xref rid=""bib32"" ref-type=""bibr""><sup>32</sup></xref><sup>,</sup><xref rid=""bib37"" ref-type=""bibr""><sup>37</sup></xref> detected in patients with AS may result in overlying photoreceptor degeneration and Müller glial cell activation.<xref rid=""bib38""",7_30,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"Müller glial cell activation.<xref rid=""bib38"" ref-type=""bibr""><sup>38</sup></xref><sup>,</sup><xref rid=""bib39"" ref-type=""bibr""><sup>39</sup></xref> Additionally, we observed abnormalities in the RPE basement membrane under electron microscopy. Consequently, we believe that the upregulation of GFAP in Col4a3<sup>−/−</sup> mice may be a secondary phenotypic outcome that warrants further investigation. One of the limitations of our study was that we did not test visual function changes in the knockout mice.",7_31,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"visual function changes in the knockout mice. Although studies on visual function changes in patients with AS have shown no definite decline in visual sensitivity related to retinal thinning,<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref><sup>,</sup><xref rid=""bib40"" ref-type=""bibr""><sup>40</sup></xref> further research on visual function in an AS model is needed. In addition, because of the small number of mice subjected to TEM analysis, more detailed ultrastructural characteristics awaited further",7_32,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"ultrastructural characteristics awaited further investigation. On the other hand, sex differences in the cardiorespiratory phenotype but not in the renal phenotype of C57BL/6 Col4a3<sup>−/−</sup> mice have been previously reported.<xref rid=""bib41"" ref-type=""bibr""><sup>41</sup></xref> Interestingly, there was no sex difference in the ocular phenotype of C57BL/6 Col4a3<sup>−/−</sup> mice in our study. However, additional studies with larger sample sizes are needed. The impact of sex on different organs of",7_33,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"needed. The impact of sex on different organs of C57BL/6 Col4a3<sup>−/−</sup> mice might vary greatly. Although previous studies did not document any pathological changes in heterozygous Col4a3<sup>+/−</sup> mice,<xref rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref><sup>,</sup><xref rid=""bib42"" ref-type=""bibr""><sup>42</sup></xref> a 3-year-long study revealed that heterozygous Col4a3<sup>+/−</sup> mice exhibited renal phenotypes of thin basement membrane nephropathy.<xref rid=""bib43""",7_34,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"basement membrane nephropathy.<xref rid=""bib43"" ref-type=""bibr""><sup>43</sup></xref> This discrepancy may be due to differences in the ages of the Col4a3<sup>+/−</sup> mice in these investigations. We speculate that heterozygous Col4a3<sup>+/−</sup> mice might also exhibit ocular manifestations of AS after developing a thin glomerular basement membrane at 30 weeks of age.<xref rid=""bib43"" ref-type=""bibr""><sup>43</sup></xref> In this study, we used homozygous Col4a3<sup>−/−</sup> mice instead of",7_35,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"homozygous Col4a3<sup>−/−</sup> mice instead of heterozygous mice. However, further investigations are needed to explore the ocular phenotype of Col4a3<sup>+/−</sup> mice. In conclusion, for the first time, we described the ocular features of an AS mouse model. Our results provided evidence that Col4a3<sup>−/−</sup> mice manifested corneal, anterior lens capsule, and retinal anomalies that were consistent with the changes in patients with AS. Col4a3<sup>−/−</sup> mice could be used as a valuable animal",7_36,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"mice could be used as a valuable animal model to study ocular lesions in AS and other ocular diseases related to the basement membrane, such as RCE, lens capsule anomalies, and ILM disorders. Further explorations are expected to examine the in-depth pathogenesis of the disease.",7_37,Characterization of Ocular Morphology in Col4a3<sup>−/−</sup> Mice as a Murine Model for Alport Syndrome,23 7 2024,,Alport_Syndrome
"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome Alport syndrome (AS), a hereditary kidney disease with a high risk for renal failure, is attributed to pathogenic variants in genes <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> that encode type IV collagen. Next-generation sequencing (NGS) is increasingly applied to the",8_0,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"sequencing (NGS) is increasingly applied to the diagnosis of AS, but complex genotype–phenotype correlation, that is, identifying the significance of variants, is still a huge clinical challenge. In this study, we reported the case of a 27-year-old Chinese woman with a family history of hematuria and proteinuria. Notably, the proband is the only one in her family with renal insufficiency. NGS was performed in this family, and it was revealed that the proband was a compound heterozygote for two variants in",8_1,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"was a compound heterozygote for two variants in the <italic toggle=""yes"">COL4A3</italic> gene: c.2990G>A inherited from her father and c.4981C>T inherited from her mother. We modeled the spatial structure of the corresponding protein and assumed that structural abnormalities led to the breakdown of type IV collagen networks, a major component of the glomerular basement membrane. Thus, the proband was diagnosed with autosomal recessive AS, characterized by severe defects of the glomerular basement membrane.",8_2,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"defects of the glomerular basement membrane. Hence, the proband showed a loss of renal function. This case presentation emphasizes the importance of NGS for AS diagnosis and introduces a novel genotype of AS. Alport syndrome (AS) is a rare genetic disorder but is also the most common hereditary kidney disease. It is characterized by hematuria, proteinuria, and progressive renal insufficiency, usually accompanied by sensorineural hearing loss and ocular abnormalities (<xref rid=""B14"" ref-type=""bibr"">Savige",8_3,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"(<xref rid=""B14"" ref-type=""bibr"">Savige et al., 2022</xref>). These symptoms are attributed to pathogenic variants in genes <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> that encode type IV collagen α3-, α4-, and α5-chains, the principal components of basement membranes in the glomerulus, cochlea, and lens (<xref rid=""B14"" ref-type=""bibr"">Savige et al., 2022</xref>). According to the modes of inheritance, AS is classified into four",8_4,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"modes of inheritance, AS is classified into four types: X-linked AS caused by pathogenic variants in the <italic toggle=""yes"">COL4A5</italic> gene; autosomal recessive AS (ARAS) caused by homozygous or compound heterozygous variants in the <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> gene; autosomal dominant AS (ADAS) caused by heterozygous variants in the <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> gene; and digenic AS caused by coexisting",8_5,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"gene; and digenic AS caused by coexisting variants in two of the genes <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> (<xref rid=""B6"" ref-type=""bibr"">Kashtan, 2021</xref>). Next-generation sequencing (NGS), which can detect variants, is an efficient tool for the diagnosis of AS (<xref rid=""B10"" ref-type=""bibr"">Moriniere et al., 2014</xref>). However, with the detection of an increasing number of novel variants, the identification of",8_6,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"number of novel variants, the identification of pathogenic genotypes has become another major clinical challenge (<xref rid=""B6"" ref-type=""bibr"">Kashtan, 2021</xref>). In this study, we reported the case of a young female patient with a family history of hematuria and proteinuria. Unfortunately and confusingly, this patient is the only one with renal insufficiency, which eventually progressed into end-stage renal disease (ESRD) in her family. This patient was ultimately diagnosed with ARAS by NGS, and a",8_7,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"was ultimately diagnosed with ARAS by NGS, and a novel severe genotype, compound heterozygote for <italic toggle=""yes"">COL4A3</italic> c.2990G>A and <italic toggle=""yes"">COL4A3</italic> c.4981C>T, was identified.  The proband presented with hematuria, proteinuria, and renal dysfunction. Glomerulonephritis was initially considered, but she failed to respond to immunosuppressive therapy and presented with a rapid progression of nephropathy. Unfortunately, she was unable to undergo a renal biopsy after",8_8,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"she was unable to undergo a renal biopsy after admission due to renal atrophy, which increased the difficulty of the diagnosis. Due to her particular family history, NGS was conducted, which showed the presence of two variants. The c.2990G>A (p.Gly997Glu) variant of the <italic toggle=""yes"">COL4A3</italic> gene, one of the proband’s variants, was inherited from her father. All patrilineal relatives of the proband with hematuria and proteinuria, regardless of age or sex, had normal renal function. Although",8_9,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"age or sex, had normal renal function. Although not all affected individuals underwent renal biopsy and genetic tests, the available results of the examinations indicated uniform thinning of the GBM and the heterozygous variant of c.2990G>A in the <italic toggle=""yes"">COL4A3</italic> gene. The uniformly thin GBM induced by defective synthesis of type IV collagen, previously referred to as “thin glomerular basement membrane nephropathy,” is caused by heterozygous variants in the <italic",8_10,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"is caused by heterozygous variants in the <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> genes and is usually associated with a better prognosis (<xref rid=""B5"" ref-type=""bibr"">Hirabayashi et al., 2022</xref>). In recent years, considering that the thin basement membrane may be an early pathological manifestation of ADAS, the term “thin glomerular basement membrane nephropathy” has been gradually replaced by “type IV collagen-related disease” (<xref rid=""B3""",8_11,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"IV collagen-related disease” (<xref rid=""B3"" ref-type=""bibr"">Comic et al., 2022</xref>) or “<italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> heterozygotes” (<xref rid=""B14"" ref-type=""bibr"">Savige et al., 2022</xref>). Three individuals with a heterozygous variant of <italic toggle=""yes"">COL4A3</italic> c.2990G>A in one family were detected in a previous study (<xref rid=""B7"" ref-type=""bibr"">Lin et al., 2014</xref>). Of these, two individuals had clinical manifestations similar",8_12,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"individuals had clinical manifestations similar to those of the affected members in the proband’s family, but the third member presented with progressive renal impairment and developed ESRD at age 55 (<xref rid=""B7"" ref-type=""bibr"">Lin et al., 2014</xref>). The dramatic phenotypic differences may be related to the presence of coexisting diseases (e.g., diabetes and hypertension), lifestyle, and so on. However, the pathogenicity of this variant, <italic toggle=""yes"">COL4A3</italic> c.2990G>A, in type IV",8_13,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"c.2990G>A, in type IV collagen-related diseases is clear. Unlike the <italic toggle=""yes"">COL4A3</italic> c.2990G>A variant, the proband’s other variant the, <italic toggle=""yes"">COL4A3</italic> c.4981C>T (p.Arg1661Cys), did not cause any symptoms of kidney disease in her mother, which is consistent with the studies conducted by <xref rid=""B15"" ref-type=""bibr"">Sienes et al. (2021</xref>) and <xref rid=""B2"" ref-type=""bibr"">Braunisch et al. (2018</xref>). Two cases, a 38-year-old male patient and a",8_14,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"Two cases, a 38-year-old male patient and a 34-year-old female patient, diagnosed with ARAS caused by compound heterozygous variants in the <italic toggle=""yes"">COL4A3</italic> gene, were reported by Sienes et al. and Braunisch et al., respectively. Both patients inherited the same variant, <italic toggle=""yes"">COL4A3</italic> c.4981C>T (p.Arg1661Cys), from their mothers, and both mothers were asymptomatic. In addition, their fathers showed normal kidney function. However, unlike our proband, these two",8_15,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"function. However, unlike our proband, these two patients had hearing impairment, which may be related to the difference in another gene variant. To some extent, these studies revealed the pathogenicity of the <italic toggle=""yes"">COL4A3</italic> c.4981C>T variant in ARAS. Although given that all patients’ mothers did not have hematuria, there is another possibility that this variant only plays a modifying role and the other variant is responsible for the clinical presentation of AS, but the phenotypic",8_16,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"clinical presentation of AS, but the phenotypic differences between patients and their fathers and even other family members further support the important role of the <italic toggle=""yes"">COL4A3</italic> c.4981C>T variant in the genetic diagnosis of ARAS. However, this still requires more clinical data or animal studies to provide sufficient evidence. The genetic variants alter the normal structure of type IV collagen and, in turn, that of the GBM, which is the main pathogenesis of AS. Each α-chain in type",8_17,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"the main pathogenesis of AS. Each α-chain in type IV collagen molecules consists of three domains: the N-terminal 7S domain, the collagenous domain, and the C-terminal NC1 domain (<xref rid=""F2"" ref-type=""fig"">Figure 2A</xref>) (<xref rid=""B17"" ref-type=""bibr"">Suh and Miner, 2013</xref>). The collagenous domain is characterized by a triple helix that comprises many Gly-X-Y repeat sequences (<xref rid=""B9"" ref-type=""bibr"">Miner, 1999</xref>). Glycine with only one hydrogen residue is smaller than the other",8_18,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"one hydrogen residue is smaller than the other amino acids and reduces steric hindrance to fit into the center of the triple-helical structure. The c.2990G>A variant in our proband induces a glycine substitution and disrupts the stability of the triple helix (<xref rid=""F2"" ref-type=""fig"">Figures 2B, C</xref>). Another variant, c.4981C>T (Arg1661Cys), is located in the NC1 domain (<xref rid=""F2"" ref-type=""fig"">Figure 2B</xref>) and is responsible for the connection between type IV collagen molecules (<xref",8_19,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"between type IV collagen molecules (<xref rid=""F2"" ref-type=""fig"">Figure 2D</xref>). The substitution of uncharged cysteine for positively charged arginine results in changes in hydrogen bonds, hydrophobic forces, and electrostatic interactions on the one hand and the possible formation of new disulfide bonds on the other hand (<xref rid=""F2"" ref-type=""fig"">Figure 2E</xref>). Consequently, the normal architecture of the NC1 domain is disrupted. All of these changes lead to defects in the type IV collagen",8_20,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"changes lead to defects in the type IV collagen network. Corresponding to one copy of the <italic toggle=""yes"">COL4A3</italic> gene with the variant, the proband’s parents have another normal copy to compensate. In the proband, however, both copies are affected. The absence of a normal α3-chain and the increased proportion of abnormal collagens are the reasons why the phenotype of the proband is more severe than that of her parents. Although there were no proven mutational “hotspots” in the <italic",8_21,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"no proven mutational “hotspots” in the <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> genes, the coexisting variant of a glycine deletion in the collagenous domain and a cysteine substitution in the NC1 domain has been increasingly observed in patients with ARAS (<xref rid=""B16"" ref-type=""bibr"">Storey et al., 2013</xref>). Considering clinical manifestations, laboratory findings, and especially genetic testing results, the proband was diagnosed with ARAS. Her poor prognosis is",8_22,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"was diagnosed with ARAS. Her poor prognosis is consistent with the observations in previous studies. The phenotypes and outcomes are largely dependent on the genotypes of AS patients. It was reported that the median age of progression to ESRD in ARAS patients was 21 years (<xref rid=""B12"" ref-type=""bibr"">Oka et al., 2014</xref>), but that of renal insufficiency in ADAS patients was 70 years (<xref rid=""B11"" ref-type=""bibr"">Nozu et al., 2019</xref>). Although there is currently no effective cure for AS,",8_23,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"there is currently no effective cure for AS, many previous studies have verified that the timely initiation of angiotensin-converting enzyme inhibitor medication confers a significant benefit in delaying progression to ESRD (<xref rid=""B18"" ref-type=""bibr"">Zhang et al., 2016</xref>; <xref rid=""B6"" ref-type=""bibr"">Kashtan, 2021</xref>; <xref rid=""B8"" ref-type=""bibr"">Mastrangelo et al., 2021</xref>; <xref rid=""B1"" ref-type=""bibr"">Boeckhaus et al., 2022</xref>; <xref rid=""B4"" ref-type=""bibr"">Gregorio et al.,",8_24,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"<xref rid=""B4"" ref-type=""bibr"">Gregorio et al., 2023</xref>), especially before impairment of renal function (<xref rid=""B13"" ref-type=""bibr"">Rheault, 2020</xref>; <xref rid=""B6"" ref-type=""bibr"">Kashtan, 2021</xref>). Unfortunately, the proband had already missed the opportunity to take angiotensin-converting enzyme inhibitor medication and progressed to ESRD at the age of only 27 years. Thus, early diagnosis and prompt treatment of AS are crucial. Recently, NGS has been increasingly used in diagnosing AS",8_25,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"NGS has been increasingly used in diagnosing AS due to its sensitivity and non-invasiveness. However, the high cost and indefinite significance of variants prevent the widespread use of NGS. The identification of the compound heterozygous variants of <italic toggle=""yes"">COL4A3</italic> c.2990G>A and <italic toggle=""yes"">COL4A3</italic> c.4981C>T in this case report expands the genotypic spectrum of ARAS. In addition, this case report reveals the need for NGS testing in individuals from families with",8_26,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"for NGS testing in individuals from families with hereditary kidney disease. It not only facilitates the early detection of AS and pathogenetic variants but also contributes to eugenics, that is, avoiding the birth of neonates with a high risk of AS. However, this study has some limitations. First, there was only one case in this study, resulting in a lack of information regarding genotype–phenotype correlations. Second, further <italic toggle=""yes"">in vitro</italic> and <italic toggle=""yes"">in",8_27,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"vitro</italic> and <italic toggle=""yes"">in vivo</italic> studies are needed to confirm the pathogenicity of the variants and their underlying mechanisms. In conclusion, the presented case report emphasizes the importance of genetic testing in individuals with a suspicion of AS. It not only assists in the diagnosis but also reveals the location and type of variant, helping to choose the appropriate treatment and predict the prognosis. More importantly, a novel combination of pathogenic variants in ARAS, the",8_28,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"combination of pathogenic variants in ARAS, the compound heterozygous variants of <italic toggle=""yes"">COL4A3</italic> c.2990G>A and <italic toggle=""yes"">COL4A3</italic> c.4981C>T, was identified in this case. This helps understand the genotype–phenotype correlation and thereby benefits the genetic diagnosis and counseling of AS.",8_29,"Case report: A novel compound heterozygous variant in the <italic toggle=""yes"">COL4A3</italic> gene was identified in a patient with autosomal recessive Alport syndrome",12 7 2024,,Alport_Syndrome
"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome Alport syndrome (AS) is the first inherited kidney disease for which the genetic basis has been established [<xref ref-type=""bibr"" rid=""CR1"">1</xref>], The clinical features of AS are eye, ear and kidney damage, which are caused by mutations in the type IV collagen genes [<xref ref-type=""bibr"" rid=""CR2"">2</xref>].",9_0,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"genes [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Pathogenic variants in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes result in defects in the synthesis of the α3, α4 and α5 chains of type IV collagen. This prevents the correct assembly of the glomerular basement membrane (GBM) collagen network and leads to AS [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. The modes of inheritance of AS are X-linked AS (XLAS), autosomal recessive",9_1,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"of AS are X-linked AS (XLAS), autosomal recessive AS (ARAS) and autosomal dominant AS (ADAS) [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. The XLAS version is caused by variants in the <italic toggle=""yes"">COL4A5</italic> gene and accounts for approximately 85% of cases. The ARAS and ADAS versions are caused by variants in the <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> genes and account for approximately 15% of cases [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. Electron",9_2,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"ref-type=""bibr"" rid=""CR5"">5</xref>]. Electron microscopy (EM) of renal biopsies from AS patients show characteristic abnormalities in the GBM. These manifest as irregular thinning and varying degrees of GBM thickening, were the dense layer splits and fragments into several strands, to form a 'basket weave' pattern [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. Classic AS is characterized by hematuria with progressive proteinuric nephropathy, GBM abnormalities, hearing loss and ocular abnormalities [<xref",9_3,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"hearing loss and ocular abnormalities [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. It accounts for at least 1–2% of all patients who receive kidney replacement therapy (KRT) [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. The clinical course in female carriers is variable and is usually milder than in males, due to inactivation of the X chromosome [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Women with XLAS can develop proteinuria but only 30% of female patients will develop end-stage renal disease by the age of",9_4,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"develop end-stage renal disease by the age of 60 [<xref ref-type=""bibr"" rid=""CR10"">10</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. In contrast, the disease is characterized by end-stage renal failure in 95% of male patients. It has also been reported that the renal phenotype in males with ADAS is significantly less severe than in males with ARAS or XLAS [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Although we have some understanding of the mechanisms and clinical phenotypes of AS, it is difficult",9_5,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"and clinical phenotypes of AS, it is difficult to distinguish thin basement membrane nephropathy (TBMN) from the initial stages of AS, particularly when persistent hematuria and thin GBM lesions are the only manifestations. However, molecular analysis of the type IV collagen genes can provide information for diagnosis, prenatal diagnosis and genetic counseling [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. In this study, four novel pathogenic variants in the <italic toggle=""yes"">COL4A3</italic>, <italic",9_6,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes were identified in 24 patients from 10 families with AS, using whole exome sequencing (WES), histological testing and bioinformatics prediction. The missense mutation in <italic toggle=""yes"">COL4A5</italic> (p.G869R, p.G787R) was validated by in vitro functional analysis.   In this study, clinical, pathological and genetic information was provided for 24 patients from 10 families.",9_7,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"was provided for 24 patients from 10 families. Ten pathogenic variants were identified in type IV collagen genes (<italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic>). Four of the mutations were novel, including a novel <italic toggle=""yes"">COL4A3</italic> missense mutation c.3509G > C (p.Gly1170Ala), two novel <italic toggle=""yes"">COL4A4</italic> missense mutation c.668G > T(p.Gly223Val), c.826G > A(p.Gly276Arg) and a novel <italic",9_8,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"c.826G > A(p.Gly276Arg) and a novel <italic toggle=""yes"">COL4A5</italic> missense mutation c.2605G > A(p.Gly869Arg). A novel <italic toggle=""yes"">UMOD</italic> missense mutation c.686 T > A (p.Met229Lys) was also identified. Type IV collagen alpha chains form a network of α1α1α2, α3α4α5 and α5α5α6 helical heterotrimers that form the mature GBM. Abnormalities in α3α4α5 alters the expression of the other two chains, which affects trimer formation in the GBM [<xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref",9_9,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR18"">18</xref>]. The molecular conformation of the collagen triple helix imposes stringent amino acid sequence constraints and requires a (GLY-X–Y) (n) repeat pattern and a high content of sub amino acids. The most common pathogenic variant is a single base substitution that leads to a glycine residue substitution, which breaks the GLY-X–Y repeat pattern. The single glycine substitution destabilizes the triple helix through a local break in",9_10,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"the triple helix through a local break in the hydrogen bond and creates a discontinuity in the alignment of the helix [<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. In this study, nine of the 11 pathogenic variants occurred in the GLY-X–Y repeat sequence. The <italic toggle=""yes"">COL4A3</italic> missense mutation (p.G1170A), the <italic toggle=""yes"">COL4A4</italic> missense mutations (p.G223V, p.G466R) and the <italic toggle=""yes"">COL4A5</italic> missense mutations (p.G869R, p.G787R) are all glycine",9_11,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"mutations (p.G869R, p.G787R) are all glycine substitutions in the GLY-X–Y repeat sequence. The <italic toggle=""yes"">COL4A3</italic> nonsense mutation in Family 7 (E405*) occurs at the second position of the GLY-X–Y repeat and the <italic toggle=""yes"">COL4A4</italic> frameshift mutation in Family 8 (p.P502Lfs*151) occurs at the third position of the repeat. The <italic toggle=""yes"">COL4A4</italic> nonsense mutation in Family 7 (p.R1377*) causes a truncation that is not within the repeat. However, a large",9_12,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"that is not within the repeat. However, a large number of repetitive sequences are present downstream of this truncation. Overall, with the exception of the <italic toggle=""yes"">COL4A4</italic> missense mutation in Family 8 (p.R1682W), all the pathogenic variants were associated with GLY-X–Y repeat sequences, which would cause a change in protein conformation, as verified by our 3D structure predictions. With the development of genetic technology, more digenic mutations in the <italic",9_13,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"technology, more digenic mutations in the <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> genes have been identified and reported [<xref ref-type=""bibr"" rid=""CR20"">20</xref>, <xref ref-type=""bibr"" rid=""CR21"">21</xref>]. Given the frequency of autosomal dominant Alport syndrome, X-linked form is no longer though to account for 85% of cases of AS. In this study, there were two families carried mutations in two genes. Family 2 had two monogenic missense mutations in the <italic",9_14,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"two monogenic missense mutations in the <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">UMOD</italic> genes, whilst Family 3 had a <italic toggle=""yes"">COL4A3</italic> missense mutation and a heterozygous <italic toggle=""yes"">COL4A4</italic> frameshift mutation. Digenic mutations are often considered to cause more severe phenotypes than single gene mutations. This phenomenon was also found in the two digenic mutant families in this study. Family 2, II3 has decreased eGFR but with no hematuria",9_15,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"2, II3 has decreased eGFR but with no hematuria or proteinuria, which was consistent with the clinical presentation of UMOD mutation-induced, autosomal dominant tubulointerstitial kidney disease (ADTKD) [<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. Serum uric acid and renal tissue uric acid also supported UMOD-induced ADTKD. In family 2, patient I-2 and II-2 carrying “only” the UMOD variant both died of uremia. II-3 has decreased eGFR but with no hematuria or proteinuria. The proband III-1 has a higher",9_16,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"or proteinuria. The proband III-1 has a higher blood uric acid level, sometimes her blood uric acid level is greater than 600umol/l, and she usually takes oral medication to lower uric acid, such as febuxostat, and can maintain normal levels of uric acid. The deposition of crystalline substances in renal tissue is likely due to uric acid. In AS caused by pathogenic variants in the <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> genes, there is a high variability in patient",9_17,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"genes, there is a high variability in patient symptoms. Some patients with a mutation, as identified by genetic testing, are asymptomatic, have isolated hematuria or present with renal failure. This presents a major obstacle for the diagnosis of AS and is highly controversial for the definition of the disease [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR23"">23</xref>–<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. In previous reports of <italic toggle=""yes"">COL4A3</italic> and",9_18,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"of <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> mutations, the terms ""familial benign hematuria (BFH)"" and ""thin GBM disease"" were used [<xref ref-type=""bibr"" rid=""CR27"">27</xref>, <xref ref-type=""bibr"" rid=""CR28"">28</xref>]. In this study, patients with <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> mutations showed thin GBM, by EM, and indicators of loss of renal function in the form of increased urinary protein and decreased eGFR, in",9_19,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"increased urinary protein and decreased eGFR, in addition to hematuria. This demonstrates that the disease is not benign, as previously defined, when it is caused by <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> mutations. In this study, BFH, TBMN and others were uniformly referred to as AS. It is generally accepted that pathogenic variants contribute to AS and the severity and progression of clinical symptoms correlate with the type of mutation. The differential impact of",9_20,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"the type of mutation. The differential impact of various mutations may be an important predictor of disease severity and frameshift mutations are often considered to be the disease-causing mutation [<xref ref-type=""bibr"" rid=""CR29"">29</xref>]. Family 3 had a <italic toggle=""yes"">COL4A4</italic> frameshift mutation (p.P502Lfs*151) that appeared to have a variable phenotype. The two mutations of II-4 were inherited from I-1 and I-2 respectively and located in different chromosomes (in trans), and the mode of",9_21,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"different chromosomes (in trans), and the mode of inheritance was AR. Two members of the family, I-1 (64-year-old, male) and III-1 (7-year-old, male), carried the frameshift mutation but their renal function was normal and they did not develop progressive hematuria. In contrast, II-2 (38-year-old, female) developed obvious hematuria. Similarly, in Family 6, Family 8 and Family 9, patients with the same pathogenic variant exhibited varying degrees of clinical symptoms. This suggested that there are",9_22,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"clinical symptoms. This suggested that there are differences in the severity of clinical symptoms in AS, which may be caused by differences in gender, epigenetic material, environmental factors, smoking and other lifestyle habits [<xref ref-type=""bibr"" rid=""CR30"">30</xref>]. This is consistent with Savige J, Torra R et al. [<xref ref-type=""bibr"" rid=""CR12"">12</xref>, <xref ref-type=""bibr"" rid=""CR25"">25</xref>, <xref ref-type=""bibr"" rid=""CR31"">31</xref>, <xref ref-type=""bibr"" rid=""CR32"">32</xref>], who",9_23,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"<xref ref-type=""bibr"" rid=""CR32"">32</xref>], who reported that AS, which included thin GBM nephropathy, has high clinical variability when caused by mutations in the <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> genes. It needs to be emphasized that COL4A4 delC frameshift mutation in I-1 does not produce a clinical phenotype, but in II-2 has full field of erythrocyte, it is a clinically and genetically heterogeneous group of disorder, and is also possible that there is some",9_24,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"disorder, and is also possible that there is some RNA mediated non sense disease taking place that manages to remove the frameshifted peptide, thereby limiting the translation of abnormal proteins to avoid leading to diseases. To date, multiple different <italic toggle=""yes"">COL4A5</italic> mutations have been identified and include deletions, frameshift mutations, nonsense mutations, splice mutations and missense mutations. Mutation of <italic toggle=""yes"">COL4A5</italic> can interfere with the synthesis",9_25,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"can interfere with the synthesis of the type IV collagen α5 chain and result in the loss of expression of the type IV collagen α3α4α5 chain in the GBM. The pathogenicity of these mutations is mostly predicted by tools such as SIFT [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. However, In vitro confirmation of <italic toggle=""yes"">COL4A5</italic> gene mutations has been rarely reported. In vitro experiments on the <italic toggle=""yes"">COL4A5</italic> missense mutations (p.G869R, p.G787R) have not been",9_26,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"mutations (p.G869R, p.G787R) have not been reported. In this study, we found that mRNA levels were significantly lower in the presence of the <italic toggle=""yes"">COL4A5</italic> c.2359G > C or c.2605G > A mutation in HEK-239 T cells, than in cells without the mutation. Subcellular localization was not altered by either missense mutation and both the wild-type and mutations were expressed in the cytoplasm. This is further evidence that the <italic toggle=""yes"">COL4A5</italic> missense mutations,",9_27,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"toggle=""yes"">COL4A5</italic> missense mutations, c.2359G > C, p.G787R and c.2605G > A, p.G869R, are deleterious. Unfortunately, due to the limitation of antibodies, we did not carry out quantitative analysis of the <italic toggle=""yes"">COL4A5</italic> protein. The pathogenic mechanism of <italic toggle=""yes"">COL4A5</italic> mutation needs further study. In conclusion, this study broadens the scope of <italic toggle=""yes"">COL4A3, COL4A4, COL4A5</italic> variants even if for most of these novel mutations",9_28,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
even if for most of these novel mutations further clinical data and functional studies are needed to define the pathogenicity. It could have an important implication for the diagnosis of AS and for genetic counselling.,9_29,"Four novel mutations identified in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> genes in 10 families with Alport syndrome",8 7 2024,,Alport_Syndrome
"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series Alport syndrome (AS), also known as hereditary progressive nephritis, is an inherited glomerulopathy characterized by hematuria, proteinuria, and progressive kidney failure, with some patients having extra-renal manifestations such as sensorineural deafness and ocular abnormalities.<xref rid=""cit0001"" ref-type=""bibr"">1</xref> The abnormalities of the glomerular",10_0,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"The abnormalities of the glomerular basement membrane (GBM) structural caused by mutations in <italic toggle=""yes"">COL4A5</italic> on chromosome X, which encodes type IV collagen α5 chain and causes X-linked AS (XLAS).<xref rid=""cit0002"" ref-type=""bibr"">2</xref> There are three inheritance patterns of AS, the X-linked genetic phenotype resulting from mutations in <italic toggle=""yes"">COL4A5</italic> gene is the most common, accounting for approximately 85% of cases,<xref rid=""cit0003""",10_1,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"approximately 85% of cases,<xref rid=""cit0003"" ref-type=""bibr"">3</xref> followed by autosomal recessive<xref rid=""cit0004"" ref-type=""bibr"">4</xref> and autosomal dominant.<xref rid=""cit0005"" ref-type=""bibr"">5</xref> Over 90% of male<xref rid=""cit0006"" ref-type=""bibr"">6</xref> and 12% of female XLAS patients are reported to develop end-stage kidney disease (ESKD) by age 40, respectively. Genotypic phenotypes exhibit a high correlation in males XLAS.<xref rid=""cit0006"" ref-type=""bibr"">6</xref> Males exhibit",10_2,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"ref-type=""bibr"">6</xref> Males exhibit proteinuria and hematuria in early childhood compared to female patients with XLAS, and the disease develops to ESKD by 25 to 3.<xref rid=""cit0007"" ref-type=""bibr"">7</xref> The severity of male patients with early onset to ESKD correlated with the type of variants, patients with nonsense variants have the most severe phenotypes, whereas patients with splicing variants have moderate phenotypes and patients with missense variants have mild phenotypes,<xref rid=""cit0008""",10_3,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"variants have mild phenotypes,<xref rid=""cit0008"" ref-type=""bibr"">8</xref> in contrast to female patients with XLAS, in whom no genotype–phenotype correlation was presented.<xref rid=""cit0009"" ref-type=""bibr"">9</xref>,<xref rid=""cit0010"" ref-type=""bibr"">10</xref> Genetic testing is more sensitive and specific than renal biopsy for the diagnosis of AS and can provide predictive information about disease severity and prognosis. It has been shown that 10% of the pathogenic variants in XLAS are typically",10_4,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"of the pathogenic variants in XLAS are typically aberrant splicing mutations,<xref rid=""cit0011"" ref-type=""bibr"">11</xref> which could exhibit a different prognosis depending on whether the variants result in truncated transcript.<xref rid=""cit0012"" ref-type=""bibr"">12</xref> In this study, we used whole-exome sequencing (WES) to identify one splicing variant in a Chinese family with XLAS and verified the pathogenicity of the mutation in vitro experiments. A five-generation pedigree with a total of 49",10_5,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"A five-generation pedigree with a total of 49 family members originating from the remote rural areas in Hainan province of China was investigated in this study (<xref rid=""f0001"" ref-type=""fig"">Figure 1a</xref>). For all participants, we collected clinical data including family relationship, gender, age at onset of disease, renal function (hematuria, proteinuria, stage of chronic kidney disease (CKD)), sensorineural hearing loss, ocular lesions and medical history. Patients’ CKD was staged according to the",10_6,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"Patients’ CKD was staged according to the K/DOQI clinical practice guideline.<xref rid=""cit0013"" ref-type=""bibr"">13</xref> There are no consanguineous marriages in the family. WES and Sanger sequencing were performed for proband (IV-7) and their parents. In vitro splicing analysis was performed to verify the effect of mutation on mRNA splicing. Peripheral blood samples were collected from 17 family members and verified by Sanger sequencing. Renal pathology of the proband’s brother (IV-6) was assessed using",10_7,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"the proband’s brother (IV-6) was assessed using hematoxylin-eosin (HE) staining, periodic acid-Schiff (PAS) staining, periodic acid silver methenamine (PASM) staining, Masson examination, immunofluorescence staining and electron microscopy (EM) analysis. Consent was obtained from all patients to collect and publish the data.",10_8,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"<fig position=""float"" id=""f0001"" fig-type=""figure""><label>Figure 1</label><caption><p>Sequence analysis of the pedigree and in vitro splicing experiments (<bold>a</bold>) pedigree of the Chinese family with XLAS. Black filled symbols represent affected individuals; The symbols with a slash correspond to deceased individuals; Arrow indicates the proband; M represent mutation (c.321+5G>A), N represent normal, / indicate not detect. (<bold>b</bold>) Sanger sequencing of the proband and his parents.",10_9,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"Sanger sequencing of the proband and his parents. (<bold>c</bold>) Electrophoresis for amplification of <italic toggle=""yes"">COL4A5</italic> cDNA from the skin tissue of healthy individual and proband. (<bold>d</bold>) Schematic overview of the region harboring c.321+5G>A mutation in <italic toggle=""yes"">COL4A5</italic> and representation of the abnormal splicing. Representation of the alternative splicing of exon 5 in <italic toggle=""yes"">COL4A5</italic>. (<bold>e</bold>) Sequencing chromatogram of",10_10,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"(<bold>e</bold>) Sequencing chromatogram of <italic toggle=""yes"">COL4A5</italic> wild-type cDNA and splice variants.</p></caption><graphic http://www.w3.org/1999/xlink href=""IJNRD-17-167-g0001"" content-type=""print-only"" position=""float""></graphic></fig> As shown in <xref rid=""t0001"" ref-type=""table"">Table 1</xref>, the progression and severity of AS varied considerably between affected individuals in the family. There were no ocular lesions or hearing loss in the proband, his mother, or other family",10_11,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"loss in the proband, his mother, or other family members. WES and Sanger sequencing were performed for proband (IV-7) and their parents. Peripheral blood samples were collected from 17 family members and verified by Sanger sequencing. Co-segregation analysis revealed that several members of the family had c.321+5G>A mutation in <italic toggle=""yes"">COL4A5</italic>; however, the severity of their clinical phenotypes was inconsistent (<xref rid=""f0001"" ref-type=""fig"">Figure 1a</xref> and <xref rid=""t0001""",10_12,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"1a</xref> and <xref rid=""t0001"" ref-type=""table"">Table 1</xref>).<table-wrap position=""float"" id=""t0001"" orientation=""landscape""><label>Table 1</label><caption><p>Clinical Data of Patients with the COL4A5 Gene Variant</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th rowspan=""1"" colspan=""1"">No.</th><th rowspan=""1"" colspan=""1"">Sex</th><th rowspan=""1"" colspan=""1"">Age (year)</th><th rowspan=""1"" colspan=""1"">Age Of Onset (year)</th><th rowspan=""1"" colspan=""1"">Hematuria</th><th rowspan=""1""",10_13,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"colspan=""1"">Hematuria</th><th rowspan=""1"" colspan=""1"">Proteinuria</th><th rowspan=""1"" colspan=""1"">Stage Of CKD</th><th rowspan=""1"" colspan=""1"">Age Of Onset CKD (year)</th><th rowspan=""1"" colspan=""1"">Ultrasound</th><th rowspan=""1"" colspan=""1"">Renal Function</th></tr></thead><tbody><tr><td rowspan=""1"" colspan=""1"">IV-7</td><td rowspan=""1"" colspan=""1"">Male</td><td rowspan=""1"" colspan=""1"">22</td><td rowspan=""1"" colspan=""1"">11</td><td rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1"" colspan=""1"">+++</td><td",10_14,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1"" colspan=""1"">V</td><td rowspan=""1"" colspan=""1"">17</td><td rowspan=""1"" colspan=""1"">Enhanced echogenicity of both renal parenchyma with indistinct corticomedullary demarcation</td><td rowspan=""1"" colspan=""1"">Abnormal</td></tr><tr><td rowspan=""1"" colspan=""1"">III-8</td><td rowspan=""1"" colspan=""1"">Female</td><td rowspan=""1"" colspan=""1"">48</td><td rowspan=""1"" colspan=""1"">34</td><td rowspan=""1"" colspan=""1"">+</td><td rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1""",10_15,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1"" colspan=""1"">V</td><td rowspan=""1"" colspan=""1"">43</td><td rowspan=""1"" colspan=""1"">Enhanced echogenicity and decreased blood flow in both renal parenchyma</td><td rowspan=""1"" colspan=""1"">Abnormal</td></tr><tr><td rowspan=""1"" colspan=""1"">IV-2</td><td rowspan=""1"" colspan=""1"">Female</td><td rowspan=""1"" colspan=""1"">23</td><td rowspan=""1"" colspan=""1"">20</td><td rowspan=""1"" colspan=""1"">+</td><td rowspan=""1"" colspan=""1"">++</td><td rowspan=""1"" colspan=""1"">III</td><td",10_16,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"rowspan=""1"" colspan=""1"">III</td><td rowspan=""1"" colspan=""1"">20</td><td rowspan=""1"" colspan=""1"">Enhanced echogenicity of both renal parenchyma with indistinct corticomedullary demarcation; echogenic enhancement of the left renal calyx margin</td><td rowspan=""1"" colspan=""1"">Abnormal</td></tr><tr><td rowspan=""1"" colspan=""1"">IV-5</td><td rowspan=""1"" colspan=""1"">Female</td><td rowspan=""1"" colspan=""1"">24</td><td rowspan=""1"" colspan=""1"">17</td><td rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1""",10_17,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1"" colspan=""1"">-</td><td rowspan=""1"" colspan=""1"">I</td><td rowspan=""1"" colspan=""1"">17</td><td rowspan=""1"" colspan=""1"">Enhanced echoes of the calyx margins of both kidneys; calcification</td><td rowspan=""1"" colspan=""1"">Normal</td></tr><tr><td rowspan=""1"" colspan=""1"">IV-6</td><td rowspan=""1"" colspan=""1"">Male</td><td rowspan=""1"" colspan=""1"">15</td><td rowspan=""1"" colspan=""1"">15</td><td rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1"" colspan=""1"">++</td><td",10_18,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"rowspan=""1"" colspan=""1"">++</td><td rowspan=""1"" colspan=""1"">I</td><td rowspan=""1"" colspan=""1"">16</td><td rowspan=""1"" colspan=""1"">Enhanced echoes of the calyx margins of both kidneys; calcification</td><td rowspan=""1"" colspan=""1"">Normal</td></tr><tr><td rowspan=""1"" colspan=""1"">IV-9</td><td rowspan=""1"" colspan=""1"">Male</td><td rowspan=""1"" colspan=""1"">34</td><td rowspan=""1"" colspan=""1"">21</td><td rowspan=""1"" colspan=""1"">+</td><td rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1"" colspan=""1"">V</td><td rowspan=""1""",10_19,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"rowspan=""1"" colspan=""1"">V</td><td rowspan=""1"" colspan=""1"">28</td><td rowspan=""1"" colspan=""1"">Macular dense shadows in the medulla of the left kidney clustered around the calyx</td><td rowspan=""1"" colspan=""1"">Normal</td></tr><tr><td rowspan=""1"" colspan=""1"">IV-17</td><td rowspan=""1"" colspan=""1"">Female</td><td rowspan=""1"" colspan=""1"">28</td><td rowspan=""1"" colspan=""1"">16</td><td rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1"" colspan=""1"">+</td><td rowspan=""1"" colspan=""1"">I</td><td rowspan=""1""",10_20,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"rowspan=""1"" colspan=""1"">I</td><td rowspan=""1"" colspan=""1"">17</td><td rowspan=""1"" colspan=""1"">Few punctate strong echoes at the cortico-medulla junction</td><td rowspan=""1"" colspan=""1"">NA</td></tr><tr><td rowspan=""1"" colspan=""1"">III-1</td><td rowspan=""1"" colspan=""1"">Female</td><td rowspan=""1"" colspan=""1"">43</td><td rowspan=""1"" colspan=""1"">31</td><td rowspan=""1"" colspan=""1"">++</td><td rowspan=""1"" colspan=""1"">+++</td><td rowspan=""1"" colspan=""1"">III</td><td rowspan=""1"" colspan=""1"">43</td><td rowspan=""1""",10_21,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"rowspan=""1"" colspan=""1"">43</td><td rowspan=""1"" colspan=""1"">NA</td><td rowspan=""1"" colspan=""1"">Abnormal</td></tr><tr><td rowspan=""1"" colspan=""1"">III-13</td><td rowspan=""1"" colspan=""1"">Female</td><td rowspan=""1"" colspan=""1"">55</td><td rowspan=""1"" colspan=""1"">54</td><td rowspan=""1"" colspan=""1"">+</td><td rowspan=""1"" colspan=""1"">+</td><td rowspan=""1"" colspan=""1"">I</td><td rowspan=""1"" colspan=""1"">54</td><td rowspan=""1"" colspan=""1"">NA</td><td rowspan=""1""",10_22,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"rowspan=""1"" colspan=""1"">NA</td><td rowspan=""1"" colspan=""1"">NA</td></tr></tbody></table><table-wrap-foot><fn id=""tfn0001""><p><bold>Abbreviations</bold>: NA, not available; “-”, negative; “+”, minor; “++”, moderate; “+++”, massive.</p></fn></table-wrap-foot></table-wrap> In this study, a novel intronic mutation in <italic toggle=""yes"">COL4A5</italic> was identified by WES and Sanger sequencing in an affected Chinese family with a history of kidney disease, which demonstrated the benefit of genetic sequencing",10_23,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"demonstrated the benefit of genetic sequencing in determining the etiology of hereditary kidney disease. In the 19th century, Fliter and Gregory et al proposed the AS clinical diagnostic criteria that most cases could be clearly diagnosed by clinical manifestations, family history, renal histopathological examination and type IV collagen α-chain staining.<xref rid=""cit0014"" ref-type=""bibr"">14</xref> However, in actual clinical work, AS patients often show atypical renal histopathological changes and lack",10_24,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"atypical renal histopathological changes and lack of unique symptoms, which usually exhibit low awareness rates of chronic kidney diseases. Unfortunately, due to the lack of symptoms, patients often do not seek medical help until renal failure has already occurred. Approximately 10% of affected individuals, however, develop kidney failure by the age of 60, making it difficult to provide effective treatments.<xref rid=""cit0015"" ref-type=""bibr"">15</xref> Male XLAS patients with hemizygous pathogenic variants",10_25,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"XLAS patients with hemizygous pathogenic variants in <italic toggle=""yes"">COL4A5</italic> have a 100% risk of progression to ESRD, and female patients with heterozygous pathogenic variants have an approximately 25% risk of developing ESRD,<xref rid=""cit0001"" ref-type=""bibr"">1</xref> which is consistent with our findings. Therefore, genetic diagnosis became an effective method for diagnosing AS,<xref rid=""cit0016"" ref-type=""bibr"">16</xref> which promoted a demand for a comprehensive understanding of the",10_26,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"a demand for a comprehensive understanding of the genetic causes of AS. Genetic analysis, such as WES, may be effective in increasing awareness and enabling early intervention in the treatment of AS, which may delay the course of AS and reduce the severity of the disease. Studies have shown that almost all females with XLAS and kidney failure had a history of proteinuria.<xref rid=""cit0017"" ref-type=""bibr"">17</xref> This is consistent with our findings that IV-5 and III-3 did not present a history of",10_27,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"that IV-5 and III-3 did not present a history of proteinuria and had stage I of ESKD compared with those females in families with a history of proteinuria. Furthermore, girls with proteinuria detected before the age of 15 years developed to ESKD more rapidly than those without proteinuria, suggesting that proteinuria is associated with a risk of serious disease. Hemizygous male patients with AS are typically more severely affected than females with heterozygotes variants,<xref rid=""cit0018""",10_28,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"with heterozygotes variants,<xref rid=""cit0018"" ref-type=""bibr"">18</xref>,<xref rid=""cit0019"" ref-type=""bibr"">19</xref> who have recurrent hematuria, early-onset proteinuria and ESKD, often requiring dialysis or kidney transplantation before thirty years old.<xref rid=""cit0020"" ref-type=""bibr"">20</xref> Female carriers of X-linked AS exhibit a lack of genotype–phenotype correlation, with significant intrafamilial variability in disease severity. The same observation is evident in our family. Despite being",10_29,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"is evident in our family. Despite being of the same age as IV-5, IV-2 progressed to CKD stage 3 with massive proteinuria, while IV-5 manifested a milder phenotype. III-8 developed ESKD at 48 years, while III-13, at 55 years, presented with microscopic hematuria with a small amount of proteinuria. This intrafamilial heterogeneity might be attributed to random X-chromosome inactivation. Research has shown that 90% of female patients with severe AS phenotype have X-chromosome inactivation of the normal",10_30,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"have X-chromosome inactivation of the normal <italic toggle=""yes"">COL4A5</italic> allele in their kidneys.<xref rid=""cit0021"" ref-type=""bibr"">21</xref> In peripheral leukocytes, the relative activity of the mutated X chromosome compared to the normal allele varies among AS heterozygotes, and this ratio is not associated with renal function.<xref rid=""cit0022"" ref-type=""bibr"">22</xref> Furthermore, proteinuria onset and progression, as well as hearing loss, are risk factors for renal failure. In this",10_31,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"loss, are risk factors for renal failure. In this family, female patients with significant proteinuria have relatively more severe disease severity,<xref rid=""cit0009"" ref-type=""bibr"">9</xref> and there are no patients with hearing abnormalities. Literatures have reported that some individuals with AS are associated with a phenotype of hypertension.<xref rid=""cit0023"" ref-type=""bibr"">23</xref> We aimed to investigate whether a genotype–phenotype correlation exists within this large family. However, we only",10_32,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"exists within this large family. However, we only observed hypertension in patient IV-2 (230/140mmHg), while no such phenotype was present in the other family members. This discrepancy might be attributed to clinical heterogeneity. It is widely acknowledged that there is a strong correlation between mutation type and phenotype in patients with XLAS. The type of variants and the location of the variant affecting the collagen α chain are the predominant factors of the age of onset of ESKD, and the likelihood",10_33,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"of the age of onset of ESKD, and the likelihood of sensorineural hearing loss and ocular abnormalities.<xref rid=""cit0024"" ref-type=""bibr"">24</xref> It was found that the male with splicing variants leading to in-frame transcription had a milder phenotype than those with out-of-frame transcription.<xref rid=""cit0007"" ref-type=""bibr"">7</xref>,<xref rid=""cit0012"" ref-type=""bibr"">12</xref> Nonsense mutations have a 90% chance of developing ESRD at age 30, and splicing mutations and missense mutations have a",10_34,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"splicing mutations and missense mutations have a 70% and 50% risk of developing ESRD, respectively.<xref rid=""cit0006"" ref-type=""bibr"">6</xref> A study analyzing 14 XLAS pedigrees with atypical splicing mutations showed that the median age of ESKD onset was 20 years and 29 years for families with truncating variants and non-truncating variants, respectively.<xref rid=""cit0012"" ref-type=""bibr"">12</xref> In our study, we identified a novel mutation, c.321+5G>A, in <italic toggle=""yes"">COL4A5</italic> gene.",10_35,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"in <italic toggle=""yes"">COL4A5</italic> gene. This mutation resulted in the production of an abnormal transcript lacking exon 5, in addition to the normal-length transcript. The expression level of <italic toggle=""yes"">COL4A5</italic> RNA in peripheral blood is extremely low, while the expression level in skin and kidney tissues is relatively high. The most direct and effective way to determine whether an intronic mutation affects splicing is to extract RNA from the patient’s kidney or skin tissue for",10_36,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"RNA from the patient’s kidney or skin tissue for analysis, which is an invasive experiment. There are also studies that use in vitro Minigene technology to analyze potential splicing mutations.<xref rid=""cit0025"" ref-type=""bibr"">25</xref> Splice variants account for a significant proportion of the total variants in XLAS, and this proportion is likely to increase with future advances in genetic analysis. It is essential to clarify the pathogenicity and transcript patterns by in vitro functional splicing",10_37,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"patterns by in vitro functional splicing assays. Our study identified an intronic variant and demonstrated its pathogenicity in vitro experiment. This finding contributes to the enrichment of database resources for AS. AS should be suspected when there is a family history of persistent glomerular hematuria and renal impairment. Furthermore, we also highlight the critical role that genetic analysis can play in personalized AS diagnosis.",10_38,"Aberrant Splicing of <italic toggle=""yes"">COL4A5</italic> Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series",04 6 2024,,Alport_Syndrome
"Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome <fig position=""float"" id=""absf1"" fig-type=""featured""><graphic http://www.w3.org/1999/xlink href=""kidney360-5-1002-g001"" position=""float""></graphic></fig>",11_0,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"Dipeptidyl peptidase-4 (DPP4) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors are both second-line options for managing glucose levels in patients with type 2 diabetes.<sup><xref rid=""B1"" ref-type=""bibr"">1</xref>,<xref rid=""B2"" ref-type=""bibr"">2</xref></sup> More recently, SGLT2 inhibitors (SGLT2i) were found to protect from CKD progression even in the absence of diabetes.<sup><xref rid=""B3"" ref-type=""bibr"">3</xref>,<xref rid=""B4"" ref-type=""bibr"">4</xref></sup> SGLT2i reduce the",11_1,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"ref-type=""bibr"">4</xref></sup> SGLT2i reduce the reabsorption of glucose in the proximal tubules, thereby reducing blood glucose levels.<sup><xref rid=""B5"" ref-type=""bibr"">5</xref></sup> Conversely, DPP4 inhibitors (DPP4i) block the DPP4 enzyme, which prevents the inactivation of glucagon-like peptide 1 (GLP-1) and stimulates insulin secretion.<sup><xref rid=""B6"" ref-type=""bibr"">6</xref>,<xref rid=""B7"" ref-type=""bibr"">7</xref></sup> Both treatments lead to a decrease in glucose availability as a metabolic",11_2,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"a decrease in glucose availability as a metabolic substrate, potentially causing adaptations in substrate utilization. Alport syndrome (AS) is a genetic condition first identified as hereditary familial congenital hemorrhagic nephritis.<sup><xref rid=""B8"" ref-type=""bibr"">8</xref></sup> Characterized by mutations in collagen type 4 genes (<italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, <italic toggle=""yes"">COL4A5</italic>),<sup><xref rid=""B9"" ref-type=""bibr"">9</xref>,<xref",11_3,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"rid=""B9"" ref-type=""bibr"">9</xref>,<xref rid=""B10"" ref-type=""bibr"">10</xref></sup> AS results in progressive kidney issues and abnormalities in both the inner ear and the eye.<sup><xref rid=""B11"" ref-type=""bibr"">11</xref>,<xref rid=""B12"" ref-type=""bibr"">12</xref></sup> Although AS is known as a nonmetabolic CKD, studies have shown disruptions in lipid metabolism in AS.<sup><xref rid=""B13"" ref-type=""bibr"">13</xref><xref rid=""B14"" ref-type=""bibr""></xref>–<xref rid=""B15"" ref-type=""bibr"">15</xref></sup> We have",11_4,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"rid=""B15"" ref-type=""bibr"">15</xref></sup> We have demonstrated that increased triglyceride and esterified cholesterol content, along with free fatty acid uptake, contributes to the progression of AS.<sup><xref rid=""B13"" ref-type=""bibr"">13</xref><xref rid=""B14"" ref-type=""bibr""></xref><xref rid=""B15"" ref-type=""bibr""></xref>–<xref rid=""B16"" ref-type=""bibr"">16</xref></sup> Although there are currently no preventive or curative therapies for AS, research suggests that reducing intrarenal lipid accumulation,",11_5,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"that reducing intrarenal lipid accumulation, such as by promoting the utilization and elimination of accumulated lipids, may offer a therapeutic option to prevent the decline in kidney function in AS.<sup><xref rid=""B13"" ref-type=""bibr"">13</xref><xref rid=""B14"" ref-type=""bibr""></xref>–<xref rid=""B15"" ref-type=""bibr"">15</xref>,<xref rid=""B17"" ref-type=""bibr"">17</xref>,<xref rid=""B18"" ref-type=""bibr"">18</xref></sup> We previously demonstrated that SGLT2i by empagliflozin prevents kidney function decline in",11_6,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"empagliflozin prevents kidney function decline in experimental AS by lowering intrarenal lipid accumulation.<sup><xref rid=""B19"" ref-type=""bibr"">19</xref></sup> In this process, SGLT2 inhibition reduces glucose reabsorption and promotes the utilization of lipids as an energy source in podocytes. As a glucose-lowering treatment for type 2 diabetes, DPP4is may cause a similar effect in substrate switch. In support, DPP4i were found to effectively lower cholesterol levels in LDL receptor-deficient",11_7,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"cholesterol levels in LDL receptor-deficient mice.<sup><xref rid=""B20"" ref-type=""bibr"">20</xref></sup> A systematic literature review also indicated that DPP4i is associated with a significant reduction in total cholesterol in patients with type 1 or type 2 diabetes.<sup><xref rid=""B21"" ref-type=""bibr"">21</xref></sup> Moreover, it has been reported that DPP4i treatment increases glucose and fatty acid uptake in the hypertrophied heart of nondiabetic mice, leading to improved myocardial energy",11_8,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"mice, leading to improved myocardial energy metabolism.<sup><xref rid=""B22"" ref-type=""bibr"">22</xref></sup> In this study, we investigated the metabolic mechanisms involved in the renoprotective benefits of linagliptin (Lina) in a mouse model of AS (<italic toggle=""yes"">Col4a3</italic><sup>−/−</sup> mice). In addition, we compared the Lina-mediated effects to the effect mediated by empagliflozin (Empa) in AS mice.   With this study, we investigated the distribution of metabolites and altered metabolism in",11_9,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"of metabolites and altered metabolism in kidney tissues from AS and WT mice using the powerful MALDI-MSI technique. We demonstrate, for the first time, the dysregulation of certain metabolites in the kidneys of AS mice. Specifically, we found perturbations in the metabolism of AdA and EPA (Figure <xref rid=""fig1"" ref-type=""fig"">1</xref>). These two PUFAs are derived from omega-6 and omega-3 fatty acids, respectively. Previous reports indicated increased AdA levels in the medium of podocytes depleted of",11_10,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"AdA levels in the medium of podocytes depleted of decaprenyl diphosphate synthase subunit 2.<sup><xref rid=""B34"" ref-type=""bibr"">34</xref></sup> Podocytes depleted of decaprenyl diphosphate synthase subunit 2 protein is responsible for coenzyme Q biosynthesis, which plays a critical role in the electron transport chain and ATP production.<sup><xref rid=""B35"" ref-type=""bibr"">35</xref>,<xref rid=""B36"" ref-type=""bibr"">36</xref></sup> Thus, it seems possible that AdA is involved in energy generation. A",11_11,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"that AdA is involved in energy generation. A high-fat diet triggers renal lipotoxicity, resulting in increased levels of renal AdA and its metabolites in mice, while reducing EPA and its metabolite levels.<sup><xref rid=""B37"" ref-type=""bibr"">37</xref></sup> This metabolic imbalance was found to be improved by activating AMP-activated protein kinase.<sup><xref rid=""B37"" ref-type=""bibr"">37</xref></sup> These findings are consistent with our observations in kidney sections of AS mice, which suggests that",11_12,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"kidney sections of AS mice, which suggests that renal lipotoxicity of metabolic and nonmetabolic origin may share similar pathophysiological processes involved in PUFA metabolism. We also found elevated levels of glucose and glucose-6 phosphate in the kidneys of AS mice (Figure <xref rid=""fig1"" ref-type=""fig"">1</xref>). Glucose-6 phosphate serves as a critical intermediate in glucose metabolism.<sup><xref rid=""B38"" ref-type=""bibr"">38</xref>,<xref rid=""B39"" ref-type=""bibr"">39</xref></sup> Although the",11_13,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"ref-type=""bibr"">39</xref></sup> Although the reason for the accumulation of glucose and its metabolic intermediate in the kidneys of AS mice remains unclear, compounds used to treat type 2 diabetes have been tested in experimental models of AS. One such compound is metformin, an antidiabetic agent, which demonstrated renal protective effects in AS mice. These effects include reduced proteinuria, renal inflammation, fibrosis, and glomerular injury.<sup><xref rid=""B40"" ref-type=""bibr"">40</xref></sup> The",11_14,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"rid=""B40"" ref-type=""bibr"">40</xref></sup> The renal protective effect of metformin thereby seems to be associated with the improvement of metabolic imbalances in glycolysis, the tricarboxylic acid cycle, and lipid metabolism.<sup><xref rid=""B40"" ref-type=""bibr"">40</xref></sup> Similarly, we demonstrate that Empa improves kidney function and lifespan in AS mice by shifting the preferred energy source from glucose to lipids leading to reduced renal lipotoxicity.<sup><xref rid=""B19""",11_15,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"reduced renal lipotoxicity.<sup><xref rid=""B19"" ref-type=""bibr"">19</xref></sup> These observations suggest that diabetic drugs, such as DPP4i, may be considered for the treatment of patients with nondiabetic CKD. To assess the potential use of DPP4i in treating nondiabetic CKD, we next treated AS mice with Lina and compared disease progression to untreated and Empa-treated AS mice (Figure <xref rid=""fig2"" ref-type=""fig"">2</xref>). The dosage of Lina used in mouse models varies. In research by Takahashi",11_16,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"in mouse models varies. In research by Takahashi <italic toggle=""yes"">et al.</italic>,<sup><xref rid=""B41"" ref-type=""bibr"">41</xref></sup> a regimen of 3 mg/kg per day Lina and/or 30 mg/kg per day Empa was used for treating diabetic db/db mice. This treatment led to a significant reduction in body weight, especially when mice were given Empa alone or in combination with Lina. In addition, in another study, ob/ob mice were treated with a higher dose of 100 mg/kg per day evogliptin, which alleviated cardiac",11_17,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"per day evogliptin, which alleviated cardiac lipotoxicity and prevented the development of diabetic cardiomyopathy.<sup><xref rid=""B42"" ref-type=""bibr"">42</xref></sup> In our mouse model, we chose to feed the mice food containing 40 mg/kg Lina, with their daily food intake approximately 3 g, a dose slightly higher than that used in the study by Takahashi. This dosing was selected based on preliminary studies where an extension in lifespan was observed. Given these promising results, we have decided to",11_18,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"Given these promising results, we have decided to continue using this dose in our study. As anticipated, Lina treatment also improved albuminuria, glomerulosclerosis, fibrosis, podocyte loss, and bodyweight loss in the experimental AS model. The effects of Lina treatment were similar to those observed with Empa treatment, and the combination of both drugs did not further improve renal function in AS mice. The absence of an additive effect was surprising, as our <italic toggle=""yes"">in vitro</italic>",11_19,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"as our <italic toggle=""yes"">in vitro</italic> mechanistic studies demonstrated that Empa and Lina affect similar metabolic pathways in different cell types in AS, that is podocytes versus tubular cells, respectively. It is, therefore, possible that other compensatory mechanisms occur <italic toggle=""yes"">in vivo</italic>. Although the survival of AS mice in all treatment groups was extended, mice still succumbed to the disease by age 10.5 weeks. Thus, additional studies to investigate whether other",11_20,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"additional studies to investigate whether other combination treatment strategies, such as the combination of Lina or Empa with inhibitors of the renin-angiotensin-aldosterone system<sup><xref rid=""B43"" ref-type=""bibr"">43</xref></sup> or finerenone, may be superior and improve the survival of AS mice are warranted. Another limitation of our data is the substantial SD observed within the treatment groups. This variability has impeded our capacity to identify significant differences between the treatment",11_21,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"significant differences between the treatment groups and the control group. Therefore, further MALDI-MSI analysis to investigate the effects of Lina on glucose and lipid metabolism is warranted. We also established immortalized mouse podocytes and tubular cells from WT and AS mice<sup><xref rid=""B14"" ref-type=""bibr"">14</xref>,<xref rid=""B19"" ref-type=""bibr"">19</xref></sup> to investigate whether Lina modulates cell respiration. We measured the oxygen consumption rate using high-resolution respirometry",11_22,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"rate using high-resolution respirometry (Figure <xref rid=""fig3"" ref-type=""fig"">3</xref>). In previous research, we found no differences in endogenous respiration between WT and AS podocytes and tubular cells.<sup><xref rid=""B19"" ref-type=""bibr"">19</xref></sup> However, AS tubular cells treated with Lina exhibited decreased glucose-driven respiration, whereas endogenous respiration and fatty acid-driven respiration remained unaffected. Interestingly, Lina treatment did not affect podocyte respiration,",11_23,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"treatment did not affect podocyte respiration, suggesting that tubular cells may be the primary target of Lina-induced metabolic changes. Because hyperglycemia and glycosuria are not symptoms of AS, it seems possible that the increased renal glucose content is the consequence of altered glucose transport within the kidney. Increased glucose content is also known to affect the expression of extracellular matrix proteins, leading to increased extracellular matrix deposition.<sup><xref rid=""B44""",11_24,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"matrix deposition.<sup><xref rid=""B44"" ref-type=""bibr"">44</xref>,<xref rid=""B45"" ref-type=""bibr"">45</xref></sup> Thus, we can speculate that the intrarenal accumulation of lipids, glucose, and their metabolites may cause glucolipotoxicity<sup><xref rid=""B46"" ref-type=""bibr"">46</xref></sup> and that it is necessary to achieve a reduction in both lipid and glucose content in the kidney to prevent disease progression in AS. Our previous finding that Empa treatment improves kidney function in AS mice<sup><xref",11_25,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"improves kidney function in AS mice<sup><xref rid=""B19"" ref-type=""bibr"">19</xref></sup> may be attributed to both increased lipid utilization and glucose excretion, thereby reducing glucolipotoxicity. The evolving data from cardiovascular outcomes trials suggest a potential kidney-protective effect of GLP-1 receptor agonists in individuals with type 2 diabetes and CKD, despite the lack of explicit indications for kidney improvement.<sup><xref rid=""B47"" ref-type=""bibr"">47</xref></sup> In cardiovascular",11_26,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"ref-type=""bibr"">47</xref></sup> In cardiovascular outcomes trials, findings related to the kidneys have often been presented as secondary evaluations after the primary emphasis on cardiovascular results.<sup><xref rid=""B48"" ref-type=""bibr"">48</xref></sup> GLP-1 receptor agonists exert indirect influence on typical risk factors for diabetic kidney disease, such as high blood sugar, hypertension, obesity, and dyslipidemia,<sup><xref rid=""B48"" ref-type=""bibr"">48</xref></sup> while also show potential direct",11_27,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"while also show potential direct effects on the kidneys by reducing oxidative stress,<sup><xref rid=""B49"" ref-type=""bibr"">49</xref></sup> inflammation,<sup><xref rid=""B50"" ref-type=""bibr"">50</xref>,<xref rid=""B51"" ref-type=""bibr"">51</xref></sup> and natriuresis.<sup><xref rid=""B16"" ref-type=""bibr"">16</xref></sup> Further research could illuminate their specific role in managing renal health for these patient populations. In summary, we have identified several dysregulated metabolites in the kidney cortices",11_28,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"dysregulated metabolites in the kidney cortices of AS mice. Among them, we found distinct differences in the content and distribution of the two PUFAs, AdA and EPA, in AS compared with WT kidneys. Interestingly, we also found increased glucose levels in AS kidneys. We furthermore demonstrated that Lina can effectively reduce the decline in kidney function and improve the lifespan of AS mice and that Lina reduces glucose-induced respiration in AS tubular cells. Taken together, our studies suggest that",11_29,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"cells. Taken together, our studies suggest that inhibiting the generation of glucose metabolites could represent a potential therapeutic strategy for treating AS. Additional studies are necessary to investigate the detrimental effects of glucose accumulation in the kidney during AS progression and to determine whether reducing renal glucose content can be a viable treatment option for the treatment of patients with AS.",11_30,Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome,7 2024,,Alport_Syndrome
"Exploration of Gene Therapy for Alport Syndrome Alport syndrome is a hereditary disease caused by mutations in the genes encoding the alpha 3, alpha 4, and alpha 5 chains of type IV collagen. It is characterized by hematuria, proteinuria, progressive renal dysfunction, hearing loss, and ocular abnormalities. The main network of type IV collagen in the glomerular basement membrane is composed of α3α4α5 heterotrimer. Mutations in these genes can lead to the replacement of this network by an immature network",12_0,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"of this network by an immature network composed of the α1α1α2 heterotrimer. Unfortunately, this immature network is unable to provide normal physical support, resulting in hematuria, proteinuria, and progressive renal dysfunction. Current treatment options for Alport syndrome include angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which aim to alleviate glomerular filtration pressure, reduce renal injury, and delay the progression of renal dysfunction. However, the effectiveness",12_1,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"of renal dysfunction. However, the effectiveness of these treatments is limited, highlighting the need for novel therapeutic strategies and medications to improve patient outcomes. Gene therapy, which involves the use of genetic material to prevent or treat diseases, holds promise for the treatment of Alport syndrome. This approach may involve the insertion or deletion of whole genes or gene fragments to restore or disrupt gene function or the editing of endogenous genes to correct genetic mutations and",12_2,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"endogenous genes to correct genetic mutations and restore functional protein synthesis. Recombinant adeno-associated virus (rAAV) vectors have shown significant progress in kidney gene therapy, with several gene therapy drugs based on these vectors reaching clinical application. Despite the challenges posed by the structural characteristics of the kidney, the development of kidney gene therapy using rAAV vectors is making continuous progress. This article provides a review of the current achievements in",12_3,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"provides a review of the current achievements in gene therapy for Alport syndrome and discusses future research directions in this field.  Alport syndrome (AS) is a prevalent hereditary kidney disease characterized by a mutation in the gene responsible for encoding collagen IV (COL4), the primary component of the glomerular basement membrane (GBM). This mutation disrupts the normal synthesis and secretion of COL4, resulting in the formation of an abnormal GBM [<xref rid=""B1-biomedicines-12-01159""",12_4,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"GBM [<xref rid=""B1-biomedicines-12-01159"" ref-type=""bibr"">1</xref>]. The GBM is an essential extracellular matrix component located between podocytes and endothelial cells, playing a key role in the function of the glomerular filtration barrier. COL4 constitutes approximately 50% of the total mass of the GBM and is vital for its stability and normal function [<xref rid=""B2-biomedicines-12-01159"" ref-type=""bibr"">2</xref>,<xref rid=""B3-biomedicines-12-01159"" ref-type=""bibr"">3</xref>]. Typically, COL4 in the",12_5,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"ref-type=""bibr"">3</xref>]. Typically, COL4 in the GBM forms a heterotrimer composed of three peptide chains: α3, α4, and α5, the majority of which are produced by podocytes. They self-assemble into a triple helical conformer through interacting at their C-terminal NC1-domains, and are then secreted to contribute to the structure of the GBM. This also explains why the C-terminal NC1-domain is crucial for the normal function of COL4 [<xref rid=""B4-biomedicines-12-01159"" ref-type=""bibr"">4</xref>]. However,",12_6,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"ref-type=""bibr"">4</xref>]. However, mutations in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> genes, responsible for editing the α3, α4, and α5 peptide chains, respectively, prevent the formation of the Col4α3α4α5 trimer. Instead, the immature GBM is partially replaced by the Col4α1α1α2 trimer, which lacks the same support strength as the Col4α3α4α5 trimer [<xref rid=""B5-biomedicines-12-01159"" ref-type=""bibr"">5</xref>,<xref",12_7,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"ref-type=""bibr"">5</xref>,<xref rid=""B6-biomedicines-12-01159"" ref-type=""bibr"">6</xref>]. This structural alteration in the GBM leads to stratification, thickening, reel-like basket changes, and barrier dysfunction [<xref rid=""B1-biomedicines-12-01159"" ref-type=""bibr"">1</xref>,<xref rid=""B7-biomedicines-12-01159"" ref-type=""bibr"">7</xref>]. Consequently, individuals with mutations in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, or <italic toggle=""yes"">COL4A5</italic> gene",12_8,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"or <italic toggle=""yes"">COL4A5</italic> gene will continue to produce incorrect peptide chains, continually exacerbating the pathological changes in the glomerular basement membrane and podocyte injury. The reported incidence of AS ranges from 1 in 5000 to 1 in 53,000 individuals [<xref rid=""B8-biomedicines-12-01159"" ref-type=""bibr"">8</xref>,<xref rid=""B9-biomedicines-12-01159"" ref-type=""bibr"">9</xref>,<xref rid=""B10-biomedicines-12-01159"" ref-type=""bibr"">10</xref>,<xref rid=""B11-biomedicines-12-01159""",12_9,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"rid=""B11-biomedicines-12-01159"" ref-type=""bibr"">11</xref>,<xref rid=""B12-biomedicines-12-01159"" ref-type=""bibr"">12</xref>]. Analysis of the genomic aggregation database reveals that the mutation rate of <italic toggle=""yes"">COL4A5</italic> is at least 1 in 2320, while that of <italic toggle=""yes"">COL4A3/4</italic> is at least 1 in 106 [<xref rid=""B12-biomedicines-12-01159"" ref-type=""bibr"">12</xref>]. Based on the largest whole exome sequencing (WES) study in CKD to date, mutations in the <italic",12_10,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"study in CKD to date, mutations in the <italic toggle=""yes"">COL4A3/4/5</italic> genes account for 30% of chronic kidney disease cases with single gene mutations, making it the second most common hereditary kidney disease after polycystic kidney disease, which represents 31% of cases [<xref rid=""B13-biomedicines-12-01159"" ref-type=""bibr"">13</xref>]. Similarly, several studies have shown that end stage kidney disease (ESKD) patients with unknown reason often have underlying AS [<xref",12_11,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"unknown reason often have underlying AS [<xref rid=""B13-biomedicines-12-01159"" ref-type=""bibr"">13</xref>,<xref rid=""B14-biomedicines-12-01159"" ref-type=""bibr"">14</xref>]. Furthermore, a significant number of COL4 mutations have been identified in patients with FSGS, indicating the importance of closely monitoring these individuals [<xref rid=""B15-biomedicines-12-01159"" ref-type=""bibr"">15</xref>].  The pathogenesis of AS is intricate, and current treatment options are unsatisfactory. The precise pathogenic",12_12,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"are unsatisfactory. The precise pathogenic mechanism resulting from COL4 mutations had been poorly characterized until the vital research conducted by Pieri M’s group. Their work found that endoplasmic reticulum stress (ERS) and unfolded protein response constituted central pathogenic mechanisms in various conditions [<xref rid=""B16-biomedicines-12-01159"" ref-type=""bibr"">16</xref>]. Furthermore, abnormal COL4 deposition, such as COL4α1α1α2, can initiate an inflammatory response and result in podocyte",12_13,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"an inflammatory response and result in podocyte injury by activating discoidin domain receptor 1 (DDR1) and integrin α2β1 [<xref rid=""B17-biomedicines-12-01159"" ref-type=""bibr"">17</xref>,<xref rid=""B18-biomedicines-12-01159"" ref-type=""bibr"">18</xref>]. Simultaneously, cell injury can lead to disruptions in energy metabolism, dysregulation of NADPH oxidase, and the accumulation of lipids, ultimately causing podocyte lipotoxic injury and apoptosis that exacerbates kidney injury [<xref",12_14,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"apoptosis that exacerbates kidney injury [<xref rid=""B19-biomedicines-12-01159"" ref-type=""bibr"">19</xref>,<xref rid=""B20-biomedicines-12-01159"" ref-type=""bibr"">20</xref>,<xref rid=""B21-biomedicines-12-01159"" ref-type=""bibr"">21</xref>]. In the studies mentioned above, the inflammatory response was identified as a critical factor. Research has shown that activating Nrf2 can boost the body’s ability to combat oxidative stress and shield cells from damage, ultimately slowing down the advancement of renal",12_15,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"ultimately slowing down the advancement of renal fibrosis [<xref rid=""B22-biomedicines-12-01159"" ref-type=""bibr"">22</xref>]. This highlights the potential role of bardoxolone methyl in this process. While the outcomes may not have met expectations, this effort remains a significant and valuable endeavor in the field of medical research [<xref rid=""B23-biomedicines-12-01159"" ref-type=""bibr"">23</xref>]. A multitude of factors contributes to the progression of AS patients to ESKD, resulting in a poor",12_16,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"of AS patients to ESKD, resulting in a poor prognosis. Treatment options for AS are currently limited, primarily relying on angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) as the standard treatments available. Although these medications can alleviate renal damage and postpone the progression to ESKD by multiple effects, such as decreasing intraglomerular pressure, their efficacy is limited, and it is imperative that treatment be initiated during the early stages",12_17,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"treatment be initiated during the early stages of the disease in order to optimize its therapeutic benefits and prolong the lifespan of the kidney [<xref rid=""B24-biomedicines-12-01159"" ref-type=""bibr"">24</xref>]. There is a growing body of experimental evidence supporting the exploration and development of new targets and mechanisms for AS treatment. Focused on ERS, we have found that excessive ERS and ERS-induced apoptosis play a significant role in podocyte injury, which could be mitigated through",12_18,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"podocyte injury, which could be mitigated through intervention in the proteasome pathway [<xref rid=""B25-biomedicines-12-01159"" ref-type=""bibr"">25</xref>]. Other promising avenues include sodium-glucose cotransporter 2 inhibitors, endothelin receptor antagonists, aldosterone antagonists, and antioxidant inflammation modulators, which aim to mitigate AS tissue damage from various angles [<xref rid=""B26-biomedicines-12-01159"" ref-type=""bibr"">26</xref>]. Additionally, the emergence of gene therapy drugs in",12_19,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"the emergence of gene therapy drugs in clinical practice offers hope for improving the current landscape of AS treatment through genetic interventions. Gene therapy holds the promise of curing diseases that are currently untreatable with conventional medications. It involves, but is not limited to, the use of genetic material to address or prevent diseases by manipulating specific genes within target cells through precise techniques. This can result in the alteration of gene function or the implementation",12_20,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"alteration of gene function or the implementation of gene editing programs within cells to facilitate internal genetic modifications [<xref rid=""B27-biomedicines-12-01159"" ref-type=""bibr"">27</xref>]. Current gene editing technologies primarily focus on somatic cells rather than germline cells, aiming to treat diseases within the patient’s body while avoiding the transmission of altered genes to future generations and the associated ethical dilemmas. The key aspect of gene therapy lies in delivering genetic",12_21,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"aspect of gene therapy lies in delivering genetic material, such as DNA or RNA, to target cells. Once inside the cell, this genetic material can carry out its intended function, either by regulating gene expression or altering cellular characteristics to combat disease. In contrast to traditional treatments involving proteins or small molecule drugs, gene therapy has the potential to provide sustained protein expression for extended periods without the need for frequent infusions. Essentially, the correct",12_22,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"for frequent infusions. Essentially, the correct genetic material can be introduced into the patient’s body to achieve a lasting therapeutic effect in a single treatment session [<xref rid=""B28-biomedicines-12-01159"" ref-type=""bibr"">28</xref>,<xref rid=""B29-biomedicines-12-01159"" ref-type=""bibr"">29</xref>]. In order to facilitate the transfer of genetic material into target cells, the use of vectors is essential. While plasmid DNA or RNA can be utilized for gene therapy, they lack the ability to target and",12_23,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"gene therapy, they lack the ability to target and enter cells to carry out normal functions without the assistance of vectors. Therefore, the use of specific vectors is essential for successful gene therapy delivery. Vectors, both viral and non-viral, are essential tolls in the transport process (<xref rid=""biomedicines-12-01159-t001"" ref-type=""table"">Table 1</xref>). Viral vectors, in particular, have undergone significant advancements to meet the requirements of gene therapy applications. They offer high",12_24,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"of gene therapy applications. They offer high transfection efficiency and the capability to express target genes within specific cells, making them preferred options for clinical gene therapy [<xref rid=""B30-biomedicines-12-01159"" ref-type=""bibr"">30</xref>]. Among the commonly used viral vectors are adenovirus, recombinant adeno-associated virus (rAAV), and lentivirus. Adenovirus, characterized by its high capacity to carry exogenous gene fragments and its broad spectrum of cell infection, was the first",12_25,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"broad spectrum of cell infection, was the first DNA virus developed for therapeutic purposes. It boasts genetic stability and significantly fewer side effects compared to traditional chemotherapy drugs, rendering it valuable in treating certain tumor diseases and preventing infections through vaccination. However, adenovirus does present certain limitations. Its high immunogenicity can trigger an immune response in the subject, potentially leading to fatal inflammation. Additionally, the duration of gene",12_26,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"inflammation. Additionally, the duration of gene expression in the body is relatively short-lived. Overcoming these challenges is crucial for advancing the development of effective therapeutic drugs using adenoviral vectors [<xref rid=""B31-biomedicines-12-01159"" ref-type=""bibr"">31</xref>,<xref rid=""B32-biomedicines-12-01159"" ref-type=""bibr"">32</xref>,<xref rid=""B33-biomedicines-12-01159"" ref-type=""bibr"">33</xref>,<xref rid=""B34-biomedicines-12-01159"" ref-type=""bibr"">34</xref>,<xref",12_27,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"ref-type=""bibr"">34</xref>,<xref rid=""B35-biomedicines-12-01159"" ref-type=""bibr"">35</xref>]. Lentivirus, being a retrovirus with a particle size of around 100 nm, presents a significant challenge in clinical applications due to its tendency for homologous recombination and integration into the host chromosome. This integration can lead to unforeseen complications such as myelodysplastic syndrome or acute leukemia [<xref rid=""B36-biomedicines-12-01159"" ref-type=""bibr"">36</xref>,<xref",12_28,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"ref-type=""bibr"">36</xref>,<xref rid=""B37-biomedicines-12-01159"" ref-type=""bibr"">37</xref>,<xref rid=""B38-biomedicines-12-01159"" ref-type=""bibr"">38</xref>]. While advancements, such as the fourth-generation lentivirus, have addressed some issues related to homologous recombination, limitations remain regarding vector titer and the difficulty in effectively targeting infected cells, thereby limiting their clinical applicability [<xref rid=""B39-biomedicines-12-01159"" ref-type=""bibr"">39</xref>,<xref",12_29,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"ref-type=""bibr"">39</xref>,<xref rid=""B40-biomedicines-12-01159"" ref-type=""bibr"">40</xref>,<xref rid=""B41-biomedicines-12-01159"" ref-type=""bibr"">41</xref>]. Currently, lentiviral vectors are primarily utilized for in vitro gene therapy applications, particularly in tumor immunotherapy. This approach allows for targeted transfection and the screening of cells for any pathogenic homologous recombination events, thereby reducing the risk of severe diseases [<xref rid=""B42-biomedicines-12-01159""",12_30,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"diseases [<xref rid=""B42-biomedicines-12-01159"" ref-type=""bibr"">42</xref>,<xref rid=""B43-biomedicines-12-01159"" ref-type=""bibr"">43</xref>]. On the other hand, recombinant adeno-associated virus (rAAV), commonly known as AAV, was initially discovered as a contaminant in adenovirus preparations. Its genome consists of single-stranded DNA approximately 4.7 kb in length, with a particle size of around 25 nm [<xref rid=""B44-biomedicines-12-01159"" ref-type=""bibr"">44</xref>]. AAV are replication-defective",12_31,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"AAV are replication-defective parvoviruses that typically require coinfection with a helper adenovirus or herpesvirus to efficiently infect cells, necessitating the use of a helper plasmid. AAV itself is non-pathogenic and has not been linked to any known human diseases. Moreover, it demonstrates low immunogenicity and exists in various natural serotypes, each with different tissue affinities, making it ideal for targeted transfection. Upon entering the host cell, the genetic material carried by AAV forms",12_32,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"cell, the genetic material carried by AAV forms concatemers in the nucleus without integrating into the host genome, enabling long-term expression that could last from months to years [<xref rid=""B45-biomedicines-12-01159"" ref-type=""bibr"">45</xref>]. Despite these favorable characteristics, several limitations hinder its clinical application, including its small capacity, potential neutralizing antibodies in some patients (particularly against AAV2 serotypes), low virus production efficiency, and high",12_33,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"low virus production efficiency, and high costs. Furthermore, animal studies have also reported severe toxicity following high-dose AAV9 administration [<xref rid=""B46-biomedicines-12-01159"" ref-type=""bibr"">46</xref>,<xref rid=""B47-biomedicines-12-01159"" ref-type=""bibr"">47</xref>,<xref rid=""B48-biomedicines-12-01159"" ref-type=""bibr"">48</xref>,<xref rid=""B49-biomedicines-12-01159"" ref-type=""bibr"">49</xref>,<xref rid=""B50-biomedicines-12-01159"" ref-type=""bibr"">50</xref>]. Addressing these challenges is",12_34,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"Addressing these challenges is essential for advancing AAV as a viral vector for widespread use. Strategies to overcome issues such as capacity constraints, immune responses, production efficiency, and toxicity must be carefully considered in clinical research to ensure the safe and effective application of AAV-based therapies. Interestingly, recent reports have highlighted the use of messenger RNA (mRNA) gene therapy delivered through lipid nanoparticles (LNPs) as a promising method to assess the safety",12_35,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"(LNPs) as a promising method to assess the safety and effectiveness of gene therapy agents in clinical trials [<xref rid=""B51-biomedicines-12-01159"" ref-type=""bibr"">51</xref>]. This approach offers a promising alternative to traditional viral vectors. The key factor in the development of AS lies in mutations of one or more of the <italic toggle=""yes"">COL4A3/A4/A5</italic> genes. These mutations result in the abnormal synthesis and folding of the α3/α4/α5 peptide chain. This leads to the formation of",12_36,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"peptide chain. This leads to the formation of abnormal COL4α3α4α5 trimers that are unable to support the COL4 skeleton network. The ultimate objective of gene therapy is to introduce healthy <italic toggle=""yes"">COL4A3/A4/A5</italic> genes into podocytes to replace the mutated genes, thereby producing a normal functional peptide chain to form COL4 and restore the function of the GBM. Reducing the synthesis of abnormal α3/α4/α5 peptide chains through DNA or RNA transduction could mitigate cellular",12_37,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"DNA or RNA transduction could mitigate cellular inflammation and damage, presenting an alternative gene therapy strategy. While the realization of this concept for clinical application is currently hindered by technological and material obstacles, some research studies have explored the potential of gene therapy in tackling AS. The groundbreaking discovery of gene therapy has spurred extensive research into transducing target genes into kidney cells for the treatment of diseases. The interaction among",12_38,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"the treatment of diseases. The interaction among <italic toggle=""yes"">COL4A3/A4/A5</italic> gene expression is pivotal for implementing AS gene therapy. In 2000, a team from France confirmed the transcriptional activity of <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> genes in podocytes of AS patients with <italic toggle=""yes"">COL4A5</italic> mutation, regardless of mutation type. This study underscores the potential for gene therapy to target specific mutated genes",12_39,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"for gene therapy to target specific mutated genes associated with AS, rather than transducing all genes linked to COL4 simultaneously [<xref rid=""B52-biomedicines-12-01159"" ref-type=""bibr"">52</xref>]. In a notable experiment, adenovirus containing full-length <italic toggle=""yes"">COL4A5</italic> cDNA was transfected into a <italic toggle=""yes"">COL4A5</italic> nonsense mutation-induced AS model dog. The transfected smooth muscle cells successfully expressed α5, aiding in extracellular secretion and COL4",12_40,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"α5, aiding in extracellular secretion and COL4 localization to the basement membrane [<xref rid=""B53-biomedicines-12-01159"" ref-type=""bibr"">53</xref>]. As AS is hereditary, the effectiveness of acquired treatments in reversing the disease phenotype is crucial. This was addressed in an experiment using an inducible <italic toggle=""yes"">COL4A3</italic> mouse model, where <italic toggle=""yes"">COL4A3</italic> expression was induced at various time points in <italic toggle=""yes"">COL4A3</italic>−/− mice using a",12_41,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"toggle=""yes"">COL4A3</italic>−/− mice using a doxycycline induction system. The results showed the correction of abnormal GBM in postnatally induced <italic toggle=""yes"">COL4A3</italic>−/− mice, leading to significantly decreased (or no) proteinuria compared to <italic toggle=""yes"">COL4A3</italic> knockout mice succumbing to renal failure and death by 8 weeks of age. Notably, normal GBM was observed in some mice even at 23 weeks of age. These findings establish a robust pathophysiological foundation and",12_42,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"a robust pathophysiological foundation and open up possibilities for the clinical application of gene therapy in AS treatment [<xref rid=""B6-biomedicines-12-01159"" ref-type=""bibr"">6</xref>]. The research team led by P. Heikkila in Finland conducted pioneering experiments involving adenovirus-mediated gene transduction in isolated human glomeruli in vitro. They successfully expressed the reporter gene, demonstrating the potential for gene therapy in disease treatment. Expanding on this achievement, the team",12_43,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"Expanding on this achievement, the team proceeded to perfuse the porcine renal artery for 2 h in vivo, achieving an impressive 85% reporter gene expression rate in glomerular cells [<xref rid=""B54-biomedicines-12-01159"" ref-type=""bibr"">54</xref>]. Subsequently, they endeavored to transfer the <italic toggle=""yes"">COL4A5</italic> gene using adenovirus in pigs, successfully expressing the α5 chain in porcine glomeruli and depositing it in the GBM. However, limitations, such as short duration of gene",12_44,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"limitations, such as short duration of gene expression, strong immunogenicity, adverse reactions, and the inability to repeat drug administration, were noted. Despite these limitations, the study provides valuable insights into the potential of gene therapy, instilling confidence in its feasibility. While not definitively proving the therapeutic benefits of gene therapy, the study lays a solid foundation for further research and development in this promising field [<xref rid=""B55-biomedicines-12-01159""",12_45,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"field [<xref rid=""B55-biomedicines-12-01159"" ref-type=""bibr"">55</xref>]. In addition to directly supplementing the expression of the deficient COL4 peptide chain in vivo, researchers have explored various indirect methods of gene therapy. One such method involves targeting renal microRNA-21 (miRNA-21), a molecule known to promote inflammation and cellular fibrosis. Studies have shown that levels of miRNA-21 are significantly elevated in <italic toggle=""yes"">COL4A3</italic>−/− AS mice. To counteract the",12_46,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"AS mice. To counteract the effects of miRNA-21, an anti-miRNA-21 oligonucleotide has been developed. This oligonucleotide has proven effective in reducing renal fibrosis, lowering proteinuria levels, preserving renal function, and increasing the survival rate of mice in experimental models. These findings suggest that oligonucleotide therapy targeting miRNA-21 may hold promise for treating AS and related conditions [<xref rid=""B56-biomedicines-12-01159"" ref-type=""bibr"">56</xref>]. Recent domestic studies",12_47,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"Recent domestic studies have confirmed the elevated expression of miRNA-21 in the kidney tissue of patients with AS. This increased expression of miRNA-21 is positively correlated with urine protein levels, serum creatinine levels, and the severity of renal histological injury, further establishing miRNA-21 as a potential therapeutic target for AS [<xref rid=""B57-biomedicines-12-01159"" ref-type=""bibr"">57</xref>]. However, a phase II trial of lademirsen, an anti-miRNA-21 agent, was prematurely terminated",12_48,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"anti-miRNA-21 agent, was prematurely terminated after an interim analysis revealed no significant improvement in renal function among patients treated with lademirsen compared to those given a placebo (NCT02855268; interim analysis data were collected from 24 patients who completed the 24-week double-blind treatment period). This setback dealt a blow to the progress of new drug development for AS. On a more positive note, the team led by Nozu K proposed an innovative approach by studying Alport mice with a",12_49,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"approach by studying Alport mice with a <italic toggle=""yes"">COL4A5</italic> nonsense mutation. By utilizing an antisense oligonucleotide (ASO) to target the splicing enhancer on the DNA exon containing the nonsense mutation site, they were able to induce skipping of the entire exon with the stop codon. This resulted in the transformation of a truncating mutation with a severe clinical phenotype into an in-frame deletion mutation. This modification led to reduced levels of urinary protein and creatinine,",12_50,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"reduced levels of urinary protein and creatinine, improved renal pathology, and partial restoration of α5 chain expression. This groundbreaking research offers a promising avenue for potential therapeutic interventions in AS and underscores the importance of continued exploration and innovation in the field of genetic disorders [<xref rid=""B58-biomedicines-12-01159"" ref-type=""bibr"">58</xref>]. Gene editing is also a vital aspect of gene therapy, though its success rate in vivo is currently low, making",12_51,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"its success rate in vivo is currently low, making practical application challenging. Nevertheless, pioneering researchers have developed a method to harvest podocytes from patients’ urine and administer them to individuals with AS, targeting podocytes bearing mutations in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A5</italic>. Employing an AAV vector to deliver the necessary genetic material, they were able to edit the mutant genes in vitro, achieving relatively efficient and stable",12_52,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"vitro, achieving relatively efficient and stable gene correction rates of 44.2% and 58.8% for <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A5</italic>, respectively [<xref rid=""B59-biomedicines-12-01159"" ref-type=""bibr"">59</xref>,<xref rid=""B60-biomedicines-12-01159"" ref-type=""bibr"">60</xref>]. In addition to direct gene editing, CRISPR/Cas9 has emerged as a therapeutic avenue utilizing a mutant variant, dead Cas9 (dCas9), with endonuclease defects. By activating the expression of the",12_53,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"defects. By activating the expression of the COL4A6 gene in podocytes, researchers prompted the production of COL4α5α5α6 trimers, thereby normalizing the structure and function of the GBM and alleviating disease symptoms. Similarly, inhibiting the expression of laminin subunit α2 in atherosclerosis using dCas9 bound to a transcriptional repressor showed promise in reducing podocyte injury and halting disease progression [<xref rid=""B61-biomedicines-12-01159"" ref-type=""bibr"">61</xref>]. In conclusion, we",12_54,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"ref-type=""bibr"">61</xref>]. In conclusion, we have developed a pattern diagram integrating the comprehensive summary of the primary mechanisms of Alport syndrome and the gene therapies currently under investigation (<xref rid=""biomedicines-12-01159-f001"" ref-type=""fig"">Figure 1</xref>) and the main approaches of novel therapies with their results (<xref rid=""biomedicines-12-01159-t002"" ref-type=""table"">Table 2</xref>). While research into AS gene therapy continues from various perspectives, progress in",12_55,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"continues from various perspectives, progress in this field has been relatively constrained compared to other organs or tissues. One significant hurdle lies in the selection of vectors. Although adenovirus has been extensively studied, its strong immunogenicity poses challenges by trigging significant immune responses in subjects. Additionally, adenovirus-mediated gene transduction in vivo exhibits short-lived expression, necessitating regular intermittent administration. This presents a significant",12_56,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"administration. This presents a significant obstacle to its clinical application. Furthermore, the possibility of the random integration of the lentivirus genome in subjects raises concerns among clinical researchers. While rAAV demonstrates promise as a vector for clinical applications, its small gene load presents a drawback. The gene load of rAAV is limited to approximately 4.7 kb, which decreases to 2.7 kb after excluding the target gene expression regulatory sequence. This poses a challenge, as the",12_57,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"sequence. This poses a challenge, as the protein-coding sequences of <italic toggle=""yes"">COL4A3/A4/A5</italic>, which are all approximately 5.0 kb, exceed the carrying capacity of rAAV [<xref rid=""B62-biomedicines-12-01159"" ref-type=""bibr"">62</xref>]. In conclusion, while advancements in AS gene therapy are underway, challenges related to vector selection and gene load limitation must be addressed to improve the feasibility of clinical applications in this field. On the other hand, glomerular podocytes",12_58,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"field. On the other hand, glomerular podocytes play a crucial role in expressing and secreting the COL4α3α4α5 trimer, making them the primary focus for AS gene therapy. However, targeting podocytes is challenging due to the restrictive glomerular filtration membrane. The glomerular basement membrane (GBM) typically permits only particles with a diameter of less than 10–50 nm and a molecular weight of less than 50 kD to pass through, with a charge barrier further hindering target gene transduction",12_59,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"further hindering target gene transduction efficiency through circulation [<xref rid=""B63-biomedicines-12-01159"" ref-type=""bibr"">63</xref>]. In a rat model, the use of an rAAV vector to introduce green fluorescent protein via renal artery injection resulted in expression only within the renal tubules, not the glomerulus. This suggests that renal artery injection may not be a practical method for the rAAV transduction of glomerular cells [<xref rid=""B64-biomedicines-12-01159"" ref-type=""bibr"">64</xref>].",12_60,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"ref-type=""bibr"">64</xref>]. Therefore, to explore alternative approaches, an endothelium-specific inducible transgene system was employed to induce <italic toggle=""yes"">COL4A3</italic> expression in <italic toggle=""yes"">COL4A3</italic>−/− mice. Unfortunately, this did not lead to the detection of the COL4α3α4α5 trimer or the restoration of the Alport disease phenotype [<xref rid=""B65-biomedicines-12-01159"" ref-type=""bibr"">65</xref>]. This outcome emphasizes the absence of specific factors regulating the",12_61,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"the absence of specific factors regulating the expression of <italic toggle=""yes"">COL4A3/A4/A5</italic> genes in cells other than podocytes, reaffirming podocytes as the primary target for AS gene therapy. Despite the challenges, there is still hope. While the intravenous administration of gene-therapy agents may be less effective in reaching glomerular podocytes, achieving efficient target gene transduction with higher viral doses is possible. Professor Saleem Ma’s team achieved successful gene",12_62,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"Saleem Ma’s team achieved successful gene transduction of podocin-targeting podocytes by administering a large virus dose into the tail vein of mice. This resulted in the successful expression of podocin in induced podocin knockout mice, leading to reduced levels of urinary protein, serum creatinine, and urea. Renal pathology also exhibited some degree of improvement [<xref rid=""B66-biomedicines-12-01159"" ref-type=""bibr"">66</xref>]. However, their study also revealed that using higher doses of rAAV in mice",12_63,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"revealed that using higher doses of rAAV in mice triggered an immune response, and the tail vein injection of rAAV resulted in non-target organ and cell transduction. This indicates the necessity for further refinement in delivery methods, dosages, and viral targeting. Despite these challenges, this study signifies a significant advancement in gene therapy for monogenic hereditary kidney diseases targeting the kidney and podocytes. Furthermore, a new solution to the rAAV capacity limitation has emerged.",12_64,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"to the rAAV capacity limitation has emerged. The dual AAV system design concept involves dividing longer target genes at specific sites, packaging them into different rAAV vectors for simultaneous delivery, and recombining them in target cells through homologous recombination to form full-length target genes [<xref rid=""B67-biomedicines-12-01159"" ref-type=""bibr"">67</xref>]. However, the dual AAV-mediated gene therapy system developed by Professor Yilai Shu and his team at Fudan University has shown promise",12_65,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"his team at Fudan University has shown promise in reversing bilateral deafness in Otof−/− mice, and it has demonstrated both efficacy and safety in clinical trials involving pediatric patients [<xref rid=""B68-biomedicines-12-01159"" ref-type=""bibr"">68</xref>,<xref rid=""B69-biomedicines-12-01159"" ref-type=""bibr"">69</xref>,<xref rid=""B70-biomedicines-12-01159"" ref-type=""bibr"">70</xref>]. The successful application of this dual AAV system not only introduces a novel strategy for gene therapy but also instills",12_66,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"novel strategy for gene therapy but also instills confidence in addressing a broad spectrum of diseases in urgent need of genetic intervention. As well as the dual AAV system, the transduction of mRNA to target cells via nanoparticles has also been extensively researched. The advancement in LNP has led to a reduction in their cytotoxicity, with certain isoforms capable of being metabolized by the human body without accumulating. Zhou’s study has demonstrated that mice with α-Gal A-deficiency showed a long",12_67,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"that mice with α-Gal A-deficiency showed a long duration of substrate reductions in tissues and plasma after a single intravenous injection of the mRNA-encoding human α-Gal A carried via LNP [<xref rid=""B71-biomedicines-12-01159"" ref-type=""bibr"">71</xref>]. Moreover, early clinical trials have further confirmed their safety as vectors [<xref rid=""B51-biomedicines-12-01159"" ref-type=""bibr"">51</xref>]. However, there are still considerable drawbacks to using this approach for the kidney. Nanoparticles",12_68,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"using this approach for the kidney. Nanoparticles carrying genes may indeed face challenges passing through the GBM, such as the human α-Gal A mRNA carried via LNP, mentioned earlier, with a particle size of 80–100 nm. While techniques such as reverse perfusion, direct injection into the renal interstitial, and electroporation have demonstrated efficacy in targeting mRNA to the kidney and treating glomerulonephritis in animal models, electroporation risks damaging the kidney itself, with a low benefit–risk",12_69,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"the kidney itself, with a low benefit–risk ratio. Similarly, retrograde perfusion and direct injection into the renal interstitial have been associated with severe pain and poor prognosis, potentially impacting patient compliance and limiting widespread applicability in clinical settings [<xref rid=""B72-biomedicines-12-01159"" ref-type=""bibr"">72</xref>]. Hence, it is evident that there remains a substantial journey ahead on the research path. With the increasing awareness of health and the wide usage of",12_70,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"awareness of health and the wide usage of genetic testing in clinics, there is a growing identification and diagnosis of individuals with AS. What was once a rare disease is now becoming more prevalent, highlighting the urgency to accelerate the development of targeted treatment approaches. Gene therapy emerges as a revolutionary treatment modality with the potential to cure this monogenic disorder. While gene therapy for kidney diseases is still in its nascent stages, the primary challenge lies in",12_71,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"its nascent stages, the primary challenge lies in effectively delivering therapeutic gene fragments to renal target cells. Despite this hurdle, researchers are actively exploring various animal models, carriers, and delivery methods to advance the field. By prioritizing gene therapy agents that have demonstrated success in other organs or tissues, we can leverage existing knowledge and spur innovation in AS gene therapy. Through ongoing research and experimentation, our aim is to achieve a significant",12_72,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"our aim is to achieve a significant breakthrough in the treatment of kidney diseases, offering renewed hope to patients affected by these conditions.",12_73,Exploration of Gene Therapy for Alport Syndrome,23 5 2024,,Alport_Syndrome
"Progress in therapeutic targets on podocyte for Alport syndrome Alport syndrome (AS) is a heredity disease caused by mutations in the COL4A3/4/5. The disease involves multiple organs, including the kidney, eye, ear, etc. A recent study showed that the predicted pathogenic mutation frequency of COL4A3/4 was about 1/106 and was 1/2320 in COL4A5, suggesting the underestimated prevalence of AS.<sup>[<xref rid=""j_jtim-2024-0005_ref_001"" ref-type=""bibr"">1</xref>]</sup> To improve monitoring and treatment, the",13_0,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"To improve monitoring and treatment, the Alport Classification Working Group recommended that diseases caused by COL4A3/4/5 mutations be uniformly classified as AS, and the designation of TBMN and COL4A5 “mutation carriers” be removed.<sup>[<xref rid=""j_jtim-2024-0005_ref_002"" ref-type=""bibr"">2</xref>]</sup> High-throughput sequencing further broadens the disease spectrum corresponding to COL4 mutation. It can also be seen in thin basement membrane nephropathy, focal segmental glomerulosclerosis, IgA",13_1,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"focal segmental glomerulosclerosis, IgA nephropathy, and diabetic kidney disease.<sup>[<xref rid=""j_jtim-2024-0005_ref_003"" ref-type=""bibr"">3</xref>,<xref rid=""j_jtim-2024-0005_ref_004"" ref-type=""bibr"">4</xref>,<xref rid=""j_jtim-2024-0005_ref_005"" ref-type=""bibr"">5</xref>]</sup> Hemizygous male and COL4A3/4 recessive inheritance patients have a 100% risk of progression to ESRD. Heterozygous female subjects have a risk to ESRD of approximately 25%. Renin-angiotensin-aldosterone system inhibitor has been the",13_2,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"system inhibitor has been the only standard medication for treating AS patients. The poor prognosis of this disease urgently needs more treatment.<sup>[<xref rid=""j_jtim-2024-0005_ref_002"" ref-type=""bibr"">2</xref>]</sup> As a terminally differentiated cell, persistent podocyte damage results in irreversible kidney impairment. Since the podocyte is primarily responsible for synthesizing the COL4A3/4/5 trimer in glomerular basement membrane (GBM), it plays a major role in developing this disease.<sup>[<xref",13_3,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"major role in developing this disease.<sup>[<xref rid=""j_jtim-2024-0005_ref_006"" ref-type=""bibr"">6</xref>]</sup> Until now, no specific drugs targeting podocytes have been developed since the pathogenesis of podocyte injury remains unclear. Here, we summarized the progress on mechanism research of podocytes in AS and the prospect for new therapeutic targets. Podocytes synthesize and secrete COL4A3/4/5 trimers predominantly in the kidney. Impaired trimer formation and GBM defection are two of the",13_4,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"trimer formation and GBM defection are two of the fundamental mechanisms contributing to AS progression.<sup>[<xref rid=""j_jtim-2024-0005_ref_007"" ref-type=""bibr"">7</xref>]</sup> To address this issue, editing mutated genes or introducing normal genes using the CRISPR/Cas9 technique or Antisense-oligonucleotides (ASO) has been conducted to prevent or slow disease progression. Daga <italic toggle=""yes"">et al</italic>. have successfully corrected Col4A3 and Col4A5 mutations in urine-derived podocytes using",13_5,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"Col4A5 mutations in urine-derived podocytes using dual-plasmid CRISPR/Cas9 gene editing. However, this approach still needs to be verified in future <italic toggle=""yes"">in vivo</italic> studies.<sup>[<xref rid=""j_jtim-2024-0005_ref_008"" ref-type=""bibr"">8</xref>]</sup> Another study showed an exon-skipping therapy using ASO to reduce disease severity in male X-linked AS.<sup>[<xref rid=""j_jtim-2024-0005_ref_009"" ref-type=""bibr"">9</xref>]</sup> This therapy selectively skipped a targeted exon containing a",13_6,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"selectively skipped a targeted exon containing a premature termination codon mutation and corrected the open reading frame. As a result, exon-skipping therapy can re-express the COL4α5 chain on glomerular and tubular basement membranes, significantly reducing proteinuria and prolonging survival in AS mice. In summary, CRISPR/Cas9 gene editing could completely correct all kinds of mutation in podocyte and therefore synthesize normal COL4α3/4/5 trimers, but concerns exist about off-target effect and lack of",13_7,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"exist about off-target effect and lack of <italic toggle=""yes"">in vivo</italic> validation. ASO therapy to skip the exon where the mutation is located, was used in truncated COL4α3/4/5 resulting from nonsense or splicing mutations. Although this is not a complete recovery, it can significantly improve the patients’ prognosis by changing the mutation types. In some cases, COL4A3/4/5 are truncated due to nonsense variants or premature termination codons (PTCs). Drug-induced PTC readthrough is a promising",13_8,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"Drug-induced PTC readthrough is a promising therapeutic strategy and has been well studied in other genetic diseases like cystic fibrosis and duchenne muscular dystrophy.<sup>[<xref rid=""j_jtim-2024-0005_ref_010"" ref-type=""bibr"">10</xref>,<xref rid=""j_jtim-2024-0005_ref_011"" ref-type=""bibr"">11</xref>]</sup> Excitingly, a study showed that 11 nonsense variants from AS patients were highly sensitive to aminoglycoside-mediated PTC readthrough, suggesting a fraction of patients could benefit from such",13_9,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"a fraction of patients could benefit from such therapy.<sup>[<xref rid=""j_jtim-2024-0005_ref_012"" ref-type=""bibr"">12</xref>]</sup> ELX-02 is a small-molecule eukaryotic ribosomal selective glycoside acting to induce read-through of PTCs. A Phase 2 open label pilot study to evaluate the safety and efficacy of ELX-02 in patients with X-linked or autosomal recessive AS with Col4A3/4/5 nonsense mutation is currently recruiting patients. Studies have shown that injecting healthy mouse or human embryonic stem",13_10,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"injecting healthy mouse or human embryonic stem cells into COL4 α 3 knockout mice promoted the re-synthesis of the COL4 α 3 chain, reshaped the GBM structure, and eventually improved the renal function of AS mice.<sup>[<xref rid=""j_jtim-2024-0005_ref_013"" ref-type=""bibr"">13</xref>]</sup> Our group demonstrated that intravenous injection of human umbilical cord mesenchymal stem cells into COL4A3 mutant mice attenuated proteinuria and renal pathological damages, and the expression of the COL4A3 chains was",13_11,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"and the expression of the COL4A3 chains was also restored to some extent.<sup>[<xref rid=""j_jtim-2024-0005_ref_014"" ref-type=""bibr"">14</xref>]</sup> Stem cell therapy might be a promising treatment option for AS patients in the future. Unfold protein reaction (UPR) promotes the synthesis of molecular chaperones involving protein folding that prevents cells from stress at an early stage. However, the mutations resulting in persistent UPR could become maladaptive and cytotoxic.<sup>[<xref",13_12,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"become maladaptive and cytotoxic.<sup>[<xref rid=""j_jtim-2024-0005_ref_015"" ref-type=""bibr"">15</xref>]</sup> Endoplasmic reticulum stress (ERS) has been discussed in many kidney diseases, including diabetic nephropathy, acute kidney injury, and chronic kidney disease.<sup>[<xref rid=""j_jtim-2024-0005_ref_015"" ref-type=""bibr"">15</xref>,<xref rid=""j_jtim-2024-0005_ref_016"" ref-type=""bibr"">16</xref>]</sup> COL4A3/4/5 mutations cause abnormal or defective proteins that fail to fold correctly. These misfolded",13_13,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"that fail to fold correctly. These misfolded proteins accumulate in the ER, leading to UPR and ERS.<sup>[<xref rid=""j_jtim-2024-0005_ref_017"" ref-type=""bibr"">17</xref>,<xref rid=""j_jtim-2024-0005_ref_018"" ref-type=""bibr"">18</xref>]</sup> One of our previous studies also indicated that MG132 (a proteasome inhibitor) intervention improved ERS-related apoptosis in podocytes with truncated COL4A3 mutation.<sup>[<xref rid=""j_jtim-2024-0005_ref_019"" ref-type=""bibr"">19</xref>]</sup> A study in fibroblast cell",13_14,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"A study in fibroblast cell lines of men with XLAS further showed Sodium 4-phenylbutyrate enhanced COL4α5 transcript levels, reduced ERS, and possibly facilitated COL4A5 extracellular transport.<sup>[<xref rid=""j_jtim-2024-0005_ref_020"" ref-type=""bibr"">20</xref>]</sup> Thus, some molecular chaperone molecules that are able to alleviate ER stress in podocytes might be a promising therapeutic approach for delaying AS progression. The cell cycle is composed of Gap 1 (G1), DNA synthesis (S), Gap 2 (G2), and",13_15,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"of Gap 1 (G1), DNA synthesis (S), Gap 2 (G2), and mitosis (M). The progression of cells through different phases of the cell cycle is mediated by cyclins and cyclin - dependent kinases (CDKs). Manipulating CDKs like CDK4/6 inhibitors has been used in halting tumor growth.<sup>[<xref rid=""j_jtim-2024-0005_ref_021"" ref-type=""bibr"">21</xref>]</sup> However, these approaches have not been thoroughly studied in glomerular disease. Research has revealed that increasing detachment of podocytes was detected in AS",13_16,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"detachment of podocytes was detected in AS patients’ urine. Ding <italic toggle=""yes"">et al</italic>. reported that the podocyte detachment rate increased 11-fold in the mutant compared to the control condition, and glomeruli lost an average of 26 podocytes per year in AS versus the controls, which equals to 2.3 podocytes per year.<sup>[<xref rid=""j_jtim-2024-0005_ref_022"" ref-type=""bibr"">22</xref>]</sup> After loss of podocytes in glomeruli, remaining podocytes reenter the cell cycle to become",13_17,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"podocytes reenter the cell cycle to become hypertrophy, which may help to cover more area on the GMB as compensation.<sup>[<xref rid=""j_jtim-2024-0005_ref_023"" ref-type=""bibr"">23</xref>]</sup> Using proteomic analysis, Frank <italic toggle=""yes"">et al</italic>. found an increasing fraction of podocytes in G1 or later cell cycle stages in XLAS mice. The podocyte becomes hypertrophic with the transition from G0 to G1.<sup>[<xref rid=""j_jtim-2024-0005_ref_024"" ref-type=""bibr"">24</xref>]</sup> Another study",13_18,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"ref-type=""bibr"">24</xref>]</sup> Another study showed a significant decrease in cyclin kinase inhibitors (p27, P21) expression in the kidneys of children with AS.<sup>[<xref rid=""j_jtim-2024-0005_ref_025"" ref-type=""bibr"">25</xref>]</sup> Therefore, cell cycle dysregulation may contribute to the pathogenesis of AS. Numerous studies proposed that cholesterol deposition plays a vital role in Alport nephropathy. Wright <italic toggle=""yes"">et al</italic>. showed that Col4a3 knockout mice exhibited",13_19,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"showed that Col4a3 knockout mice exhibited significantly elevated cholesterol accumulation in glomeruli and decreased expression of ABCA1, a gene related to cholesterol efflux and transport.<sup>[<xref rid=""j_jtim-2024-0005_ref_026"" ref-type=""bibr"">26</xref>]</sup> Non-selective cholesterol scavenger hydroxypropyl-β-cyclodextrin (HPβCD) mitigates renal cortex cholesterol accumulation, reduces proteinuria, and alleviates renal tissue inflammation and fibrosis.<sup>[<xref rid=""j_jtim-2024-0005_ref_026""",13_20,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"rid=""j_jtim-2024-0005_ref_026"" ref-type=""bibr"">26</xref>]</sup> Sterol-O-acyltransferase-1 (SOAT1) can convert free cholesterol to cholesteryl esters. Inhibition of SOAT1 reduces cholesterol esters in podocytes and promotes free cholesterol efflux through upregulation of ABCA1, thereby attenuating renal damage in AS mice.<sup>[<xref rid=""j_jtim-2024-0005_ref_027"" ref-type=""bibr"">27</xref>]</sup> Another study also found that COL1-mediated discoid domain receptor 1 (DDR1) activation in Col4α3 knockout mice",13_21,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"1 (DDR1) activation in Col4α3 knockout mice promoted fatty acid uptake by podocytes <italic toggle=""yes"">via</italic> CD36 and triggered cellular lipo-toxicity. <sup>[<xref rid=""j_jtim-2024-0005_ref_028"" ref-type=""bibr"">28</xref>]</sup> Thus, drugs that reduce serum cholesterol level such as Ezetimibe, Atorvastatin or small molecules that target ABCA1, SOAT1, and CD36 could be potential approach to treat AS. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) empagliflozin has shown its potential in",13_22,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"(SGLT2i) empagliflozin has shown its potential in treating AS mice model <italic toggle=""yes"">via</italic> switching energy substrates from glucose to fatty acids in podocytes, leading to downregulated lipo-toxicity and improved kidney.<sup>[<xref rid=""j_jtim-2024-0005_ref_029"" ref-type=""bibr"">29</xref>]</sup> Excitingly, a phase 3 clinical trial with Dapagliflozin (NCT05944016) is starting to recruit AS in children and young adults at the early stages of the disease. Altogether, these data indicate that",13_23,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"the disease. Altogether, these data indicate that designing drugs targeting lipid metabolism and mitochondria is a meaningful direction for AS treatment. Furthermore, COL4α3/4/5 defects resulted in sustained expression of the COL4α1/1/2 trimer in GBM, which exists only in the developmental stages of the kidney.<sup>[<xref rid=""j_jtim-2024-0005_ref_007"" ref-type=""bibr"">7</xref>]</sup> Abnormal collagen deposition causes podocyte injury by activating collagen receptors, like DDR1 and integrin α2β. Integrin",13_24,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"receptors, like DDR1 and integrin α2β. Integrin α2β1 deletion attenuated glomerulosclerosis and interstitial fibrosis in AS mice.<sup>[<xref rid=""j_jtim-2024-0005_ref_030"" ref-type=""bibr"">30</xref>]</sup> Loss of collagen-receptor DDR1 delayed renal fibrosis and reduced inflammation of AS mice.<sup>[<xref rid=""j_jtim-2024-0005_ref_031"" ref-type=""bibr"">31</xref>]</sup> However, selective DDR1 or Integrinα2β1 antagonist has not been developed. Additionally, endothelin-1 (ET-1) produced by glomerular",13_25,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"endothelin-1 (ET-1) produced by glomerular endothelial cells binds to endothelin A receptors expressed in mesangial cells, causing Laminin α2β1γ1 secretion and deposition in GBM. Ectopic Laminin α2 deposition in GBM activates nuclear factor ϰB (NF-ϰB), stimulates podocyte focal adhesion kinase, and increases the expression of matrix metalloproteinases and proinflammatory factors.<sup>[<xref rid=""j_jtim-2024-0005_ref_032"" ref-type=""bibr"">32</xref>,<xref rid=""j_jtim-2024-0005_ref_033""",13_26,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"rid=""j_jtim-2024-0005_ref_033"" ref-type=""bibr"">33</xref>]</sup> A Phase 2 clinical trial (AFFINITY) has been initiated to assess the efficacy and safety of Atrasentan, a selective endothelin receptor antagonist, in patients with proteinuric glomerular disease, including 20 patients with AS. Finally, oxidative stress and subsequent activation of inflammation are also important factors contributing to the development of podocyte injuries in Alport syndrome. Nuclear factor erythroid2-related factor2 (Nrf2)",13_27,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"Nuclear factor erythroid2-related factor2 (Nrf2) has recently been regarded as a major role in regulating cellular oxidative stress in podocytes. Under stress conditions, Keap1 separated from Nrf2, and Nrf2 transferred to the nucleus, promoting the expression of genes carrying antioxidant response elements and initiating antioxidation.<sup>[<xref rid=""j_jtim-2024-0005_ref_034"" ref-type=""bibr"">34</xref>,<xref rid=""j_jtim-2024-0005_ref_035"" ref-type=""bibr"">35</xref>]</sup> Nrf2 also suppresses transcription",13_28,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"Nrf2 also suppresses transcription of inflammation-related genes by inhibiting NK-ϰB activation.<sup>[<xref rid=""j_jtim-2024-0005_ref_035"" ref-type=""bibr"">35</xref>]</sup> A Phase 3 clinical trial (CARDINAL) has been conducted to investigate the safety and efficacy of bardoxolone in treating patients with AS. However, the trial’s outcomes were unsatisfactory.<sup>[<xref rid=""j_jtim-2024-0005_ref_036"" ref-type=""bibr"">36</xref>]</sup> NOX4 is the major renal reactive oxygen species (ROS) source and is",13_29,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"renal reactive oxygen species (ROS) source and is abundantly expressed in podocytes.<sup>[<xref rid=""j_jtim-2024-0005_ref_037"" ref-type=""bibr"">37</xref>]</sup> Our earliest research found that NOX4 and ROS were significantly upregulated in patients with ADAS, and increased MMP-2 and podocyte apoptosis could be rescued by NOX4 inhibition <italic toggle=""yes"">in vivo</italic> and in vitro.<sup>[<xref rid=""j_jtim-2024-0005_ref_038"" ref-type=""bibr"">38</xref>]</sup> A recent study demonstrated that",13_30,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"A recent study demonstrated that Mineralocorticoid receptor antagonist finerenone protected Col4a3-/- mice by suppressing the residual interstitial inflammation and fibrosis,<sup>[<xref rid=""j_jtim-2024-0005_ref_039"" ref-type=""bibr"">39</xref>]</sup> further studies are required to pinpoint finerenone’s precise mechanism on podocytes. We speculate that drugs targeting NF-kB activation and reducing ROS production in podocytes will effectively improve patients’ prognosis. To summarize, the podocyte injury in",13_31,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"prognosis. To summarize, the podocyte injury in AS is primarily caused by ERS, cell cycle dysregulation, lipid toxicity, inflammation, oxidation stress, and abnormal downstream cell signaling activation (<xref rid=""j_jtim-2024-0005_fig_001"" ref-type=""fig"">Figure 1</xref>). Enabling podocytes to express the correct COL4A3/4/5 through gene editing or transferring the corrected COL4A3/4/5 gene into podocytes might be the most effective way to cure the disease. Delaying the onset of the disease and reducing",13_32,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"Delaying the onset of the disease and reducing the disease progression are also essential for management of this disease. Preventing the generation of truncated proteins by exon skipping or PTCs readthrough therapy, Reducing ERS by molecular chaperone, decreasing cell detachment by modification of cell cycle, promoting lipid metabolism or cholesterol efflux in podocyte, and inhibiting inflammatory response and oxidative stress are all potential therapeutic approaches to ameliorate podocyte injury in AS.",13_33,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"<fig position=""float"" id=""j_jtim-2024-0005_fig_001"" fig-type=""figure""><label>Figure 1</label><caption><p>Pathogenic mechanisms of intrinsic cells and basement membrane in glomerulus of Alport syndrome. Created with BioRender.</p></caption><graphic http://www.w3.org/1999/xlink href=""j_jtim-2024-0005_fig_001"" position=""float""></graphic></fig>",13_34,Progress in therapeutic targets on podocyte for Alport syndrome,21 5 2024,,Alport_Syndrome
"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation Alport syndrome (AS) is clinically characterized by hematuria, proteinuria, and progressive renal dysfunction. Some patients exhibit extrarenal manifestations including sensorineural hearing loss (SNHL) and eye lesions (<xref rid=""r1"" ref-type=""bibr"">1</xref>). The renal dysfunction progresses to chronic kidney disease and end-stage kidney disease (ESKD) (<xref rid=""r2""",14_0,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"end-stage kidney disease (ESKD) (<xref rid=""r2"" ref-type=""bibr"">2</xref>). AS is the second-most common genetic kidney disease after autosomal-dominant polycystic kidney disease (<xref rid=""r3"" ref-type=""bibr"">3</xref>). Growth hormone (GH) deficiency is common in children, manifesting as short stature and developmental delay. Although AS and GH deficiency have been studied independently, no report has yet used recombinant human GH (rhGH) to treat GH deficiency in a patient with AS. We report the clinical",14_1,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"in a patient with AS. We report the clinical manifestations, renal pathology, gene mutations, and treatment of a child with autosomal dominant AS (ADAS) caused by a novel mutation in the <italic toggle=""yes"">COL4A4</italic> gene, with a literature review. ADAS is uncommon; our report extends the ADAS mutational spectrum. Although there has been no report on AS combined with GH deficiency, clinicians should comprehensively assess and appropriately treat all suspected AS patients. We present this case in",14_2,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"suspected AS patients. We present this case in accordance with the CARE reporting checklist (available at <ext-link http://www.w3.org/1999/xlink href=""https://tp.amegroups.com/article/view/10.21037/tp-23-569/rc"" ext-link-type=""uri"">https://tp.amegroups.com/article/view/10.21037/tp-23-569/rc</ext-link>).  AS is a hereditary, phenotypically heterogeneous disease that principally affects the glomeruli, the inner ear (the cochlea), and the basilar membrane of the eye; the incidence is approximately 1/10,000 to",14_3,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"eye; the incidence is approximately 1/10,000 to 1/5,000. The disease was first described by Arthur C. Alport in 1927. Also known as eye-ear-renal syndrome, AS is an inherited progressive nephritis caused by mutations in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, or <italic toggle=""yes"">COL4A5</italic> genes that encode type IV collagen (<xref rid=""r7"" ref-type=""bibr"">7</xref>). There are primarily three genetic types: X-linked-dominant inheritance (XL),",14_4,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"types: X-linked-dominant inheritance (XL), autosomal-recessive inheritance (AR), and autosomal-dominant inheritance (AD), as well as the recently proposed digenic AS (<xref rid=""r9"" ref-type=""bibr"">9</xref>-<xref rid=""r11"" ref-type=""bibr"">11</xref>). Variation in <italic toggle=""yes"">COL4A5</italic> (XL) due to deletions, duplications, substitutions, or splicing mutations are found in about 80% of AS patients. AR and AD <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> mutations",14_5,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"or <italic toggle=""yes"">COL4A4</italic> mutations (in chromosome 2) are less common. AS, with its various genetic modes of inheritance, exhibits heterogeneity in both genotype and phenotype (<xref rid=""r12"" ref-type=""bibr"">12</xref>). However, the vast majority of AS patients will progress to ESKD, making it one of the major genetic kidney diseases that lead to renal failure (<xref rid=""r9"" ref-type=""bibr"">9</xref>). We report the clinical manifestations and mutation of a patient with ADAS caused by a",14_6,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"and mutation of a patient with ADAS caused by a <italic toggle=""yes"">COL4A4</italic> mutation, and an analysis of three family members. All exhibited microscopic hematuria. The father is currently 40 years of age and the grandmother is 70. However, they do not exhibit ESKD, eye damage, and any hearing abnormalities. The literature indicates that hematuria is the most common clinical manifestation of ADAS; all other manifestations are very variable. Proteinuria is the second-most common manifestation. The",14_7,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"is the second-most common manifestation. The incidences of eye and hearing problems are low (<xref rid=""r12"" ref-type=""bibr"">12</xref>,<xref rid=""r13"" ref-type=""bibr"">13</xref>). ADAS pathogenesis is attributable to mutation of <italic toggle=""yes"">COL4A4</italic> (NM_000092) on chromosome 2. The 48 exons encode the type IV collagen α4 chain (1,690 amino acids) (<xref rid=""r14"" ref-type=""bibr"">14</xref>). Type IV collagen is the principal structural component of the GBM and consists of six different α",14_8,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"of the GBM and consists of six different α chains (α1 to α6), three of which combine to form a triple helix. The complete α chain includes a 7S amino-terminal region, an NC1 carboxy-terminal region, and a long collagen domain composed of approximately 1,400 Gly XY (X and Y are other amino acids) repeat units (<xref rid=""r15"" ref-type=""bibr"">15</xref>,<xref rid=""r16"" ref-type=""bibr"">16</xref>). The various α chains are expressed differently in various tissues; the glomerular basement, cochlear basement, and",14_9,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"the glomerular basement, cochlear basement, and lens basement membranes principally feature the α3-α4-α5 triplet where the Bowman α5-α5-α6 triplet is mainly expressed in the basement membranes of cysts and skin (<xref rid=""r17"" ref-type=""bibr"">17</xref>,<xref rid=""r18"" ref-type=""bibr"">18</xref>). We found a <italic toggle=""yes"">COL4A4</italic> mutation that deletes bases 2317–2318, changing arginine 773 to glycine (thus p.R773Gfs*14), and triggering termination at position 786. This mutation changes the",14_10,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"at position 786. This mutation changes the protein structure, compromising formation of the α3-α4-α5 triple helices of the glomerulus, cochlea, and lens basement membranes. The mutation has not been reported previously; we thus expand the ADAS mutational spectrum. This will aid future clinical research. The impact of heterozygous <italic toggle=""yes"">COL4A4</italic> mutations on renal function varies among individuals. Carriers may demonstrate compensatory mechanisms that partially alleviate the impact on",14_11,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"mechanisms that partially alleviate the impact on renal function, particularly in the early stages of the disease, where a normal allele can produce sufficient functional collagen to temporarily maintain the integrity of the GBM. The progression to renal impairment in individuals carrying a heterozygous mutation may be slower or less severe; however, as time progresses and the cumulative damage surpasses the kidney’s capacity for compensation, deterioration can occur, a process influenced by the patient’s",14_12,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"can occur, a process influenced by the patient’s age (<xref rid=""r12"" ref-type=""bibr"">12</xref>). The absence of AS symptoms in this child may be partly attributed to the patient’s younger age. The severity and onset of AS symptoms exhibit considerable variability among individuals. In the early stages, younger patients may not display typical AS symptoms, attributable to slow disease progression, robust renal compensatory abilities, and individual variability in symptom presentation. This observation",14_13,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"in symptom presentation. This observation underscores the importance of early diagnosis and monitoring in younger patients to promptly identify and manage disease progression (<xref rid=""r19"" ref-type=""bibr"">19</xref>). ADAS diagnosis is principally based on clinical manifestations, family history, EM of renal biopsy tissue, immunofluorescent staining of the basement membrane type IV collagen α chain, and genetic analysis. The criteria of the 2023 Expert Recommendations for the Diagnosis and Treatment of",14_14,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"for the Diagnosis and Treatment of AS (<xref rid=""r6"" ref-type=""bibr"">6</xref>) are: (I) renal tissue EM reveals changes including splitting, layering, uneven thickness, or a lattice-like pattern in the GBM; (II) immunofluorescence staining of renal tissue shows abnormal expression of type IV collagen α3, α4, α5 chains in the GBM or abnormal expression of the type IV collagen α5 chain in the extraglomerular basement membrane (EBM); (III) genetic testing indicates pathogenic variants in the <italic",14_15,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"indicates pathogenic variants in the <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, or <italic toggle=""yes"">COL4A5</italic> genes, including variants classified as possibly pathogenic according to ACMG criteria. Clinical presentation primarily includes persistent hematuria of glomerular origin or hematuria accompanied by proteinuria. A diagnosis of AS can be established if any of these criteria are met. In a pedigree with three affected individuals, all presenting with",14_16,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"three affected individuals, all presenting with hematuria and meeting the diagnostic criteria for AS, genetic testing revealed a heterozygous mutation in <italic toggle=""yes"">COL4A4</italic>. Pedigree analysis is consistent with autosomal recessive inheritance, confirming the diagnosis of ADAS. There is no cure or useful treatment for AS. The aim is to slow down disease progression via early drug treatment (<xref rid=""r20"" ref-type=""bibr"">20</xref>), thereby delaying ESKD development; when ESKD happens,",14_17,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"delaying ESKD development; when ESKD happens, renal replacement therapy is required (<xref rid=""r21"" ref-type=""bibr"">21</xref>). The current treatment methods include early renin-angiotensin-aldosterone system (RAAS) blockers to delay kidney disease progression followed by second-line angiotensin receptor blockers (ARBs) and aldosterone inhibitors (<xref rid=""r22"" ref-type=""bibr"">22</xref>,<xref rid=""r23"" ref-type=""bibr"">23</xref>). AS patients with only hematuria should not then be commenced on",14_18,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"only hematuria should not then be commenced on acetylcholine esterase inhibitor (ACEI) treatment, but the status of hematuria with microalbuminuria or proteinuria should be closely monitored. If repeated infections develop, RAAS blockers should commence when microalbuminuria recurs (urinary ACR >30 mg/g). Other AS/anti-inflammatory/anti-fibrosis drugs remain under development; some, such as bardoxolone methyl, are in phase III clinical trials (<xref rid=""r24"" ref-type=""bibr"">24</xref>). However, medical",14_19,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"ref-type=""bibr"">24</xref>). However, medical evidence of efficacy is lacking; there are no current recommendations. Our proband presented with hematuria and proteinuria once during follow-up. She received an ACEI for more than 5 months. She currently does not exhibit proteinuria, but long-term follow-up is still needed. The father and grandmother are scheduled for close follow-up in terms of the urinary ACR, the urinary protein level, and renal function. If albuminuria develops, RAAS blockers will be",14_20,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"If albuminuria develops, RAAS blockers will be considered. Our NGS analysis found no significant variants in GH1, GHRHR, or BTK related to the observed phenotype. Although we couldn’t directly link the <italic toggle=""yes"">COL4A4</italic> mutation to GH deficiency, GH and IGF-1’s impact on renal function highlights a promising area for further research in AS, potentially key to deciphering its disease mechanisms and formulating treatments. The kidney is a target organ of both GH and IGF-1. Both materials",14_21,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"target organ of both GH and IGF-1. Both materials regulate glomerular hemodynamics and the tubular processing of water, sodium, calcium, and phosphorus. GH increases the levels of mRNA encoding IGF-1 in the kidneys of hypophysectomized rats, and the IGF-1 levels in renal venous blood are higher than those in renal arterial blood (<xref rid=""r25"" ref-type=""bibr"">25</xref>), indicating that GH stimulates kidney IGF-1 expression. Long-term administration of recombinant human IGF-1 (rh-IGF-1) increases kidney",14_22,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"human IGF-1 (rh-IGF-1) increases kidney size and improves the glomerular filtration rate (GFR) in hypophysectomized rats, implying that IGF-1 acts directly on the kidney to support glomerular function (<xref rid=""r26"" ref-type=""bibr"">26</xref>). However, some studies have found that excessive GH levels trigger kidney hypertrophy. In mice overexpressing GH, the IGF-1 level increases, triggering kidney hypertrophy and (sometimes) glomerulosclerosis and renal failure (<xref rid=""r27""",14_23,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"and renal failure (<xref rid=""r27"" ref-type=""bibr"">27</xref>,<xref rid=""r28"" ref-type=""bibr"">28</xref>). Mice overexpressing IGF-1 exhibit kidney enlargement but not glomerulosclerosis, implying that excessive GH and IGF-1 levels have different effects on the kidneys (<xref rid=""r26"" ref-type=""bibr"">26</xref>). In summary, appropriate GH prescription may enhance kidney function and delay ESKD progression. However, excess GH may accelerate kidney deterioration. Several long-term studies have found that the",14_24,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"Several long-term studies have found that the GH doses for children with GH deficiency recommended by the current guidelines are safe; kidney function is not affected (<xref rid=""r29"" ref-type=""bibr"">29</xref>,<xref rid=""r30"" ref-type=""bibr"">30</xref>). In summary, this article reports a case of a child diagnosed with autosomal recessive AS with concomitant GH deficiency. Genetic testing revealed a novel heterozygous frameshift mutation, c.2317_2318delAG (p.R773Gfs*14). After receiving PEG-rhGH treatment",14_25,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"After receiving PEG-rhGH treatment for 1 year, the child’s height increased from 112.1 to 120 cm, with a ∆HtSDS value of 0.51 SD. These observations demonstrate that PEG-rhGH can quickly improve the height of ADAS patients without causing kidney damage, increased intracranial pressure, or thyroid dysfunction. Further follow-up until adulthood will be required to establish the long-term impact on the final height in adulthood.",14_26,"A case report: Alport syndrome and growth hormone deficiency associated with a new <italic toggle=""yes"">COL4A4</italic> mutation",17 5 2024,,Alport_Syndrome
"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome Alport Syndrome (AS) is a genetic kidney disorder characterized by progressive hearing loss and atypical eye symptoms, resulting in a poor prognosis and lack of effective targeted therapy. The primary mode of inheritance is X-linked dominant (XLAS) due to variants in the <italic toggle=""yes"">COL4A5</italic> gene. This",15_0,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"<italic toggle=""yes"">COL4A5</italic> gene. This study revealed a previously unidentified alternative form of the <italic toggle=""yes"">COL4A5</italic> gene, namely, the c.4822–10T>C variant, which was confirmed through <italic toggle=""yes"">in vitro</italic> experiments. To investigate the impact of a splicing variant on <italic toggle=""yes"">COL4A5</italic> mRNA production, an <italic toggle=""yes"">in vitro</italic> minigene splicing assay was utilized. Additionally, molecular dynamics was employed to predict",15_1,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"molecular dynamics was employed to predict the ability of α5(IV) to form a triple helix. Results from the experiment revealed that the wild-type (WT) plasmid produced two distinct mRNA products simultaneously. Sequence analysis using the BLAST database revealed a 173-bp deletion in the mRNA sequence of the first product, indicating a potential similarity to the XM_016942897.2 transcript of <italic toggle=""yes"">Pan troglodytes</italic>. The second mRNA product of the WT plasmid contained the full sequence",15_2,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"of the WT plasmid contained the full sequence of exons 51, 52, and 53, as anticipated. Conversely, the mutant (MT) plasmid generated a single mRNA product with a 173-bp deletion in exon 52, leading to the identification of the mature mRNA expression as NM_033380.2: COL4A5: c.4822_4994del. In the context of nonsense-mediated mRNA decay (NMD), the deletion c.4822_4994 results in the production of a truncated protein, p.His1608*, that terminates prematurely. This truncated protein may disrupt the secondary",15_3,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"This truncated protein may disrupt the secondary structure of α5(IV) and potentially cause an abnormal conformation of α345(IV). This study examines the relationship between the variable splicing pattern in the NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene in XLAS patients and the presence of the <italic toggle=""yes"">COL4A5</italic> gene splice variant c.4822–10T>C. Our findings indicate that the c.4822–10T>C splice variant leads to activation of nonsense-mediated mRNA degradation",15_4,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"activation of nonsense-mediated mRNA degradation (NMD) and reduced <italic toggle=""yes"">COL4A5</italic> mRNA expression, resulting in inadequate synthesis of the corresponding proteins. This aligns with the patient’s immunofluorescence results showing negative α5(IV) chain presence at the glomerular basement membrane, bursa, and tubular basement membrane, confirming the pathogenic nature of c.4822–10T>C. Alport syndrome (AS) is an inherited condition marked by the gradual deterioration of the kidneys,",15_5,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"by the gradual deterioration of the kidneys, hearing loss, and abnormalities in the eyes (<xref rid=""B9"" ref-type=""bibr"">Nozu et al., 2019</xref>). AS is caused by a variant in one of the genes <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, or <italic toggle=""yes"">COL4A5</italic>, which encode the α3-α5 chains of type IV collagen (Col-IV). There are three subtypes of AS, which are categorized according to the way it is inherited: X-linked (XLAS), autosomal recessive (ARAS), and",15_6,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"X-linked (XLAS), autosomal recessive (ARAS), and autosomal dominant (ADAS). More precisely, XLAS is the result of a variant in the <italic toggle=""yes"">COL4A5</italic> gene, which is responsible for producing α5(IV). With the progression of sequencing technology, an increasing number of variants that may result in anomalous splicing have been uncovered (<xref rid=""B3"" ref-type=""bibr"">Groopman et al., 2019</xref>; <xref rid=""B12"" ref-type=""bibr"">Yamamura et al., 2019</xref>). Validating the underlying",15_7,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"et al., 2019</xref>). Validating the underlying pathogenic mechanism is essential for determining the pathogenicity of these variants, but it requires <italic toggle=""yes"">in vitro</italic> experimental data (<xref rid=""B10"" ref-type=""bibr"">Nozu et al., 2014</xref>; <xref rid=""B2"" ref-type=""bibr"">Gao et al., 2020</xref>). Therefore, we propose that the examination of functional analysis, such as the minigene splicing assay, can help clarify the disease-causing potential of splicing variants that have",15_8,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"potential of splicing variants that have uncertain significance. By using the minigene splicing assay, it becomes possible to assess the effects of changes on splicing mechanisms without requiring a sample from the patient’s cells. The purpose of this study was to assess the accuracy and possible outcomes of a newly identified splicing variant in the <italic toggle=""yes"">COL4A5</italic> gene. We explained the techniques that can detect the harmfulness of splicing variants that could lead to AS.",15_9,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"of splicing variants that could lead to AS. Additionally, we presented a new method to predict the impact of the variants in the <italic toggle=""yes"">COL4A5</italic> gene on α345(IV) trimerization using molecular dynamics.   A strong association between genotype and phenotype (<xref rid=""B6"" ref-type=""bibr"">Jais et al., 2000</xref>; <xref rid=""B4"" ref-type=""bibr"">Gross et al., 2002</xref>; <xref rid=""B1"" ref-type=""bibr"">Bekheirnia et al., 2010</xref>) exists in XLAS. According to Jais et al., people who",15_10,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"in XLAS. According to Jais et al., people who have significant deletions and variants that cause premature termination of protein synthesis have a 90% probability of developing end-stage renal disease (ESRD) before reaching the age of 30. On the other hand, individuals with variants affecting the splicing sites face a 70% risk, while those with variants resulting in amino acid substitutions have a 50% risk (<xref rid=""B6"" ref-type=""bibr"">Jais et al., 2000</xref>). The individual being examined in this",15_11,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"The individual being examined in this research displayed continuous blood in urine and slight presence of albumin in urine since the age of 5, without any associated hearing loss or eye abnormalities. Although the patient’s current condition appears to be mild, the early appearance of symptoms indicates a possibly severe phenotype. AS was confirmed by electron microscopic examination of the glomerular basement membrane, which revealed characteristic irregular thinning and thickening, along with diffuse",15_12,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"thinning and thickening, along with diffuse basket weaving patterns. The <italic toggle=""yes"">COL4A5</italic> gene in this patient had a c.4822–10T>C variation that was not found in the gnomAD database. The parents of the patient showed no signs of kidney disease. The patient’s mother had a WT <italic toggle=""yes"">COL4A5</italic> gene and did not carry the same variant. Nevertheless, the father refused to undergo genetic testing, resulting in the unknown status of his <italic toggle=""yes"">COL4A5</italic>",15_13,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"of his <italic toggle=""yes"">COL4A5</italic> genotype. In order to evaluate the influence of the c.4822–10T>C variant on the main splicing locations, an analysis was performed utilizing different bioinformatics tools such as SpliceAI, dbscSNV_ADA, dbscSNV_RF, and varSEAK. The c.4822–10T>C variation is consistently associated with abnormal mRNA splicing, as indicated by multiple studies (<xref rid=""B8"" ref-type=""bibr"">Malone et al., 2017</xref>; <xref rid=""B5"" ref-type=""bibr"">Horinouchi et al., 2019</xref>).",15_14,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"ref-type=""bibr"">Horinouchi et al., 2019</xref>). Through our <italic toggle=""yes"">in vitro</italic> experiments, we have ultimately verified that this alteration leads to the truncation of the protein. This determination will aid in the analysis of genotype-phenotypic correlation in the patient and facilitate future predictions regarding disease progression. The GBM is composed of multiple triple helices, including α3(IV), α4(IV), and α5(IV), that join together. When there is a pathogenic variant in the",15_15,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"When there is a pathogenic variant in the encoding gene, causing a defect in one of these α chains, the GBM deteriorates, leading to the splitting of the lamina densa and resulting in the occurrence of the basket weave change. These modifications expedite the progression of glomerular sclerosis and result in impaired kidney function. The α5(IV) chains are affected by a pathogenic variant in the protein-coding gene <italic toggle=""yes"">COL4A5</italic>, leading to XLAS. This genetic alteration can result in",15_16,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"to XLAS. This genetic alteration can result in two possibilities: either a total absence or reduction of the α5-chain protein, or a protein with amino acid replacement or addition that maintains its full length. The initial situation is simple, since an unfinished protein might not operate properly, leading to the emergence of illnesses. The addition or replacement of amino acids can cause localized bending or abnormal folding of the protein, which can affect the formation of the triple helix structure.",15_17,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"the formation of the triple helix structure. Furthermore, protein molecules that are abnormally folded exhibit heightened sensitivity to proteases, rendering them more vulnerable to degradation (<xref rid=""B7"" ref-type=""bibr"">Kamura et al., 2020</xref>). Determining the severity of clinical phenotypes heavily relies on the importance of variants in the folding of the triple helix structure of the <italic toggle=""yes"">COL4A5</italic> gene. For this study, we employed molecular dynamics simulations to",15_18,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"we employed molecular dynamics simulations to analyze how the c.4822–10T>C splicing variant of the <italic toggle=""yes"">COL4A5</italic> gene affects the ability of the α5(IV) chain to form a triple helix. Our goal was to gain more in-sight into the relationship between genotype and phenotype in individuals affected by this variant (<xref rid=""B11"" ref-type=""bibr"">Salomon-Ferrer et al., 2013</xref>). The <italic toggle=""yes"">COLA45</italic> gene, also known as NM_033380.2, consists of a total of 53 exons.",15_19,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"as NM_033380.2, consists of a total of 53 exons. The sizes of the exons in <italic toggle=""yes"">COL4A5</italic>, excluding the untranslated sequences at the 5′and 3′ends, vary from 27 to 213 base pairs. Exon 1 consists of 283 base pairs, with 202 base pairs assigned to a 5′-noncoding sequence and 81 base pairs to a coding sequence. Exclusively, the signal peptide of 26 residues is encoded by the translated exon 1 sequence. Two Gly-X-Y triplets and 14 non-collagenous amino-terminal ends are encoded by exon",15_20,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"amino-terminal ends are encoded by exon 2. As a result, exons 2-47 contain the collagenous region, where exon 47 acts as a connecting exon responsible for encoding the carboxyl-terminal section of the collagenous region and a part of the non-collagenous region. The current study demonstrates that the c.4822–10T>C variant in the <italic toggle=""yes"">COL4A5</italic> gene causes the exclusion of exon 52 and exon 53 from its transcript, resulting in the production of a shortened α5(IV) chain. This truncated",15_21,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"of a shortened α5(IV) chain. This truncated chain lacks a significant portion of the NC1 region sequence, which is crucial for trimerization. All-atom molecular dynamics simulations were used to perform a 100 ns kinetic simulation procedure on the MT-α5(IV) chain. According to our findings, the MT-α5(IV) chain displayed decreased variability in the head, middle, and tail sections in comparison to the WT-α5(IV) chain. This can be attributed to the removal of the tail. As a result, the MT-α5(IV) chain",15_22,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"of the tail. As a result, the MT-α5(IV) chain exhibited a lower overall activity compared to the WT-α5(IV) chain. Simulating the trimerisation of the MT-α5(IV) chain with the WT-α3(IV) chain and the WT-α4(IV) chain for a duration of 100 ns. According to the simulation findings, even with a partial removal in the NC1 area of the MT-α5(IV) chain, the theoretical possibility of trimerisation among the three chains remains. After undergoing trimerization, the MT-α345(IV) trimer displayed considerably more",15_23,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"MT-α345(IV) trimer displayed considerably more variability in its head and tail sections in comparison to the WT-α345(IV) trimer. This implies that the stability of the MT-α345(IV) trimer was decreased at the C- and N-terminal regions, possibly because of the impact of the MT-α5(IV) chain. Consequently, this had an effect on the overall stability of the fundamental structure of the BMs. Two potential scenarios may explain the lack of α5(IV) chain expression based on the patient’s renal pathology results.",15_24,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"based on the patient’s renal pathology results. The initial situation includes the creation of a shortened α5(IV) chain caused by the c.4822–10T>C variant, which is then broken down by the protein quality assurance mechanism. The second scenario involves the production of an abnormal mRNA that is rapidly degraded by NMD, also resulting from the c.4822–10T>C variant. In either scenario, patients experience hindrance in the appropriate assembly of the α345(IV) trimer, thus requiring additional functional",15_25,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"trimer, thus requiring additional functional investigations to confirm this hypothesis. To summarize, the splice variant c.4822–10T>C in the <italic toggle=""yes"">COL4A5</italic> gene was identified in a patient with XLAS. This expands the range of variants observed in the <italic toggle=""yes"">COL4A5</italic> gene, which follows an X-linked dominant pattern of inheritance. Histopathological examination of the patient’s kidney and minigene splicing validation experiments provided evidence for the",15_26,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"validation experiments provided evidence for the pathogenicity of the variant, both <italic toggle=""yes"">in vivo</italic> and <italic toggle=""yes"">in vitro</italic>. Consequently, the findings of this investigation contribute to the advancement of our comprehension regarding the molecular pathogenesis of AS.",15_27,"The NM_033380.2 transcript of the <italic toggle=""yes"">COL4A5</italic> gene contains a variable splice site c.4822–10T>C, which has been identified as a causative factor for Alport syndrome",16 5 2024,,Alport_Syndrome
"Explaining Alport syndrome—lessons from the adult nephrology clinic Alport syndrome is a genetic kidney disease that causes worsening of kidney function over time, often progressing to kidney failure. Some types of Alport syndrome cause other symptoms and signs, including hearing loss and eye abnormalities. Research now indicates that Alport syndrome (autosomal dominant inheritance) is the most common form. Alport syndrome can have X-linked or a rare form of autosomal recessive inheritance. Traditionally, a",16_0,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"autosomal recessive inheritance. Traditionally, a kidney biopsy was used to diagnose Alport syndrome, but genetic testing provides a more precise and less invasive means of diagnosis and reveals the underlying pattern of inheritance. At present, there are no specific curative treatments for Alport syndrome however there is a strong international effort in pursuit of future therapies. Currently, angiotensin-converting enzyme inhibitors (ACEi), or an angiotensin receptor blocker (ARB) if a patient cannot",16_1,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"receptor blocker (ARB) if a patient cannot tolerate an ACEi, slow down the progression of kidney disease and can delay the onset of kidney failure by years. There are other potential treatments in research that potentially can help delay the onset of kidney issues. Early treatment of patients and identification of their at-risk relatives is a priority. People living with Alport syndrome and their doctors now benefit from an active international research community working on translating further treatments",16_2,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"working on translating further treatments into clinical practice and providing up-to-date clinical guidelines. This article is intended to educate kidney doctors and other doctors on Alport syndrome in adults, the holistic aspects of the disease, and the authors’ lessons learned from the adult kidney clinic. This article includes an <xref rid=""Sec13"" ref-type=""sec"">Appendix</xref> ‘handout’ for patients and their families in addition to patient-centred diagrams, some less-technical explanations (labelled",16_3,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"some less-technical explanations (labelled under ‘How it works’), and support group signposting intended for kidney doctors to use in the clinic setting to improve discussions with adults living with Alport syndrome. <xref rid=""Sec13"" ref-type=""sec"">Appendix</xref> Table 8 includes a glossary of terms used throughout the text. Alport syndrome is an inherited kidney disease that affects the glomeruli, is often progressive, and may be associated with sensorineural hearing loss and eye abnormalities. This",16_4,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"hearing loss and eye abnormalities. This article focusses on this collection of conditions called ’Alport syndrome’. However, there is a growing recognition that these are part of a ’spectrum' of conditions with a variable set of physical symptoms which include much milder conditions impacting the kidney compared with some of the more severe conditions that have symptoms that impact the kidney AND other parts of the body (<xref rid=""Sec13"" ref-type=""sec"">Appendix</xref> Fig. 1).",16_5,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"Indeed, one of the major changes in the Alport syndrome community is the changing terminology of the range of diseases. From a genetic perspective, all these conditions are caused by variants in the collagen IV genes: <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>] collectively called the ‘Alport genes’. Conditions previously called ‘Thin Basement",16_6,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
Conditions previously called ‘Thin Basement Membrane Nephropathy’ and ‘Benign Familial Haematuria’ are now termed by some experts in the field ‘Autosomal Dominant Alport syndrome’ even though their kidney disease is typically more mild and deafness is typically absent or occurs much later in life. Women and men with autosomal dominant Alport syndrome do not need to get unnecessarily worried by the term ‘syndrome’ as it is unlikely they will get the hearing or eye symptoms typically seen in the other,16_7,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"or eye symptoms typically seen in the other genetic forms of Alport syndrome. The search continues for an appropriate term for a disease with large clinical variability. Although classified as a ‘rare disease’, Alport syndrome is the most common genetic kidney disease in the UK and the second most common cause of kidney failure after autosomal dominant polycystic kidney disease [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. The population frequency is highest for",16_8,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"The population frequency is highest for conditions at the mild end of the spectrum, namely the autosomal dominant forms (at least 1 in 100). The population frequency is about 1 in 2000 for X-linked Alport syndrome and Autosomal Recessive Alport syndrome has an even lower population frequency [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. The core disease name ‘Alport’ comes from Dr Cecil Alport, a South African physician, who identified the inherited symptoms in a",16_9,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"who identified the inherited symptoms in a British family in 1927. Alport syndrome in adults is an important cause of kidney disease, and there is often a family history of kidney disease and potentially deafness and eye problems too. Diagnosis by genetic testing determines the type of inheritance of Alport syndrome and allows early treatment of people living with Alport syndrome and identifies their relatives that may have Alport syndrome too. Treatment with the highest tolerated dose of an ACE inhibitor",16_10,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"the highest tolerated dose of an ACE inhibitor (or an Angiotensin Receptor Blocker (ARB)) is often effective in delaying kidney disease but does not provide a cure. Newer therapies are currently in clinical trials and it is important to keep up with the latest research on treatments. See <xref rid=""Sec13"" ref-type=""sec"">Appendix</xref> Table 7 (key messages regarding Alport syndrome). See <xref rid=""Sec13"" ref-type=""sec"">Appendix</xref> Table 8 (glossary of terms).",16_11,Explaining Alport syndrome—lessons from the adult nephrology clinic,13 5 2024,,Alport_Syndrome
"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease Alport Syndrome (AS) is the most common genetic glomerular disease, and it is caused by <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> pathogenic variants. The classic phenotypic spectrum associated with AS ranges from isolated hematuria to chronic kidney disease (CKD)",17_0,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"hematuria to chronic kidney disease (CKD) with extrarenal abnormalities. Atypical presentation of the disorder is possible, and it can mislead the diagnosis. Polycystic kidney disease (PKD), which is most frequently associated with Autosomal Dominant PKD (ADPKD) due to <italic toggle=""yes"">PKD1</italic> and <italic toggle=""yes"">PKD2</italic> heterozygous variants, is emerging as a possible clinical manifestation in <italic toggle=""yes"">COL4A3-A5</italic> patients. We describe a <italic",17_1,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"patients. We describe a <italic toggle=""yes"">COL4A5</italic> novel familial frameshift variant (NM_000495.5: c.1095dup p.(Leu366ValfsTer45)), which was associated with AS and PKD in the hemizygous proband, as well as with PKD, IgA glomerulonephritis and focal segmental glomerulosclerosis (FSGS) in the heterozygous mother. Establishing the diagnosis of AS can sometimes be difficult, especially in the context of misleading family history and atypical phenotypic features. This case study supports the emerging",17_2,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"features. This case study supports the emerging genotypic and phenotypic heterogeneity in <italic toggle=""yes"">COL4A3-A5</italic>-associated disorders, as well as the recently described association between PKD and collagen type IV (Col4) defects. We highlight the importance of the accurate phenotyping of all family members and the relevance of next-generation sequencing in the differential diagnosis of hereditary kidney disease. Alport Syndrome (AS) is the most frequent hereditary disorder of the basement",17_3,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"most frequent hereditary disorder of the basement membrane (BM), and it results from defects of collagen type IV (Col4) [<xref rid=""B1-genes-15-00597"" ref-type=""bibr"">1</xref>]. X-linked AS (XLAS) accounts for the majority of cases and it is determined by pathogenic variants in <italic toggle=""yes"">COL4A5</italic> (Collagen, Type IV, α-5; MIM: 303630) [<xref rid=""B2-genes-15-00597"" ref-type=""bibr"">2</xref>]. Milder disease can occur in heterozygous women and hemizygous men with specific amino acid",17_4,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"women and hemizygous men with specific amino acid substitutions [<xref rid=""B3-genes-15-00597"" ref-type=""bibr"">3</xref>]. Autosomal recessive AS (ARAS) results from biallelic variants in <italic toggle=""yes"">COL4A3</italic> (Collagen, Type IV, α-3; MIM: 120070) or <italic toggle=""yes"">COL4A4</italic> (Collagen, Type IV, α-5; MIM: 120131); autosomal dominant inheritance (ADAS) is considered rare and is usually associated with a less severe phenotype [<xref rid=""B1-genes-15-00597"" ref-type=""bibr"">1</xref>].",17_5,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"ref-type=""bibr"">1</xref>]. Digenic inheritance has also been described in a minority of patients, with variable phenotypic features [<xref rid=""B4-genes-15-00597"" ref-type=""bibr"">4</xref>]. More than 5000 pathogenic <italic toggle=""yes"">COL4A3-COL4A5</italic> variants have been reported to date, among them major rearrangements, truncating, splicing and missense [<xref rid=""B3-genes-15-00597"" ref-type=""bibr"">3</xref>,<xref rid=""B5-genes-15-00597"" ref-type=""bibr"">5</xref>,<xref rid=""B6-genes-15-00597""",17_6,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"rid=""B6-genes-15-00597"" ref-type=""bibr"">6</xref>]. Col4 is the main structural component of the BM, as it has a primary role in supporting cell adhesion, migration, proliferation, and differentiation [<xref rid=""B7-genes-15-00597"" ref-type=""bibr"">7</xref>]. Six different Col4 genes (<italic toggle=""yes"">COL4A1-A6</italic>) encode as many distinct isoforms (a1–a6) as possible, organized in a triple helix structure. Col4 networks containing the a3, a4, and a5 chains are critical to the integrity of the",17_7,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"a5 chains are critical to the integrity of the glomerular and tubular membranes of the kidney [<xref rid=""B8-genes-15-00597"" ref-type=""bibr"">8</xref>]. Patients with <italic toggle=""yes"">COL4A3-5</italic> pathogenic variants manifest persistent hematuria and chronic kidney disease (CKD). Most men and about 15% of women with X-linked inheritance, as well as most of those with autosomal recessive disease, progress to renal failure [<xref rid=""B9-genes-15-00597"" ref-type=""bibr"">9</xref>]. Col4 is also found",17_8,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"ref-type=""bibr"">9</xref>]. Col4 is also found in the human testis, inner ear, and eye, thus explaining the characteristic extra-renal manifestations such as sensorineural hearing loss (SNHL) and eye abnormalities (i.e., lenticonus and maculopathy) [<xref rid=""B1-genes-15-00597"" ref-type=""bibr"">1</xref>]. An atypical renal presentation of AS is sometimes possible, and it can mislead the diagnosis. Notably, affected individuals who present with proteinuria rather than hematuria are often first diagnosed with",17_9,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"than hematuria are often first diagnosed with steroid-resistant nephrotic syndrome or focal segmental glomerulosclerosis (FSGS). Pathogenic <italic toggle=""yes"">COL4A3-A5</italic> variants contribute to IgA glomerulonephritis [<xref rid=""B10-genes-15-00597"" ref-type=""bibr"">10</xref>,<xref rid=""B11-genes-15-00597"" ref-type=""bibr"">11</xref>] and are the most common underlying genetic defect in individuals with familial FSGS [<xref rid=""B12-genes-15-00597"" ref-type=""bibr"">12</xref>]. Interestingly, polycystic",17_10,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"Interestingly, polycystic kidney disease (PKD) has been previously reported in few unrelated patients with <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> variants, occasionally even in the absence of other AS typical features [<xref rid=""B13-genes-15-00597"" ref-type=""bibr"">13</xref>,<xref rid=""B14-genes-15-00597"" ref-type=""bibr"">14</xref>]. In addition, different recent cohort studies have demonstrated an association between pathogenic variants in the <italic",17_11,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"between pathogenic variants in the <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> genes and the occurrence of bilateral renal cysts [<xref rid=""B15-genes-15-00597"" ref-type=""bibr"">15</xref>,<xref rid=""B16-genes-15-00597"" ref-type=""bibr"">16</xref>,<xref rid=""B17-genes-15-00597"" ref-type=""bibr"">17</xref>]. On the other hand, up to 8% of patients with suspected Autosomal Dominant PKD (ADPKD; MIM: 173900 and 613095), which is the most frequent cause of renal cystic phenotype, do",17_12,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"most frequent cause of renal cystic phenotype, do not receive a molecular diagnosis despite comprehensive screening for <italic toggle=""yes"">PKD1</italic> (Polycystin 1; MIM: 601313) and <italic toggle=""yes"">PKD2</italic> (Polycystin 2; MIM: 173910) pathogenic variants [<xref rid=""B18-genes-15-00597"" ref-type=""bibr"">18</xref>]. Here, we describe a 24-year-old male patient who presented with early-onset PKD, SNHL, and persistent hematuria in whom next-generation sequencing (NGS) analysis identified a",17_13,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"sequencing (NGS) analysis identified a <italic toggle=""yes"">COL4A5</italic> novel frameshift variant. The finding was consistent with the diagnosis of XLAS in the proband, and inheritance was traced from the proband’s mother who had PKD, IgA glomerulonephritis, and FSGS. The patient (III-1), a 24-year-old man, is the first child of Italian non-consanguineous parents (<xref rid=""genes-15-00597-f001"" ref-type=""fig"">Figure 1</xref>). He was referred to our Genetics Department to evaluate his complex",17_14,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"our Genetics Department to evaluate his complex nephrological condition. The patient was born at 39 weeks of gestational age. His mother (II-2) reported that the pregnancy was complicated by preeclampsia (PE), proteinuria, and leg edema, for which she was treated with a low-sodium diet and albumin infusions. His birth weight, length, and occipitofrontal circumference (OFC) were 2280 g (−2.43 SDS), 47.5 cm (−1.29 SDS), and 32 cm (−1.94 SDS), respectively. The Apgar score was 9 at 1 min and 9 at 5 min. The",17_15,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"Apgar score was 9 at 1 min and 9 at 5 min. The proband presented transient neonatal hypocalcemia (8 mg/dL); abdominal and cranial ultrasounds (US) were normal. Microscopic hematuria with dysmorphic red blood cells (RBCs) was first detected at 20 days and became persistent by 2 years of age. Macroscopic hematuria first manifested during a febrile episode in the first year of life, and it still occurs in the case of upper respiratory tract infections. Bilateral moderate SNHL was diagnosed at the age of 5.",17_16,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"moderate SNHL was diagnosed at the age of 5. These clinical signs led to a clinical suspicion of AS, which was subsequently confirmed by a kidney biopsy performed at the age of 22. The biopsy revealed numerous foamy macrophages in the interstitium and some in Bowman’s capsule. There was a focal inflammatory cell infiltrate (mononuclear cells) associated with the rare atrophic tubules. Moreover, there were 11 glomeruli (1 sclerotic), and the glomerular basement membranes appeared normal (on light",17_17,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"basement membranes appeared normal (on light microscopy). Immunostaining for Col4 revealed the absence of a3 and a5 chains. At the age of 12, the abdominal US showed multiple bilateral cortical cysts and the patient was diagnosed with PKD. The last abdominal US (24 years of age) showed mildly enlarged kidneys (13 cm on the left, 12 cm on the right), multiple bilateral cysts of varying sizes, with the largest on the left measuring 6.8 × 6.2 cm, and absence of extra-renal cysts (<xref",17_18,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"× 6.2 cm, and absence of extra-renal cysts (<xref rid=""genes-15-00597-f002"" ref-type=""fig"">Figure 2</xref>). After the diagnosis of AS and PKD, he started therapy with the angiotensin-converting enzyme (ACE) inhibitor enalapril (5 mg), replaced after about two years with ramipril (5 mg, to 10 mg), in association with the xanthine oxidase inhibitor allopurinol (150 mg). Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin was performed for about 6 months (at 23 years) and then",17_19,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"for about 6 months (at 23 years) and then discontinued due to side effects and the lack of benefits. Ophthalmologically, the patient reported an episode of blepharitis at the age of 18, which resulted in myopia and corneal damage in the left eye and astigmatism in the right eye. A few weeks before the evaluation in our Genetics Department, the patient was admitted to the Emergency Department for acute left back pain and macroscopic hematuria, due to the traumatic rupture of a renal cyst associated with",17_20,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"traumatic rupture of a renal cyst associated with Stage 1 Acute Kidney Injury (AKI) on chronic kidney disease (CKD) Stage G2 A3 [<xref rid=""B19-genes-15-00597"" ref-type=""bibr"">19</xref>]. At the time of the last evaluation at the age of 24 years, hematochemical tests of the proband showed uric acid within normal range (5.7 mg/dL, reference range 3.4–7 mg/dL), hyperazotemia (97 mg/dL, reference range 10–50 mg/dL), and hypercreatininemia (1.69 mg/dL, reference range 0.7–1.2 mg/dL). The eGFR (Estimated",17_21,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"range 0.7–1.2 mg/dL). The eGFR (Estimated Glomerular Filtration Rate) was 70.5 mL/min/m<sup>2</sup>, according to the CKD EPI (Chronic Kidney Disease Epidemiology Collaboration) formula [<xref rid=""B20-genes-15-00597"" ref-type=""bibr"">20</xref>]. The patient’s mother (II-2), a 51-year-old woman, reported a history of persistent microscopic hematuria with dysmorphic RBCs (first detected as a child), persistent mild proteinuria and macroscopic hematuria during febrile episodes, for which she received a",17_22,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"during febrile episodes, for which she received a clinical diagnosis of FSGS. Abdominal US, performed at 27 years and repeated at 39 years of age, showed multiple bilateral cortical cysts, consistent with a clinical diagnosis of PKD (<xref rid=""genes-15-00597-f002"" ref-type=""fig"">Figure 2</xref>). Abdominal magnetic resonance imaging (MRI) at 48 years confirmed evidence of multiple bilateral cortical cysts, some spontaneously hyperintense on T1WI, with the largest being 2 cm in the middle third of the left",17_23,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"being 2 cm in the middle third of the left kidney (Bosniak class II) [<xref rid=""B21-genes-15-00597"" ref-type=""bibr"">21</xref>]. At 31 years of age, she presented IgA glomerulonephritis (diagnosis confirmed with kidney biopsy). No other family members received a clinical diagnosis of PKD; however, the family history in the maternal line was positive for SNHL in a male cousin of the proband (III-4), and for microscopic or macroscopic persistent hematuria in numerous female members (<xref",17_24,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"hematuria in numerous female members (<xref rid=""genes-15-00597-f001"" ref-type=""fig"">Figure 1</xref>). After genetic counseling, informed consent was obtained from the proband and his parents, who underwent diagnostic molecular tests. NGS analysis was performed using the Nephropathy Solution (NES) kit (Sophia Genetics, Lausanne, Switzerland) covering the coding regions of 44 most clinically relevant genes related to a broad range of nephropathies (<italic toggle=""yes"">AGXT</italic>, <italic",17_25,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"(<italic toggle=""yes"">AGXT</italic>, <italic toggle=""yes"">AQP2</italic>, <italic toggle=""yes"">ATP6V0A4</italic>, <italic toggle=""yes"">ATP6V1B1</italic>, <italic toggle=""yes"">AVPR2</italic>, <italic toggle=""yes"">BSND</italic>, <italic toggle=""yes"">CASR</italic>, <italic toggle=""yes"">CEP290</italic>, <italic toggle=""yes"">CLCN5</italic>, <italic toggle=""yes"">CLCNKB</italic>, <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, <italic toggle=""yes"">COL4A5</italic>, <italic",17_26,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"<italic toggle=""yes"">COL4A5</italic>, <italic toggle=""yes"">CRB2</italic>, <italic toggle=""yes"">CTNS</italic>, <italic toggle=""yes"">CUBN</italic>, <italic toggle=""yes"">CYP24A1</italic>, <italic toggle=""yes"">DSTYK</italic>, <italic toggle=""yes"">EMP2</italic>, <italic toggle=""yes"">EYA1</italic>, <italic toggle=""yes"">FN1</italic>, <italic toggle=""yes"">FOXC1</italic>, <italic toggle=""yes"">GRHPR</italic>, <italic toggle=""yes"">HNF1b</italic>, <italic toggle=""yes"">KANK2</italic>, <italic",17_27,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"<italic toggle=""yes"">KANK2</italic>, <italic toggle=""yes"">KCNJ1</italic>, <italic toggle=""yes"">LAMB2</italic>, <italic toggle=""yes"">NPHS2</italic>, <italic toggle=""yes"">NR3C2</italic>, <italic toggle=""yes"">OCRL</italic>, <italic toggle=""yes"">PAX2</italic>, <italic toggle=""yes"">PHEX</italic>, <italic toggle=""yes"">PKD1</italic>, <italic toggle=""yes"">PKD2</italic>, <italic toggle=""yes"">PKHD1</italic>, <italic toggle=""yes"">SIX1</italic>, <italic toggle=""yes"">SLC12A1</italic>, <italic",17_28,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"<italic toggle=""yes"">SLC12A1</italic>, <italic toggle=""yes"">SLC12A3</italic>, <italic toggle=""yes"">SLC34A1</italic>, <italic toggle=""yes"">SLC4A1</italic>, <italic toggle=""yes"">SLC4A4</italic>, <italic toggle=""yes"">TTC21B</italic>, <italic toggle=""yes"">UMOD</italic>, <italic toggle=""yes"">WT1</italic>). Dedicated bioinformatic analysis (SOPHiA DDM platform) allows for the detection of SNV and Indels, and guarantees high performance, even in GC-rich regions and pseudogenes. The NGS analysis revealed a",17_29,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"and pseudogenes. The NGS analysis revealed a NM_000495.5: c.1095dup p.(Leu366ValfsTer45) frameshift variant in <italic toggle=""yes"">COL4A5</italic>, which was inherited from the mother (<xref rid=""app1-genes-15-00597"" ref-type=""app"">Table S1</xref>). This variant was classified as “likely pathogenic” according to the American College of Medical Genetics and Genomics (ACMGs) guidelines [<xref rid=""B22-genes-15-00597"" ref-type=""bibr"">22</xref>] and submitted to the ClinVar database (<uri",17_30,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"and submitted to the ClinVar database (<uri http://www.w3.org/1999/xlink href=""http://www.ncbi.nlm.nih.gov/clinvar/"">http://www.ncbi.nlm.nih.gov/clinvar/</uri>, accessed on 6 May 2024, accession ID: SCV005040957.1). In order to exclude any involvement of other PKD-related genes not included in the targeted panel [<xref rid=""B23-genes-15-00597"" ref-type=""bibr"">23</xref>], we performed a whole exome sequencing approach using ClinEx pro Extended Clinical Exome kit (4bases, Manno, Switzerland) on the",17_31,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"Exome kit (4bases, Manno, Switzerland) on the NovaSeq6000 platform (Illumina, San Diego, CA, USA). The presented case demonstrates a familial <italic toggle=""yes"">COL4A5</italic> novel pathogenic variant (NM_000495.5: c.1095dup) in association with AS in the hemizygous proband as well as with IgA glomerulonephritis and FSGS in the heterozygous mother. In addition, both the proband and his mother were diagnosed with PKD by the age of 12 and 27, respectively. To the best of our knowledge, the c.1095dup",17_32,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"To the best of our knowledge, the c.1095dup variant has not been previously reported in the scientific literature or in reference genomic databases (e.g., Clinvar, HGVD, gnomAD). The single nucleotide insertion produces a frameshift variant in the <italic toggle=""yes"">COL4A5</italic> gene which is predicted to cause nonsense-mediated decay (NMD). The involved exon (19 of 53) affects two functional domains: the UniProt protein CO4A5_HUMAN region of interest ‘Disordered’ and the UniProt protein CO4A5_HUMAN",17_33,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"‘Disordered’ and the UniProt protein CO4A5_HUMAN region of interest ‘Triple-helical region’. In addition, loss of function (LOF) is a known pathological mechanism in XLAS, and more than 500 pathogenic LOF variants in <italic toggle=""yes"">COL4A5</italic> have been reported to date [<xref rid=""B3-genes-15-00597"" ref-type=""bibr"">3</xref>,<xref rid=""B6-genes-15-00597"" ref-type=""bibr"">6</xref>]. Males with XLAS inevitably progress to ESRD, with the overall risk increasing with age [<xref rid=""B9-genes-15-00597""",17_34,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"with age [<xref rid=""B9-genes-15-00597"" ref-type=""bibr"">9</xref>]. Although available treatment options may delay the onset of renal impairment by limiting the progression of proteinuria and kidney disease, most affected individuals will ultimately require dialysis or a kidney transplant [<xref rid=""B24-genes-15-00597"" ref-type=""bibr"">24</xref>]. Genotype–phenotype correlation has been demonstrated with XLAS; in particular, more severe or early onset renal phenotypes are found in male carriers of <italic",17_35,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"phenotypes are found in male carriers of <italic toggle=""yes"">COL4A5</italic> large deletions or truncating variants resulting in lower or absent levels of functional protein, with 90% risk of ESRD by age 30 [<xref rid=""B25-genes-15-00597"" ref-type=""bibr"">25</xref>,<xref rid=""B26-genes-15-00597"" ref-type=""bibr"">26</xref>]. The effects of the <italic toggle=""yes"">COL4A5</italic> genotype on age at ESRD are not clear in females with XLAS, likely due to the random process of X inactivation (Lyonization) that",17_36,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"process of X inactivation (Lyonization) that explains why heterozygous females typically have a variable and generally less severe expression of X-linked recessive disorder than male relatives [<xref rid=""B27-genes-15-00597"" ref-type=""bibr"">27</xref>]. Interestingly, most women with progressive CKD due to XLAS do not have hearing loss but still have a significant probability of progression to end-stage renal disease (ESRD) [<xref rid=""B9-genes-15-00597"" ref-type=""bibr"">9</xref>]. Recently, increasing",17_37,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"ref-type=""bibr"">9</xref>]. Recently, increasing phenotypic heterogeneity has been recognized in association with Col4 defects, in addition to the classic attributable renal and extrarenal manifestations. Heterozygous pathogenic <italic toggle=""yes"">COL4A3-A5</italic> variants are commonly found in familial IgA glomerulonephritis, as the thinned glomerular BM could allow for the migration of IgA from glomerular capillaries to the mesangium [<xref rid=""B28-genes-15-00597"" ref-type=""bibr"">28</xref>], as well",17_38,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"ref-type=""bibr"">28</xref>], as well as in familial FSGS, likely due to the altered glomerular BM resulting in the loss of overlying podocytes and the subsequent development of secondary glomerular hyperfiltration [<xref rid=""B10-genes-15-00597"" ref-type=""bibr"">10</xref>]. Phenotypic imbalance in AS occurs sometimes even among individuals sharing the same pathogenic variant, and this occurrence may be partially explained by genetic modifiers (such as variant-specific allelic effects, oligogenic heredity or",17_39,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"allelic effects, oligogenic heredity or trans-allele effects in female heterozygous carriers), concurrent renal disease, chronic inflammation-mediated tissue damage, and fibrosis [<xref rid=""B29-genes-15-00597"" ref-type=""bibr"">29</xref>]. Other contributing factors, such as infection, nephrotoxic agents, smoking, hypertension, diabetes, and obesity [<xref rid=""B3-genes-15-00597"" ref-type=""bibr"">3</xref>] were excluded upon clinical examination in the subjects of the current study. The cystic phenotype has",17_40,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"of the current study. The cystic phenotype has been very rarely reported in the literature in association with AS [<xref rid=""B13-genes-15-00597"" ref-type=""bibr"">13</xref>,<xref rid=""B30-genes-15-00597"" ref-type=""bibr"">30</xref>]. However, different recent cohort studies have shown a previously unnoticed prevalence of PKD in individuals with heterozygous pathogenic variants in the <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> genes [<xref rid=""B15-genes-15-00597""",17_41,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"genes [<xref rid=""B15-genes-15-00597"" ref-type=""bibr"">15</xref>,<xref rid=""B16-genes-15-00597"" ref-type=""bibr"">16</xref>,<xref rid=""B17-genes-15-00597"" ref-type=""bibr"">17</xref>]. To date, the explanation for the cystogenesis in carriers of <italic toggle=""yes"">COL4A3-5</italic> pathogenic variants needs to be clarified. CKD is frequently associated with the development of multiple and bilateral kidney cysts in its advanced stages; the lesions are usually <0.5 cm in diameter but can be as large as 3 cm",17_42,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"<0.5 cm in diameter but can be as large as 3 cm [<xref rid=""B31-genes-15-00597"" ref-type=""bibr"">31</xref>]. This occurrence is known as acquired cystic disease (ACD) of the kidney, and renal cysts may arise primarily from proximal tubular epithelial cell proliferation due to compensatory hypertrophy in the functional nephrons [<xref rid=""B32-genes-15-00597"" ref-type=""bibr"">32</xref>,<xref rid=""B33-genes-15-00597"" ref-type=""bibr"">33</xref>]. The cystic phenotype in ADAS has been demonstrated to have a",17_43,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"phenotype in ADAS has been demonstrated to have a higher prevalence in older patients with declining eGFR [<xref rid=""B15-genes-15-00597"" ref-type=""bibr"">15</xref>,<xref rid=""B16-genes-15-00597"" ref-type=""bibr"">16</xref>,<xref rid=""B17-genes-15-00597"" ref-type=""bibr"">17</xref>]. Therefore, it has been speculated that CKD could be the concur for the development of cysts in these patients [<xref rid=""B15-genes-15-00597"" ref-type=""bibr"">15</xref>]. However, cystic phenotype can also occur in young AS",17_44,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"cystic phenotype can also occur in young AS individuals with preserved renal function, as in the present case. Whereby, it is likely that other factors are involved in the development of the trait. Albeit the α1α1α2 and α3α4α5 isoforms are not evenly distributed in the tubular and glomerular BM [<xref rid=""B8-genes-15-00597"" ref-type=""bibr"">8</xref>], it has been hypothesized that a defect involving a single gene encoding Col4 isoforms may result in abnormally reduced collagen content along the BM, and",17_45,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"reduced collagen content along the BM, and thus, in the formation of cysts of glomerular or tubular origin [<xref rid=""B30-genes-15-00597"" ref-type=""bibr"">30</xref>]. Glomerulocystic kidney disease and the cystic dilatation of Bowman’s capsule and tubules are found in experimental animal models that harbor pathogenic variants in genes encoding Col4, supporting the etiopathogenetic link between BM defects and cystogenesis in AS. [<xref rid=""B34-genes-15-00597"" ref-type=""bibr"">34</xref>,<xref",17_46,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"ref-type=""bibr"">34</xref>,<xref rid=""B35-genes-15-00597"" ref-type=""bibr"">35</xref>]. Noteworthy, PKD is a recognized phenotypic trait of HANAC (hereditary angiopathy, nephropathy, aneurysms, and muscle cramps) syndrome, an autosomal dominant disorder determined by heterozygous pathogenetic variants in the <italic toggle=""yes"">COL4A1</italic> (Collagen, Type IV, α-1; MIM: 120130) gene [<xref rid=""B36-genes-15-00597"" ref-type=""bibr"">36</xref>]. Cystic renal disease is most often ascribed within the",17_47,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"renal disease is most often ascribed within the heterogeneous group of chronic kidney diseases to ADPKD, which is determined by heterozygous pathogenic variants in <italic toggle=""yes"">PKD1</italic> and <italic toggle=""yes"">PKD2</italic> in the majority of patients [<xref rid=""B37-genes-15-00597"" ref-type=""bibr"">37</xref>]. Occasional cysts can occur in approximately one third of the unaffected population over 70, whereas the finding is uncommon in the younger age groups [<xref rid=""B38-genes-15-00597""",17_48,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"age groups [<xref rid=""B38-genes-15-00597"" ref-type=""bibr"">38</xref>]. ADPKD generally manifests a late onset and substantial variability in the severity of renal involvement and extra-kidney manifestations [<xref rid=""B18-genes-15-00597"" ref-type=""bibr"">18</xref>]. The diagnosis of ADPKD is usually established in an individual with age-specific kidney imaging criteria and an affected first-degree relative [<xref rid=""B39-genes-15-00597"" ref-type=""bibr"">39</xref>]. Nonetheless, in the current case, an",17_49,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"Nonetheless, in the current case, an extensive molecular and bioinformatic NGS analysis of the genes to date known to be associated with PKD allowed us to exclude the involvement of additive pathogenic variants to the NM_000495.5: c.1095dup p.(Leu366ValfsTer45) in <italic toggle=""yes"">COL4A5</italic>. As emerges from recent studies, the presence of smaller cysts that do not alter the size of the kidney and the absence of extra-renal lesions at US examination may be suggestive of Col4 defects rather than",17_50,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"may be suggestive of Col4 defects rather than ADPKD [<xref rid=""B13-genes-15-00597"" ref-type=""bibr"">13</xref>]. Similarly to previous evidence, cystic nephromegaly and extrarenal cystic phenotype were absent in the proband’s mother (II-2); however, at the last renal US examination, the index case (III-1) had mildly enlarged kidneys in association with PKD. Therefore, although other inherited renal conditions (e.g., ADPKD) should be excluded in the first instance in the presence of cystic nephromegaly",17_51,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"instance in the presence of cystic nephromegaly [<xref rid=""B16-genes-15-00597"" ref-type=""bibr"">16</xref>], undoubtedly Col4 ought also to be considered. To date, the association between Col4 defects and PKD has been statistically demonstrated only in carriers of variants in the COL4A3 and COL4A4 genes, yet it was observed that a significant percentage of XLAS cases had a radiological cisternal phenotype similar to that of ADAS patients [<xref rid=""B17-genes-15-00597"" ref-type=""bibr"">17</xref>]. It may be",17_52,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"ref-type=""bibr"">17</xref>]. It may be reasonable, therefore, to assume that the development of kidney cysts could be considered an incompletely penetrant consequence of XLAS as well. The presence of PKD was associated with a worse kidney outcome in ADAS cases [<xref rid=""B15-genes-15-00597"" ref-type=""bibr"">15</xref>,<xref rid=""B16-genes-15-00597"" ref-type=""bibr"">16</xref>,<xref rid=""B17-genes-15-00597"" ref-type=""bibr"">17</xref>]. While this might also be true in carriers of pathogenic variants in the",17_53,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"be true in carriers of pathogenic variants in the <italic toggle=""yes"">COL4A5</italic> gene, this was not evidenced in our patients, possibly partly due to young age and the absence of long-term follow-up. The diagnosis of cystic renal disease is often difficult on the sole basis of clinical features, family history, and even kidney histopathology. Comprehensive genetic testing allows for the accurate and early diagnosis of hereditary cystic kidney disorders. The differential diagnosis of cystic kidney",17_54,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"The differential diagnosis of cystic kidney disease at early stages is especially important for the selection of patients who will benefit the most from current therapeutic approaches. While the administration of the selective vasopressin V2 receptor (V2R) antagonist, tolvaptan, is considered the gold standard treatment for ADPKD [<xref rid=""B40-genes-15-00597"" ref-type=""bibr"">40</xref>,<xref rid=""B41-genes-15-00597"" ref-type=""bibr"">41</xref>], clinical practice recommendations for the treatment of",17_55,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"practice recommendations for the treatment of individuals with AS encourage the early use of angiotensin-converting enzyme (ACE) inhibitors that have proven efficient to reduce lifetime risk for ESRD [<xref rid=""B42-genes-15-00597"" ref-type=""bibr"">42</xref>,<xref rid=""B43-genes-15-00597"" ref-type=""bibr"">43</xref>]. In addition, as discussed above, <italic toggle=""yes"">COL4A5</italic> genotype data can suggest the renal prognosis and partially predict the timing of ESRD, thus guiding the timing and",17_56,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"the timing of ESRD, thus guiding the timing and intensity of intervention [<xref rid=""B44-genes-15-00597"" ref-type=""bibr"">44</xref>]. On the other hand, according to current knowledge, kidney cysts in patients with <italic toggle=""yes"">COL4A3-5</italic> pathogenic variants are generally asymptomatic and do not require specific treatment [<xref rid=""B16-genes-15-00597"" ref-type=""bibr"">16</xref>,<xref rid=""B30-genes-15-00597"" ref-type=""bibr"">30</xref>]. However, the correct genotypic definition in case of",17_57,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"the correct genotypic definition in case of PKD allows for ensuring the correct multisystem follow-up pathway in the patient with AS. In addition, the traumatic rupture of renal cysts, which is a known complication in ADPKD [<xref rid=""B45-genes-15-00597"" ref-type=""bibr"">45</xref>], is also possible and should be taken into account in patients with <italic toggle=""yes"">COL4A</italic> variants, as the present case points out. Finally, genetic testing allows for the identification of asymptomatic female",17_58,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"for the identification of asymptomatic female carriers, which is important because of their own and their offspring’s risk of renal failure. All women with XLAS should be offered a life-long targeted screening program and the early introduction of ACE inhibitors [<xref rid=""B43-genes-15-00597"" ref-type=""bibr"">43</xref>]. Ultimately, whereas the cystic phenotype is emerging as a finding frequently associated with Col4 defects, the differences between AS and ADPKD are subtle, and sometimes the radiological",17_59,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"ADPKD are subtle, and sometimes the radiological patterns may be entirely comparable, as in the case presented. Clinical criteria alone may, therefore, be insufficient for the differential diagnosis of phenotypically overlapping PKD syndromes in the context of misleading inheritance and atypical presentation [<xref rid=""B46-genes-15-00597"" ref-type=""bibr"">46</xref>]. Persistent microhematuria is not a hallmark of ADPKD and even less so if familial aggregation is present, whereas a personal or family",17_60,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"is present, whereas a personal or family history of hematuria with dysmorphic RBCs, proteinuria, in combination with accurate renal phenotyping, may guide the diagnostic classification toward AS [<xref rid=""B47-genes-15-00597"" ref-type=""bibr"">47</xref>]. In conclusion, the presented case further supports the relevance of NGS in the intricate differential diagnosis of hereditary renal disease and eventually direct tailored therapeutic approaches. It also supports the emerging notion that Col4-associated",17_61,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"supports the emerging notion that Col4-associated disorders should be considered when PKD is found. Notably, accurate phenotyping of all family members with a history of either hematuria or glomerulopathy may suggest prioritizing <italic toggle=""yes"">COL4A3-5</italic> screening in those patients with an early finding of PKD. Further studies are needed to clarify the pathogenesis and the prognostic significance of the cystic phenotype associated with Col4 defects and uncover possible genotype–phenotype",17_62,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
defects and uncover possible genotype–phenotype correlations.,17_63,"A Novel <italic toggle=""yes"">COL4A5</italic> Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease",08 5 2024,,Alport_Syndrome
"Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience Background: Alport syndrome (AS) is a common and heterogeneous genetic kidney disease, that often leads to end-stage kidney disease (ESKD). Methods: This is a single-center, retrospective study that included 36 adults with type IV collagen (COL4) mutations. Our main scope was to describe how genetic features influence renal survival. Results: A total of 24 different mutations were identified, of which eight had not been previously",18_0,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"of which eight had not been previously described. Mutations affecting each of the type IV collagen α chains were equally prevalent (33.3%). Most of the patients had pathogenic variants (61.1%). Most patients had a family history of kidney disease (71%). The most prevalent clinical picture was nephritic syndrome (64%). One-third of the subjects had extrarenal manifestations, 41.6% of patients had ESKD at referral, and another 8.3% developed ESKD during follow-up. The median renal survival was 42 years (95%",18_1,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"The median renal survival was 42 years (95% CI, 29.98–54.01). The COL4A4 group displayed better renal survival than the COL4A3 group (<italic toggle=""yes"">p</italic> = 0.027). Patients with missense variants had higher renal survival (<italic toggle=""yes"">p</italic> = 0.023). Hearing loss was associated with lower renal survival (<italic toggle=""yes"">p</italic> < 0.001). Conclusions: Patients with COL4A4 variants and those with missense mutations had significantly better renal survival, whereas those with",18_2,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"better renal survival, whereas those with COL4A3 variants and those with hearing loss had worse prognoses. Alport syndrome (AS) is a common and heterogeneous genetic kidney disease, characterized by structural defects of the glomerular, cochlear, and ocular basement membranes leading to renal dysfunction, sensorineural hearing loss, and ocular abnormalities [<xref rid=""B1-genes-15-00593"" ref-type=""bibr"">1</xref>]. Although traditionally considered a rare disease, with a highly geographically variable",18_3,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"disease, with a highly geographically variable prevalence [<xref rid=""B2-genes-15-00593"" ref-type=""bibr"">2</xref>,<xref rid=""B3-genes-15-00593"" ref-type=""bibr"">3</xref>], recent studies suggest that nearly 1% of the population could be at risk of having a heterozygous pathogenic variant of the genes coding the α 3 and α 4 chains of type IV collagen molecules (COL4A3 and COL4A4) [<xref rid=""B4-genes-15-00593"" ref-type=""bibr"">4</xref>]. The natural evolution of kidney involvement in AS is usually divided",18_4,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"of kidney involvement in AS is usually divided into a series of stages: microscopic hematuria, proteinuria, and progressive chronic kidney disease (CKD) [<xref rid=""B5-genes-15-00593"" ref-type=""bibr"">5</xref>,<xref rid=""B6-genes-15-00593"" ref-type=""bibr"">6</xref>,<xref rid=""B7-genes-15-00593"" ref-type=""bibr"">7</xref>]. Males with X-linked AS (XLAS) and patients with autosomal recessive AS (ARAS) display a worse clinical picture, with early onset end-stage kidney disease (ESKD) associated with extrarenal",18_5,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"kidney disease (ESKD) associated with extrarenal manifestations, whereas autosomal dominant forms of AS (ADAS) and females with XLAS usually exhibit a milder phenotype [<xref rid=""B5-genes-15-00593"" ref-type=""bibr"">5</xref>,<xref rid=""B6-genes-15-00593"" ref-type=""bibr"">6</xref>,<xref rid=""B7-genes-15-00593"" ref-type=""bibr"">7</xref>]. In recent years, the acknowledgement of a higher prevalence of ADAS has led to a paradigm shift regarding the clinical spectrum of type IV collagen disorders. It is now",18_6,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"spectrum of type IV collagen disorders. It is now recognized that some forms of AS can present as focal and segmental glomerulosclerosis (FSGS) rather than the typical clinical picture [<xref rid=""B8-genes-15-00593"" ref-type=""bibr"">8</xref>,<xref rid=""B9-genes-15-00593"" ref-type=""bibr"">9</xref>,<xref rid=""B10-genes-15-00593"" ref-type=""bibr"">10</xref>]. Due to this large phenotypic variability, making a correct diagnosis based only on clinical features is often difficult [<xref rid=""B7-genes-15-00593""",18_7,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"is often difficult [<xref rid=""B7-genes-15-00593"" ref-type=""bibr"">7</xref>], as shown by Groopman et al., who observed that only 38% of patients with variants involving type IV collagen genes (COL4) in their cohort had a correct clinical diagnosis prior to genetic testing [<xref rid=""B11-genes-15-00593"" ref-type=""bibr"">11</xref>]. In the same study, 16% of patients with AS had previously been diagnosed with FSGS based on clinical and pathological criteria [<xref rid=""B11-genes-15-00593""",18_8,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"criteria [<xref rid=""B11-genes-15-00593"" ref-type=""bibr"">11</xref>]. As genetic testing becomes more readily available, there is a growing interest in the correlations between the molecular characteristics of each variant and clinical outcomes. Previous studies have already demonstrated that patients with truncating variants and large deletions have a worse prognosis, with kidney replacement therapy (KRT) initiated at younger ages [<xref rid=""B12-genes-15-00593"" ref-type=""bibr"">12</xref>,<xref",18_9,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"ref-type=""bibr"">12</xref>,<xref rid=""B13-genes-15-00593"" ref-type=""bibr"">13</xref>,<xref rid=""B14-genes-15-00593"" ref-type=""bibr"">14</xref>]. For missense variants, which tend to have a more heterogeneous phenotype, there are multiple factors that can influence renal outcomes: the position of the substitution, the nature of the substituted amino acid, and the molecular characteristics of the substituting residue [<xref rid=""B15-genes-15-00593"" ref-type=""bibr"">15</xref>,<xref rid=""B16-genes-15-00593""",18_10,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"rid=""B16-genes-15-00593"" ref-type=""bibr"">16</xref>]. Therefore, apart from inheritance, the molecular impact of each variant can be a valuable tool for individualized prognostication. The present study aims to describe how these genetic features influence renal survival in patients with AS followed in a tertiary center.   The present study examines the natural history of patients with AS and the relationship between the characteristics of the variant and kidney survival. In our diverse cohort of 36",18_11,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"and kidney survival. In our diverse cohort of 36 patients diagnosed with AS through genetic testing, we identified that subjects with COL4A4 variants and those with missense variants had significantly better kidney survival, whereas those with COL4A3 variants and those with clinically significant hearing loss had worse renal prognoses. Owing to the large phenotypic heterogenicity and nonspecific histological lesions, current guidelines recommend genetic testing as a first-line diagnostic test whenever",18_12,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"testing as a first-line diagnostic test whenever there are clinical, histological or pedigree data suggestive of AS [<xref rid=""B7-genes-15-00593"" ref-type=""bibr"">7</xref>,<xref rid=""B35-genes-15-00593"" ref-type=""bibr"">35</xref>]. In our cohort, there was an important delay in the referral of the patients, with the median period between clinical onset and sampling for genetic testing being 4 years (IQR, 0–8.35). Therefore, our cohort included 15 subjects (41.66%) who presented in our clinic with ESKD of",18_13,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"(41.66%) who presented in our clinic with ESKD of unknown etiology, which is consistent with data reported in the literature suggesting that more than 60% of patients with CKD and COL4 variants do not have a clinical diagnosis of AS before their genetic tests. In the subgroup of patients who underwent kidney biopsies, only 60% had lesions on light or electron microscopy (LM or EM) suggestive of AS or TBM disease, which is in accordance with data reported in the literature regarding the difficulties of",18_14,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"in the literature regarding the difficulties of histologic diagnosis of AS, especially in females with XLAS and in autosomal forms [<xref rid=""B6-genes-15-00593"" ref-type=""bibr"">6</xref>]. Considering that AS can cause histologic lesions of FSGS that, in the absence of genetic testing, can be interpreted as a primary podocytopathy [<xref rid=""B36-genes-15-00593"" ref-type=""bibr"">36</xref>,<xref rid=""B37-genes-15-00593"" ref-type=""bibr"">37</xref>], we identified three patients with histologically diagnosed",18_15,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"three patients with histologically diagnosed FSGS in our cohort. All patients in this subgroup received immunosuppression before the diagnosis of COL4-related nephropathy. Nearly 30% of all our cohort received some sort of immunosuppression before the diagnosis of AS. Although not statistically significant, this group displayed higher values of proteinuria. Regarding the results of genetic testing, we identified 24 different variants involving the COL4 genes. Only seven patients were related, comprising",18_16,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"Only seven patients were related, comprising three distinct families. Our cohort included mostly variants inherited in an autosomal dominant manner (58.33%), possibly causing the delay in genetic testing because autosomal dominant forms tend to have nonspecific and variable clinical pictures with slower declines in renal function [<xref rid=""B16-genes-15-00593"" ref-type=""bibr"">16</xref>]. Our high proportion of ADAS is supported by recent data suggesting a higher frequency of these forms than previously",18_17,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"a higher frequency of these forms than previously considered, with prevalence largely ranging between 15 and 30% of AS cases [<xref rid=""B16-genes-15-00593"" ref-type=""bibr"">16</xref>,<xref rid=""B38-genes-15-00593"" ref-type=""bibr"">38</xref>]. Due to the limited number of patients, the difference between females and males with XLAS was not significant, although most men had PV and developed ESKD compared to women who had better kidney survival. Although current guidelines recommend considering only PV and",18_18,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"guidelines recommend considering only PV and LPV as disease causing [<xref rid=""B7-genes-15-00593"" ref-type=""bibr"">7</xref>,<xref rid=""B35-genes-15-00593"" ref-type=""bibr"">35</xref>], we included in our analysis six subjects with variants classified as VUS, as they had clinical and/or histological features suggestive of AS and/or FSGS. Missense variants are well known for being the most frequent type of mutation regardless of the COL4 gene involved, the vast majority being represented by glycine",18_19,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"the vast majority being represented by glycine substitutions. Accordingly, 63.9% of variants analyzed were missense mutations, with 82.6% of them involving glycine as the substituted residue. Hematuria was the most prevalent clinical finding, with 76.92% of patients having hematuria at the time of first evaluation, and nearly 84% having a personal history of hematuria before referral to our center. A total of 73.33% of our patients had proteinuria greater than 1 g/day, with more than a third of them having",18_20,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"1 g/day, with more than a third of them having nephrotic range proteinuria (36.36%). We observed a significant impact on renal function, with lower eGFR in the group with proteinuria greater than 1 g/day. None of the patients with proteinuria lower than 1 g/day developed ESKD, so comparing renal survival in the two groups was not possible. In a large retrospective study, Furlano et al. observed a five-fold increase in the risk of KRT in the presence of proteinuria [<xref rid=""B16-genes-15-00593""",18_21,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"of proteinuria [<xref rid=""B16-genes-15-00593"" ref-type=""bibr"">16</xref>], and while our results did not reach statistical significance, we observed a lower renal survival in this group of patients compared to the rest of the cohort. The natural history of AS has been extensively studied, with men hemizygous for COL4A5 mutations having a worse renal prognosis, 90% of them being on KRT by the age of 40, and females heterozygous for COL4A5 mutations having milder outcomes, with only 30% of them having ESKD",18_22,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"outcomes, with only 30% of them having ESKD by the age of 60 [<xref rid=""B5-genes-15-00593"" ref-type=""bibr"">5</xref>,<xref rid=""B39-genes-15-00593"" ref-type=""bibr"">39</xref>]. In the case of the autosomal dominant forms, the prognosis is much better, with the reported median renal survival time being above 60 years [<xref rid=""B16-genes-15-00593"" ref-type=""bibr"">16</xref>]. Both males and females with ARAS will develop ESKD by the age of 40. Although our cohort was comprised mostly of ADAS, considered in",18_23,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"was comprised mostly of ADAS, considered in the literature as having a milder phenotype [<xref rid=""B5-genes-15-00593"" ref-type=""bibr"">5</xref>,<xref rid=""B16-genes-15-00593"" ref-type=""bibr"">16</xref>], the median renal survival observed in our study was 42 years (95% CI, 29.98–54.01). In line with these findings, autosomal inherited variants also displayed a worse evolution than expected with a mean renal survival time of only 41.15 years (95% CI, 35.08–47.21). Overall, half of the patients presented with",18_24,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"Overall, half of the patients presented with or later developed ESKD, at a median age of onset of 25.5 years (IQR, 21.5–37.25), similar to the one seen in men with XLAS with mutations with an important molecular impact, such as large deletions [<xref rid=""B40-genes-15-00593"" ref-type=""bibr"">40</xref>]. Consistent with the results of Ozdemir et al., who observed a faster progression to CKD in children with COL4A3 mutations [<xref rid=""B41-genes-15-00593"" ref-type=""bibr"">41</xref>], in our cohort, patients",18_25,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"in our cohort, patients with COL4A3 variants displayed poorer prognoses, with most patients with ESKD coming from this group. The lowest renal survival time was observed in this group. Better outcomes were observed in those with COL4A4 variants, who had the highest renal survival and the highest median age at the time of ESKD diagnosis. One third (4/12) of the patients with COL4A4 variants were classified as VUS, in comparison with only one sixth (2/12) of the patients with COL4A3, explaining the",18_26,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"of the patients with COL4A3, explaining the difference in renal survival between the two groups. Furthermore, although 50% (2/4) of the patients with VUS involving COL4A4 developed ESKD, the age of onset was higher than the mean renal survival observed in the whole cohort (42 and 57 years, respectively; refer to <xref rid=""app1-genes-15-00593"" ref-type=""app"">Table S2</xref>). There was a nonsignificant tendency toward better renal survival in those with heterozygous mutations, representing the patients",18_27,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"heterozygous mutations, representing the patients with ADAS and the females with XLAS. Since there were no disparities in renal survival between VUS, PV, and LPV, we believe that the significant number of VUS patients developing ESKD (3/6, refer to <xref rid=""app1-genes-15-00593"" ref-type=""app"">Table S2</xref>) has influenced renal survival. One of the features included in the classical description of AS, bilateral sensorineural hearing loss, usually develops progressively, affecting most males with XLAS",18_28,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"progressively, affecting most males with XLAS by the age of 40 [<xref rid=""B5-genes-15-00593"" ref-type=""bibr"">5</xref>]. In our cohort, only eight out of the 28 subjects screened exhibited hearing loss (28.6%), but the real prevalence might be higher as our results were based on medical records and audiometry data were not available. Consistent with data reported in the literature on XLAS [<xref rid=""B42-genes-15-00593"" ref-type=""bibr"">42</xref>,<xref rid=""B43-genes-15-00593"" ref-type=""bibr"">43</xref>],",18_29,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"ref-type=""bibr"">43</xref>], hearing loss was associated with a poorer renal outcome in our study, as all eight patients had ESKD with a median renal survival of only 25 years (95% CI, 23.65–26.34; <italic toggle=""yes"">p</italic> < 0.001). Although there is much debate regarding the mechanism of hearing loss in AS [<xref rid=""B44-genes-15-00593"" ref-type=""bibr"">44</xref>,<xref rid=""B45-genes-15-00593"" ref-type=""bibr"">45</xref>], there are studies reporting correlations between the molecular characteristics",18_30,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"between the molecular characteristics of COL4 variants and the risk of hearing abnormalities, especially regarding the type of substituting residue in missense variants [<xref rid=""B15-genes-15-00593"" ref-type=""bibr"">15</xref>]. Our study failed to identify associations between the characteristics of the variants (i.e., gene, inheritance, pathogenicity, and type of mutations) and the risk of developing sensorineural hearing loss. There were only two patients with eye abnormalities consistent with AS in our",18_31,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"with eye abnormalities consistent with AS in our cohort, owing to the limited ophthalmological screening. Although missense variants are associated with a less severe phenotype in all forms of AS [<xref rid=""B12-genes-15-00593"" ref-type=""bibr"">12</xref>], there is a high degree of variability regarding the renal prognosis depending on the characteristics of the variant, such as the substituting residue and the position of the substitution [<xref rid=""B15-genes-15-00593"" ref-type=""bibr"">15</xref>]. In our",18_32,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"ref-type=""bibr"">15</xref>]. In our study, we managed to replicate some of these findings, with missense variants displaying a nearly 12-year increase in the mean kidney survival and a 66% reduction in the risk of developing ESKD. The characteristics of the substituting residue and the position of the substitution did not impact the renal outcomes, probably because most of the variants involved destabilizing amino acids as substituting residues and were located between exon 21 and the carboxyl terminal",18_33,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"located between exon 21 and the carboxyl terminal domain, thus already possessing a higher risk of kidney dysfunction. One of the most important limitations of this study is the relatively small size and the monocentric nature of the cohort. Data regarding proteinuria were incomplete due to the retrospective design and the use of medical records for data collection. As audiometric reports were not available, the exact prevalence of hearing loss might be higher than reported in our study. The strength of",18_34,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"than reported in our study. The strength of our study comes from the diversity of our cohort, comprising patients with different forms of AS, different types of mutations, and covering the entire clinical spectrum of COL4-related diseases. As there was a high proportion of ADAS in our cohort with lower renal survival than reported in the literature, we were able to argue that even the classically milder forms of AS can be at risk of rapid progression to ESKD. In summary, our study has identified that the",18_35,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"In summary, our study has identified that the type of variant and the α chain involved are key factors to consider when assessing the prognosis in AS. As autosomal dominant forms and missense variants, classically considered as having a milder phenotype, displayed worse kidney survival than expected, our research highlights the need for refining individual prognostication based on the molecular characteristics of each variant. Our diverse cohort illustrated the wide phenotypic spectrum of AS, which is",18_36,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"the wide phenotypic spectrum of AS, which is probably responsible for the delay in diagnosis.",18_37,Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience,07 5 2024,,Alport_Syndrome
"X-linked Alport syndrome presenting in mother and son with the same unique histopathological features Alport syndrome has been linked to three different genes, that is, <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic>. It is characterized by progressive and non-specific glomerulosclerosis with irregular thickening of the glomerular basement membrane (GBM). At times, the histopathologic picture is dominated by lesions that are consistent with",19_0,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"is dominated by lesions that are consistent with focal and segmental glomerulosclerosis or IgA nephropathy. Here, we report the cases of two related individuals (mother and son) who were diagnosed with <italic toggle=""yes"">COL4A5</italic>-related Alport syndrome due to a missense variant (p.Gly1170Ser) in a G-X-Y repeat and found to present the same highly unusual histopathological abnormalities on their kidney biopsies. One of the abnormalities shared, which does not appear to have been reported, was",19_1,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"which does not appear to have been reported, was reduced COL4A5 immunolabeling that was limited to Bowman’s capsule even though the ultrastructure of the GBM was distorted. The other abnormality was superimposed segmental IgA deposition in both individuals, accompanied by mesangial changes in the mother. We feel that these findings provide novel insight into the mechanisms of disease manifestation in Alport syndrome. They suggest, in particular, that collagen expression and/or assemblies in Bowman’s",19_2,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"collagen expression and/or assemblies in Bowman’s capsule is more vulnerable to missense mutations in <italic toggle=""yes"">COL4A5</italic> than elsewhere in the kidney. Our findings also suggest that certain coinherited gene polymorphisms act as unexpectedly important phenotypic determinants in <italic toggle=""yes"">COL4A</italic>-related disorders. Alport syndrome occurs at a prevalence of ~ 1% through mutations in <italic toggle=""yes"">COL4A3</italic> (2q36.3), <italic toggle=""yes"">COL4A4</italic> (2q36.3)",19_3,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"<italic toggle=""yes"">COL4A4</italic> (2q36.3) or <italic toggle=""yes"">COL4A5</italic> (Xq22.3) [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Progressive kidney disease is the main manifestation of this syndrome and is generally accompanied by pathognomonic distortions of the glomerular basement membrane (GBM) with varying degrees of glomerulosclerosis and tubulointerstitial fibrosis [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. At times, it can develop without such distortions and be associated with IgA",19_4,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"such distortions and be associated with IgA nephropathy (IgAN) or an IgA-like nephropathy [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. There are three types of collagen IV assemblies in the kidney: the COL4A3-4-5 and COL4A1-1-2 assemblies, which are found in the GBM and Bowman’s capsule, and the COL4A5-5-6 assembly, which is found in Bowman’s capsule alone [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. In many cases, a pathogenic mutation in one of these genes hinders",19_5,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"pathogenic mutation in one of these genes hinders trimerization and/or expression of all protomers within an assembly [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. When the mutation affects <italic toggle=""yes"">COL4A5</italic>, the gene product is often absent from both the GBM and Bowman’s capsule, and when the mutation affects <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic>, COL4A5 is often absent from the GBM but always present in Bowman’s capsule [<xref ref-type=""bibr""",19_6,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"in Bowman’s capsule [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Here, we report a unique form of <italic toggle=""yes"">COL4A5</italic>-related Alport syndrome that we have uncovered in two individuals from the same family. To us, the observed presentation was of exceptional interest for at least two reasons. First, it provided valuable insight into the effect of the mutation on the assembly of the COL4A5-based trimers. Second, it also suggested that both the molecular as well as clinical repercussions of",19_7,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"molecular as well as clinical repercussions of the primary gene defect were shaped by a coinherited predisposition. A 48-year-old woman known for systemic hypertension was referred to our Nephrology Service for longstanding microscopic hematuria and progressive chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73 m<sup>2</sup> and proteinuria of 416 mg/day at presentation. At the initial visit, the patient had two sons in apparent good health and reported no",19_8,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"two sons in apparent good health and reported no family history of kidney disease or deafness. A renal biopsy ordered to clarify the cause of CKD was suggestive of chronic IgAN (results not shown). In particular, light microscopy showed diffuse mesangial expansion with focal areas of hypercellularity, moderate glomerulosclerosis and chronic tubulointerstitial disease, immunofluorescence showed segmental IgA deposition in the mesangium and capillary loops, and electron microscopy showed occasional mesangial",19_9,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"electron microscopy showed occasional mesangial and intramembranous electron-dense deposits. COL4A2 and COL4A5 distribution in the GBM and Bowman’s capsule was otherwise uniform, and GBM thickness normal (227–318 nm). A second biopsy carried out 18 months later for worsening of the kidney function revealed similar findings by light microscopy, immunofluorescence and electron microscopy (see Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>a–c, respectively). However, two additional abnormalities were noted:",19_10,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"However, two additional abnormalities were noted: (1) immunolabeling for COL4A5 in Bowman’s capsule appeared paler as well as discontinuous (not shown) and (2) the GBM exhibited varying degrees of thickness (250–404 nm) with segmental remodeling, multilamellation and intramembranous granular particles (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>d).<fig id=""Fig1""><label>Fig. 1</label><caption><p>Results of the kidney biopsies. Images in the upper row are from the second biopsy in the mother and images in",19_11,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
the second biopsy in the mother and images in the lower row from the biopsy in the son. <bold>a</bold> Light microscopy (PAS). Glomerulus showing mesangial expansion with segmental mesangial hypercellularity (arrow). <bold>b</bold> Immunofluorescence. Mild segmental IgA deposition. <bold>c</bold> Electron microscopy. Paramesangial and mesangial electron-dense deposits (arrow). <bold>d</bold> Electron microscopy. GBM showing splitting of the lamina densa with multilamellation giving rise to a basket-weave,19_12,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
multilamellation giving rise to a basket-weave appearance (arrows). Thickness ranged from 250 to 404 nm (normal in females: 215–395 nm). <bold>e</bold> Immunofluorescence. Weak segmental IgA deposition. <bold>f</bold> Electron microscopy. GBM showing splitting of the lamina densa with multilamellation giving rise to a basket-weave appearance. <bold>g</bold> Immunofluorescence. COL4A5 immunolabeling (in green) is continuous and linear in GBM but absent in Bowman’s capsule and proximal tubular basement,19_13,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"in Bowman’s capsule and proximal tubular basement membranes (marked in red through COL4A2 immunolabeling). The figure was prepared with the CorelDRAW<sup>®</sup> Graphics Suite software</p></caption><graphic http://www.w3.org/1999/xlink href=""40620_2024_1942_Fig1_HTML"" id=""MO1""></graphic></fig> Five years later, one of the patient’s sons was found to have proteinuria (729 mg/day) and hematuria with an eGFR of more than 120 mL/min/1.73 m<sup>2</sup>. He was 29 years old and otherwise in good health. A",19_14,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"was 29 years old and otherwise in good health. A kidney biopsy showed mild global glomerulosclerosis by light microscopy along with chronic tubulointerstitial disease (not shown), weak segmental IgA deposition by immunofluorescence (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>e) and GBM alterations by electron microscopy with areas of thickening or thinning, multilamellation and intramembranous granular particles (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>f). Immunolabeling for COL4A5 in Bowman’s",19_15,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"Immunolabeling for COL4A5 in Bowman’s capsule was also absent but preserved in the GBM, and immunolabeling for COL4A2 was normal (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>g). Eventually, next generation exome sequencing revealed that both mother and son carried the pathogenic p.Gly1170Ser (c.3508G>A) missense mutation in exon 39 of <italic toggle=""yes"">COL4A5</italic>. This variant was initially detected in the son through a 343-gene panel and later confirmed in the mother by site-specific testing. It",19_16,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"in the mother by site-specific testing. It affects the first G of a G-X-Y repeat within the distal third of the collagenous domain and has been associated with Alport syndrome in at least 5 non-related families. No other variants of interest could be identified in the 51 exons of <italic toggle=""yes"">COL4A5</italic> or among the genes tested. These two cases of <italic toggle=""yes"">COL4A5</italic>-related nephropathy were remarkable for various reasons. For instance, we found that immunolabeling for COL4A5",19_17,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"instance, we found that immunolabeling for COL4A5 could be decreased or lost in Bowman’s capsule while preserved in the GBM, a finding that has never been reported in this condition before. Additionally, the ultrastructural abnormalities seen in both cases were consistent with Alport syndrome but also came with variable degrees of IgA deposition. Lastly, the p.Gly1170Ser mutation was associated with a unique yet similar histopathological portrait in both mother and son. It is intriguing that in contrast to",19_18,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"and son. It is intriguing that in contrast to Bowman’s capsule, the GBM showed preserved expression of COL4A5 in the two family members and did so even if it was ultrastructurally abnormal. One explanation could be that the COL4A3-4-5 trimers were more efficiently processed than the COL4A5-5-6 trimers by harboring only one mutation per trimer instead of two. This explanation would be in keeping with the observation that G-changing missense mutations in several of the COL4A5 G-X-Y repeats have been",19_19,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"in several of the COL4A5 G-X-Y repeats have been associated with more favorable outcomes than truncating mutations but still found to alter the structure of the GBM [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. As mentioned, Bowman’s capsule in the mother showed a segmental decrease in COL4A5 expression on the second renal biopsy. This other finding was not unexpected in that the gene defect affected chromosome X and was thus bound to be inactivated in only a",19_20,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"X and was thus bound to be inactivated in only a subgroup of cells within the kidney. It could also be for the same reason that COL4A5 expression in Bowman’s capsule appeared normal in the mother on the first biopsy, i.e., that it was preserved because the glomeruli sampled were from a region where X-inactivation was favorable. In view of the gene defect uncovered, the other interesting aspect of our report was the presence of IgA deposition in both cases and mesangiopathy in the mother. While a recent",19_21,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"and mesangiopathy in the mother. While a recent exome-wide analysis of familial IgAN from 46 pedigrees has already led to the identification of gene defects in <italic toggle=""yes"">COL4A5</italic> [<xref ref-type=""bibr"" rid=""CR7"">7</xref>], it has only been seldom reported afterwards that the two conditions could coexist. Our findings should thus be seen as a timely contribution to this emerging context. They also suggest that IgAN in Alport syndrome can take a while to manifest in its typical form as it",19_22,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"a while to manifest in its typical form as it was indeed more manifest in the mother. As for the reason that could explain why a gene defect in <italic toggle=""yes"">COL4A5</italic> can lead to IgAN, some authors have argued that GBM thinning could simply allow IgA to translocate more readily from blood to mesangium and elicit a pathological response at this new location [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Such a scenario would be congruent with the observation that IgAN has also been described with",19_23,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"that IgAN has also been described with gene defects in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic>. However, one would then wonder why mesangial deposition of the other immunoglobulins or of C3 is not a very common finding in Alport syndrome. In our view, a more plausible explanation would be that the susceptibility to develop a COL4A3-, COL4A4- or COL4A5-related form of IgAN is driven by coinherited gene polymorphisms. For instance, this renal lesion was seen in our",19_24,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"For instance, this renal lesion was seen in our blood-related cases while it has not previously been associated with the COL4A5 p.Gly1170Ser mutation. Along the same line, many individuals who were found to carry pathogenic mutations in <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> or <italic toggle=""yes"">COL4A5</italic> were also blood-related [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. As it stands, there is evidence to suggest the involvement of IgAN-associated polymorphisms",19_25,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"the involvement of IgAN-associated polymorphisms in Alport syndrome. In particular, a genome-wide association study of sporadic IgAN has led to the identification of a susceptibility locus (2q36) that encompasses the <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> genes [<xref ref-type=""bibr"" rid=""CR8"">8</xref>] and that could thus harbor a polygene through which IgA1 processing is coordinated. In the case of <italic toggle=""yes"">COL4A5</italic>, <italic",19_26,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"of <italic toggle=""yes"">COL4A5</italic>, <italic toggle=""yes"">VSIG1</italic> could correspond to another polygene of interest given that it is involved in gastrointestinal immune regulation and is also localized in locus Xq22.3 [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. A question that will need to be addressed in the course of future investigations is whether COL4-related IgAN could be treated as idiopathic IgAN, especially if galactose-deficient IgA1 were to be involved in disease progression. This",19_27,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"were to be involved in disease progression. This question will become particularly relevant if complement pathway inhibitors or B-cell-directed strategies in idiopathic IgA were eventually found to be more effective and better tolerated than the previously described approaches. In conclusion, we have reported for the first time two cases of X-linked Alport syndrome where the only structure affected by a decrease in COL4A5 immunolabeling was Bowman’s capsule and where neither <italic",19_28,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"was Bowman’s capsule and where neither <italic toggle=""yes"">COL4A3</italic> nor <italic toggle=""yes"">COL4A4</italic> could have thus been at cause. The cases described were also striking in being blood-related and both showing glomerular IgA deposition. These observations suggest that the molecular and clinical impacts of the mutation identified were conditioned in mother and son by a coinherited gene defect in or near the Xq22.3 locus.",19_29,X-linked Alport syndrome presenting in mother and son with the same unique histopathological features,26 4 2024,,Alport_Syndrome
"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family Alport syndrome (AS) is an inherited kidney disease characterised by haematuria, proteinuria, and gradual decline in kidney function. It is often associated with hearing loss and eye abnormalities [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. AS arises from abnormalities in type IV collagen, a crucial building block of the basement membrane (BM) found in the kidney, eye, and cochlea. AS is caused by",20_0,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"in the kidney, eye, and cochlea. AS is caused by mutations in the genes <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic>, encoding the chains 𝛼3, 𝛼4, and 𝛼5 of type IV collagen, respectively [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. AS is estimated to affect approximately 1 in every 5,000 to 1 in every 53,000 individuals in different populations [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. The occurrence of AS in children who undergo",20_1,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"The occurrence of AS in children who undergo renal biopsy varies between 1% and 12%, depending on the specific indications for the biopsy [<xref ref-type=""bibr"" rid=""CR4"">4</xref>–<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. AS has three different inheritance patterns: X-linked Alport syndrome (XLAS), autosomal recessive, and autosomal dominant [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. XLAS, caused by mutations in the <italic toggle=""yes"">COL4A5</italic> gene, is the predominant form of AS, accounting for",20_2,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"is the predominant form of AS, accounting for approximately 85% of the cases [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. The Xq22 chromosome is where the <italic toggle=""yes"">COL4A5</italic> gene is situated [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Currently, the Human Gene Mutation Database (<ext-link ext-link-type=""uri"" http://www.w3.org/1999/xlink href=""http://www.hgmd.org"">http://www.hgmd.org</ext-link>) contains over 1000 different versions of the <italic toggle=""yes"">COL4A5</italic> gene.",20_3,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"of the <italic toggle=""yes"">COL4A5</italic> gene. Approximately 60% of pathogenic mutations in XLAS are missense mutations, whereas frameshift and nonsense mutations account for 20% and 10%, respectively. The remaining 10% are attributed to canonical splicing mutations [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Although the exact correlation between genotypes and phenotypes in XLAS is not fully understood, it is commonly accepted that the severity of phenotypes is less pronounced with missense mutations",20_4,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"is less pronounced with missense mutations than with truncated mutations [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Patients with splicing abnormalities often exhibit severe illness [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. In this study, we used whole-exome and Sanger sequencing techniques to discover novel splicing variations in a Chinese family experiencing haematuria and proteinuria. Next, we conducted an additional analysis to examine the impact of the genetic mutation on transcription using a",20_5,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"of the genetic mutation on transcription using a minigene assay.   The AS phenotype is characterised by isolated non-progressive haematuria to progressive nephropathy with extrarenal abnormalities [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Approximately 60% are estimated to develop end-stage renal disease (ESRD) after 40 years of age. The most prevalent indications in these patients were microhaematuria and proteinuria. Mutations in COL4A5 are the main causes of AS. Here, we report a case of AS with a",20_6,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"causes of AS. Here, we report a case of AS with a novel <italic toggle=""yes"">COL4A5</italic> mutation, c.4298-8G > A. The proband’s age at onset was 13 years, and he exhibited microhaematuria and proteinuria with elevated levels of creatinine in the blood. The proband’s family history included two maternal uncles who passed away because of kidney disease, and a mother who had kidney disease, all of which led to a high suspicion of AS. High-throughput sequencing and analysis of approximately 20,000 gene",20_7,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"and analysis of approximately 20,000 gene exons and ± 10-bp intron regions in the proband’s genomic DNA revealed the <italic toggle=""yes"">COL4A5</italic> mutation c.4298-8G > A. The pathogenicity of the <italic toggle=""yes"">COL4A5</italic> variant was confirmed by clinical manifestation, human genome variation database analysis, functional software prediction, and minigene assay. According to the ACMG guidelines, the <italic toggle=""yes"">COL4A5</italic> variant was classified as a likely pathogenic",20_8,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"variant was classified as a likely pathogenic variant. The gene <italic toggle=""yes"">COL4A5</italic> is situated in region Xq22.3 and comprises a total of 51 exons. The translated product consists of 1685 amino acid residues, including a signal peptide of 26 residues, a collagenous domain of 1430 residues encoded by exons 2–47, which begins with a noncollagenous sequence of 14 residues, and a gly-Xaa-Yaa-repeat sequence interrupted at 22 locations. This is followed by a carboxyl-terminal non-collagenous",20_9,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"followed by a carboxyl-terminal non-collagenous domain of 229 residues encoded by exons 47–51 [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. The main genetic pattern of AS caused by the <italic toggle=""yes"">COL4A5</italic> mutation is X-linked dominant inheritance. Sanger sequencing confirmed that the mutation <italic toggle=""yes"">COL4A5</italic> c.4298-8G > A was present in the proband’s mother, brother, and grandmother, indicating a typical X-linked inheritance pattern. Almost all male patients with XLAS",20_10,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"pattern. Almost all male patients with XLAS have microscopic haematuria and proteinuria; the incidence of hearing loss is 32–83%, and the incidence of eye lesions is 6–35% [<xref ref-type=""bibr"" rid=""CR11"">11</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>–<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. More than 90% of female heterozygotes with XLAS have microscopic haematuria, approximately 70% have proteinuria, 6–28% have hearing loss, and 2–15% have eye lesions [<xref ref-type=""bibr""",20_11,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"and 2–15% have eye lesions [<xref ref-type=""bibr"" rid=""CR20"">20</xref>–<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. In this study, both the proband and younger brother showed microscopic haematuria and proteinuria, as well as myopia and no hearing loss. The mother of the heterozygous carrier had microscopic haematuria, proteinuria, and high myopia, whereas the grandmother had proteinuria without any other abnormal manifestations. In XLAS, hemizygous male patients usually exhibit more severe characteristics",20_12,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"usually exhibit more severe characteristics that advance to ESRD during early or middle adulthood than the heterozygous female [<xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>]. In this case, the proband’s two uncles passed away from ESRD when they were 24 and 10 years old, respectively. At the ages of 14 and 12 years, the proband and his younger sibling were both diagnosed with chronic kidney disease, and during the follow-up process, the proband progressed to ESRD",20_13,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"follow-up process, the proband progressed to ESRD by the time of submission; the proband’s mother was diagnosed with kidney disease at 31 years of age; the grandmother had been in good health and was only discovered to have proteinuria during a routine physical examination. Evidence indicates that the phenotypes of male family members are generally more severe than those of female members. This may be because women have two X chromosomes. To balance gene expression, one of the X chromosomes is randomly",20_14,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"expression, one of the X chromosomes is randomly inactivated, which can occur as early as the embryonic period, and non-inactivated normal chromosomes can partially compensate, resulting in milder disease manifestations [<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. The phenotypic differences between the proband’s mother and grandmother may have been caused by inconsistencies in gene penetrance. Disease penetrance may depend on other genetic and environmental factors [<xref ref-type=""bibr""",20_15,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"and environmental factors [<xref ref-type=""bibr"" rid=""CR24"">24</xref>]. Blood tests showed that the glomerular filtration rate of the proband’s grandfather had decreased. He visited the hospital for kidney disease 10 years prior (the details are unknown), and later, he was in good health. We believe that his kidney damage was caused by reasons other than AS. Currently, the Human Gene Mutation Database contains over 1000 versions of the <italic toggle=""yes"">COL4A5</italic> gene. More than 10% of these are",20_16,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"gene. More than 10% of these are splicing variations. In this study, an <italic toggle=""yes"">in silico</italic> assessment predicted that this variation may affect splicing. Splicing-site variations can cause truncated variation, which leads to premature codon termination, or non-truncated variation, which leads to exon jumping or intron retention. Only after the splicing variation is verified by in vitro experiments can its influence on the body be further evaluated. We used an ex vivo minigene splicing",20_17,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"evaluated. We used an ex vivo minigene splicing assay to confirm the abnormal splicing resulting from the mutation in <italic toggle=""yes"">COL4A5</italic>. The outcome indicated that the c.4298-8G > A mutation affected the regular splicing of <italic toggle=""yes"">COL4A5</italic> mRNA and produced a fresh acceptor site, leading to the retention of a 6-bp base (AAATAG) on the right side of intron 46 in COL4A5 transcripts. Consequently, two amino acids were inserted after the amino acid at position 1,432 of",20_18,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"after the amino acid at position 1,432 of α5(IV). Moreover, the I-TASSER program was employed to predict the configuration of both wild-type and altered COL4A5 proteins and to construct a model. The hydrogen bond structure of amino acids 1432–1433 underwent changes both before and after the mutation. In addition, the electrostatic potential near the 1432_1433 mutation on the protein surface transitioned from electropositive to electronegative. These observations indicate that the c.4298-8G > A variant in",20_19,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"indicate that the c.4298-8G > A variant in <italic toggle=""yes"">COL4A5</italic> could potentially impact the structural abnormalities of the BM. Liang et al. discovered a comparable mutation, c.4298–20T > A, in the <italic toggle=""yes"">COL4A5</italic> gene. This mutation causes the retention of 18 bp in intron 46 of the <italic toggle=""yes"">COL4A5</italic> mRNA, resulting in the insertion of six amino acids after the amino acid at position 1432 in α5(IV). Molecular dynamics results showed that the",20_20,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"Molecular dynamics results showed that the c.4298–20T > A variant could affect the tail stability of the α345(IV) trimer as well as the stability of the head and middle of the α345(IV) trimer. Furthermore, the simulations suggest that the structure of the mutant α345(IV) trimer changes greatly and mutation has a great influence on their configuration [<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. In our study, although only two amino acids were inserted after the amino acid at position 1,432 in α5(IV), we",20_21,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"the amino acid at position 1,432 in α5(IV), we suspect that this may also affect the stability of the α345(IV) trimer and the formation of a trimer configuration. The genotype-phenotype correlation in male XLAS is relatively well established. Jais et al. reported that splicing mutations confer a 70% probability of ESRD development by 30 years of age [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. Bekheirnia et al. reported that individuals with splice-site mutations experienced ESRD onset at an average age",20_22,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"experienced ESRD onset at an average age of 28 years old [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Horinouchi et al. reported that individuals with truncating mutations due to atypical splicing atypical developed ESRD at a median age of 20 years, whereas those with non-truncating mutations developed ESRD at a median age of 29 years [<xref ref-type=""bibr"" rid=""CR12"">12</xref>], the study revealed a disparity in kidney prognosis between the two types of splicing variants. In our study, the c.4298–8G > A",20_23,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"variants. In our study, the c.4298–8G > A variant was a non-truncating mutation, and the proband’s two maternal uncles, who may have carried the <italic toggle=""yes"">COL4A5</italic> mutation, died of kidney disease at the ages of 24 and 10, respectively. The proband has also progressed to ESRD so far, and the younger brother also has kidney damage, the kidney damage caused by the <italic toggle=""yes"">COL4A5</italic> mutation is of serious phenotype in males. For the extrarenal phenotype, the proband and",20_24,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"For the extrarenal phenotype, the proband and younger brother did not exhibit sensorineural hearing loss but only had a mild form of near-sightedness. In conclusion, the kidney phenotype caused by the splicing mutation c.4298-8G > A is considered serious. However, the present study has some limitations. Due to insufficient renal biopsy tissue samples from the proband, we were unable to perform immunofluorescence testing. Although the pathogenicity of the novel <italic toggle=""yes"">COL4A5</italic> variant",20_25,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"<italic toggle=""yes"">COL4A5</italic> variant is explained by the clinical phenotype of the proband, his family history of kidney disease, pedigree analysis, bioinformatics predictions, and minigene assays, further functional studies are needed to determine the impact of the variant on <italic toggle=""yes"">COL4A5</italic> gene expression and function. We discovered a splicing variant, c.4298-8G > A, in the <italic toggle=""yes"">COL4A5</italic> gene in a patient with XLAS, and verified its splicing effect",20_26,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"with XLAS, and verified its splicing effect using a minigene assay. The mutation was assessed as likely pathogenic. This research broadens the range of mutations linked to the XLAS and enhances our understanding of the correlation between XLAS genotypes and phenotypes.",20_27,"A novel <italic toggle=""yes"">COL4A5</italic> splicing mutation causes alport syndrome in a Chinese family",26 4 2024,,Alport_Syndrome
"Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome Podocytes are the rate-limiting glomerular cells for type IV collagen production, and horizontal gene transfer or cell fusion with stem cells regenerates the renal parenchyma in Alport syndrome. Glomerular filtration relies on the type IV collagen (ColIV) network of the glomerular basement membrane, namely, in the triple helical molecules containing the α3, α4, and α5 chains of ColIV. Loss of function",21_0,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"α3, α4, and α5 chains of ColIV. Loss of function mutations in the genes encoding these chains (<italic toggle=""yes"">Col4a3</italic>, <italic toggle=""yes"">Col4a4</italic>, and <italic toggle=""yes"">Col4a5</italic>) is associated with the loss of renal function observed in Alport syndrome (AS). Precise understanding of the cellular basis for the patho-mechanism remains unknown and a specific therapy for this disease does not currently exist. Here, we generated a novel allele for the conditional deletion of",21_1,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"a novel allele for the conditional deletion of <italic toggle=""yes"">Col4a3</italic> in different glomerular cell types in mice. We found that podocytes specifically generate α3 chains in the developing glomerular basement membrane, and that its absence is sufficient to impair glomerular filtration as seen in AS. Next, we show that horizontal gene transfer, enhanced by TGFβ1 and using allogenic bone marrow–derived mesenchymal stem cells and induced pluripotent stem cells, rescues <italic",21_2,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"induced pluripotent stem cells, rescues <italic toggle=""yes"">Col4a3</italic> expression and revive kidney function in Col4a3-deficient AS mice. Our proof-of-concept study supports that horizontal gene transfer such as cell fusion enables cell-based therapy in Alport syndrome. Alport syndrome (AS), the progressive hereditary kidney disease that is estimated to impact approximately 1 in 50,000 newborns, is associated with aberrant glomerular basement membrane (GBM) type IV collagen composition, and it",21_3,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"(GBM) type IV collagen composition, and it remains a clinical challenge that ultimately requires renal transplant. GBM defects in AS arise from mutations in either of the three genes (<italic toggle=""yes"">Col4a3</italic>, <italic toggle=""yes"">Col4a4</italic>, or <italic toggle=""yes"">Col4a5</italic> genes) that encode for three chains of type IV collagen, respectively (<xref rid=""bib21"" ref-type=""bibr"">Hudson et al, 2003</xref>; <xref rid=""bib12"" ref-type=""bibr"">Cosgrove et al, 2007</xref>; <xref",21_4,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"et al, 2007</xref>; <xref rid=""bib27"" ref-type=""bibr"">LeBleu et al, 2010</xref>; <xref rid=""bib11"" ref-type=""bibr"">Cosgrove & Liu, 2017</xref>; <xref rid=""bib8"" ref-type=""bibr"">Boudko et al, 2022</xref>). Patho-mechanistic studies suggest that loss of one chain type can lead to loss of the other two chain types due to the obligate requirement for integration of the three α-chain types into the triple helical type IV collagen molecule (α3α4α5 triple helical protomers). Interestingly, loss of GBM type IV",21_5,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"protomers). Interestingly, loss of GBM type IV collagen α3, α4, or α5 chain leads to compensation by α1 and α2 chains (α1α2α1 triple helical protomers), but this does not confer the structural and functional integrity for proper glomerular filtration (<xref rid=""bib33"" ref-type=""bibr"">Naylor et al, 2021</xref>). Non-targeted therapies for glomerular and interstitial renal diseases have been tested with some benefit in patients with Alport syndrome, but they failed to prevent renal failure (<xref",21_6,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"but they failed to prevent renal failure (<xref rid=""bib24"" ref-type=""bibr"">Katayama et al, 2014</xref>; <xref rid=""bib36"" ref-type=""bibr"">Omachi & Miner, 2019</xref>; <xref rid=""bib10"" ref-type=""bibr"">Chavez et al, 2022</xref>; <xref rid=""bib14"" ref-type=""bibr"">Daga et al, 2022</xref>). Previously, systemic infusion of unfractionated bone marrow–derived cells and embryonic stem cells were reported to restore the GBM type IV collagen composition in <italic toggle=""yes"">Col4a3</italic> knock out",21_7,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"in <italic toggle=""yes"">Col4a3</italic> knock out (Col4a3<sup>KO</sup>) mice (a mouse model for AS) with increased survival, improved renal function, and histopathological regeneration of glomeruli (<xref rid=""bib39"" ref-type=""bibr"">Prodromidi et al, 2006</xref>; <xref rid=""bib43"" ref-type=""bibr"">Sugimoto et al, 2006</xref>). These proof-of-concept studies raise the question as to the precise function of stem cells in the regeneration of the kidney glomeruli and their clinical translation potential (<xref",21_8,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"and their clinical translation potential (<xref rid=""bib20"" ref-type=""bibr"">Heidet et al, 2003</xref>; <xref rid=""bib19"" ref-type=""bibr"">Gross et al, 2009</xref>; <xref rid=""bib26"" ref-type=""bibr"">LeBleu et al, 2009</xref>; <xref rid=""bib29"" ref-type=""bibr"">Lin et al, 2014</xref>). Glomerular endothelial cells and podocytes are hypothesized to contribute to the α3α4α5 type IV collagen of the GBM (<xref rid=""bib1"" ref-type=""bibr"">Abrahamson et al, 2009</xref>), but genetic evidence is still lacking. To",21_9,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"but genetic evidence is still lacking. To address this issue directly, we generated a novel genetically engineered mouse that enables the conditional deletion of <italic toggle=""yes"">Col4α3</italic> in specific cell types to identify the origin of GBM type IV collagen. Using cell fate-mapping strategies, we designed experiments to define the underlying mechanism associated with stem cell–based rescue of renal failure in Col4a3<sup>KO</sup> mice, utilizing allogenic bone marrow–derived mesenchymal stem",21_10,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"allogenic bone marrow–derived mesenchymal stem cells (MSC) and induced pluripotent stem cells (IPS).  We previously reported on several cell-based approaches to restore the type IV collagen network necessary for GBM function in murine models of Alport syndrome (Col4a3<sup>KO</sup> mice) (<xref rid=""bib43"" ref-type=""bibr"">Sugimoto et al, 2006</xref>; <xref rid=""bib26"" ref-type=""bibr"">LeBleu et al, 2009</xref>). Here we have specifically investigated bone marrow–derived MSC and iPSC in the treatment of mice",21_11,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"MSC and iPSC in the treatment of mice with the genetic defect associated with Alport syndrome. We also report on a novel genetically engineered allele to reveal that podocytes are the dominant producers of type IV collagen in the developing kidney GBM. Our results also show that loss of <italic toggle=""yes"">Col4a3</italic> in endothelial cells is insufficient to generate the GBM defect associated with Alport syndrome, underscoring the critical role for podocytes in GBM type IV collagen production. These",21_12,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"in GBM type IV collagen production. These findings are in agreement with reports that used transgenes to rescue the type IV collagen network in Col4a3<sup>KO</sup> mice, which showed that expression of the missing type IV collagen in podocytes (<xref rid=""bib29"" ref-type=""bibr"">Lin et al, 2014</xref>), but not in endothelial cells (<xref rid=""bib18"" ref-type=""bibr"">Funk et al, 2019</xref>), is sufficient to restore GBM function. Our genetic approach shows that podocyte horizontal gene transfer or cell",21_13,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"that podocyte horizontal gene transfer or cell fusion with exogenously administered unfractionated bone marrow cells, bone marrow–derived MSC or iPSC was associated with in de novo expression of the missing type IV collagen and improves renal outcome in Col4a3<sup>KO</sup> recipient mice. Whereas the use of undifferentiated iPSC is unlikely to have clinical utility, our proof-of-concept experiments support an undifferentiated state of donor cells may be a feature necessary for successful horizontal gene",21_14,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"feature necessary for successful horizontal gene transfer or cell fusion. Further study and precise definition of cell sources and state would be necessary to advance cell-based therapy for Alport syndrome. Horizontal transfer of genetic material in vivo was previously reported in distinct pathologies using extracellular vesicles or nanotubes (<xref rid=""bib9"" ref-type=""bibr"">Burghoff et al, 2008</xref>; <xref rid=""bib46"" ref-type=""bibr"">Tome et al, 2009</xref>; <xref rid=""bib47"" ref-type=""bibr"">Uygur et",21_15,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"<xref rid=""bib47"" ref-type=""bibr"">Uygur et al, 2019</xref>; <xref rid=""bib6"" ref-type=""bibr"">Barutta et al, 2021</xref>). Beyond horizontal transfer of a limited amount of genetic material, cell fusion with the formation of a sable heterokaryon capable of genetic rescue remains challenging to ascertain. Prior studies also inform on the potential of bone marrow–derived cells generating possible heterokaryon with podocytes (<xref rid=""bib38"" ref-type=""bibr"">Poulsom et al, 2003</xref>; <xref rid=""bib39""",21_16,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"et al, 2003</xref>; <xref rid=""bib39"" ref-type=""bibr"">Prodromidi et al, 2006</xref>). Cell fusion in adult tissue is reported as a rare biological event in the liver (<xref rid=""bib3"" ref-type=""bibr"">Alvarez-Dolado et al, 2003</xref>; <xref rid=""bib48"" ref-type=""bibr"">Vassilopoulos et al, 2003</xref>; <xref rid=""bib17"" ref-type=""bibr"">Fujimiya et al, 2007</xref>), neuronal tissues (<xref rid=""bib22"" ref-type=""bibr"">Johansson et al, 2008</xref>), and skeletal muscle regeneration (<xref rid=""bib5""",21_17,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"skeletal muscle regeneration (<xref rid=""bib5"" ref-type=""bibr"">Andrade et al, 2005</xref>). Bone marrow–derived cells appear to adopt the phenotype of the cells they fuse with (<xref rid=""bib45"" ref-type=""bibr"">Terada et al, 2002</xref>) and spontaneous cell fusion appears to promote genetic reprogramming (<xref rid=""bib50"" ref-type=""bibr"">Ying et al, 2002</xref>; <xref rid=""bib4"" ref-type=""bibr"">Ambrosi & Rasmussen, 2005</xref>; <xref rid=""bib2"" ref-type=""bibr"">Alvarez-Dolado, 2007</xref>; <xref",21_18,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"2007</xref>; <xref rid=""bib7"" ref-type=""bibr"">Bonde et al, 2010</xref>). Our study indicates that the expression of the podocyte lineage transgene (Podocin-Cre) was induced in MSC following fusion with podocytes and that horizontal gene transfer or cell fusion events, as evidenced by PCR-based capture of recombined reporter alleles, were increased by TGFβ1. Inflammatory processes are known to promote cell fusion (<xref rid=""bib22"" ref-type=""bibr"">Johansson et al, 2008</xref>; <xref rid=""bib40""",21_19,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"et al, 2008</xref>; <xref rid=""bib40"" ref-type=""bibr"">Singec & Snyder, 2008</xref>; <xref rid=""bib15"" ref-type=""bibr"">Davies et al, 2009</xref>), and our studies suggest that TGFβ1—an inflammatory Th2 cytokine—likely mediates cell fusion in this setting by bringing donor and recipient cells into a close proximity, or by serving as a direct catalyst of heterotypic cell fusion. Irradiation of tissue, promoting inflammatory responses, may also partake in enhancing cell fusion. iPSC also demonstrated",21_20,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"in enhancing cell fusion. iPSC also demonstrated horizontal gene transfer/cell fusion with glomerular epithelial cells in a TGFβ1-dependent manner to induce genetic reprogramming and facilitate kidney regeneration. The host-directed expression of the donor <italic toggle=""yes"">Col4a3</italic> gene following fusion of stem cells was associated with a dynamic gene expression reprogramming controlled in part by TGFβ1. Notably, TGFβ1 has been implicated in the differentiation of podocytes and cell cycle",21_21,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"the differentiation of podocytes and cell cycle progression (<xref rid=""bib49"" ref-type=""bibr"">Wu et al, 2005</xref>; <xref rid=""bib16"" ref-type=""bibr"">Frank et al, 2022</xref>), which may be more permissive to reprogramming of gene expression following cell fusion. Collectively our studies inform on the association of horizontal gene transfer or cell fusion with the rescue of the renal phenotype; however, it remains unknown from our studies how much of the horizontal gene transfer/cell fusion is directly",21_22,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"horizontal gene transfer/cell fusion is directly responsible for de novo Col4a3 expression. Our experiments suggest that the genetic information of the “donor” stem cell was modified by the “recipient host” cell to facilitate a combined genetic program. The significant kidney regenerative potential of iPSC in this setting is likely realized because of the generation of heterokaryons which allow for a corrective gene expression reprogramming, restoring <italic toggle=""yes"">Col4a3</italic> expression and",21_23,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"toggle=""yes"">Col4a3</italic> expression and re-establishing the normal biochemical composition of the GBM of Col4a3<sup>KO</sup> mice (<xref rid=""bib45"" ref-type=""bibr"">Terada et al, 2002</xref>; <xref rid=""bib4"" ref-type=""bibr"">Ambrosi & Rasmussen, 2005</xref>). Recent advances using CRISPR/Cas9 editing showed possible corrections in the mutations in <italic toggle=""yes"">Col4a3</italic> and <italic toggle=""yes"">Col4a5</italic> in podocytes collected from patient urine (<xref rid=""bib13""",21_24,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"collected from patient urine (<xref rid=""bib13"" ref-type=""bibr"">Daga et al, 2020</xref>). Given previous reports that engraftment of human chorionic stem cells in Col4a3<sup>KO</sup> mice can rescue the renal phenotype (<xref rid=""bib32"" ref-type=""bibr"">Moschidou et al, 2016</xref>), our results with cord blood–derived MSCs offer a potential avenue for autologous cell-based therapies for patients with Alport syndrome. Whereas horizontal gene transfer or cell fusion was captured in the kidneys of",21_25,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"or cell fusion was captured in the kidneys of Col4a3<sup>KO</sup> mice transplanted with NG2-cre transgenic donor bone marrow, the significance of mesangial cell/pericyte fusion is unknown. The contribution of mesangial cells to the GBM Col4a3 chain for functional recovery is less likely, given that these cells are not directly adjacent to the GBM. Our findings with MSC are also different from a previously report that used single injection of bone marrow–derived MSC to treat Col4a3<sup>KO</sup> without",21_26,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"MSC to treat Col4a3<sup>KO</sup> without efficacy (<xref rid=""bib39"" ref-type=""bibr"">Prodromidi et al, 2006</xref>). This distinction is likely due to differences in the state and number of the MSCs used for treatment in irradiated mice (<xref rid=""bib39"" ref-type=""bibr"">Prodromidi et al, 2006</xref>), and this warrants further study. New therapies for Alport syndrome are urgently needed (<xref rid=""bib10"" ref-type=""bibr"">Chavez et al, 2022</xref>), and cell- or gene-based therapies hold the promise of",21_27,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
cell- or gene-based therapies hold the promise of correcting the genetic defects responsible for this devastating renal disease that impacts children.,21_28,Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome,28 3 2024,,Alport_Syndrome
"Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases Alport syndrome (AS) is a progressive hereditary kidney disease characterized by hematuria, proteinuria, and progressive kidney dysfunction accompanied by sensorineural hearing loss and ocular abnormalities. Pathogenic <italic toggle=""yes"">COL4A3-5</italic> variants can result in different AS spectra. Further, kidney cysts have been reported in adults with AS. However, the relationship between kidney cysts and AS remains unclear. Here, we",22_0,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"kidney cysts and AS remains unclear. Here, we report 3 cases of AS in children that occurred with kidney cysts. The patient in case 1 was initially diagnosed with IgA nephropathy at the age of 8 years but later developed bilateral multiple kidney cysts at the age of 17 years, suggesting autosomal-dominant polycystic kidney disease. Whole-exome sequencing identified a pathogenic <italic toggle=""yes"">COL4A5</italic> variant and confirmed the AS diagnosis. The patients in cases 2 and 3 had already been",22_1,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"The patients in cases 2 and 3 had already been diagnosed with X-linked AS using kidney biopsy and genetic analysis. Initial kidney ultrasonography showed nephromegaly; however, kidney cyst formation was observed during their annual follow-up. Our study supports the association between AS and kidney cysts. Kidney cysts in adolescents with suspected AS should not discourage clinicians from testing for pathogenic <italic toggle=""yes"">COL4A3-COL4A5</italic> variants. Early detection of kidney cysts is critical",22_2,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"Early detection of kidney cysts is critical because it may indicate kidney disease progression. Alport syndrome (AS) typically presents with hematuria, proteinuria, and progressive kidney failure, often accompanied by sensorineural hearing impairment and ocular problems.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> It is caused by pathogenic <italic toggle=""yes"">COL4A3-5</italic> variants encoding the α3-5 chains of collagen type IV of the basement membranes. A recent classification scheme",22_3,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"membranes. A recent classification scheme categorizes <italic toggle=""yes"">COL4A3-5</italic> diseases into X-linked, autosomal, and digenic AS.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> X-linked inheritance is caused by pathogenic <italic toggle=""yes"">COL4A5</italic> variants. Hemizygous male and female patients have 100% and 25% risk of progression to kidney failure, respectively.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> With the broad implementation of next-generation sequencing, the",22_4,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"implementation of next-generation sequencing, the spectrum of kidney phenotypes associated with pathogenic <italic toggle=""yes"">COL4A3-5</italic> variants has widened. The expanded phenotypic spectrum of AS may present with focal segmental glomerulosclerosis, idiopathic chronic kidney disease, steroid-resistant nephrotic syndrome, familial IgA nephropathy, and kidney cysts.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref> Kidney cysts have been reported in adults with pathogenic <italic",22_5,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"been reported in adults with pathogenic <italic toggle=""yes"">COL4A3-5</italic> variants.<xref rid=""bib3"" ref-type=""bibr"">3</xref>, <xref rid=""bib4"" ref-type=""bibr"">4</xref>, <xref rid=""bib5"" ref-type=""bibr"">5</xref>, <xref rid=""bib6"" ref-type=""bibr"">6</xref> We report 3 cases of X-linked AS in children manifesting with kidney cysts since adolescence. This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of MacKay Memorial Hospital",22_6,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"Review Board of MacKay Memorial Hospital (approval no.: 23MMHIS088e; April 20, 2023). Following the ethics review, the hospital review board affirmed the ethical compliance of the study and authorized the publication of the findings.  Pathogenic <italic toggle=""yes"">COL4A3-5</italic> variants may account for focal segmental glomerulosclerosis, kidney failure, and familial IgA nephropathy in 30%, 10%, and 20% of cases, respectively.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref> Furthermore, pathogenic",22_7,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"Furthermore, pathogenic <italic toggle=""yes"">COL4A3-5</italic> variants have been detected in adults with multiple kidney cysts.<xref rid=""bib3"" ref-type=""bibr"">3</xref>, <xref rid=""bib4"" ref-type=""bibr"">4</xref>, <xref rid=""bib5"" ref-type=""bibr"">5</xref>, <xref rid=""bib6"" ref-type=""bibr"">6</xref> The age of cyst onset is unknown. To the best of our knowledge, this is the first study to report that children with AS may develop kidney cysts during adolescence. The incidence of and association between kidney",22_8,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"The incidence of and association between kidney cysts and AS remain unclear. Limited studies have reported AS with kidney cysts in adults.<xref rid=""bib3"" ref-type=""bibr"">3</xref>, <xref rid=""bib4"" ref-type=""bibr"">4</xref>, <xref rid=""bib5"" ref-type=""bibr"">5</xref>, <xref rid=""bib6"" ref-type=""bibr"">6</xref> Pierides et al<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref> first found multiple small or large kidney cysts in 4 older patients from 236 family members at risk for heterozygous pathogenic",22_9,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"members at risk for heterozygous pathogenic <italic toggle=""yes"">COL4A3</italic> variants. Sevillano et al<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> found that 56% of patients with thin basement membrane disease who had hypertension, proteinuria, and chronic kidney disease had multiple kidney cysts, whereas those without proteinuria showed no cysts. The development of kidney cysts in thin basement membrane disease may predict unfavorable complications, including proteinuria, hypertension, and",22_10,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"including proteinuria, hypertension, and impaired kidney function.<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> Gulati et al<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> reported 6 cases of pathogenic type IV collagen variants among 18 individuals with multiple kidney cysts, either without pathogenic <italic toggle=""yes"">PKD</italic> variants or with a thin basement membrane disease diagnosis. Savige et al<xref rid=""bib6"" ref-type=""bibr""><sup>6</sup></xref> confirmed X-linked AS in a man with",22_11,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"confirmed X-linked AS in a man with uremia who had bilateral kidney cysts of undetermined etiology. <xref rid=""tbl1"" ref-type=""table"">Table 1</xref> summarizes the reported clinical and genetic features of AS with kidney cysts, including our patients who are children. Cysts occur in both men and women with pathogenic <italic toggle=""yes"">COL4A3-5</italic> variants. Apart from our 3 patients, most patients with kidney cysts were aged older than 40 years.<xref rid=""bib3"" ref-type=""bibr"">3</xref>, <xref",22_12,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"rid=""bib3"" ref-type=""bibr"">3</xref>, <xref rid=""bib4"" ref-type=""bibr"">4</xref>, <xref rid=""bib5"" ref-type=""bibr"">5</xref>, <xref rid=""bib6"" ref-type=""bibr"">6</xref> Cysts always occur bilaterally in relatively large kidneys and vary in size and number. In our patients, most cysts were initially found in the medulla; however, they may affect both the cortex and medulla.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> Cysts may be detected",22_13,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"Cysts may be detected in patients with normal or impaired kidney function. However, cyst formation usually follows pre-existing proteinuria.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> Furthermore, it often coexists with the focal segmental glomerulosclerosis pathology on biopsy, suggesting more severe basement membrane damage.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib4""",22_14,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref> In case 2, the patient had proteinuria at 5 years of age and developed cysts at 15 years of age. However, her sister, who had the same pathogenic variant, only experienced microscopic hematuria with no cysts. Cyst formation may indicate proteinuria and chronic kidney disease progression.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> Distinguishing AS from ADPKD is crucial; cysts in AS are",22_15,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"AS from ADPKD is crucial; cysts in AS are smaller and fewer and do not usually distort the kidney outline or significantly increase the kidney volume.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib6"" ref-type=""bibr""><sup>6</sup></xref> With progressive cystic enlargement, patient 1 was misdiagnosed with ADPKD. In case of difficulty in differentiating AS and ADPKD, genetic analysis can confirm the diagnosis and rule out the coincidence of both entities. Established proteinuria",22_16,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"of both entities. Established proteinuria in ADPKD occurs late and is always associated with impaired kidney function and an extremely large kidney volume, differing significantly from the course of AS with kidney cysts.<xref rid=""bib7"" ref-type=""bibr""><sup>7</sup></xref><table-wrap position=""float"" id=""tbl1""><label>Table 1</label><caption><p>A Summary of the Clinical and Genetic Features of Patients With a Documented Kidney Cyst in Alport Syndrome</p></caption><table frame=""hsides""",22_17,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"Syndrome</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th></th><th>Age (y)/Sex (S) or Gender (G)<xref rid=""tbl1fna"" ref-type=""table-fn"">a</xref></th><th>Initial Diagnosis</th><th>SCr (mg/dL)</th><th>eGFR (mL/min/1.73 m<sup>2</sup>)/CKD Stage</th><th>Proteinuria</th><th>Kidney Size R/L (cm)</th><th>Kidney Cysts</th><th>Size of the Largest Cyst (mm)</th><th>Pathogenic Type IV Collagen Variant</th></tr></thead><tbody><tr><td colspan=""2""><bold>Pierides et al</bold><xref rid=""bib4""",22_18,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"et al</bold><xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><bold>Pedigrees 1</bold></td><td></td><td>FSGS, TBMD</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><bold>Pedigrees 2</bold></td><td></td><td>FSGS, TBMD</td><td></td><td></td><td></td><td></td><td></td><td></td><td>COL4A3: c.G1334E</td></tr><tr><td><bold>Pedigrees 3</bold></td><td></td><td>FSGS, EM",22_19,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"3</bold></td><td></td><td>FSGS, EM ND</td><td></td><td></td><td></td><td></td><td></td><td></td><td>COL4A3: c.G871C</td></tr><tr><td><bold>Pedigrees 4</bold></td><td></td><td>FSGS, EM ND</td><td></td><td></td><td></td><td></td><td></td><td></td><td>COL4A3: c.G871C</td></tr><tr><td colspan=""10""><bold>Sevillano et al</bold><xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><sup>,</sup><xref rid=""tbl1fnb"" ref-type=""table-fn"">b</xref></td></tr><tr><td><bold>Case 1</bold></td><td>54/F",22_20,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"1</bold></td><td>54/F (G)</td><td>TBMD</td><td>0.5</td><td>136</td><td>0.43 (g/day)</td><td>11.6/11.2</td><td>2 in RK, 1 in LK</td><td>45</td><td></td></tr><tr><td><bold>Case 2</bold></td><td>61/M (G)</td><td>TBMD</td><td>0.9</td><td>87</td><td>1.34 (g/day)</td><td>12/12</td><td>Multiple, bilateral</td><td>20</td><td></td></tr><tr><td><bold>Case 3</bold></td><td>71/F (G)</td><td>TBMD</td><td>1.7</td><td>30</td><td>0.29 (g/day)</td><td>9/10</td><td>Multiple,",22_21,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"(g/day)</td><td>9/10</td><td>Multiple, bilateral</td><td>20</td><td></td></tr><tr><td><bold>Case 4</bold></td><td>68/M (G)</td><td>TBMD</td><td>1.9</td><td>36</td><td>0.26 (g/day)</td><td>9.4/10</td><td>Multiple, bilateral</td><td>51</td><td></td></tr><tr><td><bold>Case 5</bold></td><td>37/M (G)</td><td>TBMD</td><td>0.9</td><td>93</td><td>3.76 (g/day)</td><td>12/13</td><td>1 in RK, 10 in LK</td><td>30</td><td></td></tr><tr><td><bold>Case 6</bold></td><td>66/F",22_22,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"6</bold></td><td>66/F (G)</td><td>TBMD</td><td>0.5</td><td>108</td><td>0.34 (g/day)</td><td>12.2/12.8</td><td>Multiple, bilateral</td><td>10</td><td></td></tr><tr><td><bold>Case 7</bold></td><td>64/M (G)</td><td>TBMD</td><td>3.1</td><td>21</td><td>0.32 (g/day)</td><td>10/10</td><td>4 in RK, 2 in LK</td><td>40</td><td></td></tr><tr><td colspan=""10""><bold>Sevillano et al</bold><xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><bold>and Gulati et al</bold><xref rid=""bib3""",22_23,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"Gulati et al</bold><xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref><sup>,</sup><xref rid=""tbl1fnc"" ref-type=""table-fn"">c</xref></td></tr><tr><td><bold>Case 8</bold></td><td>28/M (S)</td><td>TBMD</td><td></td><td>CKD stage 3</td><td>Yes</td><td>11.8/11.3</td><td>Multiple, bilateral</td><td>20</td><td>COL4A4: exon46:c.4503dupA</td></tr><tr><td><bold>Case 9</bold></td><td>42/M (S)</td><td>TBMD</td><td></td><td>CKD stage 3</td><td>Yes</td><td>16.7/17.0</td><td>Multiple, bilateral</td><td>70</td><td>COL4A4:",22_24,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"bilateral</td><td>70</td><td>COL4A4: exon24: c.1697– 1G>C</td></tr><tr><td colspan=""10""><bold>Gulati et al</bold><xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref><sup>,</sup><xref rid=""tbl1fnc"" ref-type=""table-fn"">c</xref></td></tr><tr><td><bold>Case 10</bold></td><td>25/M (S)</td><td>NMD-ADPKD</td><td></td><td>125</td><td></td><td></td><td>Multiple, bilateral</td><td></td><td>COL4A4: exon28: c.G2383A</td></tr><tr><td><bold>Case 11</bold></td><td>52/F (S)</td><td>FSGS, TBMD</td><td></td><td>CKD stage",22_25,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"(S)</td><td>FSGS, TBMD</td><td></td><td>CKD stage 4</td><td></td><td>11.0/10.5</td><td>Multiple, bilateral</td><td></td><td>COL4A4: exon 39: c.3704delC</td></tr><tr><td><bold>Case 12</bold></td><td>49/F (S)</td><td>TBMD</td><td></td><td>CKD stage 2</td><td>No</td><td>10.5/10.9</td><td>Few, bilateral</td><td></td><td>COL4A5: exon16: c.C899T</td></tr><tr><td colspan=""10""><bold>Savige et al</bold><xref rid=""bib6"" ref-type=""bibr""><sup>6</sup></xref></td></tr><tr><td><bold>Case 13</bold></td><td>49/M",22_26,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"13</bold></td><td>49/M (S)</td><td>Kidney failure, unknown cause</td><td>3.3</td><td>20</td><td>128.6 (mg/mmol)<xref rid=""tbl1fne"" ref-type=""table-fn"">e</xref></td><td></td><td>Multiple, bilateral</td><td>40</td><td>COL4A5: c.358G>A</td></tr><tr><td colspan=""10""><bold>Present cases</bold><xref rid=""tbl1fnd"" ref-type=""table-fn"">d</xref></td></tr><tr><td><bold>Case 14</bold></td><td>17/F (S)</td><td>Familial IgA nephropathy</td><td>0.9</td><td>82</td><td>0.7 (mg/mg)<xref rid=""tbl1fnf""",22_27,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"(mg/mg)<xref rid=""tbl1fnf"" ref-type=""table-fn"">f</xref></td><td>18.6/16.0</td><td>Multiple, bilateral</td><td>24</td><td>COL4A5: c.3511C>T</td></tr><tr><td><bold>Case 15</bold></td><td>15/F (S)</td><td>AS</td><td>0.4</td><td>97</td><td>0.54 (mg/mg)<xref rid=""tbl1fnf"" ref-type=""table-fn"">f</xref></td><td>9.8/12.9</td><td>Multiple, LK</td><td>10</td><td>COL4A5:c.716G>T</td></tr><tr><td><bold>Case 16</bold></td><td>14/M (S)</td><td>SRNS, FSGS</td><td>0.7</td><td>156</td><td>0.49 (mg/mg)<xref rid=""tbl1fnf""",22_28,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"(mg/mg)<xref rid=""tbl1fnf"" ref-type=""table-fn"">f</xref></td><td>10.3/10.7</td><td>4 in RK, 2 in LK</td><td>9.2</td><td>COL4A5: Exon 19-21 deletion</td></tr></tbody></table><table-wrap-foot><fn id=""tspara0015""><p><italic toggle=""yes"">Note</italic>: Conversion factor for units: SCr in mg/dL to μmol/L, ×88.4.</p></fn><fn id=""tspara0020""><p>Abbreviations: AS, Alport syndrome; CKD, chronic kidney disease; eGFR, estimated glomerular filtrate rate; EM, electron microscopy; F, female; FSGS, focal segmental",22_29,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"microscopy; F, female; FSGS, focal segmental glomerulosclerosis; G, Gender; LK, left kidney; M, male; ND, not done; NMD-ADPKD, no pathogenic PKD variant detected–autosomal-dominant polycystic kidney disease; NS, nephrotic syndrome; RK, right kidney; S, Sex; SCr, serum creatinine; SRNS, steroid-resistant nephrotic syndrome; TBMD, thin basement membrane disease.</p></fn></table-wrap-foot><table-wrap-foot><fn id=""tbl1fna""><label>a</label><p id=""ntpara0015"">Sex refers to the biological characteristics that",22_30,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"refers to the biological characteristics that define humans as male or female. Gender refers to the socially constructed roles, behaviors, expressions, and identities that a society considers appropriate for males, females, and other genders.</p></fn></table-wrap-foot><table-wrap-foot><fn id=""tbl1fnb""><label>b</label><p id=""ntpara0020"">The clinical features of the cases were recorded at the end of the follow-up period.</p></fn></table-wrap-foot><table-wrap-foot><fn id=""tbl1fnc""><label>c</label><p",22_31,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"id=""tbl1fnc""><label>c</label><p id=""ntpara0025"">The ages of the cases were recorded at clinical/imaging or histopathologic diagnosis of ADPKD or TBMD.</p></fn></table-wrap-foot><table-wrap-foot><fn id=""tbl1fnd""><label>d</label><p id=""ntpara0030"">The clinical features of the cases were recorded at the time when kidney cysts were detected.</p></fn></table-wrap-foot><table-wrap-foot><fn id=""tbl1fne""><label>e</label><p id=""ntpara0035"">Proteinuria (spot urine albumin-creatinine",22_32,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"(spot urine albumin-creatinine ratio).</p></fn></table-wrap-foot><table-wrap-foot><fn id=""tbl1fnf""><label>f</label><p id=""ntpara0040"">Proteinuria (spot urine protein-creatinine ratio).</p></fn></table-wrap-foot></table-wrap> Symptoms of X-linked AS are considered milder in women. However, approximately 25% of female patients with pathogenic <italic toggle=""yes"">COL4A5</italic> variants can have significant symptoms and progressive kidney dysfunction in old age.<xref rid=""bib1""",22_33,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"kidney dysfunction in old age.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> The 2 girls in this study exhibited persistent hematuria, proteinuria, and nephromegaly from early childhood before cyst development. Unexpectedly, patient 1 experienced progressive cystic enlargement and developed kidney failure at 28 years of age, suggesting that cyst formation could be a marker of early kidney function deterioration in women with X-linked AS. Further investigation into the causal relationship between cyst",22_34,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"into the causal relationship between cyst formation and kidney outcomes in patients with AS is warranted. The pathogenesis of AS-associated kidney cysts remains unclear. Weakening of the basement membrane owing to abnormal type IV collagen in the distal tubule or glomerulus may induce or favor cyst formation. Dilated tubules and cystic dilatation of Bowman’s space observed in animal models, including a mouse model with pathogenic <italic toggle=""yes"">COL4A4-5</italic> variants and an autosomal-dominant AS",22_35,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"variants and an autosomal-dominant AS dog model, support this hypothesis.<xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref><sup>,</sup><xref rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref> In our cases, initial biopsy performed before cysts were evident on imaging did not reveal cysts. Instead, all patients showed distal tubule dilatation on pathology (<xref rid=""fig1"" ref-type=""fig"">Fig 1</xref>H, I, and J), and cysts were initially found in the medullary area. Whether distal tubule dilatation will",22_36,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"area. Whether distal tubule dilatation will eventually lead to cysts is unclear; however, we found that before the appearance of multiple kidney cysts on ultrasonography, the involved kidney usually becomes larger, like early ultrasound findings of ADPKD.<xref rid=""bib10"" ref-type=""bibr""><sup>10</sup></xref> In conclusion, although the cystic kidney phenotype may not be a predominant clinical manifestation of AS, our study strengthens the association between AS and kidney cysts. Kidney cysts in adolescents",22_37,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"AS and kidney cysts. Kidney cysts in adolescents or adults with suspected AS should not discourage clinicians from testing for pathogenic <italic toggle=""yes"">COL4A3-5</italic> variants. Early detection of kidney cysts is vital because it may indicate kidney disease progression. Further studies are required to elucidate the pathogenesis of cyst formation and its influence on kidney outcomes.",22_38,Kidney Cysts in Children With Alport Syndrome: A Report of 3 Cases,25 3 2024,,Alport_Syndrome
"Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China Alport syndrome (AS) is one of the most common human fatal hereditary renal diseases. Its prevalence is reported as 1 in 5000–50 000 live births.<xref rid=""R1"" ref-type=""bibr"">1 2</xref> A deficiency of type IV collagen chains α3, α4 or α5 in the basement membranes of renal glomerulus, eyes and ears is caused by mutations in <italic toggle=""yes"">COL4A3</italic>,",23_0,"Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China",2024,,Alport_Syndrome
"in <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic> or <italic toggle=""yes"">COL4A5</italic>, respectively.<xref rid=""R2"" ref-type=""bibr"">2</xref> Therefore, AS is characterised by haematuria, albuminuria and a progressive decline of renal function,<xref rid=""R3"" ref-type=""bibr"">3</xref> as well as sensorineural hearing loss<xref rid=""R4"" ref-type=""bibr"">4</xref> and ocular abnormalities.<xref rid=""R5"" ref-type=""bibr"">5</xref> Patient outcomes depend on whether the disease is",23_1,"Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China",2024,,Alport_Syndrome
"Patient outcomes depend on whether the disease is X-linked or autosomal.<xref rid=""R6"" ref-type=""bibr"">6 7</xref> X-linked disease caused by <italic toggle=""yes"">COL4A5</italic> mutations makes up 85% of cases.<xref rid=""R6"" ref-type=""bibr"">6</xref> Moreover, male patients with <italic toggle=""yes"">COL4A5</italic> deficiency are at high risk to develop end-stage renal disease (ESRD). Current treatments for patients with microalbuminuria focuses on symptom relief using angiotensin-converting enzyme",23_2,"Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China",2024,,Alport_Syndrome
"relief using angiotensin-converting enzyme inhibitors<xref rid=""R7"" ref-type=""bibr"">7 8</xref> or angiotensin receptor blockers<xref rid=""R3"" ref-type=""bibr"">3 9 10</xref> to reduce proteinuria and delay ESRD. However, long-term safety and efficacy in young children with early microalbuminuria require further study.<xref rid=""R11"" ref-type=""bibr"">11</xref> Other novel therapeutic strategies focus on chronic inflammation<xref rid=""R12"" ref-type=""bibr"">12 13</xref> and fibrosis<xref rid=""R14""",23_3,"Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China",2024,,Alport_Syndrome
"13</xref> and fibrosis<xref rid=""R14"" ref-type=""bibr"">14</xref> induced by abnormalities of type IV collagen. The anti-inflammatory and anti-fibrosis therapies<xref rid=""R15"" ref-type=""bibr"">15</xref> are still in research.<xref rid=""R16"" ref-type=""bibr"">16–18</xref> Recently, mesenchymal stem cells (MSCs) have emerged as a promising therapeutic strategy for chronic kidney disease (CKD) attributing to their anti-inflammatory and anti-fibrosis properties. Preliminary benefits have been observed in",23_4,"Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China",2024,,Alport_Syndrome
"Preliminary benefits have been observed in preclinical and clinical studies of lupus nephritis,<xref rid=""R19"" ref-type=""bibr"">19 20</xref> diabetic nephropathy<xref rid=""R21"" ref-type=""bibr"">21–23</xref> and focal segmental glomerulosclerosis.<xref rid=""R24"" ref-type=""bibr"">24</xref> For AS, the therapeutic potential of MSCs had been shown in previous studies using <italic toggle=""yes"">COL4A3</italic> deficient mice.<xref rid=""R25"" ref-type=""bibr"">25 26</xref> As patients with <italic",23_5,"Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China",2024,,Alport_Syndrome
"26</xref> As patients with <italic toggle=""yes"">COL4A5</italic> deficiency make up the majority of cases and face a high risk of developing ESRD, we have conducted a preclinical study using <italic toggle=""yes"">COL4A5</italic> deficient mice to evaluate the therapeutic potential of human umbilical cord mesenchymal stem cell (hUC-MSC). Relief of albuminuria and longer life times were shown in the MSC-treatment group with significant alleviation of nephritis and fibrosis. Further clinical trials are still",23_6,"Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China",2024,,Alport_Syndrome
"and fibrosis. Further clinical trials are still needed to confirm the safety and therapeutic potential of hUC-MSC transfusion for patients with AS. Therefore, we plan to conduct a single-arm, first-in-human trial to investigate the safety and preliminary efficacy of hUC-MSC in paediatric patients with early-stage AS. We expect that the findings of our study will provide the first clinical evidence about the safety and preliminary efficacy of hUC-MSC in children with AS.",23_7,"Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China",2024,,Alport_Syndrome
"Alport syndrome and Alport kidney diseases – elucidating the disease spectrum Collagen IV is a class of extracellular matrix protein found ubiquitously in basement membranes of various organs, including kidneys [<xref rid=""R1"" ref-type=""bibr"">1</xref>]. Six collagen IV α chains, α1(IV) to α6(IV), encoded by <italic toggle=""yes"">COL4A1</italic> to <italic toggle=""yes"">COL4A6</italic> genes, respectively, assemble into three different heterotrimers: collagen α1α1α2(IV), α3α4α5(IV), and α5α5α6(IV). Collagen",24_0,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"α1α1α2(IV), α3α4α5(IV), and α5α5α6(IV). Collagen α3α4α5(IV) is the major component of the mature glomerular basement membrane (GBM), though there is a thin layer of collagen α1α1α2(IV) at the GBM's endothelial aspect (Fig. <xref rid=""F1"" ref-type=""fig"">1</xref>a, b). Pathogenic variants in <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, or <italic toggle=""yes"">COL4A5</italic> leading to absence or disruption of the GBM collagen α3α4α5(IV) network (Figs. <xref rid=""F1""",24_1,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"collagen α3α4α5(IV) network (Figs. <xref rid=""F1"" ref-type=""fig"">1</xref> and <xref rid=""F2"" ref-type=""fig"">2</xref>) cause Alport syndrome (AS) [<xref rid=""R2"" ref-type=""bibr"">2</xref>,<xref rid=""R3"" ref-type=""bibr"">3</xref>]; thus, these will be referred to as Alport genes in this article.  The “classic” AS presentation is characterized by childhood-onset hematuria, later onset proteinuria, progressive decline in kidney function, and kidney failure (KF) in adolescence or young adulthood, along with",24_2,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"in adolescence or young adulthood, along with sensorineural hearing loss, and eye abnormalities [<xref rid=""R4"" ref-type=""bibr"">4</xref>,<xref rid=""R5"" ref-type=""bibr"">5</xref>]. Because <italic toggle=""yes"">COL4A5</italic> is X-linked, male patients with X-linked Alport syndrome (XLAS) typically exhibit more severe symptoms than females with XLAS. In contrast, <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> are on chromosome 2, and variants cause the more rare autosomal",24_3,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"2, and variants cause the more rare autosomal recessive Alport syndrome (ARAS), which affects males and females equally [<xref rid=""R1"" ref-type=""bibr"">1</xref>]. Heterozygous <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> variants have been linked to thin basement membrane nephropathy (TBMN), also called benign familial hematuria (BFH) [<xref rid=""R6"" ref-type=""bibr"">6</xref>]. However, these are now considered disfavored terms for less severe kidney diseases within the",24_4,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"terms for less severe kidney diseases within the Alport spectrum, and in some cases have been classified as autosomal forms of AS [<xref rid=""R7"" ref-type=""bibr"">7</xref>]. Moreover, a variable degree of GBM thinning is in some cases the only early pathologic finding in diseases within the Alport spectrum and is quite common, making “thinning of GBM” a nonspecific finding (Table <xref rid=""T1"" ref-type=""table"">1</xref>). Therefore, it has been suggested that “thin basement membrane lesion” be used as a",24_5,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"that “thin basement membrane lesion” be used as a term to describe the pathology rather than to justify a diagnosis of TBMN as a specific disease entity [<xref rid=""R7"" ref-type=""bibr"">7</xref>]. With the increased utilization of molecular genetic testing in clinical practice, pathogenic variants in Alport genes have been increasingly reported in patients with diverse clinical presentations, including a more proteinuria-predominant phenotype (nephrotic-range proteinuria or steroid-resistant nephrotic",24_6,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"proteinuria or steroid-resistant nephrotic syndrome) [<xref rid=""R8"" ref-type=""bibr"">8</xref>,<xref rid=""R9"" ref-type=""bibr"">9</xref>], kidney failure of unknown etiology [<xref rid=""R10"" ref-type=""bibr"">10</xref>], familial immunoglobulin A (IgA) nephropathy with thin basement membrane [<xref rid=""R11"" ref-type=""bibr"">11</xref>], and renal cysts in whom polycystic kidney disease has been ruled out [<xref rid=""R12"" ref-type=""bibr"">12</xref>,<xref rid=""R13"" ref-type=""bibr"">13</xref>]. Several studies also",24_7,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"ref-type=""bibr"">13</xref>]. Several studies also consistently reported that pathogenic Alport gene variants are the most frequently found genetic abnormalities in adult-onset familial nephrosis with focal segmental glomerulosclerosis (FSGS) lesions [<xref rid=""R8"" ref-type=""bibr"">8</xref>,<xref rid=""R9"" ref-type=""bibr"">9</xref>]. Detection of Alport gene variants among patients with diverse clinical presentations challenges the traditional classification of AS/TBMN/BFH/ADAS, and newer terms such as",24_8,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"of AS/TBMN/BFH/ADAS, and newer terms such as “spectrum of Alport syndrome”, “Alport-related nephropathy”, “collagen IV related renal disease”, and “collagen IV associated nephropathy” have been used in the literature to denote the kidney disease states linked to pathogenic variants in <italic toggle=""yes"">COL4A3/A4/A5</italic>. This review aims to summarize the different clinical manifestations in this disease spectrum and the challenges in categorizing patients due to overlapping and inconsistent",24_9,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"patients due to overlapping and inconsistent presentations and the complex genetics involved. We also put forth the term “Alport kidney disease” to describe nonsyndromic kidney disease resulting from pathogenic variants in the Alport genes. Importantly, retention of “Alport” distinguishes <italic toggle=""yes"">COL4A3/A4/A5</italic> nephropathies from the much rarer ones caused by variants in <italic toggle=""yes"">COL4A1</italic> and <italic toggle=""yes"">COL4A2</italic> (Gould syndrome) [<xref rid=""R14""",24_10,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"(Gould syndrome) [<xref rid=""R14"" ref-type=""bibr"">14</xref>]. We hope this term will be considered for adoption by relevant stakeholders, including patients, clinicians, geneticists, and scientists. Based on the diverse kidney phenotypes described above, we propose that the spectrum of kidney diseases associated with pathogenic Alport gene variants be categorized into four groups: classic severe AS (male hemizygous XLAS and ARAS of either sex); mild to moderate AS (female heterozygous XLAS, ADAS, and",24_11,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"moderate AS (female heterozygous XLAS, ADAS, and digenic AS); Alport kidney disease with predominant proteinuria, steroid-resistant nephrotic syndrome, and FSGS lesions (AD); and hematuric Alport kidney disease, a mild condition that portrays the clinical picture of thin basement membrane lesions with very minimal risk of KF (AD) (Table <xref rid=""T1"" ref-type=""table"">1</xref>). We note that not every patient with a pathogenic variant in an Alport gene will fit perfectly in a specific group, as many",24_12,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"will fit perfectly in a specific group, as many factors can impact disease manifestation. Moreover, disease classification can be dynamic, as patients initially placed into a less severe group may develop severe/high-risk features, emphasizing the importance of follow-up for patients in all groups, as previously suggested [<xref rid=""R7"" ref-type=""bibr"">7</xref>]. This category encompasses hemizygous males with XLAS and males or females with ARAS. Rare females with biallelic pathogenic <italic",24_13,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"Rare females with biallelic pathogenic <italic toggle=""yes"">COL4A5</italic> variants would also fit in this category [<xref rid=""R15"" ref-type=""bibr"">15</xref>]. These patients generally exhibit a 100% penetrance of hematuria since infancy. Albuminuria develops later and is an indicator of kidney disease progression; KF is inevitable. In males with XLAS, 70% reach kidney failure by the age of 30 years, and 90% at 40 years [<xref rid=""R16"" ref-type=""bibr"">16</xref>,<xref rid=""R17""",24_14,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"ref-type=""bibr"">16</xref>,<xref rid=""R17"" ref-type=""bibr"">17</xref>]. Electron microscopy of kidney biopsies usually shows diffusely thinned GBMs at early stages, and GBM lamellation and characteristic basket-weave at later stages [<xref rid=""R18"" ref-type=""bibr"">18</xref>]. Extrarenal features due to lack or dysfunction of collagen α3α4α5(IV) in cochlea and lens/retina/cornea basement membranes are common but not always present. Some hearing loss occurs in 90% of patients before the age of 40 [<xref",24_15,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"in 90% of patients before the age of 40 [<xref rid=""R16"" ref-type=""bibr"">16</xref>]. Fleck retinopathy is common and can aid in the diagnosis of AS [<xref rid=""R19"" ref-type=""bibr"">19</xref>,<xref rid=""R20"" ref-type=""bibr"">20</xref>]. Peripheral fleck retinopathy is present in most cases of XLAS and ARAS, whereas central fleck retinopathy is present in 50–60% of patients with XLAS and ARAS. Both central fleck retinopathy and anterior lenticonus are associated with an increased risk of early-onset kidney",24_16,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"with an increased risk of early-onset kidney failure [<xref rid=""R20"" ref-type=""bibr"">20</xref>]. Genotype–phenotype correlations in this category of patients are relatively straightforward. According to the Leiden Open Variation Database (LOVD; <ext-link http://www.w3.org/1999/xlink href=""https://www.lovd.nl/"" ext-link-type=""uri"">https://www.lovd.nl</ext-link>), the mean age at kidney failure was 25.1 ± 10.6 years overall in males with XLAS, 20.4 ± 5.0 years in those with nonsense variants,",24_17,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"20.4 ± 5.0 years in those with nonsense variants, 21.1 ± 6.8 years in those with deletions, 25.2 ± 10.7 years in those with canonical splice site variants, 28.45 ± 12.4 years in those with collagenous-domain Gly substitutions, and 40.7 ± 17.6 years in those with non-Gly substitutions [<xref rid=""R21"" ref-type=""bibr"">21<sup>▪</sup></xref>]. The molecular defect that best explains the most severe AS phenotypes is the lack of the collagen α3α4α5(IV) network in the GBM. Males with hemizygous truncating <italic",24_18,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"the GBM. Males with hemizygous truncating <italic toggle=""yes"">COL4A5</italic> variants or patients with homozygous/compound heterozygous truncating <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> variants cannot produce collagen α3α4α5(IV) heterotrimers, resulting in their complete absence from the GBM (Fig. <xref rid=""F1"" ref-type=""fig"">1</xref>c) and the most severe presentations. In contrast, patients with positive collagen α3α4α5(IV) staining by immunohistochemistry (Fig.",24_19,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"α3α4α5(IV) staining by immunohistochemistry (Fig. <xref rid=""F1"" ref-type=""fig"">1</xref>d), most of whom should have missense variants (often glycine substitutions), show a lower degree of albuminuria and older age at KF [<xref rid=""R22"" ref-type=""bibr"">22</xref>,<xref rid=""R23"" ref-type=""bibr"">23</xref>]. This strongly suggests a correlation between genotype and the presence or absence of collagen α3α4α5(IV) in the GBM, even if the collagen IV is abnormal. This category includes a group of genetically",24_20,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"This category includes a group of genetically heterogeneous patients, but they all share milder and more slowly progressive AS phenotypes, usually reaching KF after age 40. Extra-renal features are less common than in severe classic AS or are absent. Patients that fall into this category are females with heterozygous <italic toggle=""yes"">COL4A5</italic> variants, patients with heterozygous <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> variants who show symptoms of AS (ADAS),",24_21,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"variants who show symptoms of AS (ADAS), and patients with digenic AS. Deltas <italic toggle=""yes"">et al.</italic> were the first to demonstrate a link between proteinuria with FSGS lesions and heterozygous variants in <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic>[<xref rid=""R37"" ref-type=""bibr"">37</xref>,<xref rid=""R38"" ref-type=""bibr"">38</xref>], and they have studied additional families that support this link [<xref rid=""R39"" ref-type=""bibr"">39</xref>–<xref rid=""R41""",24_22,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"ref-type=""bibr"">39</xref>–<xref rid=""R41"" ref-type=""bibr"">41</xref>]. Several other independent sequencing initiatives have shown that about 10% of patients with FSGS lesions and heavy proteinuria have variants in Alport genes, primarily heterozygous variants in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic>[<xref rid=""R8"" ref-type=""bibr"">8</xref>–<xref rid=""R10"" ref-type=""bibr"">10</xref>,<xref rid=""R42"" ref-type=""bibr"">42</xref>,<xref rid=""R43"" ref-type=""bibr"">43</xref>].",24_23,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"rid=""R43"" ref-type=""bibr"">43</xref>]. These patients do not have ocular abnormalities and only rarely experience hearing loss, usually later in life, making it difficult for physicians to order genetic testing for Alport gene variants. Nevertheless, they carry a high risk of kidney disease progression, reaching KF at 40–65 years, later than classic severe AS [<xref rid=""R8"" ref-type=""bibr"">8</xref>,<xref rid=""R9"" ref-type=""bibr"">9</xref>]. In most of these patients, electron microscopy only showed",24_24,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"these patients, electron microscopy only showed segmental thinning or splitting of GBM [<xref rid=""R9"" ref-type=""bibr"">9</xref>,<xref rid=""R42"" ref-type=""bibr"">42</xref>], which is not characteristic of AS; though FSGS lesions are expected to develop late in the course of classic AS, they are associated with GBM basket-weave thickening and tubulointerstitial scarring. This suggests the possibility that some Alport gene variants may cause the proteinuria-predominant phenotype associated with FSGS lesions",24_25,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"phenotype associated with FSGS lesions [<xref rid=""R44"" ref-type=""bibr"">44</xref>]. Secreted solely by podocytes, the production of aberrant collagen α3α4α5(IV) may affect podocyte homeostasis, resulting in podocyte damage, proteinuria, and development of FSGS lesions [<xref rid=""R45"" ref-type=""bibr"">45</xref>]. Knockin of a human <italic toggle=""yes"">COL4A3</italic> variant that expresses misfolded collagen α3(IV) chains into mice increased the unfolded protein response pathway, which can be linked to",24_26,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"protein response pathway, which can be linked to podocyte endoplasmic reticulum stress [<xref rid=""R46"" ref-type=""bibr"">46</xref>]. This may explain why heterozygous substitution variants are associated with more severe proteinuria than heterozygous truncating variants [<xref rid=""R33"" ref-type=""bibr"">33</xref><sup>▪▪</sup>] and why not all patients harboring heterozygous <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> variants have proteinuria-predominant phenotypes. Some",24_27,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"have proteinuria-predominant phenotypes. Some authorities suggest proteinuria and FSGS lesions that occur in this subgroup of patients are results of other genetic modifiers that could have been overlooked [<xref rid=""R47"" ref-type=""bibr"">47</xref>,<xref rid=""R48"" ref-type=""bibr"">48<sup>▪</sup></xref>]. However, most cohorts reporting the link between Alport gene variants and FSGS lesions also examined other genes implicated in nephrotic syndrome but could not detect any variants [<xref rid=""R8""",24_28,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"but could not detect any variants [<xref rid=""R8"" ref-type=""bibr"">8</xref>,<xref rid=""R9"" ref-type=""bibr"">9</xref>]. This last group covers a subgroup of individuals carrying heterozygous pathogenic variants in <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic>, estimated to be around 1% of the population, ∼70% of whom have hematuria [<xref rid=""R32"" ref-type=""bibr"">32</xref>]. This group encompasses the largest proportion of the whole disease spectrum. Unlike patients in groups 2",24_29,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"disease spectrum. Unlike patients in groups 2 and 3, most individuals in this group have only isolated microscopic hematuria associated with thin GBM without any high-risk features (such as proteinuria), putting them at a slightly increased risk of developing KF late in life. These are the patients whom Kashtan <italic toggle=""yes"">et al.</italic>[<xref rid=""R7"" ref-type=""bibr"">7</xref>] previously suggested should be made cognizant of this risk and to be proactive about monitoring and treatment according",24_30,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"about monitoring and treatment according to expert recommendations [<xref rid=""R49"" ref-type=""bibr"">49</xref>,<xref rid=""R50"" ref-type=""bibr"">50</xref>]. A subset of these individuals will be parents or siblings of patients with ARAS and will be aware of the importance of maintaining kidney health. Although this group of patients has a benign prognosis, as what was assumed for those with thin basement membrane lesions, it should be emphasized that their underlying Alport gene status may be similar to ADAS.",24_31,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"Alport gene status may be similar to ADAS. The type of variant or other modifying factors such as hypertension, obesity, and other comorbidities could be what differentiate these patients from ADAS, but this remains uncertain. Moreover, polygenic risk factors can impact the chances that <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> heterozygous individuals develop severe phenotypes [<xref rid=""R51"" ref-type=""bibr"">51</xref><sup>▪▪</sup>]. In any event, some individuals",24_32,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"In any event, some individuals initially placed into Group 4 will develop symptoms over the course of decades and will need to be recategorized. The genetic and clinical complexities of Alport syndrome and the related Alport kidney diseases make the classification of patients with less severe manifestations difficult and subjective. These patients are much more numerous than those with classic severe AS, so there is an urgency to ensure that they receive appropriate attention and care from nephrologists",24_33,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"appropriate attention and care from nephrologists even if the risk of KF is low. This led the Alport Syndrome Classification Working Group to suggest the diagnosis of autosomal AS for any individuals with heterozygous <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> variants [<xref rid=""R7"" ref-type=""bibr"">7</xref>], including those with isolated thin basement membrane lesions who might never reach KF. Although the working group recommended classifying patients based on mode of",24_34,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"recommended classifying patients based on mode of inheritance, in this review we proposed a more detailed patient classification across the disease spectrum by severity of AS phenotypes, from the classic severe AS (XLAS in males and ARAS), in which there is no intact collagen α3α4α5(IV) in the GBM, to hematuric Alport kidney disease, the most favorable prognosis with only a slightly increased risk of KF over the general population. We also emphasized those patients with a proteinuria-predominant Alport",24_35,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"patients with a proteinuria-predominant Alport kidney disease presentation (Group 3) who might be diagnosed as FSGS and given unnecessary immunosuppressive therapy. With the growing evidence for genotype–phenotype correlations, the phenotype-based classification somewhat follows the underlying genetic abnormalities. Establishing a solid link between GBM collagen IV defects (Figs. <xref rid=""F1"" ref-type=""fig"">1</xref> and <xref rid=""F2"" ref-type=""fig"">2</xref>) and clinical presentation will lead to better",24_36,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"and clinical presentation will lead to better patient classification, risk stratification, and improved patient care.",24_37,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"<italic toggle=""yes"">We thank André Weinstock (Alport Syndrome Foundation), Susie Gear (Alport UK), Rachel Lennon (University of Manchester, UK), and Judy Savige (University of Melbourne) for helpful discussions that led to the descriptor “Alport Kidney Diseases”.</italic>",24_38,Alport syndrome and Alport kidney diseases – elucidating the disease spectrum,5 2024,,Alport_Syndrome
"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity Alport syndrome is a hereditary chronic kidney disease, attributed to rare pathogenic variants in either of three collagen genes (<italic toggle=""yes"">COL4A3/4/5</italic>) with most localized in <italic toggle=""yes"">COL4A5</italic>. Trimeric type IV Collagen α3α4α5 is essential for the glomerular basement membrane that forms the kidney filtration",25_0,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"membrane that forms the kidney filtration barrier. A means to functionally assess the many candidate variants and determine pathogenicity is urgently needed. We used <italic toggle=""yes"">Drosophila</italic>, an established model for kidney disease, and identify <italic toggle=""yes"">Col4a1</italic> as the functional homolog of human <italic toggle=""yes"">COL4A5</italic> in the fly nephrocyte (equivalent of human podocyte). Fly nephrocytes deficient for <italic toggle=""yes"">Col4a1</italic> showed an irregular",25_1,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"toggle=""yes"">Col4a1</italic> showed an irregular and thickened basement membrane and significantly reduced nephrocyte filtration function. This phenotype was restored by expressing human reference (wildtype) <italic toggle=""yes"">COL4A5</italic>, but not by <italic toggle=""yes"">COL4A5</italic> carrying any of three established pathogenic patient-derived variants. We then screened seven additional patient <italic toggle=""yes"">COL4A5</italic> variants; their ClinVar classification was either likely pathogenic",25_2,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"classification was either likely pathogenic or of uncertain significance. The findings support pathogenicity for four of these variants; the three others were found benign. Thus, demonstrating the effectiveness of this <italic toggle=""yes"">Drosophila</italic> in vivo kidney platform in providing the urgently needed variant-level functional validation. <italic toggle=""yes"">Drosophila</italic>, an established model of kidney disease, was used to develop an in vivo functional screen to determine causation for",25_3,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"vivo functional screen to determine causation for <italic toggle=""yes"">COL4A5</italic> genetic variants linked to Alport syndrome, a progressive nephropathy. Alport syndrome, also known as hereditary nephritis, is a rare progressive kidney disease characterized by hematuria and proteinuria that often presents with hearing loss and ocular abnormalities (<xref rid=""R2"" ref-type=""bibr"">Alport, 1927</xref>; <xref rid=""R11"" ref-type=""bibr"">Flinter, 1997</xref>; <xref rid=""R22"" ref-type=""bibr"">Hertz et al.,",25_4,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"<xref rid=""R22"" ref-type=""bibr"">Hertz et al., 2015</xref>; <xref rid=""R43"" ref-type=""bibr"">Spear and Slusser, 1972</xref>). Kidney pathology is marked by glomerular basement membrane (GBM) splitting and lamellation (<xref rid=""R5"" ref-type=""bibr"">Barsotti et al., 2001</xref>; <xref rid=""R24"" ref-type=""bibr"">Kalluri et al., 1997</xref>; <xref rid=""R28"" ref-type=""bibr"">Longo et al., 2006</xref>; <xref rid=""R35"" ref-type=""bibr"">Noël, 2000</xref>). The GBM lies between the capillary epithelium and the podocyte",25_5,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"between the capillary epithelium and the podocyte foot processes and is an essential part of the kidney filtration unit. Key components of its scaffolding are Collagen IV α3α4α5 trimers (<xref rid=""R32"" ref-type=""bibr"">Naylor et al., 2021</xref>). Alport syndrome is caused by mutations in the genes that encode these Collagen type IV alpha proteins (<italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic>) (<xref rid=""R3"" ref-type=""bibr"">Artuso et",25_6,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"(<xref rid=""R3"" ref-type=""bibr"">Artuso et al., 2012</xref>; <xref rid=""R4"" ref-type=""bibr"">Barker et al., 1990</xref>; <xref rid=""R6"" ref-type=""bibr"">Cameron-Christie et al., 2019</xref>; <xref rid=""R9"" ref-type=""bibr"">Fallerini et al., 2014</xref>; <xref rid=""R17"" ref-type=""bibr"">Hadjipanagi et al., 2022</xref>; <xref rid=""R20"" ref-type=""bibr"">Heiskari et al., 1996</xref>; <xref rid=""R23"" ref-type=""bibr"">Hudson, 2004</xref>; <xref rid=""R28"" ref-type=""bibr"">Longo et al., 2006</xref>; <xref rid=""R38""",25_7,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"et al., 2006</xref>; <xref rid=""R38"" ref-type=""bibr"">Pokidysheva et al., 2021</xref>; <xref rid=""R48"" ref-type=""bibr"">Zhang et al., 2019</xref>). The mutations inhibit trimeric protein complex formation which prevents a pivotal developmental switch from Collagen type IV α1 and α2 isoforms in fetal kidney to the α3, α4, and α5 isoforms in mature podocytes (<xref rid=""R19"" ref-type=""bibr"">Harvey et al., 1998</xref>; <xref rid=""R24"" ref-type=""bibr"">Kalluri et al., 1997</xref>; <xref rid=""R31""",25_8,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"et al., 1997</xref>; <xref rid=""R31"" ref-type=""bibr"">Miner and Sanes, 1994</xref>). This leaves the collagen scaffold more vulnerable to proteolysis by collagenases and cathepsins, which are required for GBM maintenance and turnover during normal conditions (<xref rid=""R16"" ref-type=""bibr"">Gunwar et al., 1998</xref>; <xref rid=""R46"" ref-type=""bibr"">Zeisberg et al., 2006</xref>). Over time, the GBM deteriorates, resulting in the characteristic GBM splitting and lamellation observed in Alport patient kidney",25_9,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"and lamellation observed in Alport patient kidney biopsies (<xref rid=""R5"" ref-type=""bibr"">Barsotti et al., 2001</xref>; <xref rid=""R24"" ref-type=""bibr"">Kalluri et al., 1997</xref>; <xref rid=""R28"" ref-type=""bibr"">Longo et al., 2006</xref>; <xref rid=""R35"" ref-type=""bibr"">Noël, 2000</xref>). To date, nearly 2,000 variants in the <italic toggle=""yes"">COL4A(3,4,5)</italic> genes have been linked to Alport syndrome: Most mutations are in the X-linked <italic toggle=""yes"">COL4A5</italic> gene (<xref rid=""R8""",25_10,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"toggle=""yes"">COL4A5</italic> gene (<xref rid=""R8"" ref-type=""bibr"">Daga et al., 2022</xref>; <xref rid=""R41"" ref-type=""bibr"">Savige et al., 2021</xref>), mutations in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> on chromosome 2 are often autosomal recessive (<xref rid=""R8"" ref-type=""bibr"">Daga et al., 2022</xref>); in addition, oligogenicity has been reported (<xref rid=""R8"" ref-type=""bibr"">Daga et al., 2022</xref>; <xref rid=""R41"" ref-type=""bibr"">Savige et al., 2021</xref>;",25_11,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"ref-type=""bibr"">Savige et al., 2021</xref>; <xref rid=""R49"" ref-type=""bibr"">Zhang et al., 2021</xref>). One of the biggest challenges facing nephrologists today is determining whether variants of unknown significance in <italic toggle=""yes"">COL4A</italic> genes found in patients with glomerulonephritis or proteinuric kidney diseases are actually causing/contributing to the patient’s condition. A reliance on bioinformatic predictions to determine pathogenicity is imperfectly accurate, which is not",25_12,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"is imperfectly accurate, which is not acceptable when making patient-care decisions. The availability of variant-specific functional data would address this need. Nephrocytes are the <italic toggle=""yes"">Drosophila</italic> equivalent of mammalian podocytes as both have dynamic slit diaphragm structures that carry out the critical filtration functions to maintain water and electrolyte homeostasis in the blood (<xref rid=""R45"" ref-type=""bibr"">Weavers et al., 2009</xref>). Even though the fly nephrocyte",25_13,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"al., 2009</xref>). Even though the fly nephrocyte effectively has an inside-out filtration structure, consisting of lacuna channels and a basement membrane, nephrocytes and podocytes share many molecular and ultrastructural features. In fact, most genes associated with kidney disease in patients have functional homologs in the fly nephrocyte (<xref rid=""R12"" ref-type=""bibr"">Fu et al., 2017</xref>; <xref rid=""R39"" ref-type=""bibr"">Rani and Gautam, 2018</xref>) and in both kidney cells endocytosis and",25_14,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"and in both kidney cells endocytosis and exocytosis are essential for the formation and maintenance of the slit diaphragm filtration structure (<xref rid=""R26"" ref-type=""bibr"">Lang et al., 2022</xref>; <xref rid=""R44"" ref-type=""bibr"">Wang et al., 2021</xref>; <xref rid=""R45"" ref-type=""bibr"">Weavers et al., 2009</xref>; <xref rid=""R52"" ref-type=""bibr"">Zhuang et al., 2009</xref>). The fly system has already shown its effectiveness in an in vivo functional renal gene discovery screen (<xref rid=""R12""",25_15,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"renal gene discovery screen (<xref rid=""R12"" ref-type=""bibr"">Fu et al., 2017</xref>; <xref rid=""R21"" ref-type=""bibr"">Hermle et al., 2017</xref>; <xref rid=""R39"" ref-type=""bibr"">Rani and Gautam, 2018</xref>; <xref rid=""R47"" ref-type=""bibr"">Zhang et al., 2013</xref>). Here, we use <italic toggle=""yes"">Drosophila</italic> to develop an efficient screening platform to provide functional validation for patient derived <italic toggle=""yes"">COL4A5</italic> variants associated with Alport syndrome using data from",25_16,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"associated with Alport syndrome using data from participants in the Chronic Kidney Disease in Children (CKiD) cohort.  Collagen IV is an ancient protein that evolved over millions of years, yet its protein components are highly conserved (<xref rid=""R10"" ref-type=""bibr"">Fidler et al., 2017</xref>). Humans carry six genes that encode collagen IV proteins, whereas the typically leaner fly genome carries two, with vertebrate α1, α3, and α5 designated α1-like, and vertebrate α2, α4, and α6 designated α2-like",25_17,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"and vertebrate α2, α4, and α6 designated α2-like (<xref rid=""R10"" ref-type=""bibr"">Fidler et al., 2017</xref>). Our data are in line with this designation. Fly nephrocytes deficient for <italic toggle=""yes"">Col4a1</italic> displayed irregular thickness of the basement membrane and significantly reduced uptake function (<xref rid=""F1"" ref-type=""fig"">Figures 1</xref>–<xref rid=""F3"" ref-type=""fig"">3</xref>; <xref rid=""SD1"" ref-type=""supplementary-material"">Supplementary Figure S1</xref>). These findings are",25_18,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"Figure S1</xref>). These findings are reminiscent of the clinical observations in patients with Alport syndrome, in whom kidney biopsies have shown GBM thinning, thickening, and irregularities, with subsequent filtration defects, kidney dysfunction and ultimately failure (<xref rid=""R5"" ref-type=""bibr"">Barsotti et al., 2001</xref>; <xref rid=""R24"" ref-type=""bibr"">Kalluri et al., 1997</xref>; <xref rid=""R28"" ref-type=""bibr"">Longo et al., 2006</xref>; <xref rid=""R35"" ref-type=""bibr"">Noël, 2000</xref>).",25_19,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"rid=""R35"" ref-type=""bibr"">Noël, 2000</xref>). Moreover, when we expressed human reference (wildtype) <italic toggle=""yes"">COL4A5</italic> in these <italic toggle=""yes"">Col4A1</italic> deficient fly nephrocytes their phenotype resolved, and filtration function was restored (<xref rid=""F1"" ref-type=""fig"">Figures 1</xref>–<xref rid=""F3"" ref-type=""fig"">3</xref>; <xref rid=""SD1"" ref-type=""supplementary-material"">Supplementary Figure S1</xref>). Together the data indicate that in nephrocytes <italic",25_20,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"the data indicate that in nephrocytes <italic toggle=""yes"">Drosophila</italic> Col4a1 is the functional homolog of human COL4A5 in podocytes and demonstrate that flies with <italic toggle=""yes"">Col4a1</italic>-deficient nephrocytes provide a relevant research model for Alport syndrome. To functionally assess variants associated with Alport syndrome, we adapted our gene replacement <italic toggle=""yes"">Drosophila</italic> model for variant-level validation. Instead of human reference (wildtype) <italic",25_21,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"Instead of human reference (wildtype) <italic toggle=""yes"">COL4A5</italic> in the <italic toggle=""yes"">Col4a1</italic>-deficient nephrocytes, we expressed human <italic toggle=""yes"">COL4A5</italic> that carried patient variants. We validated our approach by first assessing variants with strong pathogenic evidence, then we applied the method to seven additional variants of varying clinical significance (<xref rid=""F3"" ref-type=""fig"">Figure 3</xref>; <xref rid=""F6"" ref-type=""fig"">Figure 6</xref>). This",25_22,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"rid=""F6"" ref-type=""fig"">Figure 6</xref>). This provided in vivo functional evidence to support their pathogenic classification, corroborating the three pathogenic variants, and supporting classification or reclassification for the others (<xref rid=""F7"" ref-type=""fig"">Figure 7</xref>). For two of the variants with limited prior information, we included longitudinal standardized clinical data for two independent patients. Both were diagnosed with Alport syndrome marked by rapid progression; the data in the",25_23,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"marked by rapid progression; the data in the fly supported pathogenicity for both variants (<xref rid=""F6"" ref-type=""fig"">Figure 6</xref>). Altogether these data show that the <italic toggle=""yes"">Drosophila</italic> platform can provide a fast and economical screen to assess functional pathogenicity of variants in <italic toggle=""yes"">COL4A5</italic> associated with Alport syndrome. Knowing which variants are likely pathogenic, backed by functional data, can aid clinical diagnosis and help focus research",25_24,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"aid clinical diagnosis and help focus research efforts. Furthermore, our system could be readily adapted to include variants in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic>. The many variants in <italic toggle=""yes"">COL4A5</italic> and their varying pathogenic effect, put to question whether variant location in the type IV Collagen protein contributes to pathogenicity (<xref rid=""R8"" ref-type=""bibr"">Daga et al., 2022</xref>; <xref rid=""R41"" ref-type=""bibr"">Savige et al.,",25_25,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"<xref rid=""R41"" ref-type=""bibr"">Savige et al., 2021</xref>; <xref rid=""R49"" ref-type=""bibr"">Zhang et al., 2021</xref>). Using <italic toggle=""yes"">Drosophila</italic>, we tested variants that were either in the triple helix or in the NC1 (a.k.a., C4) domain, at which the three chains of the collagen fiber interact. All variants located in the NC1 domain were pathogenic, whereas some variants in the triple-helix maintained functionality, thus not supporting their pathogenic nature (<xref rid=""F4""",25_26,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"their pathogenic nature (<xref rid=""F4"" ref-type=""fig"">Figures 4</xref>–<xref rid=""F6"" ref-type=""fig"">6</xref>). Whereas Polymorphism Phenotyping (PolyPhen) prediction scores of the possible impact of an amino acid substitution on the structure and function of a human protein (<xref rid=""R1"" ref-type=""bibr"">Adzhubei et al., 2010</xref>) at times are in conflict with next-generation sequencing findings in Alport syndrome patient families (<xref rid=""R3"" ref-type=""bibr"">Artuso et al., 2012</xref>)—mammalian",25_27,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"et al., 2012</xref>)—mammalian model systems (see review (<xref rid=""R34"" ref-type=""bibr"">Nikolaou and Deltas, 2022</xref>)) typically lack the large-scale screening capabilities needed to answer this question—<italic toggle=""yes"">Drosophila</italic> is well-suited for large-scale screens. Our fly system could be readily scaled to screen many variants across all COL4A5 protein domains. The findings could provide valuable insight into whether variants in certain domains are more detrimental than others,",25_28,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"certain domains are more detrimental than others, which could aid diagnostic application and the prioritization of research efforts. The knowledge of genetic diagnosis in clinical management of kidney disease has been shown to improve patient outcomes (<xref rid=""R15"" ref-type=""bibr"">Groopman et al., 2019</xref>; <xref rid=""R33"" ref-type=""bibr"">Nestor et al., 2020</xref>). Particularly in light of phenocopies, for example, Alport syndrome may clinically present itself as focal segmental glomerulosclerosis",25_29,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"itself as focal segmental glomerulosclerosis (FSGS) or steroid-resistant nephrotic syndrome (SRNS) (<xref rid=""R40"" ref-type=""bibr"">Riedhammer et al., 2020</xref>). Different affected proteins might indicate a different pathomechanism, each of which requires a different targeted treatment approach. Aside from Alport syndrome in this study, flies have been successfully used to assess causality for genetic variants associated with diverse forms of kidney disease, including SRNS (example studies (<xref",25_30,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"disease, including SRNS (example studies (<xref rid=""R14"" ref-type=""bibr"">Gonçalves et al., 2018</xref>; <xref rid=""R21"" ref-type=""bibr"">Hermle et al., 2017</xref>; <xref rid=""R29"" ref-type=""bibr"">Lovric et al., 2017</xref>; <xref rid=""R30"" ref-type=""bibr"">Milosavljevic et al., 2022</xref>; <xref rid=""R36"" ref-type=""bibr"">Odenthal et al., 2023</xref>; <xref rid=""R47"" ref-type=""bibr"">Zhang et al., 2013</xref>; <xref rid=""R50"" ref-type=""bibr"">Zhao et al., 2019</xref>; <xref rid=""R51"" ref-type=""bibr"">Zhu et",25_31,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"<xref rid=""R51"" ref-type=""bibr"">Zhu et al., 2017</xref>)). Therefore, our <italic toggle=""yes"">Drosophila</italic> in vivo nephrocyte functional screening system for patient derived genetic variants could be applied to clinical variants associated with other nephropathies.",25_32,"A <italic toggle=""yes"">Drosophila</italic> model to screen Alport syndrome <italic toggle=""yes"">COL4A5</italic> variants for their functional pathogenicity",11 3 2024,,Alport_Syndrome
"Genetic diagnosis of Alport syndrome in 16 Chinese families  Pathogenic variants were revealed by WES in each family, and the co‐segregation with renal presentation was confirmed by PCR. Our findings expand the spectrum of gene variation. Alport syndrome (AS) is an inherited glomerular disease that is the second most common hereditary kidney disease leading to renal failure after autosomal dominant polycystic kidney disease (Savige et al., <xref rid=""mgg32406-bib-0015"" ref-type=""bibr"">2013</xref>). AS is",26_0,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"ref-type=""bibr"">2013</xref>). AS is characterized by hematuria, proteinuria, and progressive renal failure, and some patients are accompanied by extrarenal manifestations (Rheault et al., <xref rid=""mgg32406-bib-0013"" ref-type=""bibr"">2020</xref>). The mutations of those genes <italic toggle=""yes"">COL4A3/4/5</italic> (OMIM 303630, 120070, and 120131) are responsible for the disease. AS can be transmitted as an X‐linked, autosomal recessive, autosomal dominant disorder, or digenic inheritance (Kashtan, <xref",26_1,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"disorder, or digenic inheritance (Kashtan, <xref rid=""mgg32406-bib-0007"" ref-type=""bibr"">2021</xref>). Therefore, AS has strong genetic heterogeneity. Traditionally, the clinical diagnosis of AS is based on histopathological findings, especially by electron microscopy. Most importantly, a positive family history of renal failure helps to make a diagnosis decision. In addition, the extra‐renal manifestations including sensorineural hearing loss and ocular abnormality are also helpful. However, the electron",26_2,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"are also helpful. However, the electron microscopic findings of renal biopsy may be atypical for those young patients, who are often <ext-link http://www.w3.org/1999/xlink href=""http://www.baidu.com/link?url=58UV_bfmeB9Tlv5BK5wC5CCBLqFvuZFv0zCgeqHuC48iUWqjSpx2EXf0EQL2RF8A6nIj8Th_dDrGzg312jbhUYGyx80TIkCZKbH63lhLXFC"" ext-link-type=""uri"">misdiagnosed</ext-link>. Thin basement membrane (TBM) is often found among AS patients, but this feature is not specific enough to distinguish AS patients from other types of",26_3,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"to distinguish AS patients from other types of renal diseases. In addition, mutations of other genes can also lead to TBM. For example, a recent report showed that unusual TBM was found in a patient with nail‐patella syndrome (NPS), which was caused by a heterozygous variant in the LMX1B gene (Morimoto et al., <xref rid=""mgg32406-bib-0009"" ref-type=""bibr"">2021</xref>). Moreover, patients with primary diagnosis of familial focal segmental glomerulosclerosis (FSGS) have been proved to have variants in",26_4,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"(FSGS) have been proved to have variants in <italic toggle=""yes"">COL4</italic> genes (Papazachariou et al., <xref rid=""mgg32406-bib-0011"" ref-type=""bibr"">2017</xref>). Therefore, genetic testing is the best way to make a precise diagnosis. Recently, the advances in comprehensive genetic analysis have enabled genetic testing to be performed for the diagnosis of AS first‐line diagnosis (Caliskan & Lentine, <xref rid=""mgg32406-bib-0002"" ref-type=""bibr"">2022</xref>). Genetic testing is much more sensitive and",26_5,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"Genetic testing is much more sensitive and specific to the diagnosis of Alport syndrome, and can provide predictive information about disease severity and prognosis (Kashtan & Gross, <xref rid=""mgg32406-bib-0008"" ref-type=""bibr"">2021</xref>). It is also very important to aid treatment decisions and to give genetic counseling for patient's family. Recent expert guidelines recommend genetic testing for the diagnosis of AS (Savige, Mack, et al., <xref rid=""mgg32406-bib-0017"" ref-type=""bibr"">2021</xref>). The",26_6,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"ref-type=""bibr"">2021</xref>). The <italic toggle=""yes"">COL4A3, COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> genes consist of approximately 50 exons, and the main strategy for gene screening in AS has become targeted sequencing, which captures all exons and exon‐intron boundaries of all three genes, along with comprehensive sequencing analysis by NGS (Nozu et al., <xref rid=""mgg32406-bib-0010"" ref-type=""bibr"">2019</xref>). To date, more than 3000 different pathogenic variants in the <italic",26_7,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"3000 different pathogenic variants in the <italic toggle=""yes"">COL4A3, COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> genes are recorded (Weber et al., <xref rid=""mgg32406-bib-0020"" ref-type=""bibr"">2016</xref>). However, it appears that many possible variants of these genes are still unknown. Although genetic testing is an accurate method to make a final diagnosis, it is hard to pick up those patients for genetic testing. Considering the expense of genetic testing, a cohort of suspected AS",26_8,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"of genetic testing, a cohort of suspected AS patients were subject to genetic testing in this study, which was mainly based on the clinical presentation. Here, we report the results of mutational analysis and the genotype–phenotype correlations in the cohort of patients. We report the genetic diagnosis of autosomal dominant and X‐linked Alport Syndrome in 16 Chinese families. Further details of patient recruitment, medical history, pedigree, and methodology are provided in Supporting Information",26_9,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"are provided in Supporting Information (Appendix <xref rid=""mgg32406-supitem-0001"" ref-type=""supplementary-material"">S1</xref> and Figure <xref rid=""mgg32406-supitem-0002"" ref-type=""supplementary-material"">S1</xref>).  In the current study, we used WES for genetic diagnosis of 16 AS families. Fifteen variants in <italic toggle=""yes"">COL4A3, COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> genes were found, which enlarged the variant spectrum in the Han Chinese population. AS is thought to be a",26_10,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"the Han Chinese population. AS is thought to be a rare disorder, but its prevalence might be underestimated. According to a recent study (Gibson et al., <xref rid=""mgg32406-bib-0004"" ref-type=""bibr"">2021</xref>), the predicted pathogenic <italic toggle=""yes"">COL4A5</italic> variants were found in at least one in 2320 individuals and the predicted pathogenic heterozygous <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic> variants affected one in 106 of the population, although the",26_11,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"one in 106 of the population, although the clinical presentation is not recorded as that high. Therefore, AS is thought to be the most common inherited kidney disease, even more prevalent than autosomal dominant polycystic kidney disease. Clinical features of AS patients range from isolated hematuria to kidney failure, as well as extrarenal manifestations. Notably, three probands were diagnosed earlier than their parents, whose renal presentations were just microscopic hematuria. Their renal presentations",26_12,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"microscopic hematuria. Their renal presentations were found according to the nephrologist's advice. This observation indicated a huge inter‐ and intrafamilial variability of renal presentations among AS patients. In the current study, five probands had been found with unilateral or bilateral kidney cysts. Two patients had bilateral well‐formed renal cysts, and 3 patients had unilateral renal cysts, all of which were single, not multiple. This is different from that in polycystic kidney disease, which is",26_13,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"from that in polycystic kidney disease, which is mainly caused by mutations of PKD1 or PKD2. Interestingly, renal cysts of AS patients were also reported in other studies (Gulati et al., <xref rid=""mgg32406-bib-0005"" ref-type=""bibr"">2019</xref>; Savige, Storey, et al., <xref rid=""mgg32406-bib-0018"" ref-type=""bibr"">2021</xref>). According to the guidelines for genetic testing and management of AS, experts now advocate genetic testing for persistent hematuria, even when a heterozygous pathogenic <italic",26_14,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"even when a heterozygous pathogenic <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> is suspected, and cascade testing of their first‐degree family members because of their risk of impaired kidney function (Savige et al., <xref rid=""mgg32406-bib-0016"" ref-type=""bibr"">2022</xref>). Compared with those gene‐panel designs, WES helps to identify the potential variants contributing to the phenotypes (Bullich et al., <xref rid=""mgg32406-bib-0001"" ref-type=""bibr"">2018</xref>). In fact,",26_15,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"ref-type=""bibr"">2018</xref>). In fact, we did find other disease‐causing variant (<italic toggle=""yes"">GJB2</italic>, NM_004004 c.109G>A) in Family P5. The homozygous variant also can lead to hearing loss. Thus, the role of this variant cannot be ruled out. Besides, WES also helps to identify the modifier genes of AS. Recently, Takemon Y et al. identified several loci associated with the variation in albuminuria and GFR in a mouse model, including a locus on the X chromosome associated with X inactivation",26_16,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"the X chromosome associated with X inactivation and a locus on chromosome 2 containing <italic toggle=""yes"">Fmn1</italic> (Takemon et al., <xref rid=""mgg32406-bib-0019"" ref-type=""bibr"">2021</xref>). Therefore, genetic analysis based on WES of AS patients will shed light on the full understanding of the correlation of genotypes and phenotypes. Among these AS families, renal failure was most frequently observed in patients with variants of <italic toggle=""yes"">COL4A5</italic> gene. In the eight families with",26_17,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"gene. In the eight families with variants of <italic toggle=""yes"">COL4A5</italic> gene, there were eight patients who died of ERSD, who were presumed to have pathogenic variants. In addition, four patients had ERSD. However, patients with heterozygous variants of <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> had better renal outcomes. This observation was consistent with previous reports (Savige, <xref rid=""mgg32406-bib-0014"" ref-type=""bibr"">2022</xref>). However,",26_18,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"ref-type=""bibr"">2022</xref>). However, heterozygous subjects with pathogenic variants of <italic toggle=""yes"">COL4A3/A4</italic> gene are not expected to live a healthy life. Moreover, reports have shown that some patients with a primary diagnosis of familial FSGS proved to have variants in <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> genes (Deltas et al., <xref rid=""mgg32406-bib-0003"" ref-type=""bibr"">2015</xref>; Pierides et al., <xref rid=""mgg32406-bib-0012""",26_19,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"Pierides et al., <xref rid=""mgg32406-bib-0012"" ref-type=""bibr"">2009</xref>). In this report, the proband of P11 had a pathogenic variant of <italic toggle=""yes"">COL4A3</italic> gene, and had presentations of chronic renal failure and FSGS. As our samples are rather small, it is hard to draw a conclusion of the correlation of genotypes and phenotypes. In current study, eight variants were never reported. This suggested that the mutation spectrum of AS was very broad. Notably, three variants involved in RNA",26_20,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"broad. Notably, three variants involved in RNA splicing were found. Two variants located at the conservational splicing sites. One variant was adjacent to the splicing sites. Actually, it is difficult to distinguish the intronic variants leading to splicing errors from those harmless polymorphisms. To date, there are several in silico approaches to assess the function of intronic variants, but functional analysis is needed to confirm the results in silico (Jian et al., <xref rid=""mgg32406-bib-0006""",26_21,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"(Jian et al., <xref rid=""mgg32406-bib-0006"" ref-type=""bibr"">2014</xref>). The splicing errors induced by intronic variants can also be analyzed by in vivo assay, if possible. In family P6, we confirmed the splicing error by analyzing the RT‐PCR products, which was similar to our previous report (Wu et al., <xref rid=""mgg32406-bib-0021"" ref-type=""bibr"">2021</xref>). Therefore, the intronic variants should be fully investigated, especially for those adjacent to the conservational splicing sites. In",26_22,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"adjacent to the conservational splicing sites. In conclusion, the pathogenic intronic variants in <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic> genes were identified by WES in Chinese AS families. Our findings enlarged the mutational spectrum of AS. Identification of these pathogenic variants helps to understand the relationship between phenotypes and genotypes of AS. Bo Zhang conceived and designed research; Bo Zhang and Tangli Xiao",26_23,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"and designed research; Bo Zhang and Tangli Xiao performed the genetic investigations, Tangli Xiao, Jun Zhang and Li Liu collected patient data, Tangli Xiao drafted manuscript, Bo Zhang revised manuscript. All authors read and approved the final manuscript. The authors have no conflicts of interest to declare. Written informed consents to participate in the study were obtained from the patients and their parents. The present study was ethically approved by the Ethics Committee of Xinqiao Hospital at Army",26_24,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"the Ethics Committee of Xinqiao Hospital at Army Medical University (Chongqing, China). All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration.",26_25,Genetic diagnosis of Alport syndrome in 16 Chinese families,03 3 2024,,Alport_Syndrome
"Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome
 
Chronic kidney disease (CKD) is associated with renal metabolic disturbances, including impaired fatty acid oxidation (FAO). Nicotinamide adenine dinucleotide (NAD
<sup>+</sup>
) is a small molecule that participates in hundreds of metabolism-related reactions. NAD
<sup>+</sup>
levels are decreased in CKD, and NAD
<sup>+</sup>
supplementation is protective. However, both the mechanism of how NAD",27_0,"
Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome
",29 2 2024,,Alport_Syndrome
"<sup>+</sup>
supplementation protects from CKD, as well as the cell types most responsible, are poorly understood. Using a mouse model of Alport syndrome, we show that nicotinamide riboside (NR), an NAD
<sup>+</sup>",27_1,"
Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome
",29 2 2024,,Alport_Syndrome
"precursor, stimulates renal peroxisome proliferator-activated receptor α signaling and restores FAO in the proximal tubules, thereby protecting from CKD in both sexes. Bulk RNA-sequencing shows that renal metabolic pathways are impaired in Alport mice and dramatically activated by NR in both sexes. These transcriptional changes are confirmed by orthogonal imaging techniques and biochemical assays. Single nuclei RNA-sequencing and spatial transcriptomics, both the first of their kind from Alport mice, show",27_2,"
Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome
",29 2 2024,,Alport_Syndrome
"the first of their kind from Alport mice, show that NAD",27_3,"
Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome
",29 2 2024,,Alport_Syndrome
"<sup>+</sup>
supplementation restores FAO in the proximal tubules with minimal effects on the podocytes. Finally, we also report, for the first time, sex differences at the transcriptional level in this Alport model. Male Alport mice had more severe inflammation and fibrosis than female mice at the transcriptional level. In summary, the data herein identify both the protective mechanism and location of NAD
<sup>+</sup>
supplementation in this model of CKD.
 Full text not available in PMC",27_4,"
Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome
",29 2 2024,,Alport_Syndrome
"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study <italic toggle=""yes"">Background</italic>. Characteristics of X-linked Alport syndrome (XLAS) in a cohort of Chinese children. <italic toggle=""yes"">Methods</italic>. This work is a retrospective study covering the clinical information, pathological data, and gene sequencing results of 32 cases with XLAS from 2011 to 2022. <italic toggle=""yes"">Results</italic>. Among these 32 patients, the",28_0,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"Among these 32 patients, the youngest age of onset was 3 months. Renal biopsy was performed on 29 children. The lamellated glomerular basement membrane was observed in 19 children using electron microscopy (65.5%). Of the 26 samples tested, 73.1% were found to be negative for collagen-a5 under immunohistochemical staining, showing clinical significance. Next-generation sequencing (NGS) detected 27 pathogenic gene mutations. A total of 15.4% of patients carried de novo mutations. <italic",28_1,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"of patients carried de novo mutations. <italic toggle=""yes"">Conclusions</italic>. The boys with XLAS showed more typical pathological performance than the girls. Patients with severe mutation were more likely to have proteinuria and hearing impairment. Renal pathology combined with NSG is an important means of diagnosis of AS. Alport syndrome (AS) is a hereditary disorder in which chronic kidney disease (CKD) progresses to end-stage renal disease (ESRD), sensorineural hearing loss, and ocular",28_2,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"(ESRD), sensorineural hearing loss, and ocular abnormalities.<sup>",28_3,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"<xref rid=""bibr1-2333794X231221935"" ref-type=""bibr"">1</xref>
</sup> Alport syndrome has 3 modes of inheritance: X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS), and autosomal dominant Alport syndrome (ADAS).The more severe XLAS affects about one in 2000,<sup>
<xref rid=""bibr2-2333794X231221935"" ref-type=""bibr"">2</xref>
</sup> because of a mutation in the <italic toggle=""yes"">COL4A5</italic> gene, which encodes the type 4 collagen a5 chain.<sup>",28_4,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"<xref rid=""bibr3-2333794X231221935"" ref-type=""bibr"">3</xref>",28_5,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"</sup> In this study, we provide the clinical information, pathological data, and gene sequencing results of 32 cases with childhood XLAS. AS is a form of familial nephritis caused by defects in type IV collagen, which is composed of a heterotrimer of α chains 3, 4, and 5. Type IV collagen makes up most of the network of basement membranes in the glomerular basement membrane, cochlea, cornea, lens capsule, and retina, which explains much of the phenotype.<sup><xref rid=""bibr8-2333794X231221935""",28_6,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"rid=""bibr8-2333794X231221935"" ref-type=""bibr"">8</xref><xref rid=""bibr9-2333794X231221935"" ref-type=""bibr""></xref>–<xref rid=""bibr10-2333794X231221935"" ref-type=""bibr"">10</xref></sup> AS may present clinical symptoms in infancy. In our data, children under 3 years old were often misdiagnosed with urinary tract infections. Doctors in primary hospitals did not screen patients by family history, which suggests that the primary doctors in China lack knowledge of AS, consistent with Ding Jie’s report.<sup>",28_7,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"<xref rid=""bibr11-2333794X231221935"" ref-type=""bibr"">11</xref>",28_8,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"</sup> We only diagnosed 4 cases of XLAS before 2016. With the development of renal biopsy and genetic testing, the number of XLAS diagnosis is increasing annually. None of our ophthalmic examinations had any positive results. The specific ocular manifestations include anterior lenticonus, posterior subcapsular cataract, posterior polymorphous dystrophy, and retinal flecks.<sup><xref rid=""bibr12-2333794X231221935"" ref-type=""bibr"">12</xref>,<xref rid=""bibr13-2333794X231221935""",28_9,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"rid=""bibr13-2333794X231221935"" ref-type=""bibr"">13</xref></sup> These abnormalities occur in up to 70% of all patients with AS.<sup>",28_10,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"<xref rid=""bibr13-2333794X231221935"" ref-type=""bibr"">13</xref>
</sup> Due to the progressive nature of the disease, the ocular findings of AS are more prevalent in adult patients.<sup>
<xref rid=""bibr14-2333794X231221935"" ref-type=""bibr"">14</xref>
</sup> However, ophthalmologists’ inadequate skill may have kept the detection rate of ocular lesions artificially low.<sup>
<xref rid=""bibr15-2333794X231221935"" ref-type=""bibr"">15</xref>",28_11,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"</sup> Seda Karaca Adıyeke found that the optical coherence tomography (OCT) examination provides valuable information suitable for identifying the structural changes associated with AS and evaluating relevant ocular findings.<sup>
<xref rid=""bibr16-2333794X231221935"" ref-type=""bibr"">16</xref>",28_12,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"</sup> We should pay attention to the OCT examination during follow-up. We found the rate at which immunohistochemical staining did not detect collagen-a5 and the lamellated GBM to be relevant. However, the earliest change in AS is diffuse thinning of the GBM. Women and children with XLAS may show thinning of the GBM as their only symptom.<sup>
<xref rid=""bibr17-2333794X231221935"" ref-type=""bibr"">17</xref>",28_13,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"</sup> In our data, 3 girls showed undetectable levels of a5 (COLIV) chain (3/7, 42.86%), and only 2 girls (2/7, 28.57%) had typical changes in GBM. Attempting to diagnose AS using pathological manifestations alone may lead to missed diagnosis, particularly in girls. If AS is suspected in female children, especially when the renal pathology is atypical, genetic testing should be performed for further confirmation. Here, 15.4% of patients were found to carry <italic toggle=""yes"">de novo</italic> mutations,",28_14,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"<italic toggle=""yes"">de novo</italic> mutations, which indicates that the renal pathology combined with NSG is an important means of diagnosing AS. The kidney function of patient No. 22 has declined. His mother had microscopic hematuria, and his uncle passed away at the age of 20 due to end-stage renal disease. This patient’s genetic variation site is c.2215(exon28) C>G, a mutation previously reported. According to ACMG guidelines,<sup>",28_15,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"<xref rid=""bibr4-2333794X231221935"" ref-type=""bibr"">4</xref>",28_16,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"</sup> this mutation is classified as a probable pathogenic variant. Notably, Patients No. 10 and No. 11 share the same genetic variation, indicating genetic heterogeneity in this cohort. Some scholars have reported that kidney prognosis is significantly closely related to mutation type.<sup><xref rid=""bibr18-2333794X231221935"" ref-type=""bibr"">18</xref><xref rid=""bibr19-2333794X231221935"" ref-type=""bibr""></xref>–<xref rid=""bibr20-2333794X231221935"" ref-type=""bibr"">20</xref></sup> We found that patients",28_17,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"We found that patients still in childhood who had severe genetic mutations were more likely to have proteinuria and hearing impairment than children with missense mutations. The rate at which collagen-a5 was not detected in kidney tissues under immunofluorescence staining was higher than in children with missense mutations. Bekheirnia also found deduced premature termination of the collagen-5(IV) chain to be associated with large and small deletions, and truncation and splice mutations cause the most",28_18,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
truncation and splice mutations cause the most severe clinical phenotype. Missense mutations result in a less severe phenotype.<sup>,28_19,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"<xref rid=""bibr21-2333794X231221935"" ref-type=""bibr"">21</xref>",28_20,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"</sup> Our data showed only one child with decreased renal function at the time of the study, but patients with severe genetic mutations were more likely to have proteinuria, and proteinuria is a high-risk factor for deterioration of renal function,<sup><xref rid=""bibr22-2333794X231221935"" ref-type=""bibr"">22</xref>,<xref rid=""bibr23-2333794X231221935"" ref-type=""bibr"">23</xref></sup> so long-term follow-up is needed. Jais found the risk of developing hearing loss before 30 years of age was approximately 60%",28_21,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"loss before 30 years of age was approximately 60% in patients with missense mutations, as opposed to 90% for the other types of mutations. The probability of developing hearing loss before the age of 30 years in male patients was affected by the type of <italic toggle=""yes"">COL4A5</italic> mutation.<sup>",28_22,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"<xref rid=""bibr18-2333794X231221935"" ref-type=""bibr"">18</xref>
</sup> Xiao Zhang reported that hearing loss in China usually started at school age and gradually increased over time. Xiao Zhang also found missense mutations less likely to lead to hearing loss than other mutations (rearrangement, deletion, insertion, and point mutations).<sup>
<xref rid=""bibr24-2333794X231221935"" ref-type=""bibr"">24</xref>",28_23,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"</sup> These conclusions are consistent with our observations. Our study has some limitations. It is a single-center retrospective study with a small number of cases. Sample size calculation was not conducted.There were no significant differences in the mode of onset mode between Group A and Group B, which may be related to the number of cases. Additionally, we did not perform follow-up. In summary, our findings indicate that during childhood, boys with XLAS exhibited more typical pathological features",28_24,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"XLAS exhibited more typical pathological features compared to girls. Additionally, patients with severe mutations were more prone to developing proteinuria and hearing impairment. Combining renal pathology with NSG proves to be a crucial diagnostic approach for AS.",28_25,"Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study",19 1 2024,,Alport_Syndrome
"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report Alport syndrome (AS) is a hereditary kidney disease with manifestations that include hematuria, proteinuria, progressive kidney failure, sensorineural hearing loss, and ocular lesions [<xref rid=""B1"" ref-type=""bibr"">1</xref>]. The pathological mechanism of AS is glomerular basement membrane (GBM) abnormalities due to pathogenic variants in genes encoding the",29_0,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"due to pathogenic variants in genes encoding the α3, α4, and α5 chains of type IV collagen [<xref rid=""B2"" ref-type=""bibr"">2</xref>]. X-linked dominant hereditary type AS (XLAS) is most common and is caused by variants in <italic toggle=""yes"">COL4A5</italic>, located on chromosome Xq2. Autosomal recessive AS and autosomal dominant AS are caused by variants in <italic toggle=""yes"">COL4A3</italic> and <italic toggle=""yes"">COL4A4</italic>, which are located at 2q36.3 [<xref rid=""B3"" ref-type=""bibr"">3</xref>].",29_1,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"2q36.3 [<xref rid=""B3"" ref-type=""bibr"">3</xref>]. In patients with XLAS, proteinuria becomes evident in early childhood. The median kidney survival period (age at onset of kidney failure) is 35 years, but the age at onset of kidney failure differs significantly among patients, based on genotype differences [<xref rid=""B4"" ref-type=""bibr"">4</xref>]. To date, >1,000 variants have been identified in XLAS [<xref rid=""B5"" ref-type=""bibr"">5</xref>]. However, there have been few reports of cases of male digenic",29_2,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"have been few reports of cases of male digenic AS caused by variants in <italic toggle=""yes"">COL4A5</italic> and another. Here, we present a case of AS with novel digenic missense variants in <italic toggle=""yes"">COL4A4</italic> (c.827G>C, p.Gly276Ala) and <italic toggle=""yes"">COL4A5</italic> (c.4369G>C, p.Gly1457Arg) without kidney function impairment. The CARE Checklist has been completed by the authors for this case report, attached as online supplementary material (for all online suppl. material, see",29_3,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"material (for all online suppl. material, see <ext-link http://www.w3.org/1999/xlink href=""10.1159/000535493"" ext-link-type=""doi"">https://doi.org/10.1159/000535493</ext-link>). The patient was a 29-year-old Japanese man who was referred to our hospital because of persistent microscopic hematuria and proteinuria. He had a significant familial history of abnormal urinalysis. His maternal and paternal grandmothers had proteinuria and hematuria, his mother had both hematuria and proteinuria since she was a",29_4,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"both hematuria and proteinuria since she was a teenager, and his sister also presented with microscopic hematuria. However, none of the family members had kidney impairment. The pedigree of the patient’s family is shown in <xref rid=""F1"" ref-type=""fig"">Figure 1</xref>. Upon admission, body temperature was 36.8°C and blood pressure was 125/83 mm Hg. Optometry and otolaryngologic examinations revealed no abnormalities, although the patient subsequently developed sensorineural hearing loss. Physical",29_5,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"developed sensorineural hearing loss. Physical examination findings were unremarkable for the heart, lungs, abdomen, and nervous system. Laboratory and urinary data at the time of admission are shown in <xref rid=""T1"" ref-type=""table"">Table 1</xref>. Urinalysis indicated proteinuria (3+) and occult blood (2+), and a spot urine protein/creatine ratio of 2.30 g/gCr. Serum creatinine was 0.90 mg/dL, estimated glomerular filtration rate was 87.45 mL/min/1.73 m<sup>2</sup>, blood urea nitrogen was 14 mg/dL, and",29_6,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"blood urea nitrogen was 14 mg/dL, and albumin was 4.0 g/dL. Serum C3 and C4 were 111 and 20.5 mg/dL, respectively. Due to these findings, a kidney biopsy was performed. Light microscopy revealed 21 glomeruli, of which 4 exhibited global glomerulosclerosis and 4 exhibited segmental sclerosis of the collapsed type. All other glomeruli showed no significant alterations. Interstitial fibrosis and foam cells were apparent on periodic acid-Schiff staining (<xref rid=""F2"" ref-type=""fig"">Fig. 2</xref>a).",29_7,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"(<xref rid=""F2"" ref-type=""fig"">Fig. 2</xref>a). Immunofluorescence staining for IgG, IgA, IgM, C1q, C3, and fibrinogen was not significant. Double immunofluorescence staining for α1 (red) and α5 (green) showed that the GBM and Bowman’s capsule were negative for α5 (<xref rid=""F2"" ref-type=""fig"">Fig. 2</xref>b). Electron microscopy revealed irregular thickening with lamellation and segmental thinning of the GBM (<xref rid=""F2"" ref-type=""fig"">Fig. 2</xref>c, d). Based on his family history and findings",29_8,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"d). Based on his family history and findings suggestive of AS, a genetic evaluation was performed using comprehensive sequence analysis of multiple podocyte related genes, including <italic toggle=""yes"">COL4A3</italic>, <italic toggle=""yes"">COL4A4</italic>, and <italic toggle=""yes"">COL4A5</italic>, in the patient. Variants were validated using Sanger sequencing in the pedigree analysis, with sequencing of 193 genes. The target bases were covered at a depth of more than 100 folds, with 100% coverage. The",29_9,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"of more than 100 folds, with 100% coverage. The mean base-read-depth was 460-fold in COL4A3, 447-fold in COL4A4, and 241-fold in COL4A5. This study was approved by the Institutional Review Board of Kobe University of Medicine, and written informed consent was obtained. Mutational analyses of COL4A3, COL4A4, and COL4A5 were performed using polymerase chain reaction and direct sequencing of genomic DNA for family members. The results showed that the patient had a compound heterozygous missense variant",29_10,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"had a compound heterozygous missense variant (c.827G>C; p.Gly276Ala) in exon 1 of COL4A4 and a hemizygous missense variant (c.4369G>C; p.Gly1457Arg) in exon 49 of <italic toggle=""yes"">COL4A5</italic>. Variants were also found in exon 1 of COL4A4 in his father, in exon 47 of <italic toggle=""yes"">COL4A5</italic> in his mother, and in exons 1 and 47 of COL4A4 and COL4A5, respectively, in his sister (<xref rid=""F3"" ref-type=""fig"">Fig. 3</xref>). According to the ACMG classification, the heterozygous missense",29_11,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"ACMG classification, the heterozygous missense variant c.827G>C was classified as pathogenic (PS<sub>1</sub>+PM<sub>1</sub>+PM<sub>2</sub>+PP<sub>2</sub>+PP<sub>3</sub>), and the hemizygous missense variant c.4351G>C was classified as likely pathogenic (PM<sub>1</sub>+PM<sub>2</sub>+PM<sub>5</sub>+PP<sub>2</sub>+PP<sub>3</sub>). Genetic analysis in our patient revealed a heterozygous missense variant c.827G>C in <italic toggle=""yes"">COL4A4</italic>, resulting in a glycine to alanine substitution at",29_12,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"resulting in a glycine to alanine substitution at position 276 in exon 1, and a hemizygous missense variant c.4351G>C in <italic toggle=""yes"">COL4A5</italic>, resulting in a glycine to arginine substitution at position 1,457 in exon 49. Based on his family history and the results of genetic testing, our patient was diagnosed with digenic AS due to novel missense variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic>. AS is a hereditary disease caused by a genetic variant",29_13,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"a hereditary disease caused by a genetic variant resulting in type IV collagen dysplasia [<xref rid=""B6"" ref-type=""bibr"">6</xref>]. Type IV collagen constitutes the basement membrane of systemic tissues and consists of three α chains in a triple helical structure. The combination of the three α chains is organ-specific, with α3-α4-α5 present in the GBM and α5-α5-α6 in the Bowman’s capsule membrane [<xref rid=""B7"" ref-type=""bibr"">7</xref>]. <italic toggle=""yes"">COL4A5</italic> encodes collagen α5 chain and",29_14,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"encodes collagen α5 chain and is the causative gene for XLAS. α5 chain consists of an N-terminal domain, C-terminal domain, and collagenous domain, and includes a triple helix and a non-helical region [<xref rid=""B8"" ref-type=""bibr"">8</xref>, <xref rid=""B9"" ref-type=""bibr"">9</xref>]. The collagen triple helix conformation requires a (Gly-X-Y)<sub>n</sub> repeat amino acid sequence, in which the glycine contributes to the stability of the triple helix [<xref rid=""B8"" ref-type=""bibr"">8</xref>, <xref",29_15,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"[<xref rid=""B8"" ref-type=""bibr"">8</xref>, <xref rid=""B10"" ref-type=""bibr"">10</xref>]. Therefore, missense variant in the collagenous domain of <italic toggle=""yes"">COL4A3, COL4A4, COL4A5</italic> disrupt structural motifs in collagen comprising the (Gly-X-Y)<sub>n</sub> repeat amino acid sequence. There are significant clinical differences between patients with missense variants in <italic toggle=""yes"">COL4A5</italic> and other genotypes [<xref rid=""B11"" ref-type=""bibr"">11</xref>]. Similar missense variant",29_16,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"Similar missense variant of glycine in exons 1–20 to that in the present case have been associated with onset of kidney failure at a median age of 30.1 years [<xref rid=""B12"" ref-type=""bibr"">12</xref>], and variants closer to the 5′ side were associated with a milder phenotype. Furthermore, patients with missense variants were recently reported to have a longer median kidney survival period of 40 years (35–45 years), compared to those with other truncating variants (nonsense variants, small insertion, or",29_17,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"variants (nonsense variants, small insertion, or deletion) [<xref rid=""B4"" ref-type=""bibr"">4</xref>]. A case of a male patient with mild XLAS with a missense variant and presenting only with hematuria at age 38 has also been reported [<xref rid=""B13"" ref-type=""bibr"">13</xref>]. Most individuals with heterozygous variants in COL4A3 or COL4A4 result in thin basement membrane nephropathy without kidney dysfunction [<xref rid=""B14"" ref-type=""bibr"">14</xref>]. Autosomal recessive AS is caused by homozygous or",29_18,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"Autosomal recessive AS is caused by homozygous or compound heterozygous variants in the COL4A3 and COL4A4 genes, whereas autosomal dominant AS occurs due to heterozygous variants. Thus, the phenotypes of heterozygous variants vary from no urinary abnormality to kidney failure. Hirabayashi et al. [<xref rid=""B15"" ref-type=""bibr"">15</xref>] reported a woman with the same c.827G>C variant in COL4A4 as that in our case, who did not exhibit kidney impairment or proteinuria. Conversely, Imafuku et al. [<xref",29_19,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"or proteinuria. Conversely, Imafuku et al. [<xref rid=""B16"" ref-type=""bibr"">16</xref>] described a man with the same variant who progressed to kidney failure at age 62. Additionally, Deltas et al. [<xref rid=""B17"" ref-type=""bibr"">17</xref>] found that 35% of patients with heterozygous COL4A3/A4 variants develop kidney failure. It is difficult to determine if the effect of heterozygous variants in <italic toggle=""yes"">COL4A3</italic> or <italic toggle=""yes"">COL4A4</italic> in XLAS results in more severe",29_20,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"in XLAS results in more severe disease because there are few reports of cases with digenic variants. A review of digenic AS in <italic toggle=""yes"">COL4A5</italic> and another variant identified two cases with hypomorphic <italic toggle=""yes"">COL4A5</italic> variants that caused severe disease [<xref rid=""B18"" ref-type=""bibr"">18</xref>–<xref rid=""B20"" ref-type=""bibr"">20</xref>]. However, digenic XLAS with <italic toggle=""yes"">COL4A5</italic> variants in males was not associated with increased proteinuria",29_21,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"was not associated with increased proteinuria or kidney function impairment [<xref rid=""B21"" ref-type=""bibr"">21</xref>]. These reports suggest that digenic XLAS with mild variants in COL4A5 and additional variants in COL4A3 or COL4A4 may not be associated with more severe disease in males. Our patient had mild digenic variants without kidney function impairment, hearing loss, or ocular abnormalities. We believe that digenic AS with missense variants is likely to be less severe; however, there are no",29_22,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"likely to be less severe; however, there are no reported cases of long-term renal survival with XLAS, and we are planning careful follow-up with attention to possible increased proteinuria and kidney function impairment. There is currently no specific treatment for AS. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs) significantly reduce urine protein and delay progression to kidney failure in AS [<xref rid=""B22"" ref-type=""bibr"">22</xref>, <xref rid=""B23""",29_23,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"ref-type=""bibr"">22</xref>, <xref rid=""B23"" ref-type=""bibr"">23</xref>]. Bardoxolone methyl activates nuclear factor erythroid-2-related factor 2 (Nrf2) and suppresses nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). A phase 3, multicenter, double-blind, placebo-controlled, randomized trial showed that bardoxolone methyl improved the decline in estimated glomerular filtration rate but did not improve the time to onset of kidney failure in AS [<xref rid=""B24"" ref-type=""bibr"">24</xref>].",29_24,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"AS [<xref rid=""B24"" ref-type=""bibr"">24</xref>]. Moreover, exon-skipping therapy is under development for severe XLAS with severe variants, such as nonsense variants in males, using an antisense oligonucleotide to replace these variants with milder variants [<xref rid=""B25"" ref-type=""bibr"">25</xref>]. In our patient, treatment with an ARB resulted in a significant decrease in proteinuria from 2.3 to 1.1 g/gCr after kidney biopsy. In conclusion, we have presented a case of digenic AS with novel missense",29_25,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"a case of digenic AS with novel missense variants. The novel genotype in this case provides more information on the genotype-phenotype correlation of digenic AS, but long-term follow-up is required. Further accumulation of cases is needed for understanding of digenic AS with missense variants. We are indebted to the nephrologists and nursing staff at Osaka Metropolitan University Hospital and to the patient for their assistance with this case. This report does not include any experiments on humans or",29_26,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"does not include any experiments on humans or animals. This study protocol was reviewed and approved by Kobe University of Medicine, approval number [301]. Written informed consent was obtained from the patient for publication of the details of their medical case and any accompanying images. All procedures involving human participants were in accordance with the ethical standards of the institution at which the work was conducted and with the 1964 Declaration of Helsinki and its later amendments or",29_27,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"of Helsinki and its later amendments or comparable ethical standards. H.U. reported personal fees from Astellas Pharma Co. Ltd., Mitsubishi Tanabe Pharma Co. Ltd., Mochida Pharma Co. Ltd., Kyowa Kirin Co. Ltd., and Otsuka Pharmaceutical Co. Ltd. K.M. reported grants from Mitsubishi Tanabe Pharma Co. Ltd., Kyowa Kirin Co. Ltd., and Torii Pharmaceutical Co., Ltd. and personal fees from Astellas Pharma Co. Ltd., Bayer Yakuhin Co. Ltd., Chugai Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Kyowa",29_28,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"Co. Ltd., Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Torii Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. S.N. reported personal fees from Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Co. Ltd., Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Torii Pharmaceutical Co. Ltd., Novel Pharma, and Ono Pharmaceutical Co. Ltd. K.N. is a member of advisory groups for Kyowa Kirin Co. Ltd., Toa Eiyo Ltd., and Taisho Pharmaceutical Co. Ltd. He received speaker’s bureaus from Sumitomo Pharma",29_29,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"received speaker’s bureaus from Sumitomo Pharma Co. Ltd., Chugai Pharmaceutical Co. Ltd., and Kyowa Kirin Co., Ltd. He obtained a patent with Daiichi Sankyo Pharma Co., Ltd. for developing exon-skipping therapy for Alport syndrome patients. M.E. reported grants from Mitsubishi Tanabe, Kowa, Eisai, Chugai Pharmaceutical, and Bayer, personal fees from Novo Nordisk Pharma, Sanofi, and AstraZeneca, and grants and personal fees from Ono Pharmaceutical, Nippon Boehringer Ingelheim, Sumitomo Pharmaceutical, and",29_30,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
"Ingelheim, Sumitomo Pharmaceutical, and Kyowa Kirin Co. Ltd. The authors declare that they have no other conflicts of interest regarding the study. While we have received honoraria and grants unrelated to this study, we have not received any specific funding for this research. H.U., K.M., S.N., K.W., R.N., F.M., K.S., C.O., J.H., A.T., N.M., T.S., and K.N. were responsible for the clinical management of the patient and for preparing the draft version of the manuscript. M.E. read and approved the",29_31,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
of the manuscript. M.E. read and approved the manuscript. All authors participated in the writing of the manuscript and read and approved the final version.,29_32,"Novel Digenic Variants in <italic toggle=""yes"">COL4A4</italic> and <italic toggle=""yes"">COL4A5</italic> Causing X-Linked Alport Syndrome: A Case Report",3 1 2024,,Alport_Syndrome
